Metabolic Alterations in Prostate Cancer Pathogenesis

Doctoral Thesis

Amaia Arruabarrena-Aristorena

Director: Arkaitz Carracedo Pérez

2016
Metabolic Alterations in Prostate Cancer Pathogenesis

Doctoral Thesis

Report of the experimental work to apply for the grade of Doctor in Biological Sciences, into the Doctorate Programme of Molecular Biology and Biomedicine of the University of the Basque Country. The work herein has been performed by Amaia Arruabarrena Aristorena at the Center for Cooperative Research in Biosciences (CIC bioGUNE) under the mentorship of Dr. Arkaitz Carracedo Pérez.

Amaia Arruabarrena Aristorena

2016

Supported by:

(c)2016 AMAIA ARRUBARRENA ARISTORENA
"Lo que sabemos es una gota,
lo que ignoramos un inmenso océano"

(Isaac Newton)

Zuei aita ta ama.
Zuri bruja.
Zuri poroki.
-Dox: non-induced
+ Dox: induced with doxycycline
µg: microgram
µM: microMolar
1,3-DAP: 1,3-diaminopropane
1C: one carbon
3PG: 3-phosphoglycerate
4E-BP: Eukaryotic Translation Initiation Factor 4E-binding Protein
a.u.: arbitrary units
aa: amino acid
AAALAC: Association for Assessment and Accreditation of Laboratory Animal Care International
ABC: Avidin/Biotin Complex
ABD: ATP-binding cassette
ACF: Aberrant Crypt Foci
ACN: Acetonitrile
AD: Alzheimer`s disease
AGC: cAMP-dependent, cGMP-dependent and protein kinase C protein kinase family
AKT: Protein Kinase B, PKB
AMD1/Amd1: Human/Murine S-adenosylmethionine decarboxylase
Amp: Ampicillin
AP: Anterior Prostate
APAO: Acetylpolyamine Oxidase
APC: Adenomatous Polyposis Coli
AR: Androgen Receptor
Arg, R: Arginine
ATCC: American Type Culture Collection
Atg13: Autophagy-related protein 13
ATG5: Autophagy related 5 homolog
ATG7: Autophagy related 7
ATM: Ataxia telangiectasia mutated protein kinase
ATP: Adenosine Triphosphate
AZ: antizyme
AZI: antizyme inhibitor
BAD: Bcl-2-associated death promoter protein
BCAA: Branched Chain Amino Acids
BCKA: Branched Chain Ketoacids
bHLH-LZ: basic Helix-Loop-Helix-Leucine Zipper
Bhmt: Betaine-homocysteine S-methyltransferase
BIOEF: Basque biobank for research
BPE: Bovine Pituitary Extract
BPH: Benign Prostatic Hyperplasia
BRRS: Bannayan-Riley-Ruvalcaba syndrome
Cad: Cadaverine
CAD: Carbamoyl-Phosphate Synthetase 2
CBS/Cbs: Human/Murine Cystathionine β Synthase
CDK-4: Cyclin-dependent kinase 4
cDNA: complementary DNA
CEIC: Clinical Research Ethics Committee
Chow: regular diet
CHX: Cyclohexamide
CI: Confidence Interval
CID: Collision Induced Dissociation
c-MYC: Myc proto-oncogene protein
Cre: recombinase
CRPC: Castration-Resistant Prostate Cancer
CS: Cowden syndrome
Cth: Murine Cystathionase
Cys: Cysteine, C
CZ: Central Zone
dcSAM: decarboxylated S-adenosylmethionine
DEPTOR: DEP domain containing mTOR-interacting protein
DFMO: α-difluoromethylornithine
DG: Diglyceride
DHS: Deoxyhypusine Synthase
DLP: Dorso-Lateral Prostate
Abbreviations

DMSO: Dimethyl Sulfoxide
DNA: Desoxyribonucleic Acid
DOHH: Deoxyhypusine Hydroxylase
DRE: Digital Rectal Examination
DTT: Dithiothreitol
DU145\textsuperscript{MYC-AMD1-HA WT}: DU145 cells overexpressing AMD1 fused to HA and myc tags
EGF 1-53: Epidermal Growth Factor 1-53
EGFR: Epidermal Growth Factor Receptor
eIF2a: eukaryotic translation initiation factor 2 complex
eIF4G: eukaryotic Initiation Factor 4G
eIF5A: eukaryotic translation initiation factor 5A
EMT: Epithelial-Mesenchymal Transition
ES: Embryonic Stem
ETBF: enterotoxigenic \textit{Bacteroides fragilis}
ETC: Electron Transport Chain
FA: Formaldehyde
FAD: Flavin Adenine Dinucleotide
FAO: Fatty Acid Oxidation
FAP: Familial Adenomatous Polyposis
FAT: Familial Adenomatous Polyposis
FATC: C terminus of FRAP-ATM-TRRAP complex
FBS: Fetal Bovine Serum
FDR: False Discovery Rate
FI-ToF-MS: Flow Injection-Time-of-Flight Mass Spectrometry
FKBP12: Peptidyl-prolyl cis-trans isomerase FKBP12
floX: loxP recognition sequences
FOXO: Forkhead Box Family of Transcription Factors
FRAP: Fluorescence recovery after photobleaching
FRB: FKBP12-rapamycin binding
GEMM: Genetic Engineered Mouse Model
GlcNAc: N-acetylglucosamine
GLDC: Glycine decarboxylase
Gin: glutamine, Q
Glu: Glutamate, E
Gly: Glycine, G
\textit{Gnmt} \textsuperscript{−/−}: Whole body \textit{Gnmt} knockout
\textit{GNMT/Gnmt}: Human/Murine Glycine N-methyltransferase
\textit{Gnmt} \textsuperscript{+/−}: Whole body \textit{Gnmt} wild-type
GPCR: G-protein-coupled receptor
GSK3: Glycogen Synthase Kinase 3
H&E: Haematoxylin and Eosin
h: hour
\textit{H2O2}: Hydrogen Peroxide
HBP: Hexosamine Biosynthetic Pathway
HBS: HEPES-Buffered Solution
HCC: Hepatocellular Carcinoma
HCys: Homocysteine
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HGPIN: High Grade Prostatic Intraepithelial Neoplasia
HPLC: High-Performance Liquid Chromatography
H-Ras: GTPase HRas
IARC: International Agency for Research in Cancer
IGF-1R: Insulin-like growth factor 1 receptor
IHC: Immunohistochemistry
Ile: Isoleucine, I
INPP4B: Inositol Polyphosphate 4-phosphatase type II
IPA: Ingenuity Pathway Analysis
IRES: Internal Ribosome Entry Sites
IRS1: Insulin Receptor Substrate 1
JNK: c-Jun N-terminal kinase
KDa: Kilodalton
KFSD: Keratosis Follicularis Spinulosa Decalvans
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kg</td>
<td>kilogram</td>
</tr>
<tr>
<td>$K_m$</td>
<td>Michaelis constant</td>
</tr>
<tr>
<td>KRAS</td>
<td>GTPase KRas</td>
</tr>
<tr>
<td>LBE</td>
<td>LST8-binding element</td>
</tr>
<tr>
<td>LC/MS</td>
<td>Liquid Chromatography / Mass Spectrometry</td>
</tr>
<tr>
<td>LDD</td>
<td>Lhermitte-Duclos disease</td>
</tr>
<tr>
<td>Leu</td>
<td>Leucine, L</td>
</tr>
<tr>
<td>$m/z$</td>
<td>mass to charge ratio</td>
</tr>
<tr>
<td>Mat2</td>
<td>Methionine adenosyltransferase II</td>
</tr>
<tr>
<td>MAX</td>
<td>Protein max</td>
</tr>
<tr>
<td>MDM2</td>
<td>Mouse Double Minute 2 homolog</td>
</tr>
<tr>
<td>Met Def</td>
<td>methionine restricted</td>
</tr>
<tr>
<td>Met</td>
<td>methionine, M</td>
</tr>
<tr>
<td>MFA</td>
<td>Metabolic Flux Analysis</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>MGBG</td>
<td>methylglyoxal-bis (guanylhydrazone)</td>
</tr>
<tr>
<td>MK</td>
<td>MK2206</td>
</tr>
<tr>
<td>mLST8</td>
<td>mammalian lethal with sec-13 protein 8</td>
</tr>
<tr>
<td>mM</td>
<td>milli Molar</td>
</tr>
<tr>
<td>mm$^3$</td>
<td>cubic milimeters</td>
</tr>
<tr>
<td>Mo</td>
<td>Month</td>
</tr>
<tr>
<td>Mock</td>
<td>empty vector</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger RNA</td>
</tr>
<tr>
<td>MS/Ms</td>
<td>Human/Murine Methionine Synthase</td>
</tr>
<tr>
<td>$m$Sin1</td>
<td>mammalian stress-activated map kinase-interacting protein 1</td>
</tr>
<tr>
<td>MTA</td>
<td>Methylthioadenosine</td>
</tr>
<tr>
<td>MTD</td>
<td>Maximum-Tolerated Dose</td>
</tr>
<tr>
<td>m-THF</td>
<td>methyl-tetrahydrofolate</td>
</tr>
<tr>
<td>Mthfr</td>
<td>Murine Methylenetetrahydrofolate reductase</td>
</tr>
<tr>
<td>mTOR</td>
<td>Mechanistic Target of Rapamycin</td>
</tr>
<tr>
<td>mTORC1</td>
<td>Mechanistic Target of Rapamycin Complex 1</td>
</tr>
<tr>
<td>mTORC2</td>
<td>Mechanistic Target of Rapamycin Complex 2</td>
</tr>
<tr>
<td>NAD</td>
<td>Nicotinamide Adenine Dinucleotide</td>
</tr>
<tr>
<td>FC</td>
<td>Fold Change</td>
</tr>
<tr>
<td>NADPH</td>
<td>Nicotinamide Adenine Dinucleotide Phosphate</td>
</tr>
<tr>
<td>NAFLD</td>
<td>Non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NE</td>
<td>Neuroendocrine</td>
</tr>
<tr>
<td>nM</td>
<td>nano Molar</td>
</tr>
<tr>
<td>N-MYC</td>
<td>N-myc proto-oncogene protein</td>
</tr>
<tr>
<td>NNMT</td>
<td>Nicotinamide N-Methyltransferase</td>
</tr>
<tr>
<td>NP</td>
<td>Nanoparticle</td>
</tr>
<tr>
<td>ODC1/Odc1</td>
<td>Human/Murine Ornithine Decarboxylase 1</td>
</tr>
<tr>
<td>OGT</td>
<td>O-GlcNAc Tranferase</td>
</tr>
<tr>
<td>ORF</td>
<td>Open Reading Frame</td>
</tr>
<tr>
<td>OXPHOS</td>
<td>Oxidative Phosphorylation</td>
</tr>
<tr>
<td>p21$^{Cip1/WAF1}$</td>
<td>Cyclin-dependent kinase inhibitor 1</td>
</tr>
<tr>
<td>p27$^{Kip1}$</td>
<td>Cyclin-dependent kinase inhibitor p27</td>
</tr>
<tr>
<td>p53</td>
<td>Tumor protein p53</td>
</tr>
<tr>
<td>PA</td>
<td>Polyamine</td>
</tr>
<tr>
<td>Paox</td>
<td>Murine Peroxisomal N1-Acetyl-Spd/Spm Oxidase</td>
</tr>
<tr>
<td>PB</td>
<td>Probasin</td>
</tr>
<tr>
<td>PB-Cre</td>
<td>Probasin-Cre</td>
</tr>
<tr>
<td>PC</td>
<td>Phosphatidylcholine</td>
</tr>
<tr>
<td>PCA</td>
<td>Prostate Cancer</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase Chain Reaction</td>
</tr>
<tr>
<td>PD</td>
<td>Parkinson’s disease</td>
</tr>
<tr>
<td>PDK1</td>
<td>Phosphoinositide-dependent kinase 1</td>
</tr>
<tr>
<td>PDs</td>
<td>pharmacodynamics</td>
</tr>
<tr>
<td>PDTX</td>
<td>Patient Derived Tumor Xenograft</td>
</tr>
<tr>
<td>PE</td>
<td>Phosphatidylethanolamine</td>
</tr>
<tr>
<td>PEG</td>
<td>Polyethylene glycol</td>
</tr>
<tr>
<td>PEMT/Pemt</td>
<td>Human/Murine Phosphatidylethanolamine N methyltransferase</td>
</tr>
<tr>
<td>PET</td>
<td>Positron Emission Tomography</td>
</tr>
</tbody>
</table>
Abbreviations

PFA: Paraformaldehyde  
PH: Pleckstrin-homology  
PHTS: PTEN hamartoma tumor syndromes  
PI: Propidium Iodide  
P3K: Phosphoinositide 3-kinase  
PICS: Pten-loss induced cellular senescence  
PIKK: PI3K-related kinase  
PIN: Prostatic Intraepithelial Neoplasia  
PPIP2: Phosphatidylinositol-4,5-bisphosphate, P(4,5)P$_2$  
PPIP3: Phosphatidylinositol-3,4,5-trisphosphate, P(3,4,5)P$_3$  
PKCa: Protein Kinase C-α  
PKR: IFN-induced double-stranded RNA-dependent protein kinase  
PKs: pharmacokinetics  
PLP: Pyridoxal Phosphate  
PPARγ: Peroxisome Proliferator-activated Receptor gamma  
PPP: Pentose Phosphate Pathway  
PPRE: PPAR response element  
PRAS40: Proline-Rich AKT Substrate 40 kDa  
PRE: Polyamine-responsive element  
proAMD1/proAmd1: Human/Murine AMD1 proenzyme  
protor1/2: protein observed with rictor 1 and 2  
PSA: Prostate-Specific Antigen  
PSVs: polyamine-sequestering vesicles  
Pten<sup>+</sup>: Pten heterozygosity, Pten heterozygous  
PTEN<sup>C124S</sup>: catalytically inactive PTEN  
Pten<sup>Wt</sup>: hypomorphic Pten mutant  
Pten<sup>pc<sub>+/−</sub></sup>: Pten prostate-specific knockout  
Pten<sup>pc<sub>−/−</sub></sup>: Pten prostate-specific wild-type  
PTEN<sup>WT</sup>: PTEN wild-type  
PTEN: Phosphatase and tensin homolog  
Put: Putrescine  
PZ: Peripheral Zone  
RAD001: Everolimus  
RAFT: rapamycin and FKBP12 target  
Rapa, R: Rapamycin  
RAPTOR: Regulatory-associated protein of mammalian Target Of Rapamycin  
REDD1: Damage-inducible transcript 4 protein (DDIT4)  
RICCTOR: Rapamycin-insensitive Companion of mammalian Target Of Rapamycin  
RIPA: RadioImunoPrecipitation Assay buffer  
RNA: Ribonucleic Acid  
ROS: Reactive Oxygen Species  
RP: Radical Prostatectomy  
RT: Retention Time  
RT: Room Temperature  
RTK: Receptor Tyrosine Kinase  
RT-QPCR: Real Time-Quantitative-Polymerase Chain Reaction  
S6K: Ribosomal Protein S6 Kinase  
SAH: S-adenosylhomocysteine  
Sahh: Murine S-adenosylhomocysteine hydrolase  
SAM: S-adenosylmethionine  
SAM486A: (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene) hydrazinecarboximidamide dihydrochloride  
Sardh: Sarcosine dehydrogenase  
SCD1: stearoyl-CoA desaturase 1  
Ser: Serine, S  
SGK1: Glucocorticoid-induced Protein Kinase 1  
SH2: Src-homology 2  
SHIPI: Src-homology 2 (SH2)-containing phosphatase 1  
SHIP2: Src-homology 2 (SH2)-containing phosphatase 2  
shRNA: short-hairpin RNA
Abbreviations

**shSC**: short-hairpin Scramble

**SLC**: solute carrier

**Slc3a2**: Murine Solute Carrier Family 3 Member 2

**SMO**: Spermine Oxidase

**SN**: Supernatant

**SNP**: Single-nucleotide Polymorphism

**Spd**: Spermidine, N-(3-aminopropyl)butane-1,4-diamine

**SpdS**: Spermidine Synthase

**Spm**: Spermine, N,N′-bis(3-aminopropyl)butane-1,4-diamine

**SpmS**: Spermine Synthase

**SRS**: Snyder-Robinson syndrome

**SSAT1/Ssat1**: Human/Murine Spermidine/spermine N1-acetyltransferase

**Std Er**: Standard Error

**T**: Torin-1

**TBS-T**: Tris-Buffered Saline solution containing Tween-20

**TCA (solution)**: Trichloroacetic acid

**TCA**: Tricarboxylic Acid Cycle

**TCEP**: tris(2-carboxyethyl)phosphine

**TG**: Triglyceride

**THF**: Tetrahydrofolate

**Thr**: Threonine, T

**TNM**: Tumor, Node, Metastasis

**ToF-MS**: Time-of-Flight Mass Spectrometry

**TRAMP**: transgenic adenocarcinoma of the mouse prostate

**TRRAP**: Transformation/Transcription Domain Associated Protein

**TSC2**: Tuberous Sclerosis 2 Protein

**t-SSAT1**: truncated SSAT1

**TURP**: Trans-Urethral Resection of the Prostate

**TZ**: Transition Zone

**ULK1/2**: serine/threonine-protein kinase ULK1/2

**uORF**: upstream Open Reading Frame

**UPLC-MS**: Ultra-high Performance Liquid-Cromatography coupled to Mass Spectrometry

**UPR**: Unfolded Protein Response

**UTR**: Untranslated Region

**V**: Vehicle

**Val**: Valine, V

**VP**: Ventral Prostate

**WHO**: World Health Organization

**WT**: Wild-Type

**XIC**: Extracted Ion Chromatogram
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMMARY</td>
<td>.................................</td>
<td>37</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>.................................</td>
<td>37</td>
</tr>
<tr>
<td>I CANCER</td>
<td>.................................</td>
<td>39</td>
</tr>
<tr>
<td>I.1 CANCER HALLMARKS AND TUMOR PROGRESSION</td>
<td>.................................</td>
<td>39</td>
</tr>
<tr>
<td>II PROSTATE CANCER</td>
<td>.................................</td>
<td>41</td>
</tr>
<tr>
<td>II.1 HUMAN AND MURINE PROSTATE PHYSIOLOGY</td>
<td>.................................</td>
<td>41</td>
</tr>
<tr>
<td>II.2 PROSTATE CANCER PROGRESSION MODEL</td>
<td>.................................</td>
<td>43</td>
</tr>
<tr>
<td>II.3 PROSTATE CANCER PATHOLOGY AND TREATMENT</td>
<td>.................................</td>
<td>44</td>
</tr>
<tr>
<td>II.3.1 PROSTATE CANCER PATHOLOGY</td>
<td>.................................</td>
<td>44</td>
</tr>
<tr>
<td>II.3.2 PROSTATE CANCER TREATMENT</td>
<td>.................................</td>
<td>46</td>
</tr>
<tr>
<td>III PI3K PATHWAY AND CANCER</td>
<td>.................................</td>
<td>46</td>
</tr>
<tr>
<td>III.1 PI3K PATHWAY</td>
<td>.................................</td>
<td>46</td>
</tr>
<tr>
<td>III.1.1 STRUCTURAL AND BIOCHEMICAL CHARACTERISTICS OF CLASS I PI3K</td>
<td>.................................</td>
<td>46</td>
</tr>
<tr>
<td>III.1.2 SIGNALING DOWNSTREAM CLASS I PI3K</td>
<td>.................................</td>
<td>47</td>
</tr>
<tr>
<td>III.1.3 KEY MEDIATORS DOWNSTREAM PI3K</td>
<td>.................................</td>
<td>48</td>
</tr>
<tr>
<td>III.1.3.1 AKT</td>
<td>.................................</td>
<td>48</td>
</tr>
<tr>
<td>III.1.3.2 mTOR</td>
<td>.................................</td>
<td>49</td>
</tr>
<tr>
<td>III.1.3.3 PTEN</td>
<td>.................................</td>
<td>50</td>
</tr>
<tr>
<td>III.2 PI3K PATHWAY Deregulation in Cancer</td>
<td>.................................</td>
<td>51</td>
</tr>
<tr>
<td>III.3 Genetic Models of <em>Pten</em> Loss in Vivo</td>
<td>.................................</td>
<td>52</td>
</tr>
<tr>
<td>III.3.1 Genetic Models of <em>Pten</em> Germline Mutations</td>
<td>.................................</td>
<td>53</td>
</tr>
<tr>
<td>III.3.2 Genetic Models of Prostate-Specific <em>Pten</em> Deletion</td>
<td>.................................</td>
<td>53</td>
</tr>
<tr>
<td>IV METABOLIC Deregulation and CANCER</td>
<td>.................................</td>
<td>55</td>
</tr>
<tr>
<td>IV.1 Warburg Effect</td>
<td>.................................</td>
<td>55</td>
</tr>
<tr>
<td>IV.2 1C METABOLISM</td>
<td>.................................</td>
<td>56</td>
</tr>
<tr>
<td>IV.3 Other Metabolic Alterations</td>
<td>.................................</td>
<td>56</td>
</tr>
<tr>
<td>V POLYAMINES</td>
<td>.................................</td>
<td>57</td>
</tr>
<tr>
<td>V.1 Definition of Polyamines</td>
<td>.................................</td>
<td>57</td>
</tr>
<tr>
<td>V.2 Polyamine Functions</td>
<td>.................................</td>
<td>58</td>
</tr>
<tr>
<td>V.2.1 Regulation of Gene Expression</td>
<td>.................................</td>
<td>58</td>
</tr>
<tr>
<td>V.2.2 Control of Cell Proliferation</td>
<td>.................................</td>
<td>58</td>
</tr>
</tbody>
</table>
MATERIALS AND METHODS ........................................................................... 75

I  IN VIVO AND EX VIVO ASSAYS .................................................................. 77

I.1  ANALYSIS OF TISSUE SAMPLES ................................................................. 77
I.1.1  ANALYSIS OF MURINE SAMPLES ............................................................ 77
I.1.1.1  Genetically engineered mouse models (GEMM) ............................. 77
I.1.1.2  Xenograft models in nude mice ....................................................... 77
I.1.1.2.1  AMD1 OE in vivo ......................................................................... 78
I.1.1.2.2  AMD1 Silencing in vivo ................................................................. 78
I.1.1.3  Preclinical trials ................................................................................ 78
I.1.1.3.1  RAD001 treatment in vivo ............................................................ 78
I.1.1.3.2  SAM486A treatment in vivo .......................................................... 79
I.1.1.3.3  Methionine restriction in vivo ....................................................... 79
I.1.2  ANALYSIS OF HUMAN SPECIMENS ..................................................... 80
I.2  METHODS .................................................................................................. 81
I.2.1  GENOTYPING ....................................................................................... 81
I.2.1.1  Genomic DNA purification from mouse tail .................................... 81
I.2.1.2  Polymerase Chain Reaction (PCR) for genotyping ......................... 82
I.2.2  PATHOLOGICAL ANALYSIS OF PROSTATE TISSUES ...................... 83
I.2.2.1  Tissue processing, paraffin embedding and sectioning .................... 83
I.2.2.2  Slide processing for immunohistochemistry .................................... 83
I.2.2.2.1 Haematoxylin and Eosin (H&E) staining ....................................... 84
I.2.2.2.2 Ki67 and RpS65235-236 staining .................................................. 84
I.2.2.2.3 AMD1 staining and scoring .......................................................... 84
I.2.3  MOLECULAR ANALYSIS OF PROSTATE TISSUES .......................... 85
# Index

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.2.3.1 Gene expression analysis of murine prostate tissues</td>
<td>85</td>
</tr>
<tr>
<td>I.2.3.2 Protein expression analysis of murine prostate tissues</td>
<td>85</td>
</tr>
<tr>
<td>I.2.4 Metabolomic Analysis of Murine Prostate tissues</td>
<td>85</td>
</tr>
<tr>
<td>I.2.4.1 Time of Flight-Mass Spectrometry (ToF-MS)</td>
<td>85</td>
</tr>
<tr>
<td>I.2.4.2 Liquid Chromatography-Mass Spectrometry (LC/MS)</td>
<td>86</td>
</tr>
<tr>
<td>I.2.4.3 Targeted metabolomics by UPLC-MS</td>
<td>86</td>
</tr>
<tr>
<td>I.2.4.4 Metabolic Flux Analysis (MFA)</td>
<td>86</td>
</tr>
<tr>
<td>II IN VITRO ASSAYS</td>
<td>87</td>
</tr>
<tr>
<td>II.1 MATERIALS</td>
<td>87</td>
</tr>
<tr>
<td>II.1.1 Cell lines and culture conditions</td>
<td>87</td>
</tr>
<tr>
<td>II.1.2 Drugs</td>
<td>88</td>
</tr>
<tr>
<td>II.2 METHODS</td>
<td>89</td>
</tr>
<tr>
<td>II.2.1 Cloning</td>
<td>89</td>
</tr>
<tr>
<td>II.2.2 Virus production and target cell line infection</td>
<td>91</td>
</tr>
<tr>
<td>II.2.2.1 Transient transfection in HEK293 cells</td>
<td>92</td>
</tr>
<tr>
<td>II.2.2.2 Lentivirus production and target cell-line infection</td>
<td>93</td>
</tr>
<tr>
<td>II.2.2.2.1 Second Generation Lentivirus production</td>
<td>93</td>
</tr>
<tr>
<td>II.2.2.2.2 Third Generation Lentivirus production</td>
<td>94</td>
</tr>
<tr>
<td>II.2.2.2.3 Constitutive Silencing of AMD1</td>
<td>96</td>
</tr>
<tr>
<td>II.2.2.2.4 Inducible AMD1 silencing</td>
<td>96</td>
</tr>
<tr>
<td>II.2.2.3 Retrovirus production and target cell-line infection</td>
<td>96</td>
</tr>
<tr>
<td>II.2.3 CELLULAR ANALYSIS</td>
<td>98</td>
</tr>
<tr>
<td>II.2.3.1 Cell-growth analysis by crystal violet staining</td>
<td>98</td>
</tr>
<tr>
<td>II.2.3.2 Anchorage-independent growth (Soft agar)</td>
<td>98</td>
</tr>
<tr>
<td>II.2.3.3 Foci formation assay</td>
<td>98</td>
</tr>
<tr>
<td>II.2.3.4 DNA synthesis rate analysis by bromodeoxyuridine (BrdU)</td>
<td>99</td>
</tr>
<tr>
<td>II.2.3.4.1 BrdU Incorporation</td>
<td>99</td>
</tr>
<tr>
<td>II.2.3.4.2 BrdU exposure and detection by immunofluorescence (IF)</td>
<td>99</td>
</tr>
<tr>
<td>II.2.3.5 Cell cycle analysis</td>
<td>99</td>
</tr>
<tr>
<td>II.2.4 MOLECULAR ASSAYS</td>
<td>100</td>
</tr>
<tr>
<td>II.2.4.1 Gene expression analysis</td>
<td>100</td>
</tr>
<tr>
<td>II.2.4.1.1 RNA extraction and retrotranscription</td>
<td>100</td>
</tr>
<tr>
<td>II.2.4.1.2 Real time quantitative PCR (RT-Q-PCR)</td>
<td>100</td>
</tr>
<tr>
<td>II.2.4.2 Protein expression analysis</td>
<td>101</td>
</tr>
<tr>
<td>II.2.4.2.1 Protein extraction</td>
<td>101</td>
</tr>
<tr>
<td>II.2.4.2.2 Western Blotting (WB)</td>
<td>102</td>
</tr>
<tr>
<td>II.2.4.2.3 Protein Immunoprecipitation (IP) Assay</td>
<td>102</td>
</tr>
<tr>
<td>II.2.4.2.4 AMD1 translation rate by 35S-Met labelling</td>
<td>103</td>
</tr>
<tr>
<td>II.2.4.2.5 Polysome Profiling</td>
<td>103</td>
</tr>
<tr>
<td>II.2.4.2.5.1 Sample extraction</td>
<td>104</td>
</tr>
<tr>
<td>II.2.4.2.5.2 Sample processing</td>
<td>105</td>
</tr>
<tr>
<td>II.2.4.2.6 Phosphoproteomics</td>
<td>105</td>
</tr>
<tr>
<td>II.2.4.2.6.1 Sample Preparation</td>
<td>105</td>
</tr>
</tbody>
</table>
I INTEGRATIVE METABOLIC STUDY TO UNCOVER METABOLIC ALTERATIONS UNDERLYING PROSTATE CANCER (PCA) ......................................................... 111

I.1 TOF-MS METABOLOMICS. ............................................................. 114
I.1.1 Tricarboxylic Acid Cycle (TCA) .............................................. 115
I.1.2 Amino Sugar Synthesis Pathway ........................................... 117
I.1.3 Branched Chain Amino Acid (BCAA) Metabolism ......................... 117
I.1.4 Serine, Glycine (Gly) and one-carbon (1C) Metabolism ................ 117
I.1.2 LC/MS METABOLIC STUDY TO QUANTIFY METABOLIC ALTERATIONS IN PCA .......................................................... 121
I.1.2.1 LC/MS metabolomics in murine samples ................................ 121
I.1.2.1.1 Branched chain amino-acid metabolism ............................... 121
I.1.2.1.2 Urea cycle ........................................................................ 121
I.1.2.1.3 Methionine cycle .............................................................. 121
I.1.2.1.4 Trans-sulphuration reactions ........................................... 123
I.1.2.1.5 Polyamine synthesis and catabolism pathways ..................... 123
I.1.2.2 LC/MS metabolic study to validate GEMM findings in human prostate cancer specimens 124
I.1.3 IN VIVO\(^{13}\)C-LABELED METHIONINE MFA ........................................ 127
I.1.3.1 Pilot experiment of\(^{13}\)C\(_5\) labeled metabolic flux analysis (MFA) to establish the experimental settings for in vivo analysis .................................................. 127
I.1.3.2 In vivo \(^{13}\)C-labeled methionine MFA demonstrates the increased flux of methionine towards polyamine metabolism in PCa ................................................. 128

II ELUCIDATION OF THE MECHANISM OF ACTION UNDERLYING THE METABOLIC ALTERATIONS OBSERVED IN PCA ......................................................................... 135

II.1 EVALUATION OF TRANSCRIPTIONAL CHANGES AS DRIVERS OF THE POLYAMINE METABOLIC SWITCH ....135
II.1.1 TRANSCRIPT ANALYSIS OF GENES WITHIN THE METHIONINE/POLYAMINE AND RELATED PATHWAYS .... 135
II.1.1.1 Gene expression of polyamine metabolism-related enzymes ........ 135
II.1.1.2 Gene expression of enzymes implicated in polyamine catabolism .................................................................................. 136
II.1.1.3 Gene expression of folate metabolism related enzymes ............. 138
II.2  EVALUATION OF POST-TRANSCRIPTIONAL CHANGES AS DRIVERS OF THE POLYAMINE METABOLIC SWITCH

II.2.1  ANALYSIS OF AMD1 PROTEIN LEVELS IN PTEN+/− vs. PTEN−/− MICE.................................................. 146
II.2.2  REGULATION OF AMD1 DOWNSTREAM PTEN ................................................................. 147
II.2.3  DECONSTRUCTION OF PI3K CASCADE BY PHARMACOLOGICAL INHIBITION ............... 148
II.2.4  PRECLINICAL TRIAL OF RAD001 TO VALIDATE mTORC1 REGULATION OF AMD1 IN VIVO ... 152
II.2.5  MOLECULAR MECHANISM OF REGULATION OF AMD1 DOWNSTREAM mTORC1 ...... 153
II.2.5.1  Regulation through ODC1 upregulation and putrescine increase .................................. 154
II.2.5.2  Regulation through increased autophagy ................................................................. 156
II.2.5.3  Regulation through translation initiation control ...................................................... 157
II.2.5.4  Regulation of proAMD1 stability ............................................................................. 158
II.2.5.5  mTORC1 regulation of AMD1 levels through direct phosphorylation ...................... 159
II.2.6  TARGETS DOWNSTREAM AMD1 .................................................................................. 161

RESULTS AND DISCUSSION ........................................................................................................ 168

III  ANALYSIS OF THE THERAPEUTIC POTENTIAL OF TARGETING AMD1 AND EVALUATION OF PROSPECTIVE THERAPIES ........................................................................... 169

III.1  ANALYSIS OF THE THERAPEUTIC POTENTIAL OF TARGETING AMD1 ................................................. 169
III.1.1  GENETIC MODULATION OF AMD1 LEVELS IN VITRO ............................................................. 169
III.1.1.1  Ectopic expression of AMD1 by lentiviral transduction .................................................. 169
III.1.1.2  AMD1 silencing by lentiviral transduction. ................................................................. 170
III.1.1.3  Pharmacological modulation of AMD1 levels in vitro .................................................. 174
III.1.2  AMD1 MODULATION IN VIVO ....................................................................................... 175
III.1.2.1  AMD1 ectopic expression in vivo ................................................................................ 175
III.1.2.2  AMD1 silencing in vivo ............................................................................................ 176

III.2  EVALUATION OF POTENTIAL THERAPIES .............................................................................. 178
III.2.1  NUTRITIONAL MODULATION ....................................................................................... 178
III.2.2  SAM486A PRECLINICAL TRIAL .................................................................................. 184
III.2.3  ANALYSIS OF AMD1 LEVELS IN A CLINICAL TRIAL OF RAD001 .............................. 188

GENERAL DISCUSSION .............................................................................................................. 193

I  THE REVOLUTION OF OMICS: MILESTONES AND REMAINING CHALLENGES IN CANCER RESEARCH ............................................................................................................. 195
OMICS DEVELOPMENT AND CANCER RESEARCH .................................................................195
CHALLENGES AND FUTURE PROSPECTS OF METABOLOMICS IN EUKARYOTES .................196

II THE INTERPLAY OF MTORC1 SIGNALING AND POLYAMINE METABOLISM IN CANCER AND BEYOND .......................................................... 198

THE CROSSTALK BETWEEN SIGNALING AND METABOLISM IN CANCER ..........................................................198
SIGNALING-METABOLISM CROSSTALK BEYOND CANCER .................................................200

III AMD1 AS A PREDICTIVE BIOMARKER AND TARGET IN ProSTATE CANCER ............... 202

CONCLUSIONS ....................................................................................................................206

BIBLIOGRAPHY .................................................................................................................... 210
INTRODUCTION
Figure I1. Representation of the multi-step tumor progression model. .................................................................39
Figure I2. Schematic representations showing the revisited hallmarks of cancer by Hanahan and Weinberg, 2011. .................................................................40
Figure I3. Anatomy and histology of male human and murine reproductive system. ...............................................42
Figure I4. Schematic showing the prostate cancer progression model. .................................................................43
Figure I5. Grading systems employed for histopathological evaluation of prostate cancer. ............................47
Figure I6. Schematic depicting domain structure of the catalytic and regulatory subunits of class I PI3Ks. .............48
Figure I7. Signaling downstream class I PI3Ks. ....................................................................................................49
Figure I8. mTOR forms two distinct complexes .................................................................................................50
Figure I9. Prostate-specific Pten knockout mouse model. ...................................................................................54
Figure I10. Role of polyamines in cell physiology ............................................................................................59
Figure I11. Methionine cycle and polyamine pathway connection. .....................................................................61
Figure I12. Putative mechanism models for polyamine uptake, accumulation and sequestration into vesicles in mammalian cells. ...........................................62
Figure I13. Ornithine decarboxylase 1 (ODC1) and antizyme (AZ) regulation. ....................................................64
Figure I14. AMD1 processing mechanism. ........................................................................................................65
Figure I15. Different levels of AMD1 regulation .................................................................................................66

MATERIALS AND METHODS
Figure M1. Schematic showing the experimental design of the RAD001 preclinical trial. .....................................78
Figure M2. Schematic showing the experimental design of the SAM486A preclinical trial. ..............................79
RESULTS AND DISCUSSION I

FigureR1....................................................................................................................112
General experimental design of *in vivo* experiments.
FigureR2....................................................................................................................113
Experimental design of the integrative metabolomic study.
RESULTS AND DISCUSSION II

Figure R3.................................................................................................................................116
ToF-MS study unraveled increasing number of metabolic alterations through PCa development.

Figure R4............................................................................................................................................118
ToF-MS enrichment analysis uncovered alterations in amino sugar synthesis pathway, BCAA metabolism, TCA and Ser and Gly metabolism in PCa pathogenesis.

Figure R5............................................................................................................................................120
The inclusion criteria established narrowed the number of consistently altered metabolites.

Figure R6............................................................................................................................................122
LC/MS analysis confirmed the altered metabolic pathways detected by ToF-MS.

Figure R7............................................................................................................................................123
Diagram summarizing the main metabolic alterations observed by LC/MS.

Figure R8............................................................................................................................................125
LC/MS analysis of PCa patients’ specimens compared to BPH samples confirmed the metabolic alterations observed in the PCa GEMM.

Figure R9............................................................................................................................................126
Diagram summarizing the main metabolic alterations observed by LC/MS in PCa patients’ specimens

Figure R10............................................................................................................................................127
Experimental design of in vivo MFA pilot experiment.

Figure R11............................................................................................................................................128
In vivo flux pilot experiment to set up optimal conditions.

Figure R12............................................................................................................................................129
Experimental design of in vivo metabolic flux experiment.

Figure R13............................................................................................................................................130
The in vivo metabolic flux experiment confirmed in a dynamic setting the increased flux towards polyamine synthesis pathway through SAM decarboxylation.

Figure R14............................................................................................................................................130
The fractional labeling data from the in vivo MFA experiment reinforces the rewiring towards SAM decarboxylation and polyamine synthesis.

Figure R15............................................................................................................................................131
Diagram summarizing the main metabolic alterations observed in the in vivo U-13C5-methionine MFA experiment by LC/MS.

Figure R16............................................................................................................................................137
Transcript analysis of the expression levels of enzymes involved in 1C metabolism and polyamine synthesis pathways.
Phosphorylation of residue S298 in proAMD1 decreases its stability and processing.

**Figure R34.** proAMD1 phosphorylation in S298 residue is decreased upon mTORC1 inhibition.

mTORC1 regulates stability of proAMD1.

**Figure R27.** mTORC1 downstream PI3K regulates AMD1 at protein levels.

mTORC1 regulation of AMD1 is conserved in vivo.

**Figure R28.** Hypothetical means of AMD1 regulation downstream mTORC1.

mTORC1 regulates AMD1 protein expression.

**Figure R25.** mTORC1 regulates dcSAM production.

mTORC1 downstream PI3K regulates AMD1 at protein levels.

**Figure R27.** mTORC1 regulation of AMD1 is conserved in vivo.

mTORC1 regulation of AMD1 does not depend on ODC1 nor on putrescine levels.

**Figure R30.** mTORC1 does not regulate AMD1 through autophagy induction.

mTORC1 does not regulate initiation of AMD1 translation.

**Figure R32.** mTORC1 regulates stability of proAMD1.

proAMD1 phosphorylation in S298 residue is decreased upon mTORC1 inhibition.

**Figure R34.** Phosphorylation of residue S298 in proAMD1 decreases its stability and processing.
RESULTS AND DISCUSSION III

mTORC1 phosphorylates proAMD1 in residue S298 increasing its stability and allowing its processing.

Proteomic study to elucidate the mechanistic program induced downstream AMD1.

AMD1 inhibition and silencing induce a proteomic profile regulated by MYC, which shows similarity with profiles obtained upon mTORC1 inhibition.

MYC levels correlate with AMD1 levels.

AMD1 under the regulation of mTORC1 might induce a transcriptional program controlled by c-MYC.

Figure Index

FigureR35..................................................................................................................161

FigureR36..................................................................................................................162

FigureR37..................................................................................................................163

FigureR38..................................................................................................................164

FigureR39..................................................................................................................165

FigureR40..................................................................................................................170

Impact of AMD1 over-expression in PCa growth.

FigureR41..................................................................................................................171

Impact of constitutive AMD1 silencing in PCa growth in DU145 cells.

Figure R42. .............................................................................................................171

Impact of constitutive AMD1 silencing in PCa growth in PC3 cells.

FigureR43..................................................................................................................172

Impact of inducible AMD1 silencing in PCa growth.

FigureR44..................................................................................................................173

Rescue experiment to revert the phenotype upon inducible AMD1 silencing.

FigureR45..................................................................................................................174

Impact of pharmacological AMD1 inhibition with SAM486A in PCa growth.

FigureR46..................................................................................................................175

Impact of AMD1 over-expression in PCa oncogenicity in vivo.

FigureR47..................................................................................................................177

Impact of inducible AMD1 silencing in PCa oncogenicity in vivo.

FigureR48..................................................................................................................180

Impact of short-term methionine restriction in PCa metabolism in vivo.

FigureR49..................................................................................................................181

Impact of short-term methionine restriction in PCa metabolism in vivo.

FigureR50..................................................................................................................182

Impact of long-term methionine restriction in PCa metabolism in vivo.

FigureR51..................................................................................................................183

Impact of long-term methionine restriction in PCa metabolism in vivo.
Figure Index

Figure R52. Impact of pharmacological AMD1 inhibition with SAM486A in PCa oncogenicity in vivo. .................................185
Figure R53. Impact of pharmacological AMD1 inhibition with SAM486A in PCa metabolism. ........................................186
Figure R54. Impact of pharmacological mTORC1 inhibition with RAD001 on AMD1 levels in a clinical trial. .........................189
Figure R55. Impact of pharmacological mTORC1 inhibition with RAD001 on AMD1 levels in a clinical trial. .........................190

GENERAL DISCUSSION

Figure D1. Schematic representation of polyamine pools according to the observed in Pten pc-/- mice and upon AMD1 inhibition with SAM486A. .................................................................197
Figure D2. Schematic representation of the hypothesis postulating increased flux through polyamine pathway in prostate cancer. .................................................................................................197
Figure D3. Scheme depicting the anabolic processes regulated downstream mTORC1, including AMD1 regulation and polyamine production. ..............................................................199
Figure D4. Interplay between PI3K-mTORC1 signaling and polyamine levels. .................................................................201
SUMMARY

Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cell growth, proliferation and promote cancer initiation and progression. In this thesis work we describe a novel molecular mechanism by which mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. Through the integrative metabolomics analysis of a mouse model and human biopsies of prostate cancer, we identified alterations in tumors impacting on the production of decarboxylated S-Adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, we demonstrate that this metabolic rewiring stems from mTORC1-mediated post-transcriptional control of S-Adenosylmethionine decarboxylase 1 (AMD1). This novel molecular regulation was pharmacologically validated in samples from murine pre-clinical and human clinical trials with Everolimus. Importantly, we demonstrate that manipulation of AMD1 levels and activity dictates prostate cancer oncogenicity. The results in this thesis provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Introduction
I CANCER

Cancer refers to the uncontrolled proliferation of cells that leads to the formation of an abnormal cellular mass, denominated tumor. This term encompasses more than 100 different forms of the disease, as virtually every tissue can spawn one or more cancer types (Weinberg, 1996). Importantly, each of them requires unique diagnosis and treatment. Nevertheless, a common shared feature of tumors is the aberrant proliferation of malignant or transformed cells (Hanahan and Weinberg, 2000).

According to the World Health Organization (WHO, data collected by the International Agency for Research in Cancer (IARC) on the last Globocan 2012 report), cancer is one of the leading causes of morbidity and mortality worldwide. Indeed, more than 8 million people die from cancer every year, which covers 13% of all deaths worldwide. Of note, new cancer cases are estimated to increase in a 70% over the next two decades (http://www.who.int/cancer/en/). In Europe, 3.5 million new cases were estimated in 2012. The most common cancer types were breast (13.5%), colorectal (13%), prostate (12.1%) and lung (11.9%), representing 50.5% of the overall estimated burden of cancer in Europe in 2012 (Ferlay et al., 2013). All these key facts underscore the need and relevance for cancer research.

I.1 Cancer hallmarks and tumor progression

After decades of research, cancer is widely accepted as a primarily genetic disease (Vogelstein and Kinzler, 2004). Cancer development is a sequential, multistep and complex process of mutations that accumulate leading to transformation and clonal expansion of cells (3 to 7 mutagenic events are suggested to be required) (Vogelstein and Kinzler, 1993; Hahn and Weinberg, 2002). Multiple studies performing comparative analysis of genetic alterations in early versus late stage tumors support this notion (Yokota, 2000). Subsequent genetic and epigenetic alterations would convert normal cells into premalignant cells, premalignant cells into transformed cells and transformed cells into metastatic cells (Fig. I1). Thus, this progressive accumulation of

Adapted from Stratton MR, Campbell PJ and Futreal PA, Nat Rev 2009

Figure I1. Representation of the multi-step tumor progression model.
alterations would imply increasing malignancy and aggressiveness of the tumor (Nowell, 2002). The cumulative nature of this process and the monoclonal and polyclonal expansion of transformed cells, in turn supports the heterogeneity of primary and metastatic tumors (Yokota, 2000).

There are three type of genes whose alteration is considered relevant to tumorigenesis: oncogenes, tumor-suppressor genes and genomic stability genes. Both gain of function alterations of oncogenes and loss of function alterations of tumor-suppressor genes lead to uncontrolled proliferation of cells driving the neoplastic process. Alterations in the third group of genes lead to increased mutation rate, which can affect the function of oncogenes and tumor suppressors (Nowell, 2002; Vogelstein and Kinzler, 2004).

In an effort to unify and identify common features of cancer cells, Hanahan and Weinberg proposed, more than a decade ago, six capabilities that a cell must acquire to engage malignant growth: i) self-sufficiency of growth signals, ii) insensitivity to growth-inhibitory signals, iii) evasion of apoptosis, iv) limitless replicative potential, v) sustained angiogenesis and vi) tissue invasion and metastasis (Hanahan and Weinberg, 2000). In order to acquire these capabilities, it was postulated that cells would need to acquire an enabling characteristic: genome instability (consequence of the malfunction of genomic integrity control mechanisms), hence increasing mutation rate (Nowell, 2002). With the intense research in the field during the following decade, increased knowledge regarding tumor initiation, progression and dissemination led to revisiting

\[ Adapted \text{ from Hanahan D and Weinberg RA, Cell Rev 2011 } \]
these hallmarks. Together with the aforementioned genomic instability, the inflammatory state of premalignant and malignant cells arose as a second enabling characteristic. Indeed, cells of the immune system were suggested to act as promoters of tumor progression by producing growth, survival and angiogenic factors, extracellular matrix-modifying enzymes, epithelial-mesenchimal transition (EMT)-inducing signals and reactive oxygen species (ROS) in the tumor microenvironment (Hanahan and Weinberg, 2011). Importantly, two other capabilities of cancer cells were introduced in the list of cancer hallmarks due to their relevance in the development of the disease: avoiding immune destruction and reprogramming energy metabolism. Increasing evidence supports the notion that deregulation of metabolism is a direct response to growth factor signaling (Ward and Thompson, 2012) (Fig. I2).

II PROSTATE CANCER
II.1 Human and murine prostate physiology

The prostate is part of the male reproductive system, and is the largest accessory gland in the body (Bhavsar et al., 2014). The glandular tissue of the prostate secretes an alkaline fluid that helps maintain sperm motility. The smooth muscle of the prostate gland contracts during ejaculation to contribute to the expulsion of semen from the urethra (Scandalon VC and Sanders T, 2007). For further comprehension of this work we will describe in depth the anatomic and histological characteristics of human and murine prostate.

The human prostate gland is about 3 cm high by 4 cm wide by 2 cm deep, about the size of a walnut, and it is located just below the urinary bladder. It is conical in shape and surrounds the first 2.5 cm of the urethra as it emerges from the bladder (Scandalon VC and Sanders T, 2007) (Fig. I3A-B). The human prostate is a single organ that forms a pseudocapsule consisting of glandular and stromal elements (Bhavsar et al., 2014). In humans, this gland is organized in four zones following the branching pattern of the prostate ducts: the central (CZ), which surrounds the urethra; the transition zone (TZ), anterior to the urethra, the peripheral (PZ), posterior to the urethra and the fibromuscular stroma that separates the prostate from the rectum (Knoblaugh and True, 2012) (Fig. I3C). The PZ is relatively accessible for transrectal biopsies to sample the prostate for prostatic adenocarcinoma. The PZ is the largest of the zones, encompassing approximately 70% of the glandular tissue, while the CZ and the PZ account for approximately 25% and 5% of the glandular tissue, respectively (Bhavsar et al., 2014).

The mouse prostate gland is divided into three distinct lobes: the dorsolateral lobe (DLP), which has butterfly shape and surrounds the urethra; the ventral (VP), leaf-shaped, gelatinous and located above the urethra and toward midline; and the anterior lobes (AP), located cranial to the other lobes and attached to the lesser curvature of the seminal vesicles (Knoblaugh and True, 2012) (Fig. I3D). Histologically, each of the lobes is surrounded by a thin mesothelium-lined
delicate capsule. The glandular prostate is separated from the capsule by loose fibroadipose tissue containing major vessels, nerves, and ganglia. The individual mouse prostate lobes are composed of a series of branching ducts, which are formed by few layers of spindle cells and eosinophilic collagen (Shappell et al., 2004). The individual murine prostate lobes show distinctive histological features. The DLP is lined by cuboidal and columnar epithelium, with moderate infolding, granular cytoplasm with eosinophilic secretions and basally located uniform nuclei. The VP is mostly lined by cuboidal epithelium, with spare infolding, abundant homogeneous pale secretions and small basally located nuclei. The AP lobes are lined by cuboidal to columnar epithelium with a papillary pattern, contain granular cytoplasm with homogeneous eosinophilic secretions and centrally located nuclei (Knoblaugh and True, 2012).

Similarly, the human prostate ducts are constituted of cuboidal to columnar epithelium composed of a layer of basal cells and a luminal layer of differentiated secretory cells, with small subpopulations showing differentiated neuroendocrine (NE) phenotype, which represent less than 1% of prostate epithelial cells (Shappell et al., 2004; Knoblaugh and True, 2012) (Fig. I3E).

![Figure I3](http://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq)

Adapted from: Knoblaugh S and True L, Comparative Anatomy and Histology: A Mouse and Human Atlas, Elsevier 2012

Adapted from Shen MM and Abate-Shen C, Genes and Dev 2010

Figure I3. Anatomy and histology of male human and murine reproductive system. A, Picture of human anatomy showing the localization of the prostate gland. B, Picture of murine anatomy showing the different organs constituting the male reproductive system. C-D, Schematics of the anatomy of the different zones and lobes of human (C) and murine (D) prostates. E, Schematic depicting the different cellular types in a histological section of a human prostate duct.
Importantly, the individual prostate zones or lobes have different embryologic origins and can be distinguished not only by the appearance and anatomic features, but by the biological functions and susceptibility to pathology (Bhavsar et al., 2014). Of note, although the mouse DLP has sometimes been assessed as the most homologous to the human PZ, the developing lobes are identifiable only in the embryo in humans. Thus there is no supporting evidence nor consensus agreement among pathologists for a direct correlation between the specific mouse prostate lobes and the human prostate zones (Shappell et al., 2004). Furthermore, overall, the mouse prostate has a modest stromal component compared to that of the human prostate (Knoblaugh and True, 2012). Hence, there are fundamental anatomic differences between the human and murine prostates that should be considered when studying the neoplastic development of this organ.

II.2 Prostate cancer progression model

In spite of the anatomic and histological differences between the human and murine prostate structures, prostate cancer progression occurs in a strikingly similar manner in mice and humans (Nardella et al., 2010a).

Prostate cancer starts from the accumulation of genetic alterations in the epithelium of the prostatic gland, which leads to prostatic intraepithelial neoplasia (PIN) and can progress to high-grade prostatic intraepithelial neoplasia (HGPIN). The progressive accumulation of further genetic insults leads to more aggressive and malignant lesions, which thereby disrupt the basement membrane and invade the surrounding stroma, leading to an invasive carcinoma (Nardella et al., 2010). This carcinoma can stay confined in the prostate or invade other organs, causing metastasis and ultimately resulting in lethality (Abate-Shen and Shen, 2002) (Fig. I4).

PIN is characterized by cellular proliferating foci within preexisting ducts and acini with cytologic changes, such as nuclear and nucleolar enlargement. In this kind of premalignant neoplasia, inversion of the normal epithelial proliferation orientation occurs, cells proliferating from the basal cell compartment to the luminal space. PIN progresses into HGPIN, which is usually

---

Figure I4. Schematic showing the prostate cancer progression model.

Adapted from Abate-Shen C and Shen MM Trends in Gen 2002.
multicentric and is commonly found in the PZ. Early stromal invasion, which is the earliest evidence of carcinoma, occurs at sites with basal cell disruption in ducts with HGPIN (Bostwick et al., 2004). Cancer cells require the acquisition of another capability in order to survive upon loss of contact with the basement membrane, evasion of anoikis signals. Anoikis is a programmed cell death induced upon cell detachment from extracellular matrix. Resistance to this type of cell death is of vital importance in cancer progression (Paoli et al., 2013). Prostate cancer invariably metastasizes to bone, although lung, liver and pleura are secondary metastasis sites (Bubendorf et al., 2000).

II.3 Prostate cancer pathology and treatment

II.3.1 Prostate cancer pathology

According to the last Globocan 2012 report of the IARC, 1.1 million men were diagnosed of prostate cancer in 2012 worldwide and the disease caused 307,000 deaths (http://www.who.int/cancer/en/). This cancer type is the second most frequent and the fifth cause of death from cancer in men worldwide. In Europe it represents the most frequent cancer type in men, with 417,000 new cases and 92,000 deaths in 2012 (Ferlay et al., 2013).

Age is the main risk factor for prostate cancer. Indeed, it is estimated that approximately 95% of men older than 70 present benign prostatic hyperplasia (BPH) (Valkenburg and Williams, 2011). In the same line, PIN and HGPIN incidence positively correlate with age. Indeed, PIN shows a frequency of 9% and 22% in men in their 20s and 30s respectively (Bostwick et al., 2004). However, the etiologic factors related to prostate cancer are various and encompass, apart from the age, familiar history, race, diet, lifestyle factors and hormonal influences (Isaacs et al., 2002).

BPH usually arises from the TZ. In contrast, PIN and HGPIN are rarely seen in this zone (Shappell et al., 2004) and commonly occur in the PZ. Indeed, the PZ harbors the majority of prostate carcinomas (70%) (Abate-Shen and Shen, 2002). Based on the zonal difference in the incidence of BPH and prostate carcinoma and the fact that stromal cell proliferation is a major feature of BPH, this benign lesion is not contemplated as the precursor of prostatic invasive carcinoma. Instead, PIN is considered the precursor lesion of this disease (Isaacs et al., 2002). BPH histological alterations are very common in the TZ and show increasing incidence with age. Actually, BPH lesions have been observed in 80-90% of radical prostatectomies (RP) performed, while only 20% of significant prostate cancers (PCas) have their origin in the TZ (Shappell et al., 2004).
Prostate cancer is suspected on the basis of digital rectal examination (DRE) and/or prostate-specific antigen (PSA) levels (http://uroweb.org/individual-guidelines/oncology-guidelines/). PSA is a kallikrein-related serine protease produced in normal prostatic tissue with the physiological role of liquefying seminal fluid. However, this peptidase is also produced in BPH and PCa and is thought to be released into the blood due to disruption of normal prostate architecture, especially in PCa where basal layer of cells is lost (Lilja et al., 2008). However, definitive diagnosis depends on histological verification of carcinoma in prostate biopsies obtained by trans-urethral resection of the prostate (TURP) or prostatectomy (http://uroweb.org/individual-guidelines/oncology-guidelines/). These biopsies are histopathologically evaluated and classified according to two different methods, the Gleason Score and the TNM (Tumor, Node, Metastasis) system (Shen and Abate-Shen, 2010). The Gleason Score classifies the tumors according to the differentiation level (from 1 to 5) of their most prevalent architecture and assigns a combined score, calculated from the sum of the two most common patterns (Mellinger et al., 1967; Humphrey, 2004) (Fig. 15). The TNM system encompasses evaluation of the primary tumor status, from prostate-confined to invasive (T1-4), absence or presence of lymph node involvement (N0 or 1) and absence or presence and degree of metastasis (M0-1a-c) (Ohori et al., 1994; Shen and Abate-Shen, 2010) (Fig. 15).

Figure 15. Grading systems employed for histopathological evaluation of prostate cancer. A, Schematic picture depicting the histological patterns for prostate cancer grading according to Gleason Score system. B, Table describing the extent of primary tumor (T), lymph node involvement (N) and presence/absence of metastasis according to TNM grading system.
II.3.2 Prostate cancer treatment

Based on the DRE, PSA analysis and the histopathological evaluation of the biopsies, different therapeutic options are proposed to the patient following the *Guidelines on Prostate Cancer*, assessed by Urology Associations, and the treatment election is reached in agreement.

In general, the treatment options for prostate cancer comprise surgical excision of the prostate (RP), radiotherapy (irradiation through external beam therapy or implantation of radioactive “seeds” - brachytherapy), hormonal therapy (androgen deprivation therapy or chemical castration) and chemotherapy (docetaxel) (Shen and Abate-Shen, 2010).

In patients with low and intermediate risk PCa, RP or brachytherapy are normally the first-line therapy. Biochemical recurrence is considered when a gradual increase of PSA is observed after first line treatment. Then, chemical castration (androgen deprivation therapy) is suggested. In high risk PCa, RP or radiotherapy in combination with hormonal therapy is recommended. If the patient exhibits an increase of PSA or appearance of Fluorodeoxyglucose-PET (positron emission tomography) positive masses after androgen deprivation, alternative hormonal therapies or chemotherapy are recommended. Chemotherapy is usually the therapy of choice when cancer develops into metastasis. However, the therapeutic alternatives are subject to individual and personalized consideration. For those patients with low risk indolent prostate cancer, active surveillance is emerging as the main recommendation, with the aim of minimizing over-treatment and treatment-related side-effects (Wadman, 2015). According to this option, patients remain under close surveillance to decide on the therapeutic strategy if the cancer progresses (http://uroweb.org/individual-guidelines/oncology-guidelines/). Nevertheless, the lack of information on long-term outcome and biomarkers for eligibility criteria seeds uncertainty regarding this strategy (Chamie et al., 2015).

III PI3K PATHWAY AND CANCER

III.1 PI3K Pathway

Phosphoinositide 3-kinases (PI3Ks) are a family of conserved lipid kinases that catalyze the phosphorylation of the 3’-hydroxyl group of phosphatidylinositol and phosphatidylinositides (Katso et al., 2001). This reaction unleashes an array of intracellular signaling pathways implicated in the control of cellular proliferation, growth, survival, motility and metabolism (Thorpe et al., 2015).

III.1.1 Structural and biochemical characteristics of class I PI3K

PI3Ks are classified into three classes (I-III) according to substrate specificity and structure. Little is known about the functional role of class II and III PI3Ks. In mammals, class I PI3Ks are divided into two subfamilies depending on the receptor they respond to. Class IA PI3Ks are activated by
growth factor receptor tyrosine kinases (RTKs), while class IB PI3Ks are activated by G-protein-coupled receptors (GPCRs). We will focus on class IA PI3Ks for in-depth description.

Class IA PI3Ks are heterodimers composed of two subunits, the catalytic subunit p110 and the regulatory subunit p85, which maintains p110 with low activity in basal conditions and functions as an adaptor to couple it to activated protein tyrosine kinases (Hiles et al., 1992). There are three highly homologous catalytic subunit isoforms, p110α, p110β and p110δ, which associate with any of the five regulatory subunit isoforms: p85α, p55α, p50α, p85β and p55γ (Fig. I6).

III.1.2 Signaling downstream class I PI3K

Growth factors signal through receptor tyrosine kinases, which recruit scaffold and signaling proteins (including PI3K) through autophosphorylation of their C-terminal tail. p85-p110 heterodimer interacts with phosphorylated tyrosines in RTKs, gets activated and converts plasma membrane lipid phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2; PIP2] into phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3; PIP3]. This lipid phosphorylation is the signal for proteins that contain pleckstrin-homology (PH) domains, to be recruited to the plasma membrane and bind to PIP3 (Cantley, 2002). Examples of these proteins are serine-threonine kinase AKT (Protein kinase B, PKB) and phosphoinositide-dependent kinase 1 (PDK1). Once AKT is phosphorylated by PDK1 and mechanistic target of rapamycin (mTOR) complex 2 (mTORC2) and activated, it phosphorylates multiple downstream targets, including glycogen synthase kinase 3 (GSK3) and the forkhead box family of transcription factors (FOXOs). AKT also activates mTORC1 through phosphorylation of its upstream regulators srine-proline-rich AKT substrate40 KDa (PRAS40, activatory regulation) and tuberous sclerosis 2 protein (TSC2, inhibitory regulation) (Liu et al., 2009b). The control of the intensity and duration of this signaling pathway is controlled by three type of phosphatases. Src-homology 2 (SH2)-containing phosphatases (SHIP1 and SHIP2), inositol polyphosphate 4-phosphatase type II (INPP4B) and Phosphatase and tensin homolog (PTEN) dephosphorylate position 5, 4 or 3 of the inositol ring; respectively (Fig. I7).
III.1.3 Key mediators downstream PI3K

We will focus in key effectors downstream PI3K for the correct understanding of this work.

III.1.3.1 AKT

AKT or PKBα was first discovered in the genome of the retrovirus AKT-8 in murine T-cell lymphoma (Alessi et al., 1996). There are three AKT isoforms (AKT1/PKBα, AKT2/PKBβ and AKT3/PKBγ), all belonging to the cAMP-dependent, cGMP-dependent and protein kinase C (AGC) kinase family (Lawlor and Alessi, 2001). The three distinct isoforms are ubiquitously expressed in all cell and tissue types, although AKT3 seems to have a more restricted expression pattern (Toker and Yoeli-Lerner, 2006).

Upon binding to PIP3, AKT gets phosphorylated and activated by PDK1 and mTORC2, in turn phosphorylating a variety of downstream targets to regulate many different cellular processes (Cantley, 2002) (Fig. I7). AKT is known to promote cell survival by inhibiting pro-apoptotic proteins, such as Bcl-2-associated death promoter protein (BAD) (Datta et al., 1997), or by inhibiting the transcription factors FOXO1/3/4 and tumor protein p53 (p53) (Tran et al., 2003). In the same line, an important role has been attributed to AKT in cell growth and proliferation (Manning and Cantley, 2007). AKT was reported to activate mTORC1 (through the inhibition of the negative regulator TSC2 (Inoki et al., 2002; Manning et al., 2002)), as well as to inhibit cyclin-dependent kinase inhibitors Cyclin-dependent kinase inhibitor p27 (p27kip1) (Liang et al., 2002).
and Cyclin-dependent kinase inhibitor 1 (p21^{Cip1/WAF1cell}) (Zhou et al., 2001), to promote cell growth and proliferation. Through the regulation of the aforementioned and other targets, AKT has been also implicated in the regulation of angiogenesis, cellular metabolism and cell migration and invasion (Manning and Cantley, 2007). Importantly, germline deletion of AKT1 or AKT3 have been reported to result in growth defects in vivo (Engelman et al., 2006).

**III.1.3.2 mTOR**

mTOR was first discovered as the target complex of the immunosuppressant rapamycin, in complex with peptidyl-prolyl cis-trans isomerase FKBP12 (FKBP12), and it was therefore named rapamycin and FKBP12 target (RAFT) (Brown et al., 1994; Sabatini et al., 1994). This complex contains two components of 245KDa and 35KDa, which were designated RAFT1 and RAFT2 respectively. RAFT1 was found to show high homology with yeast proteins TOR1 and TOR2 and thereby it was considered the mammalian homolog of yeast TOR proteins (Sabatini et al., 1994).

mTOR is a serine/threonine protein kinase that belongs to the PI3K-related kinase (PIKK) family and forms two distinct complexes, mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2 by interacting with some shared and other specific proteins (Abraham and Gibbons, 2007). The shared components of both complexes are the catalytic mTOR subunit, mammalian lethal withsec-13 protein 8 (mLST8), DEP domain containing mTOR-interacting protein (DEPTOR) and the Tti1/Tel2 complex. However, while mTORC1 specifically interacts with regulatory-associated protein of mammalian target of rapamycin (RAPTOR) and proline-rich Akt substrate40 KDa (PRAS40), mTORC2 is formed of rapamycin-insensitive companion of mTOR (RICTOR), mammalian stress-activated map kinase-interacting protein 1 (mSin1) and protein observed with rictor 1 and 2 (protor1/2) (Laplante and Sabatini, 2012) (Fig. I8).

This kinase shows a phylogenetically conserved amino acidic sequence that consists of: up to 20 HEAT motifs repeated in tandem, a FAT [FRAP (FKBP12–rapamycin-associated protein)-ATM (ataxia telangiectasia mutated)-TRRAP (transactivation/transformation-domain-associated protein) complex] domain and the catalytic kinase domain, which contains a FKBP12-rapamycin binding (FRB) domain, a LST8-binding element (LBE) and a FATC (C terminus of FRAP-ATM-TRRAP complex) domain (Bjornsti and Houghton, 2004; Saran et al., 2015).

Contrary to mTORC1, the knowledge regarding the function and signaling cascade of mTORC2 is scarce. While insensitive to nutrients, this mTOR complex responds to growth factors through PI3K (Laplante and Sabatini, 2012). mTORC2 regulates cellular processes such us growth, proliferation, survival, metabolism, apoptosis, ion transport and cytoskeletal rearrangements through the direct phosphorylation of several AGC kinase subfamily members, including AKT, serum- and glucocorticoid-induced protein kinase 1 (SGK1) and protein kinase C-α (PKCα) (Saran et al., 2015). Although originally thought to be rapamycin insensitive, long term treatments have been shown to inhibit mTORC2 in a cell type-dependent fashion (Laplante and Sabatini, 2012).
The identification of rapamycin has allowed a deeper characterization of the functions and regulation of mTORC1 (Saran et al., 2015). mTORC1 is considered a master sensor of extracellular and intracellular nutrient and energy status, capable of translating multiple signals into the coordination and regulation of anabolic and catabolic processes to sustain cell growth (Dibble and Manning, 2013a). Through transcriptional, translational (Ma and Blenis, 2009) and post-translational mechanisms mediated by its downstream targets ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein (4E-BP), mTORC1 stimulates the synthesis of macromolecules (lipids, proteins and nucleic acids), promotes the production of adenosine triphosphate (ATP), nicotinamide adenine dinucleotide phosphate (NADPH) and macromolecule precursors and inhibits degradative processes, such as lipolysis, β-oxidation and autophagy (Dibble and Cantley, 2015).

III.1.3.3 PTEN

PTEN is a dual lipid and protein phosphatase and one of the phosphatases known to degrade PIP3 by dephosphorylating the phosphate group on position D3 of the inositol ring (Blanco-Aparicio et al., 2007) (Fig. 17). Due to its biochemical function, it plays a primordial role in the regulation of the PI3K-AKT-mTORC1 axis and it is involved in multiple cellular processes. Indeed, through many of the aforementioned mechanisms, PTEN activity has been related to cell metabolism, motility and polarity, self-renewal capacity, tumor microenvironment regulation and senescence (Song et al., 2012). Regarding this last mentioned function, Pten loss was reported to result in a distinct type of senescence, referred to as Pten-loss-induced cellular senescence (PICS) (Alimonti et al., 2010). Importantly, PTEN has been demonstrated to exert relevant phosphatase-independent functions in the nucleus (Serra H, 2015; Song et al., 2011a). PTEN has been also attributed PI3K-AKT-mTORC1 pathway independent roles. PTEN was shown to exert its tumor suppressive effect through c-jun N-terminal kinase (JNK) and IFN-induced double-stranded RNA-dependent protein kinase (PKR)-eukaryotic translation initiation factor 2 complex...
(eIF2α) phosphorylation in an AKT-independent manner (Mounir et al., 2009; Vivanco et al., 2007).

III.2 PI3K Pathway deregulation in cancer

Hyperactivation of the PI3K pathway is known to contribute to human cancer (Cantley, 2002). Human cancer genomic studies revealed that many components of the PI3K pathway are frequently affected by germline or somatic mutations in a wide variety of human tumors, underscoring the relevance of this signaling cascade in the disease (Liu et al., 2009b). Indeed, deregulation of this oncogenic cascade commonly occurs by activating mutations in growth factor receptors, the PIK3CA gene coding for the catalytic subunit p110α or AKT, as well as loss of function of the tumor suppressor PTEN or TSC1/2 (Marone et al., 2008).

As aforementioned, activating alterations (mutations and amplification) in PI3K are frequent in multiple cancer types (Samuels et al., 2004). The oncogenic capacity of class I PI3K was first demonstrated in the late 1990s (Thorpe et al., 2015). However, the high incidence of mutations of this kinase in human cancers was discovered in 2004, when Samuels and colleagues found it to be altered in 32% of colorectal cancers, 27% of glioblastomas and 25% of gastric cancers, among others. Furthermore, these mutations were reported to arise late in tumorigenesis, suggesting a role in invasiveness (Samuels et al., 2004). Although missense mutations have been reported in all p110α domains, mutations in each domain lead to different mechanisms of aberrantly activating the pathway. In turn, mutations in the helical domain prevent p110α inhibition by p85 or facilitate its interaction with insulin receptor substrate 1 (IRS1), mutations in the kinase domain enhance the interaction with lipid membranes, and other mutations mimic conformational changes of active PI3K (Thorpe et al., 2015).

AKT is also amplified and mutated in cancer (Carracedo and Pandolfi, 2008). In fact, the activating mutation E17K in the PH domain of AKT makes it growth factor-independent, leading to its aberrant localization to the membrane and the stimulation of downstream signaling (Carpten et al., 2007). However, distinct AKT isoforms may show tumor-specific alterations. Indeed, while AKT1 amplification has mainly been detected in gastric cancer, somatic mutations on AKT1 have been described in breast, colorectal, ovarian, lung, and bladder cancers (Martini et al., 2014). In contrast, AKT2 amplification has been frequently detected in ovarian, breast, colorectal, and pancreatic tumors, while AKT3 appears amplified in breast and prostate cancers (Agarwal et al., 2013). Finally, the activating mutation E17K has been identified on AKT3 in melanoma (Davies et al., 2008).

Importantly, few cancer-related somatic mutations in MTOR have been functionally characterized, recently some mutations leading to mTOR hyperactivation and nutrient signaling
and resistance have been reported. In addition, hyperactivation of upstream kinases (PI3K, AKT) or growth factor receptors, as well as loss of upstream negative regulators (PTEN, TSC1/2) can lead to hyperactivation of mTOR (Dancey, 2010). Oncogenic PI3K-mTORC1 overactivation confers addiction to the pathway. Indeed, PTEN loss driven prostate cancer has been reverted by tissue-specific mTOR deletion in the mouse prostate (Guertin et al., 2009).

Nevertheless, the most common mechanism triggering hyperactivation of PI3K pathway is somatic loss of PTEN due to genetic or epigenetic alterations (Thorpe et al., 2015). In fact, when PTEN is deleted, mutated or otherwise inactivated, PI3K effectors, in particular AKT, are activated in the absence of any other stimulus (Cully et al., 2006). Sequencing of PTEN revealed that it is one of the most commonly mutated and deleted tumor suppressors among human cancers (Carracedo et al., 2011). In the same line, multiple tumors show alterations in its protein expression, in PTEN locus methylation or loss of heterozygosity (Marone et al., 2008). Genetic alterations in PTEN encompass from point mutations to large chromosomal deletions (Nardella et al., 2010a). These mutations are mostly missense and non-sense localized in exons 5,7 and 8, that encode the phosphatase domain (Marone et al., 2008). Of note, PTEN mutations can either affect both alleles (specially in endometrial cancer and glioblastoma) or only one allele, as observed in glioma, prostate, breast or lung, among others (Nardella et al., 2010a).

In prostate cancer, approximately 30% of patients with castration-resistant prostate cancer (CRPC) harbor mutations in PIK3CA (Sarker et al., 2009). However, the relevance of PTEN loss of function is better described. In fact, approximately 25% of prostate HG-PINs and 70% of prostate cancers at early stage show heterozygous alterations in PTEN (Yoshimoto et al., 2006). Of note, prostate tumors tend to select for PTEN heterozygous inactivation at presentation and loss the other allele later in the progression of the disease (Carracedo and Pandolfi, 2008).

### III.3 Genetic models of Pten loss in vivo

In line with its implication in a plethora of cellular processes, mutations in PTEN have been identified in multiple sporadic malignancies and in cancer-susceptibility syndromes (Nardella et al., 2010a). Germline mutations and deletions of PTEN are associated with the development of several autosomal dominant syndromes collectively named as PTEN hamartoma tumor syndromes (PHTS). PHTS include Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Lhermitte-Duclos disease (LDD), Proteus syndrome, and Proteus-like syndrome (Hollander et al., 2011). These patients suffer from hamartomas with cancer predisposition in different organs. Macrocephaly development has also been described in the first two syndromes (Nardella et al., 2010a). The relevance of the tumor-suppressor role of PTEN led to the development of multiple Pten knockout mouse models with the aim of studying the effects of its loss of function in vivo.
III.3.1 Genetic models of Pten germline mutations

In the last decade of the twentieth century, mouse engineering experienced important advances, including the development of the genotypeering technology. Gene targeting brought the possibility of introducing specific mutations by homologous recombination into endogenous genes of embryonic stem (ES) cells, and transmitting these changes in the germline through mice breeding (Jonkers and Berns, 2002).

Homozygous Pten loss is lethal at day E7.5 post-fertilization, which highlights an essential role of Pten in embryonic development (Di Cristofano et al., 1998). In the same line, hypomorphic Pten mutants (Pten<sup>−/−</sup>) showed a partial rescue of embryonic lethality, leading to some viable mice albeit at a lower frequency than expected according to Mendelian ratios (Trotman et al., 2003). Pten heterozygosity (Pten<sup>+/−</sup>) was reported to cause dysplastic and hyperplastic alterations in prostate, skin and colon resembling CS, BRRS and LDD features. Furthermore, spontaneous development of tumors of various histological origins was described in Pten<sup>+/−</sup> mice (Di Cristofano et al., 1998). Importantly, Pten hypomorphic mice showed increased aggressiveness, with massive prostatic hyperplasia and invasive PCa (Trotman et al., 2003). In conclusion, these “hypomorphic Pten allelic series” revealed that subtle variations in Pten expression levels result in dose-dependent pathological alterations (Nardella et al., 2010a).

III.3.2 Genetic models of prostate-specific Pten deletion

Germline knockouts have been widely employed for the study of gene function in vivo. Although these conventional knockouts are useful to ascertain gene function during development, they exhibit intrinsic limitations to model postnatal pathologies, mostly due to their whole body range of action (Wu et al., 2001). To circumvent the consequence of losing Pten in all cells of the body, and to study the impact of Pten loss in a given tissue, conditional tissue-specific Pten knockout mouse models were employed (Jonkers and Berns, 2002). Conditional gene knockout techniques, such as the Cre-loxP recombination system, bypass some of the limitations of conventional gene-targeting. This technique combines the use of the bacteriophage P1 site-specific DNA recombinase (Cre) and the creation of conditional target alleles in mice expressing Cre under the control of cell type-specific or inducible promoters (Wu et al., 2001). Cre excises DNA sequences located between two unidirectional loxP recognition sequences (“flox”), leaving one loxP site on the linear DNA.
To achieve specific deletion of *Pten* in the prostate, *Pten*\(^{loxP/loxP}\) mice were crossed with *Probasin-Cre* (*PB-Cre*) transgenic mice. In *PB-Cre* transgenic mice Cre recombinase is expressed specifically in the prostate epithelium post-puberty due to its regulation by the rat *Probasin* (*PB*) gene promoter, which is an androgen responsive promoter (Nardella et al., 2010a). Two distinct versions of the *PB* promoter have been utilized to perform these crosses, *PB-Cre* and *PB-Cre4*, where in *PB-Cre4* mice Cre expression is driven by a composite promoter, *ARR2*\(*PB*\), which is a more potent derivative of the original rat *PB*. Indeed, Cre expression under *ARR2*\(*PB*\) promoter led to widespread *Pten* deletion in the prostate epithelium, prostate enlargement and more aggressive invasive PCa with multifocal origin compared to original *PB* promoter driven phenotype (Trotman et al., 2003). We will focus on *PB-Cre4* mice phenotype for further considerations regarding prostate-specific deletion driven models, which is the model that was employed in this thesis work. Homozygous prostate-specific *Pten* deletion leads to HG-PIN development at 9 weeks of age. Moreover, after bypassing *Pten* loss induced senescence at 11 weeks of age, these HG-PIN lesions further progress into full penetrance invasive PCa by 6 months. Although disease aggressiveness increased with time, these mice did not show metastatic lesions (Chen et al., 2005) (Fig. I9).

---

**Figure I9.** Prostate-specific *Pten* knockout mouse model. Representation of the genotype (wild-type, heterozygous or homozygous)-phenotype (PIN or PCa) correlation at early (3Mo) and late (6 Mo) stages of the disease.
IV METABOLIC DEREGULATION AND CANCER

IV.1 Warburg effect

The first evidence reporting the deregulation of metabolism in cancer were provided by Otto Warburg in the early 1920s (Warburg et al., 1927). This German physiologist observed that tumor cells consumed more glucose than normal tissues, which suggested a relevant differential characteristic of normal versus cancerous cells (Warburg, 1956a). However, this data was left aside for many years in cancer research until the beginning of twenty first century, when reports claiming the importance of alterations in metabolic enzymes in cancer pathogenesis started to arise (Possemato et al., 2011; Reitman et al., 2011). Increasing evidence claim that oncogenic alterations in metabolic enzymes can directly trigger the deregulation of cancer cell metabolism (Ward and Thompson, 2012), but it is widely accepted that metabolism in cancer is regulated at large by signaling alterations. The consolidation of this field has led to the consideration of the deregulation of metabolism in cancer as a hallmark of the disease (Hanahan and Weinberg, 2011).

Normal cells uptake glucose, they convert it into pyruvate and incorporate it in the Tricarboxylic Acid Cycle (TCA) to obtain 36 molecules of ATP from a single molecule of glucose through oxidative phosphorylation. However, tumoral cells or cells with high proliferation rates uptake higher amounts of glucose and convert it into lactate even in the presence of oxygen, yielding 4 ATP in a process defined as aerobic glycolysis or “Warburg effect” (Vander Heiden et al., 2009). Recently, more information about how the Warburg effect can be energetically sustained has been provided. Lactate production from glucose in cancer cells occurs 10-100 times faster than complete glucose oxidation through oxidative phosphorylation in the mitochondria (Shestov et al., 2014). Hence, this inherent difference in kinetics would explain the choice for anaerobic glycolysis of cancer cells (Liberti and Locasale, 2016). It is worth noting that cells with a higher metabolic rate would also exhibit a selective advantage under limited nutrient and energy availability conditions (such as the tumor microenvironment) and conditions of high rapid ATP demand (Epstein et al., 2014).

Aerobic glycolysis has also been proposed as an adaptation to use glucose for the production of anabolic intermediates and NADPH (Vander Heiden et al., 2009). In fact, glycolytic intermediates in cancer cells are diverted into branching pathways, such as, pentose phosphate pathway (PPP), hexosamine biosynthesis pathway or the de novo serine synthesis (50% of glucose) and one carbon (1C) metabolism, in order to obtain biosynthetic precursors (Pavlova and Thompson, 2016).
IV.2 1C metabolism

1C metabolism accepts inputs, such as glucose or amino acids and processes them to produce outputs for anabolic processes. Thus, this pathway is considered a nutrient status integrator (Locasale, 2013). 1C metabolism encompasses folate and methionine (Met) cycle. This cyclic metabolic network is fueled by a carbon unit from serine (Ser) conversion to glycine (Gly) and subsequent glycine cleavage, which then is transferred through biochemical reactions to other metabolic pathways. Folate is reduced by a number of enzymes, leading to the production of methyl-tetrahydrofolate (m-THF), which couples folate cycle to Met cycle, and further tetrahydrofolate (THF) generation (Amelio et al., 2014). Importantly, virtually all biomolecules require substrates from 1C metabolism for their synthesis. 1C metabolism is also connected to trans-sulphuration pathway through an intermediate of Met cycle, homocysteine, and is implicated in the maintenance of cellular Redox balance, through the NADPH/NADP ratio balance and glutathione production, and in the methylation capacity of the cell, through the regulation of S-adenosylmethionine (SAM) levels (Locasale, 2013).

Ser, one of the fuels of this pathway, can be synthesized de novo, from a glycolysis intermediate, 3-phosphoglycerate (3PG) (Locasale, 2013). Importantly, this pathway has been shown to correlate with tumorigenesis (Snell, 1984). Indeed, Ser and not Gly, was demonstrated to selectively support 1C metabolism and proliferation of cancer cells (Labuschagne et al., 2014). Likewise, glycine metabolism, glycine decarboxylase (GLDC) and the glycine-cleavage system have also been implicated in cell tranformation and tumorigenesis (Zhang et al., 2012; Wang et al., 2009).

IV.3 Other metabolic alterations

Recent advances in cancer research have proven that deregulation of metabolism in cancer extends beyond the previously thought unique objective of adapting to the enhanced anabolic processes required for proliferation (Ward and Thompson, 2012). Cancer cells exhibit increased uptake of other growth-supporting substrates, like glutamine, which was observed more than 50 years ago (Eagle, 1955). The transcription factor myc proto-oncogene protein (c-MYC) (often amplified in tumors) induces glutamine utilization (Wang et al., 2011), providing nitrogen for purine and pyrimidine synthesis, non-essential amino acids and polyamines (Pavlova and Thompson, 2016), as well as carbons for anaplerosis (a process through which the activity of the tricarboxylic acid cycle is sustained by providing additional alpha ketoglutarate).

Some cancer cells also exhibit opportunistic modes of nutrient acquisition (Pavlova and Thompson, 2016). In fact, mutant RAS-transformed cells recover free amino acids from extracellular proteins, through internalization by macropinocytosis and lysosomal degradation (Commissso et al., 2013). Remarkably, this mode of aminoacid uptake is inhibited by mTORC1 (Palm et al., 2015). In the same line, mutant GTPase KRas (KRAS)-expressing cells are more prone to elicit entosis, the engulfment and digestion of entire living cells, as a means of amino acid
recovery (Krajcovic et al., 2013). Furthermore, upon inhibition of stearoyl-CoA desaturase (SCD)1 in hypoxic conditions, these cells are able to scavenge serum fatty acids (Kamphorst et al., 2013).

Metabolic reprogramming of cancer cells leads to the production of metabolites such as acetyl-CoA, that are substrate for histone acetyl transferases, resulting in increased acetylation of growth-related genes and subsequent increased growth (Cai et al., 2011). Thus, the metabolic reprogramming in cancer allows the direct transmission of growth signals to metabolic enzymes (Pavlova and Thompson, 2016).

V POLYAMINES

Polyamine metabolism is a physiologically relevant pathway that has been extensively related to proliferation. Owing to their multiple roles in essential cellular processes, their concentrations are strictly controlled at several levels, by regulation of the enzymes implicated in their synthesis and catabolism. This fact underscores the importance of fine-tuning the availability of polyamines. The deregulation of these enzymes has been therefore implicated in multiple diseases, and especially in cancer pathogenesis.

V.1 Definition of polyamines

Polyamines are ubiquitous essential small polycationic molecules derived from amino acids. Since Antonie Van Leewenheuk identified some crystals in seminal fluid corresponding to spermine (Spm) in 1678, more polyamines have been described, such as putrescine (Put) (in the late 1800s), spermidine (Spd) (at the beginning of twentieth century), cadaverine (Cad) and 1,3-diaminopropane (1,3-DAP). The first three are the most common ones, especially in mammals. Polyamines contain two amino groups in the case of primary diamines (Put, 1,4-diaminobutane; and Cad, 1,5-diaminopentane), while three and four amino groups are present in the structure of Spd (N-(3-aminopropyl)butane-1,4-diamine) and Spm (N,N′-bis(3-aminopropyl)butane-1,4-diamine), respectively. Polyamine content varies among species. For instance, intracellular content of Spd (1-3 mM) is higher than Put content (0.1-0.2 mM) in most bacteria, whereas in Escherichia coli Put is the predominant polyamine (10-30 mM) (Shah and Swiatlo, 2008). In the same line, Cad is mainly present in bacteria and plants, with a reduced abundance in the remaining species (Kusano et al., 2008).

These positively charged aliphatic hydrocarbon molecules are relevant for the maintenance of essential cellular processes. Indeed, due to their overall positive charge at physiological pH, they are known to bind macromolecules with acidic nature, such as nucleic acids, proteins and phospholipids (Pegg, 2009a) and cause effects on gene expression, cell proliferation and cellular stress (Miller-Fleming et al., 2015). Owing to their high interactive capacity, the free polyamine concentration is markedly lower than total polyamine content, which
also explains the fact that slight alterations in polyamine levels may have critical consequences on cell function (Pegg, 2009a).

**V.2 Polyamine functions**

**V.2.1 Regulation of gene expression**

Polyamines are able to affect gene expression by different means (Fig. I10). These molecules are considered condensation agents that remodel chromatin structure by creating electrostatic bonds between deoxyribonucleic acid (DNA) and phosphate charges that stabilize the nucleic acid. In the same line, natural and synthetic polyamines precipitate DNA, depending on their concentration (Childs et al., 2003). Polyamines regulate the transcription rate of several genes, the oncogenic transcription factor c-MYC among them (Kumar et al., 2009). Interestingly, amplification of N-myc proto-oncogene protein (N-MYC), another transcription factor from the same family, has been reported to induce overexpression of ornithine decarboxylase 1 (ODC1), one of the rate-limiting enzymes of the polyamine synthesis pathway, in neuroblastoma (Hogarty et al., 2008). This fact emphasizes the presence of feedback loops in polyamine related regulation.

To try to understand the physiological role of polyamines, their distribution among acidic molecules in cells has been determined. Importantly, most polyamines form a ribonucleic acid (RNA)-bound complex, as assessed in bovine lymphocytes and rat liver, what suggests that these polycations could alter the structure of RNA (Igarashi and Kashiwagi, 2010) and regulate protein translation. Indeed, polyamines can induce the translation of a group of genes, named the “Polyamine modulon”, both in prokaryotes (Yoshida et al., 2004) and eukaryotes (Nishimura et al., 2009a). Interestingly, polyamines regulate translation initiation and elongation (Yoshida et al., 2002) as well as the phosphorylation of factors involved in translation (Landau et al., 2010).

**V.2.2 Control of cell proliferation**

Polyamines have been widely related to proliferation and growth (Fig. I10). Apparently, this regulation occurs through different mechanisms in prokaryotes and eukaryotes. In prokaryotes, as aforementioned, translation of growth-related transcription factors is induced in response to polyamines, according to the metabolic conditions. However, polyamines show a putative role in cell cycle progression in eukaryotes (Oredsson, 2003), although the exact mechanism underlying this activity remains to be elucidated (Miller-Fleming et al., 2015).
Another proliferation-related function of polyamines, especially of Spd, is to serve as substrate for the unique post-translational modification of eukaryotic translation initiation factor 5A (eIF5A), hypusination (Cooper et al., 1982). This exclusive modification is based on the formation of hypusine, a basic amino acid, by adding the 4-aminobutyl moiety of Spd to Lys50 in eIF5A (Park et al., 2009). The hypusination process consists of two enzymatic steps, deoxyhypusine intermediate formation by deoxyhypusine synthase (DHS), which transfers the 4-aminobutyl moiety from Spd to Lys50; and hydroxylation of deoxyhypusine by deoxyhypusine hydroxylase (DOHH) to form active eIF5A (Park et al., 2009). These two enzymes responsible for hypusination and eIF5A are highly conserved from archaea to eukaryotes, which suggests a vital role of this translation initiation factor in cell viability. Indeed, deletion of both eIF5A homologues in yeast (Hyp2 and Anb2) is lethal (Schnier et al., 1991), as well as eIF5A homozygous deletion in mice (Nishimura et al., 2012). Although eIF5A was initially described as a translation initiation factor, it was later demonstrated that it does not play an essential role in initiation, but binds to translating ribosomes and elongation factors, in an hypusine-dependent manner (Zanelli et al., 2006).

Finally, polyamines have been reported to affect signaling pathways by modulating phosphorylation of key regulatory proteins, such as kinases (AKT, GSK-3β, cyclin-dependent kinase 4, CDK-4), transcription factors (p53), E3 ubiquitin-protein ligases (murine double minute 2, Mdm2) and signaling receptors (EGFR), among others (Pegg, 2009a).
V.2.3 Implication in cellular stress

Polyamines have been associated to the protection of cells against multiple types of cellular stresses, such as ROS, changes in pH, osmotic pressure and temperature (Miller-Fleming et al., 2015) (Fig. I10).

Due to their polycationic nature, polyamines can function as ROS scavengers, by binding to alkyl, hydroxyl and peroxyl radicals and superoxide to protect DNA from oxidative stress (Fujisawa and Kadoma, 2005; Ha et al., 1998). Another reported function of polyamines is the induction of the defense mechanisms against stress. Evidence supporting this fact have been provided in E. coli, where Put and Spd upregulate the transcription of the stress-related transcription factors OxyR, SoxRS and RpoS (Tkachenko and Nesterova, 2003); in yeast, where overexpression of the polyamine exporter Tpo1 sensitizes cells to H$_2$O$_2$ (Krüger et al., 2013); and plants, where polyamines protect Arabidopsis from heat stress (Sagor et al., 2012). Polyamines also have the capacity to bind to proteins. This ability allows them, for instance, to bind to porins (membrane proteins that form channels) and inhibit them to prevent acidic and osmotic stress (Iyer and Delcour, 1997). In response to osmotic stress, polyamines can further act as “osmolytes”, accumulating for protection (Groppa and Benavides, 2007) or being excreted to balance charge alterations (Schiller et al., 2000).

We will focus on naturally occurring polyamines in mammals to delve into their synthesis, catabolism and transport. These processes are very tightly controlled through the specialized and unconventional means of regulation of the enzymes in polyamine metabolism.

V.3 Polyamine metabolism

V.3.1 Polyamine synthesis

Polyamines are synthesized from two proteinogenic amino acids, the essential amino acid methionine (Met, M) and the non-essential amino acid arginine (Arg, R). Arg is converted into ornithine, a non-proteinogenic amino acid that is the real substrate for the synthesis of the first polyamine synthesized in the pathway, Put (Lee and MacLean, 2011). There are two rate-limiting and equally relevant enzymes implicated in the synthesis of polyamines, ODC1 and S-adenosylmethionine decarboxylase (AMD1) (Pegg, 2009a) (Fig. I11). Both branches of the pathway start with a decarboxylation reaction. Ornithine is decarboxylated by ODC1 to form Put (Nowotarski et al., 2013). The other branch of the pathway is fueled with methionine, which is converted into SAM, the substrate that is then decarboxylated by AMD1 to form decarboxylated S-adenosylmethionine (dcSAM) (Miller-Fleming et al., 2015). This metabolite is the aminopropyl donor for the synthesis of the other two polyamines present in mammals, Spd and Spm (Pegg, 2013).
The aminopropyl group is transferred to Put and Spd in consecutive reactions catalyzed by two aminopropyltransferases, spermidine synthase (SpdS) and spermine synthase (SpmS), respectively (Rhee et al., 2007) (Fig. I11).

### V.3.2 Polyamine catabolism

Polyamine concentration is not only regulated through their synthesis, but also through tightly regulated catabolic reactions. Polyamine catabolism consists of two main reactions, acetylation and oxidation (Fig. I11).

Acetylation of Spd and Spm, is catalyzed by Spermidine/spermine N₁-acetyltransferase (SSAT). This inducible enzyme transfers the acetyl group from acetyl-coenzyme A to the N₁ position of either Spd or Spm (Casero and Marton, 2007), forming N₁-acetylspermidine or N₁-acetylspermine. Acetylation of polyamines reduces their positive charge, which decreases their ability to bind to macromolecules and makes them prone to be excreted (Pegg, 2013). Alternatively, they become substrates for acetylpolyamine oxidase (APAO). Oxidases can be classified according to the cofactor they require, flavin adenine dinucleotide (FAD) or copper (Cu²⁺). On the one hand, FAD-dependent oxidases include: APAO, which efficiently acts on N₁-acetylspermine and N₁-acetylspermidine and converts them into Spd and Put, respectively; and spermine oxidase (SMO), which shows a very high selectivity for spermine. These two enzymes generate reactive aldehydes and H₂O₂ thereby causing oxidative stress (Pegg, 2009a). On the other hand, there are Cu²⁺-containing oxidases, including: diamine oxidase, which degrades putrescine into Δ1-pyrroline, ammonia and H₂O₂; and serum amine oxidase, which transforms Spd and Spm to produce amino aldehydes, ammonia and H₂O₂. Importantly, oxidation products of
serum polyamine oxidase or SMO can undergo spontaneous β elimination producing acrolein, a metabolite that shows very high toxicity (Pegg, 2013) (Fig. I11).

V.3.3 Polyamine transport

Polyamine transport may play an important role in the regulation of total polyamine pools through their uptake (Casero and Marton, 2007) and excretion (Pegg, 2009a). Despite their central function, polyamine-specific transport systems in mammals are not very well understood yet, although several mechanisms implying endocytosis have been suggested (Miller-Fleming et al., 2015) (Fig. I12).

Adapted from Poulin R, Casero RA and Soulet D, Amino Acids 2012
Soulet et al. proposed a mechanism by which polyamines may be transported into the cell through an unknown transporter powered by membrane potential (model 1). Immediately after internalization, polyamines would accumulate into polyamine-sequestering vesicles (PSVs) through V-ATPase activity-bearing transporters (Soulet et al., 2004). Other models claim the implication of glycosaminoglycans (model 2) (Belting et al., 2003) or caveolin-1 (model 3) (Uemura et al., 2010) in the internalization process of polyamines. Model 2 only provides an explanation for spermine transport and both model 2 and 3 do not solve the steps of polyamine release from vesicles (Poulin et al., 2011). In the last years, a number of membrane proteins from solute carrier (SLC) and ATP-binding cassette (ABC) protein superfamilies have been suggested as putative polyamine transporters, such as SLC22A1 and SLC22A2, SLC3A2, SLC12A8A, SLC22A16 and MDR1 (from ABC superfamily) (Abdulhussein and Wallace, 2013).

V.4 Rate Limiting enzymes of the pathway

The polyamine pathway is tightly regulated by two rate-limiting enzymes implicated in the synthesis of these molecules. On the one hand, synthesis of the first polyamine in the synthetic pathway from decarboxylation of the amino acid ornithine is catalyzed by ODC1. On the other hand, the pathway relies on another important checkpoint control at the production of the other main substrate required for polyamine synthesis, dcSAM. This reaction is driven by AMD1, which decarboxylates SAM to produce dcSAM.

V.4.1 ODC1

ODC1 is the first rate-limiting enzyme in the synthesis of polyamines. This enzyme requires pyridoxal phosphate (PLP) as a cofactor (Pegg, 2009a). An active ODC1 homodimer is the responsible for the synthesis of the diamine Put by decarboxylating ornithine (Pegg, 2006). The expression of ODC1 is tightly regulated at multiple levels, from transcription to degradation (Shantz and Pegg, 1999) (Fig. 113). This enzyme is of key importance for life, as demonstrated by Odc1 deletion in vivo, which results in early lethality at E3.5 days post-fertilization (Pendeville et al., 2001).

At transcriptional level, ODC1 expression responds to multiple stimuli, such as growth factors, hormones and tumor promoter signals. At the translational level, ODC1 messenger RNA (mRNA) contains both elements that reduce translation efficiency (a 5’untranslated region (UTR)
with a strong secondary structure, a small upstream open reading frame, uORF, and a GC-rich sequence) (Shantz and Pegg, 1999) and elements that enhance translation (internal ribosome entry sites, IRES) (Pyronnet et al., 2000). However, the most unusual and complex regulatory step of ODC1 is its degradation. ODC1 shows a half-life of 10-30 minutes, which suggests a very tight regulation of protein stability. This decarboxylase is degraded through the proteasome, although this process is independent of ubiquitination. Instead, ODC1 depends on antizyme (AZ) binding, which has high affinity for ODC1 monomers, for recognition by the proteasome and degradation (Coffino, 2001). AZ is encoded by two adjacent ORFs and its synthesis is regulated by a +1 frameshift event that happens in high polyamine concentration conditions (Hayashi and Murakami, 1995; Nilsson et al., 1997). Importantly, AZ is also regulated by an antizyme inhibitor (AZi), which is highly homologous to ODC1 but lacks catalytic activity (Fujita et al., 1982). AZ has higher affinity for AZi than ODC1, thus allowing ODC1 dimerization and activation upon AZi expression.

V.4.2 AMD1

AMD1 is the second rate limiting enzyme in polyamine synthesis pathway and the responsible for dcSAM production. To ensure that AMD1 does not deplete the pool of SAM, which is essential to maintain the methylation capacity of the cell (Locasale, 2013), this enzyme is expressed at very low levels. dcSAM is an essential substrate for polyamine synthesis, because it donates the aminopropyl group for Spd and Spm synthesis. In turn, AMD1 levels are very strictly regulated at
multiple levels, such as transcription, translation, processing and degradation. Put positively regulates AMD1 levels, whereas Spd and Spm negatively regulate the enzyme (Pegg, 2009b). The vital relevance of AMD1 is further supported by the fact that homozygous deletion of AMD1 is lethal between E3.5 and E6.5 days post-fertilization (Nishimura et al., 2002).

V.4.2.1 AMD1 regulation

V.4.2.1.1 AMD1 processing

This decarboxylase has a pyruvoyl prosthetic group covalently bound. AMD1 is synthesized as an inactive proenzyme (proAMD1) of 38 KDa, which requires to undergo an autocatalytic serinolysis between glutamic acid 67 and Ser68 (Stanley et al., 1989) to generate the two different subunits (a and b) that will in turn dimerize and form the active heterotetramer (Pegg et al., 1998) (Fig. I14). This process is activated by Put in mammals (Stanley and Pegg, 1991).

![Figure I14. AMD1 processing mechanism. Schematic representation of the autocatalytic serinolysis process that the inactive proenzyme form of AMD1 suffers in order to produce the subunits “a” and “b” that will in turn dimerize giving the active mature enzyme.](image)

V.4.2.1.2 AMD1 transcription

Regulation of AMD1 transcription has not been clarified yet. There is some evidence suggesting that AMD1 mRNA levels are upregulated in response to growth factors and Spd depletion. Indeed, human AMD1 promoter has been reported to contain a spd-responsive element (or polyamine-responsive element, PRE), although the experimental evidence are inconclusive (Pegg et al., 1998) (Fig. I15).

V.4.2.1.3 AMD1 translation
AMD1 translation is regulated by uORFs. AMD1 mRNA contains a small ORF 14 nucleotides downstream the 5’ CAP that encodes for the hexapeptide MAGDIS (Hill and Morris, 1992).

During translation of this peptide, when ribosomes reach the translation of last Ser (S) ribosomal stalling occurs, blocking the entrance of the ribosome to the AMD1 start codon. Spd and Spm stabilize the complex formed by the peptidyl-tRNA associated to the ribosome, inhibiting translation of AMD1 (Law et al., 2001; Raney et al., 2002) (Fig. I15).

**V.4.2.1.4 AMD1 degradation**

AMD1 in its proenzyme form shows a very short half-life (less than 1 h), and in some species the turnover takes less than five minutes. Importantly, the turnover is accelerated when Spd and Spm concentrations are high and no further polyamine synthesis is required (Miller-Fleming et al., 2015). AMD1 degradation occurs through polyubiquitination via the 26S proteasome (Yerlikaya and Stanley, 2004). In the reaction chain that takes place to produce dcSAM, the last step consists on protonation of Cα of the product for the correct release of dcSAM and regeneration of the pyruvate. However, under some circumstances, Cα of the prosthetic group is protonated leading to the formation of alanine instead of pyruvate and to the release of an aldehyde group. This substrate-mediated transamination process irreversibly inactivates AMD1 (Pegg, 2009b).
Furthermore, this transformation has been suggested to cause conformational changes in the enzyme that would make it more accessible to ubiquitination and prone to proteasome-dependent degradation (Yerlikaya and Stanley, 2004) (Fig. 115).

### V.5 Polyamines and disease

As a consequence of their multiple and varied physiological roles, polyamines have been implicated in a considerable number of pathologies. Nevertheless, there is only one inherited human disease directly associated to a genetic alteration in polyamine synthesis pathway, the Snyder-Robinson syndrome (SRS). This syndrome is caused by a splice mutation in SpmS gene located in chromosome X and characteristic features of this disorder encompass mental retardation, osteoporosis, facial asymmetry, hypotonia and movement disorders (Lauren Cason et al., 2003). There is also evidence reporting duplication of Ssatl gene (encoding for SSAT1) as the responsible for keratosis follicularis spinulosa decalvans (KFSD), although further patient studies are required to conclude a direct relationship (Pegg, 2009a).

Ageing has been shown to negatively correlate with polyamine levels. In line with this fact, some age-related neurodegenerative diseases, such as Parkinson’s disease (PD) or Alzheimer’s disease (AD) show increased polyamine levels, suggesting a deranged polyamine pathway. However, these observations in PD and AD were reported to be polyamine and cell-type specific and no causative demonstration has been achieved yet (Miller-Fleming et al., 2015; Minois et al., 2011). At molecular level, polyamines have been shown to promote α-synuclein (Antony et al., 2003; Krasnoslobodtsev et al., 2012) and β-amyloid (Luo et al., 2013) aggregation in PD and AD, respectively. These results were not unexpected, based on the interaction capacity of polyamines, and thus, in vivo experiments showing the extent and relevance of the effect of polyamines on the formation of these aggregates are warranted (Minois et al., 2011). In the same line, while some polyamines, such as Spm, have been related to ischemic neuronal injury in stroke (Duan et al., 2011), others, as Put, have been shown neuroprotective effects against epilepsy (Bell et al., 2011). Polyamines are also associated with inflammatory responses, leading to an overall increase in inflammatory conditions, such as pancreatitis (Minois et al., 2011) and the capacity to recruit macrophages. Whether polyamines play a pro- or anti-inflammatory role still remains elusive (Puntambekar et al., 2011). In the same line, polyamines ameliorate parasitic infection-related symptoms, probably by improving the adaptive immune response and leading to a beneficial outcome of the disease (Nishimura et al., 2009b).

Of note, byproducts of polyamine metabolism have been involved in multiple diseases. The potential toxic role of acrolein was already suggested a century ago. Ever since, this aldehyde has been associated with neurological damage due to stroke or dementia, neurological disease and renal failure (Minois et al., 2011).
V.5.1 Polyamines and cancer

Polyamines have been widely associated to active proliferation and cancer (Gerner and Meyskens, 2004a; Soda, 2011). The association of polyamines with this disease was first reported by Russell and Snyder in 1968, who demonstrated a dramatic increase of ODC1 in STAT-1 sarcoma (Russell and Snyder, 1968). Thenceforth, higher polyamine concentration upon neoplastic transformation has been reported in a variety of cancer types, such as colorectal, breast or prostate cancer (Kingsnorth et al., 1984; Cañizares et al., 1999; Schipper et al., 2000).

Expression and activity of polyamine biosynthetic and catabolic enzymes have been related to cancer status (Soda, 2011). In this sense, upregulation of ODC1 in the intestinal mucosa of familial adenomatous polyposis (FAP) patients is the best described example. In this inheritable form of colon cancer, the tumor suppressor adenomatous polyposis coli (APC) appears mutated or lost, which upregulates the expression of MYC oncogene, leading to aberrant growth and cancer (Gerner and Meyskens, 2004a). ODC1 is a direct transcriptional target of MYC (Bello-Fernandez et al., 1993; Peña et al., 1993), and its expression has been correlated with colon cancer risk. Moreover, a single-nucleotide polymorphism (SNP) (G315A) in intron 1 of ODC1, which lies between two consensus MYC binding sites (E boxes), was reported to affect ODC1 transcription, due to the selective binding of the transcriptional repressor and MYC antagonist MAD1. Based on this molecular mechanism, it was found that individuals homozygous for this allele showed a reduction in colon poly development and cancer risk. Of note, aspirin use was observed to further decrease colon cancer risk in an allele-independent manner, through the activation of SSAT (Martínez et al., 2003). In vivo, ODC1 overexpression alone was not sufficient to induce tumorigenesis (Alhonen et al., 1995; Smith et al., 1998), whereas targeted ODC1 expression to the skin, under the control of K6 keratin promoter, caused increased susceptibility to skin tumor development upon different carcinogen induction (Chen et al., 2000; O’Brien et al., 1997). Of note, the development of skin tumors is polyamine-dependent, as it is reduced upon ODC1 inhibition with difluoromethylornithine (DFMO) (Smith et al., 1998), targeted AZ overexpression in the skin (Feith et al., 2001) or ODC1 heterozygosity (Guo et al., 2005). Likewise, ODC1 has also been related to other oncogenes. This enzyme is necessary to induce active H-Ras GTPase-driven oncogenic transformation in vitro (Shantz and Pegg, 1998) and to cooperate with H-Ras in the promotion of epidermal tumors in vivo (Smith et al., 1998).

Catabolic enzymes such as SSAT1 or SMO have also been related to the disease. These enzymes are also under the regulation of mutant KRAS. KRAS inactivates peroxisome proliferator-activated receptor gamma (PPARγ), which in turn fails to bind the PPAR response element (PPRE) in SSAT1 promoter (Gerner and Meyskens, 2004a). Nonetheless, studies using transgenic SSAT1 overexpression exhibit conflicting results. Overexpression of Ssat1 in the skin (K6/SSAT) (Coleman et al., 2002) or whole Ssat1 overexpression in combination with ApcMinmutation (which develop colon cancer) (Tucker et al., 2005) showed increased incidence of skin and intestinal tumors, respectively. Conversely, transgenic expression of Sat1 (Pietilä et al., 2001) in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model (which
INTRODUCTION

develops prostate cancer) (Kee et al., 2004) led to significant reduction in tumor incidence. However, germline Ssat1 overexpression is known to cause multiple pleiotropic phenotypes that difficult drawing carcinogenesis-related conclusions. Furthermore, contrary to the targeted K6/SSAT mice, the SSAT1 transgenic expression in TRAMP mice led to a profound depletion of polyamines, through the inhibition of a compensatory increase of polyamine synthesis that would support tumor growth (Casero and Pegg, 2009).

SMO has recently been linked to carcinogenesis. Increased expression of this polyamine catabolic enzyme has been observed in inflammatory-associated cancers. Specifically, infectious agents such as enterotoxigenic Bacteroides fragilis (ETBF) and Helicobacter pylori induce an inflammatory state that increases colorectal cancer risk (bowel disease and colitis) and colon cancer (Ulger Toprak et al., 2006), and gastric cancer (Chaturvedi et al., 2011), respectively. In both cases the bacterial infection was demonstrated to increase SMO expression, resulting in DNA damage and apoptosis (Xu et al., 2004). This data was validated with the inhibitor of SMO MDL72527 and SMO knockdown. In this line, SMO expression was reported to be increased as an early event in PCa development, although further studies are warranted in order to assess the role of SMO-induced ROS in prostate carcinogenesis (Goodwin et al., 2008).
Despite decades of investigation on prostate cancer (PCa), it remains the fifth cause of death among men worldwide. This fact underscores the necessity to develop more selective and efficient therapies that would ensure disease eradication. Deregulation of energetic metabolism has recently been postulated as one of the hallmarks of cancer (Hanahan and Weinberg, 2011). This thesis work stems from the interest in deciphering the metabolic cues implicated in PCa initiation and progression, and is based in the following hypothesis: **Oncogenic events trigger the deregulation of metabolism in prostate cancer, thus revealing potential therapeutic strategies.**

We based our work on the premise that there is strong conservation in the metabolic signals that regulate murine and human PCa pathogenesis. Therefore, we propose to perform a discovery study based on integrative metabolomics, starting from a conditional tissue specific Pten knockout mouse model of PCa (Chen et al., 2005; Nardella et al., 2010b). We integrated, validated and deconstructed this data using PCa patient specimens and PCa cell lines. In order to test this hypothesis, we establish the following specific aims:

- **Aim1: To identify metabolic alterations underlying prostate cancer pathogenesis**
  To characterize metabolic alterations at the core of PCa, we undertook an integrative metabolomics approach. Recent innovation in metabolomics instrumentation and development of bioinformatic tools (Patti et al., 2012) offers the opportunity to select the most suitable metabolomics approach:
  1.1 Time-of-flight Mass Spectrometry (ToF-MS) to establish the panoramic semiquantitative view of prostate cancer metabolism.
  1.2 Liquid Chromatography-Mass Spectrometry (LC/MS) to focus on most altered and relevant pathways and analyze them quantitatively.
  1.3 Metabolic Flux Analysis (MFA) to validate the data in a dynamic setting, which accurately represents metabolic nature.

- **Aim2: To elucidate the molecular mechanism underlying the metabolic regulation observed in PCa**
  PTEN is a tumor suppressor that regulates the oncogenic PI3K pathway, which has been reported to be altered in a large fraction of human cancers (Carracedo and Pandolﬁ, 2008; Engelman et al., 2006). Importantly, alterations in Pten have been observed in up to seventy percent of prostate cancers (Song et al., 2012). Hence, our mouse model, driven by the loss of Pten, will allow us to study the interconnection between the metabolic alterations observed and the hyper-activation of this oncogenic cascade. To ascertain the molecular mechanism triggering the metabolic alterations we will rely on two main strategies:
    2.1 Evaluation of transcriptional changes as drivers of the polyamine metabolic switch.
    2.2 Evaluation of post-transcriptional changes as drivers of the polyamine metabolic switch.
Aim3: To ascertain the therapeutic potential of targeting the altered metabolic pathway and evaluation of prospective therapies

Based on the need of new selective and efficient therapies that would drive us towards precision medicine, we will approach this aim in two ways:

3.1 Genetic and pharmacological modulation of potential targets \textit{in vitro} and \textit{in vivo} to test their therapeutic potential.

3.2 Evaluation of \textit{in vivo} therapeutic strategies based on the target with highest potential.
Materials and Methods
I IN VIVO AND EX VIVO ASSAYS

I.1 Analysis of tissue samples

I.1.1 Analysis of murine samples

All mouse experiments were carried out following the ethical guidelines established by the Biosafety and Animal Welfare Committee at CIC bioGUNE. The procedures employed were carried out following the recommendations from AAALAC. Mice were housed under controlled environmental conditions, such as time-controlled lighting on standard 12:12 light:dark cycles, controlled temperature at 22 ± 2ºC and 30-50% relative humidity. Mice were fed regular Chow diet ad libitum, unless otherwise specified based on experimental designs. Mice were fasted for 6h prior to tissue harvest (9 am-3 pm) in order to prevent metabolic alterations due to immediate food intake. At experimental end-point, all mice were sacrificed by CO₂ inhalation followed by cervical dislocation.

I.1.1.1 Genetically engineered mouse models (GEMM)

In this thesis work we have studied three genetic alterations in mice: Cre recombinase-dependent Pten conditional deletion (Chen et al., 2005), whole body Gnmt mutation (Luka et al., 2006) and Cre recombinase expression under the control of androgen-dependent ARR2B Probasin promoter (Pb-Cre4). The Pb-Cre4 transgene allowed us to delete Pten in the prostate epithelium at puberty. The conditional tissue specific Pten knockout (C57BL6/129sv; Pb-Cre4; Pten lox/lox) model was kindly provided by Dr. Pandolfi (Chen et al., 2005). The whole body Gnmt knockout (C57BL6) was kindly provided by Dr. Martinez-Chantar (Luka et al., 2006). We generated a mouse line which we named PGN by breeding Pten prostate-specific knockout mice (Pb-Cre4Pten lox/lox) and Gnmt knockout mice. We intercrossed these two lines for at least three generations to obtain a founder colony with mixed homogeneous background. Probasin Cre was always retained in male mice, since in females Pb-Cre4 expression in utero can lead to recombination in embryos during pregnancy. Prostate Pten-deleted male mice were termed Pten pc+/- (heterozygous) or Pten pc-/- (homozygous knockout). We generated a mouse colony of Pten pc+/- for metabolomic characterization and preclinical studies. Gnmt +/- and wildtype counterparts were generated to evaluate the relevance of this gene in prostate cancer (PCa) pathogenesis and metabolism. For the PGN line, Pten pc+/- Gnmt +/- and Pten pc+/- Gnmt +/- mice were generated for pathological and metabolomics studies. The time of analysis was based on the experimental design, and it is indicated in the results section.

I.1.1.2 Xenograft models in nude mice

DU145 cells in suspension were injected subcutaneously into immunocompromised 8-10-week-old male nude mice (Harlan). Measurement of tumor size was performed every two-three days.
and tumor volume was estimated using the following formula: \( \text{volume} = \text{length} \times \text{width}^2 \times 0.526 \). Final tumor weight was measured upon tissue harvest at the experimental end point.

### I.1.1.2.1 AMD1 OE in vivo

DU145 cells transduced with either empty vector (Mock) or AMD1 expressing construct (DU145\textsuperscript{MYC-AMD1-HA WT}) (4x 10\(^6\) cells per condition) in PBS (supplemented with 5µM glucose) suspension were mixed at 1:1 ratio with Matrigel (Corning Cat# 354230) in a final volume of 100µL and injected subcutaneously in two flanks per mouse (6 mice, n=12 per condition).

### I.1.1.2.2 AMD1 Silencing in vivo

A suspension of DU145 cells (in PBS supplemented with 5µM glucose) transduced with a lentiviral inducible vector (TET-pLKO; Addgene Plasmid #21915) containing shRNA for AMD1 (SIGMATRCN0000078462) (7,5 x 10\(^6\) cells per condition) was mixed at 2:1 ratio with Matrigel (Corning Cat# 354230) in a final volume of 150 µL and injected subcutaneously in two flanks per mouse. Injected nude mice were fed regular Chow diet until tumors reached an average volume of 150mm\(^3\). Then mice (according to cage distribution) were fed doxycycline-containing diet (specifications are reflected in the datasheet in Anex) to induce AMD1 silencing or were maintained in chow food as control (7 mice, n=14 per condition).

### I.1.1.3 Preclinical trials

#### I.1.1.3.1 RAD001 treatment in vivo

The RAD001 preclinical trial was performed following the experimental design in Fig. M1. Two month-old Pten\textsuperscript{pc-/-} mice were administered either vehicle (polyethylene glycol, PEG) or RAD001 (10mg/Kg) six days a week during four weeks by oral gavage. At the experimental end-point, mice were euthanized as specified in I.1.1. and tissues of experimental interest were harvested.

![Figure M1. Schematic showing the experimental design of the RAD001 preclinical trial.](image-url)
I.1.1.3.2 SAM486A treatment in vivo

The SAM486A preclinical trial was performed following the experimental design in Fig. M2. Two month-old *Pten* \textsuperscript{pc-/-} mice were administered either vehicle (0,9% NaCl) or SAM486A (2mg/Kg or 5mg/Kg) five days a week during four weeks by intraperitoneal injection. At the experimental endpoint, mice were sacrificed as specified in I.1.1. and tissues of experimental interest were harvested.

![Figure M2. Schematic showing the experimental design of the SAM486A preclinical trial.](image)

I.1.1.3.3 Methionine restriction in vivo

Methionine restriction preclinical trials were performed following the experimental design detailed in Fig. M3 and Fig. M4 for one month- and four month-long experiments, respectively. Mice were weighed weekly to control diet safety. See Annex for diet specifications. At the experimental endpoint, mice were sacrificed as specified in I.1.1. and tissues of experimental interest were harvested.

![Figure M3. Schematic showing the experimental design of the methionine restriction preclinical trial for four weeks.](image)
Analysis of human specimens

All prostate specimens were obtained upon informed consent and with evaluation and approval from the corresponding ethics committee (CEIC code OHEUN11-12 and OHEUN14-14). Sample and pathological information from PCa and benign prostatic hyperplasia (BPH) patients used for LC/MS was obtained from the Basque biobank for research (BIOEF), and is specified in Table M1. The clinical-pathological information about the biopsies from the clinical trial with Everolimus is described in Table M2.

Table M1: Detailed data of patient specimens from The Bioef Foundation biobank, describing sample type, specific characteristics of the sample and aggressiveness parameters of prostate cancer samples (Gleason Score and TNM Classification)

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sample type</th>
<th>Characteristics</th>
<th>Gleason</th>
<th>TNM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>BPH</td>
<td>Hiperplasia. Squamousmetaplasia foci</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 2</td>
<td>BPH</td>
<td>Glandular hiperplasia mixed with estroma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 3</td>
<td>BPH</td>
<td>Glandular hiperplasia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 4</td>
<td>BPH</td>
<td>Glandular hiperplasia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 5</td>
<td>BPH</td>
<td>60% glandular, 40% estromal hiperplasia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 6</td>
<td>BPH</td>
<td>40% glandular, 60% estromal hiperplasia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 7</td>
<td>PCa</td>
<td>Prostate adenocarcinoma</td>
<td>7</td>
<td>T2</td>
</tr>
<tr>
<td>Patient 8</td>
<td>PCa</td>
<td>Prostate adenocarcinoma with mucinous component</td>
<td>7</td>
<td>T1c</td>
</tr>
<tr>
<td>Patient 9</td>
<td>PCa</td>
<td>Prostate adenocarcinoma</td>
<td>7</td>
<td>T2a</td>
</tr>
<tr>
<td>Patient 10</td>
<td>PCa</td>
<td>Prostate adenocarcinoma</td>
<td>6</td>
<td>T1c</td>
</tr>
<tr>
<td>Patient 11</td>
<td>PCa</td>
<td>Prostate adenocarcinoma</td>
<td>7</td>
<td>T2c</td>
</tr>
<tr>
<td>Patient 12</td>
<td>PCa</td>
<td>Prostate adenocarcinoma</td>
<td>6</td>
<td>T2b</td>
</tr>
</tbody>
</table>
**Materials and Methods**

Table M2: Detailed data of patient biopsies from the clinical trial with Everolimus.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Day</th>
<th>Localization</th>
<th>Primary Tumor</th>
<th>Localization</th>
<th>Dose (mg)</th>
<th>Administration</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>Pre-tr.</td>
<td>liver Mx</td>
<td>colon</td>
<td>liver Mx</td>
<td>20</td>
<td>weekly</td>
<td>PD</td>
</tr>
<tr>
<td>P2</td>
<td>Pre-tr.</td>
<td>breast</td>
<td>breast</td>
<td>liver M</td>
<td>5</td>
<td>daily</td>
<td>PD</td>
</tr>
<tr>
<td>P3</td>
<td>Pre-tr.</td>
<td>breast</td>
<td>breast</td>
<td>skin</td>
<td>5</td>
<td>daily</td>
<td>PD</td>
</tr>
<tr>
<td>P4</td>
<td>Pre-tr.</td>
<td>breast</td>
<td>breast</td>
<td>skin</td>
<td>20</td>
<td>weekly</td>
<td>PD</td>
</tr>
<tr>
<td>P5</td>
<td>Pre-tr.</td>
<td>liver Mx</td>
<td>colon</td>
<td>liver Mx</td>
<td>50</td>
<td>weekly</td>
<td>PD</td>
</tr>
<tr>
<td>P6</td>
<td>Pre-tr.</td>
<td>liver Mx</td>
<td>pancreas</td>
<td>liver Mx</td>
<td>50</td>
<td>weekly</td>
<td>PD</td>
</tr>
<tr>
<td>P7</td>
<td>Pre-tr.</td>
<td>breast</td>
<td>breast</td>
<td>skin</td>
<td>50</td>
<td>weekly</td>
<td>PD</td>
</tr>
<tr>
<td>P8</td>
<td>Pre-tr.</td>
<td>melanoma axila</td>
<td>melanoma</td>
<td>axilar lymph node</td>
<td>10</td>
<td>daily</td>
<td>PD</td>
</tr>
<tr>
<td>P9</td>
<td>Pre-tr.</td>
<td>liver Mx</td>
<td>liver Mx</td>
<td>liver Mx</td>
<td>5</td>
<td>daily</td>
<td>SD</td>
</tr>
<tr>
<td>P10</td>
<td>Pre-tr.</td>
<td>breast</td>
<td>breast</td>
<td>skin</td>
<td>50</td>
<td>weekly</td>
<td>PD</td>
</tr>
<tr>
<td>P11</td>
<td>Pre-tr.</td>
<td>breast</td>
<td>breast</td>
<td>skin</td>
<td>50</td>
<td>daily</td>
<td>PD</td>
</tr>
<tr>
<td>P12</td>
<td>Pre-tr.</td>
<td>liver Mx</td>
<td>liver Mx</td>
<td>liver Mx</td>
<td>10</td>
<td>daily</td>
<td>PD</td>
</tr>
<tr>
<td>P13</td>
<td>Pre-tr.</td>
<td>maxilar</td>
<td>H&amp;N</td>
<td>maxilar</td>
<td>10</td>
<td>daily</td>
<td>NA</td>
</tr>
<tr>
<td>P14</td>
<td>Pre-tr.</td>
<td>breast</td>
<td>breast</td>
<td>skin</td>
<td>20</td>
<td>weekly</td>
<td>NA</td>
</tr>
</tbody>
</table>

I.2 Methods

I.2.1 Genotyping

Breeding and tag and tailing was carried out by anmial house personnel. Genotyping was performed by technicians in the Carracedo lab, Sonia Fernández and Pilar Sanchez-Mosquera (CIC bioGUNE).

I.2.1.1 Genomic DNA purification from mouse tail

Mouse tail samples (0.2-1cm) were lysed in 195uL of lysis buffer [100mM NaCl, 50mM Tris-HCl (pH 8.0), 25mM EDTA, 0.5% SDS or 100mM NaCl, 50mM Tris-HCl (pH 8.0), 5mM EDTA, 1% SDS] with 5uL of Proteinase K (stock 10mg/ml; Fluka) for 3-6h at 55°C.

Once soft tissue was solubilized, 200µl of phenol/chloroform/isoamyl (25:24:1) were added to separate DNA (in upper aqueous phase) from denaturalized proteins (in interphase) and RNA and lipids (in lower organic phase) by mixing well by inversion and centrifugation for 15 min at 14,000rpm at room temperature. DNA containing aqueous phase was transferred to new tubes and washed/precipitated by adding 15uL sodium acetate (3M) and 400uL of 100% ethanol and...
incubated at -20°C overnight to enhance precipitation. Samples were centrifuged 10min at 14000rpm at 4°C and supernatant was discarded to dry DNA pellets. Dry pellets were resuspended in 50-100uL H2O (up to 500uL for tail fragments of 1cm).

I.2.1.2 Polymerase Chain Reaction (PCR) for genotyping

For genotyping, extracted mouse tail DNAs (1μL) were subjected to Polymerase Chain Reactions (PCR), optimized with specific primers (specified in Table M3) and PCR programs (See Fig. M5) for each gene of interest. All PCR assays were performed with DNA Polymerase Mix AccuStart™II PCR SuperMix (Quanta Biosciences).

Table M3: Specific primer sequences used for genotyping mouse colonies.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward 5’-3’</th>
<th>Reverse 5’-3’</th>
<th>Band size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pten</td>
<td>TGTTTTTGGACCATTAAGTGGGCTGTG</td>
<td>AAAAGTTCCCCTGCTGATGATTTGT</td>
<td>Pten pc+ 350bp, Pten pc lox 480bp</td>
</tr>
<tr>
<td>Cre</td>
<td>GGTGCAAGTTGAATAACCAGA</td>
<td>CGGTATTGAACCTCCAGGC</td>
<td>850bp</td>
</tr>
<tr>
<td>Gnat +</td>
<td>GTACCGCAGGAGTACAAGCG</td>
<td>CAATCGCAGGGAAAGACGC</td>
<td>330bp</td>
</tr>
<tr>
<td>Gnat -</td>
<td>CAATCGCAGGGAAAGACGC</td>
<td>CTGAATGAACTGCAGGACG</td>
<td>1151bp</td>
</tr>
</tbody>
</table>

Figure M5. PCR programs followed for mouse tail DNA amplification and genotyping.
I.2.2 Pathological analysis of prostate tissues

At the experimental end-point of all *in vivo* genetic mouse model experiments, one of each prostate lobes (AP, DLP and VP) was fixed in 10% neutral buffered formalin and stored at 4°C for 24 hours to allow tissue fixation for pathological analysis. All the tissue processing and staining steps were performed by Sonia Fernández (CIC bioGUNE).

I.2.2.1 Tissue processing, paraffin embedding and sectioning

After 24 hour fixation tissues were dehydrated and infiltrated with paraffin following the steps in Table M4. Infiltrated tissues were then embedded in paraffin blocks.

Table M4: Steps followed to process mice tissues.

<table>
<thead>
<tr>
<th>Tray</th>
<th>Time</th>
<th>Reagent</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>10 min</td>
<td>50% alcohol</td>
<td>Dehydration</td>
</tr>
<tr>
<td>T2</td>
<td>1 h 30 min</td>
<td>70% alcohol</td>
<td>Dehydration</td>
</tr>
<tr>
<td>T3</td>
<td>1 h 30 min</td>
<td>80% alcohol</td>
<td>Dehydration</td>
</tr>
<tr>
<td>T4</td>
<td>1 h 30 min</td>
<td>96% alcohol</td>
<td>Dehydration</td>
</tr>
<tr>
<td>T5</td>
<td>1 h 30 min</td>
<td>100% alcohol</td>
<td>Dehydration</td>
</tr>
<tr>
<td>T6</td>
<td>1 h 30 min</td>
<td>100% alcohol</td>
<td>Dehydration</td>
</tr>
<tr>
<td>T7</td>
<td>1 h 30 min</td>
<td>100% alcohol</td>
<td>Dehydration</td>
</tr>
<tr>
<td>T8</td>
<td>45 min</td>
<td>Citrosol or Xylene substitute</td>
<td>Rinse, replace the alcohol with citrosol</td>
</tr>
<tr>
<td>T9</td>
<td>2 h</td>
<td>Paraffin</td>
<td>Replace the citrosol with paraffin</td>
</tr>
<tr>
<td>T10</td>
<td>2 h</td>
<td>Paraffin</td>
<td>Replace the citrosol with paraffin</td>
</tr>
</tbody>
</table>

Ice-cold paraffin blocks were sectioned to obtain 3 μm sections, which were then adhered to slides for tissue staining and analysis.

I.2.2.2 Slide processing for immunohistochemistry

Tissue slides were de-paraffined and hydrated, following steps in Table M5, to allow immunohistochemical analysis.

Table M5: Steps followed to process tissue slides for immunochemistry.

<table>
<thead>
<tr>
<th>Time</th>
<th>Repeats</th>
<th>Reagent</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-15 min</td>
<td>Twice</td>
<td>Citrosol or Xylene substitute</td>
<td>Hydration</td>
</tr>
<tr>
<td>3 min</td>
<td>Twice</td>
<td>100% alcohol</td>
<td>Hydration</td>
</tr>
<tr>
<td>3 min</td>
<td>Twice</td>
<td>95% alcohol</td>
<td>Hydration</td>
</tr>
<tr>
<td>3 min</td>
<td>Twice</td>
<td>dH2O</td>
<td>Hydration</td>
</tr>
</tbody>
</table>

After the desired staining in each case, slides were dehydrated with 95% and 100% alcohol and cleared in xylene for final coverslip mounting with DPX.
I.2.2.2.1 Haematoxylin and Eosin (H&E) staining

Slides were incubated in haematoxylin for 5 min and rinsed in water for 1 min. After haematoxylin staining, they were incubated in acid alcohol (70% alcohol, 3% HCl) for 2 seconds for controlled leaching of non-specific background coloration and rinsed again in water (1 min). Finally, slides were incubated in eosin for 2 min and mounted.

I.2.2.2.2 Ki67 and RpS6S235-236 staining

Antigen retrieval was performed with citrate buffer (pH 6) in steamer (30 min). H$_2$O$_2$ was used to block the endogenous peroxidase, followed by blocking with goat serum and primary antibody [Ki67, Thermo MA5-14520 (1:100); RpS6S235-236, CST #4858 (1:500)] incubation overnight at 4 ºC. Goat anti-rabbit IgG antibody [Vector Laboratories, Cat# BA-1000 (1:1000)] was incubated at room temperature for 30 min. IHC detection was performed with the VECTASTAIN Elite ABC Kit (Cat# PK-6100) from Vector Laboratories and developed with DAB. A schematic of the procedure is shown in Fig. M6.

I.2.2.2.3 AMD1 staining and scoring

Immunohistochemical analysis of AMD1 [Proteintech, 11052-1-AP (1:100)] was performed using DAKO EnVision™ Flex High pH (Tris/EDTA pH 9) (DAKO) (Technical details are shown in Fig. M6) The scoring system was based on the quantification of the percentage of cells negative (0), low (1+), medium (2+) or high (3+) immunoreactivity. Subsequently, h-score was calculated as follows: $H = [\text{percentage of cells 1+}] + [2 \times \text{percentage of cells 2+}] + [3 \times \text{percentage of cells 3+}]$.

Figure M6. Schematic of immunohistochemistry procedures. A, Avidin/Biotin Complex (ABC) method. B, DAKO EnVision Flex method.
I.2.3 Molecular analysis of prostate tissues

At the experimental end-point of all the in vivo experiments, one of the prostate lobes (AP, DLP and VP) was snap frozen in liquid nitrogen immediately after extraction for molecular or metabolomic analysis.

For molecular analysis, prostate tissues were homogenized with Precellys technology in the presence of ceramic beads, using two cycles of 30 seconds at 5000rpm.

I.2.3.1 Gene expression analysis of murine prostate tissues

For RNA extraction from prostatic tissue, samples were incubated overnight in the presence of RNA later ICE® (Thermo) at -20°C. Prostate tissues were homogenized in the presence of TRizol® reagent (Thermo) and RNA extraction was performed by TRizol method and subsequent Macherey Nagel RNA extraction kit (Ref# 740955.250) (Ugalde-Olano et al., 2015). Retrotranscription and gene expression analysis by Real Time-Quantitative-Polymerase Chain Reaction (RT-QPCR) were then performed as explained in II.2.4.1.1. and II.2.4.1.2.

I.2.3.2 Protein expression analysis of murine prostate tissues

For protein extraction from prostatic tissue, the homogenization was performed in the presence of 400uL of RIPA lysis buffer containing 2mM phosphatase inhibitors (sodium fluoride, sodium orthovanadate and β-glycerophosphate) and two tablets of protease inhibitor cocktail (Roche). Protein extraction and western blotting were then performed as explained in II.2.4.2.1. and II.2.4.2.2.

I.2.4 Metabolomic analysis of murine prostate tissues

Prostate tissues for metabolomic analysis were directly shipped frozen in dry ice for metabolite extraction by Agios Pharmaceuticals.

I.2.4.1 Time of Flight-Mass Spectometry (ToF-MS)

Following normalization to cell number or tissue weight, metabolites were extracted with cold 80/20 (v/v) methanol/water. Samples were then dried and stored at -80°C until MS analysis. High-throughput Time-Of-Flight analysis was conducted using flow injection analysis as previously described (Fuhrer et al., 2011.). In short, samples were re-suspended and injected on an Agilent 1100 coupled with an Agilent 6520 QToF mass spectrometer with an electrospray ionization source. Mobile phase consisted of 60/40 methanol/water with 0.1% formic acid and was used to deliver 2µL of each sample to the MS, flowing at 150µL/min. Data was collected in positive mode with 4 GHz HiRes resolving power with internal lock masses. Data processing was conducted with Matlab R2010b.
I.2.4.2 Liquid Chromatography-Mass Spectrometry (LC/MS)

Quantitative liquid chromatography/mass spectrometry (LCMS) was conducted as previously described (Jha et al., 2015). A Thermo Accela 1250 pump delivered a gradient of 0.025% heptafluorobutyric acid, 0.1% formic acid in water and acetonitrile at 400µL/min. Stationary phase was an Atlantis T3, 3µm, 2.1x150mm column. A QExactive Mass Spectrometer was used at 70,000 resolving power to acquire data in full-scan mode. Data analysis was conducted in MAVEN (Melamud et al., 2010) and Spotfire.

I.2.4.3 Targeted metabolomics by UPLC-MS

Levels of dcSAM in cell cultures and tissues were analyzed by ultra-high performance liquid-chromatography coupled to mass spectrometry (UPLC-MS). Briefly, extraction and homogenization was done in methanol/acetic acid (80/20 %v/v) Speed-vacuum-dried metabolites were solubilized in 100 µL of a mixture of water/acetonitrile (40/60 %v/v) and injected onto the UPLC/MS system (Acquity and SYNAPT G2, Waters, Manchester). The extracted ion traces were obtained for dcSAM (RT = 3.0', m/z 355.16) and putrescine (RT = 2.67', m/z 89.1079). Corrected signals were normalized to relative cell number.

I.2.4.4 Metabolic Flux Analysis (MFA)

U-\textsuperscript{13}C\textsubscript{5}-L-methionine was purchased from Cambridge Isotope laboratories and administered intravenously (by tail vein injection, performed by Dr. Beraza). A pilot experiment was performed to establish final concentrations and time-points. For the pilot experiment, final concentrations of 100mg/Kg or 400mg/Kg for 3, 6, 10 and 24 hour pulses were tested. From the pilot experiment, 100mg/Kg dose and two time-points (1hour to detect methionine cycle related metabolites; 10hours to detect polyamine pathway related metabolites) were set. After 1hour and 10 hour pulses with U-\textsuperscript{13}C\textsubscript{5}-L-methionine mice were sacrificed as specified in I.1.1. and tissues of experimental interest were harvested.
II IN VITRO ASSAYS

II.1 Materials

II.1.1 Cell lines and culture conditions

Human prostate carcinoma cell lines (PC3, LNCaP, DU145) were purchased from Leibniz-Institut DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH), who provided authentication certificate, or American Type Culture Collection (ATCC) in the case of RWPE1, PWRE1 and 22RV1 cell-lines. Virus packaging cell lines 293FT and Phoenix Ampho and C4.2 were generously provided by the laboratory of Dr. Rosa Barrio and Pier Paolo Pandolfi, respectively. PC3, DU145, Phoenix Ampho and 293FT cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco Cat# 41966-029), while LNCaP, C4.2 and 22RV1 were cultured in RPMI 1640 Medium (Gibco Cat# 61870-010; with GlutaMAX supplement). Both culture medias were complemented with 10% inactivated Fetal Bovine Serum (FBS) (Gibco), from same lot and previously analyzed to ensure experimental reproducibility, and 1% Penicillin/Streptomycin (Gibco) (complete media). RWPE1 and PWR1E benign prostate primary cell lines were cultured in Keratinocyte-Serum Free Medium (K-SFM; Gibco Cat# 17005-034), supplemented with human recombinant Epidermal Growth Factor 1-53 (EGF 1-53) and Bovine Pituitary Extract (BPE). See Table M6 for cell line specifications.

Table M6: Detailed list of the characteristics of the different PCa cell-lines employed in the work.
All cell lines were grown at 37°C in a humidified atmosphere of 5% CO₂. Cells were regularly cultured in 100mm dishes and split every 2-3 days, maintaining them below 80-90% density, up to 30 passages maximum. To split the cells they were incubated in a trypsin-EDTA solution (Gibco) at 0.05% for 3-5 minutes at 37°C and resuspended in fresh complete media. All cell-lines were periodically analyzed by PCR for mycoplasma presence and replaced or treated in case of positive result. For cell counting, after trypsinization, cells were diluted 1:2 in Trypan Blue Dye (Amresco) and 10μL were loaded in a Neubauer chamber to count viable cells by optical microscopy (Olympus CKX31). The Trypan Blue dye allows to determine cell viability based on the fact that damaged or dead cells show disrupted plasma membrane and allow the internalization of the dye staining their cytoplasm in blue, while alive cells remain non-stained. In general experiments were performed with technical duplicates or triplicates and a minimum of three biological replicates (n=3 minimum).

**Table M7**: Approximate cell-number seeded according to each experimental technique.

<table>
<thead>
<tr>
<th>Assay</th>
<th>PC3</th>
<th>LNCaP</th>
<th>DU145</th>
<th>22RV1</th>
<th>Plate type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein/RNA extraction</td>
<td>100000</td>
<td>300000</td>
<td>120000</td>
<td></td>
<td>6-well plate</td>
</tr>
<tr>
<td>Growth Curves</td>
<td>5000</td>
<td>30000</td>
<td>7500</td>
<td></td>
<td>12-well plate</td>
</tr>
<tr>
<td>Soft Agar</td>
<td>2500</td>
<td>5000</td>
<td>3000</td>
<td></td>
<td>6-well plate</td>
</tr>
<tr>
<td>Foci Formation</td>
<td></td>
<td></td>
<td></td>
<td>500</td>
<td></td>
</tr>
<tr>
<td>Cell-Cycle</td>
<td></td>
<td></td>
<td></td>
<td>250000</td>
<td>6-well plate</td>
</tr>
<tr>
<td>BrDU Incorporition</td>
<td></td>
<td></td>
<td></td>
<td>40000</td>
<td>12-well plate</td>
</tr>
<tr>
<td>Metabolomics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GNTM OE</td>
<td>350000</td>
<td>100000</td>
<td>425000</td>
<td>200000</td>
<td>100mm plate</td>
</tr>
<tr>
<td>AMD1 acute Silencing</td>
<td>100000-110000</td>
<td>120000-200000</td>
<td></td>
<td></td>
<td>6-well plate</td>
</tr>
<tr>
<td>AMD1 Inducible Silencing</td>
<td>50000-100000</td>
<td></td>
<td></td>
<td></td>
<td>6-well plate</td>
</tr>
<tr>
<td>AMD1 OE</td>
<td>200000</td>
<td></td>
<td></td>
<td></td>
<td>6-well plate</td>
</tr>
</tbody>
</table>

**II.1.2 Drugs**

Information regarding the different inhibitors and drugs used for this thesis work are depicted in **Table M8**.

**Table M8**: Commercial information and experimental specifications for the different drugs used throughout the thesis work.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Supplier</th>
<th>Dose</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapamycin</td>
<td>LC Laboratories (Cat. # R-5000)</td>
<td>20nM</td>
<td>Specific mTOR inhibitor</td>
</tr>
<tr>
<td>RAD001 (Everolimus)</td>
<td>Provided by Dr. Alimonti and Dr. Serra</td>
<td>10mg/Kg</td>
<td>Rapamycin derivative, mTOR inhibitor</td>
</tr>
<tr>
<td>Torin-1</td>
<td>Tocris Bioscience (Cat.#4247)</td>
<td>125-250nM</td>
<td>Potent and selective ATP-competitive mTORC1 and mTORC2 inhibitor</td>
</tr>
<tr>
<td>MK2206</td>
<td>Shelleckchem (Cat.# S1078)</td>
<td>500nM</td>
<td>Highly selective allosteric pan-AKT inhibitor</td>
</tr>
<tr>
<td>SAM486A</td>
<td>Novartis</td>
<td>0.5-1μM</td>
<td>Competitive AMD1 inhibitor</td>
</tr>
<tr>
<td>Cicloheximide</td>
<td>Sigma</td>
<td>5μg/mL</td>
<td>Protein synthesis inhibitor in eukaryotes</td>
</tr>
<tr>
<td>MG132</td>
<td>Provided by Dr. Rodriguez</td>
<td>5μM</td>
<td>Potent, membrane-permeable proteasome inhibitor</td>
</tr>
</tbody>
</table>
II.2 Methods

II.2.1 Cloning

Different cloning strategies were followed to obtain the lentiviral and retroviral vectors required for GNMT overexpression, PTEN (Wild-Type, WT; and C124S) re-expression, and AMD1 overexpression and silencing. The different strategies are briefly detailed below (See Table M9 for primer specifications):

HA-GNMT-TRIPZ:

PCEP4-GNMT vector was amplified using high-fidelity PCR with the primers specified in Table M9 (GNMT01 and GNMT02) to generate a HA-GNMT cassette containing the restriction sites for AgeI-MluI. GNMT01 and GNMT02 provide Kozak, ATG, and stop sequences. The resulting amplicon was subcloned with TOPO Cloning technology. Then, TOPO was digested with AgeI-MluI and the GNMT bearing fragment was introduced in an inducible TRIPZ vector.

TRIPZ-YFP-PTEN (WT and C124S, catalytic-dead mutant):

TRIPZ-FF3shRNA was digested with AgeI-MluI, which releases the tRFP, shRNAmir, and barcode from the plasmid backbone. Vector was gel-purified. Using PTEN expression clones (WT or C124S; from Dr. Pandolfi’s lab), a YFP-GSG-PTEN cassette was created by overlap-extension PCR using high-fidelity PCR (KAPA Biosystems). Outer primers PTEN03 and PTEN02 provide Kozak, ATG, and stop sequences. Inner bridging primers (PTEN04 and PTEN05) join the YFP and PTEN portions with a flexible Gly-Ser linker. The final resulting amplicon (~1.9kb) was cleaned up, digested with AgeI-MluI, gel-purified and cloned into TRIPZ-FF3shRNA AgeI-MluI. Colonies were screened by restriction digest and positives confirmed by Sanger sequencing.

sh3 AMD1 pLKO Tet ON:

Lentiviral inducible pLKO Tet ON vector was opened using AgeI-EcoRI (Fermentas/Takara-Clontech). Specific shRNA sequences for AMD1 were obtained from SIGMA (MISSION® shRNA) (see Table M9). Complementary primers were designed, in which an EcoRI site was added in the 5’ end, coinciding with complementary AgeI site in the template sequence. For the annealing, 11.25 µL of each primer were added to a 25 µL reaction with 2.5µL 10X annealing buffer (100mM NaCl, 50 mM HEPES, pH=7.4). The reaction was added to a preheated thermoblock (95°C), allowed to incubate for 5 min, and then the thermoblock was switched off, allowing slow cooling to room temperature. 2.5 µl of annealed oligos were ligated to 4µl of linearized vector, in a reaction of 10 µl, with 2 µl of 5x Invitrogen ligase buffer and 1.5 µl of NBE ligase (Invitrogen). After 1hr of incubation at room temperature (RT), ligation was transformed into competent XL-10 Gold E. coli and selected on Amp plates. Positive colonies were confirmed by restriction digest and Sanger sequencing.
Table M9: Information about the specific primers utilized for the different cloning approaches.

<table>
<thead>
<tr>
<th>Number</th>
<th>Name</th>
<th>Purpose</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>GNMT01</td>
<td>AgeI-HA-GNMT F</td>
<td>To produce a PCR product with AgeI restriction site in 5’end</td>
<td>ACCCGTGCCACGATggcttacctgacagtgtcctgacagtgtccagtacagctggGACCCGT GCACGGGACCCGC</td>
</tr>
<tr>
<td>GNMT02</td>
<td>HA-GNMT-MluI R</td>
<td>To produce a PCR product with AgeI restriction site</td>
<td>AGCGGTTCAGTCGTCTCCTGATAG</td>
</tr>
<tr>
<td>PTEN02</td>
<td>MluI.PTEN.rev</td>
<td>2-step PCR cloning of PTEN WT and mutants with YFP tag; for cloning as AgeI-MluI into TRIPZ</td>
<td>gatacagcgcgtAGACTTTTTGTGATGCTGATGCT</td>
</tr>
<tr>
<td>PTEN03</td>
<td>AgeI.KozGFP.f or</td>
<td>2-step PCR cloning of PTEN WT and mutants with YFP tag; for cloning as AgeI-MluI into TRIPZ</td>
<td>gatacagcgcgtccacattGTGAGCAAG GGCAGGGAGC</td>
</tr>
<tr>
<td>PTEN04</td>
<td>GFP.GSG.PTEN.for</td>
<td>2-step PCR cloning of PTEN WT and mutants with YFP tag; for cloning as AgeI-MluI into TRIPZ</td>
<td>GCCATGGACGAGCTGTACAGGCC CATCAAAAGAG</td>
</tr>
<tr>
<td>PTEN05</td>
<td>GFP.GSG.PTEN.rev</td>
<td>2-step PCR cloning of PTEN WT and mutants with YFP tag; for cloning as AgeI-MluI into TRIPZ</td>
<td>CTCTTTGATGAGCTGTCATAGcgc CTGTCAGCAGCTATCAAAAGAG</td>
</tr>
<tr>
<td>sh3AMD T01</td>
<td>sh3 AMD top</td>
<td>To introduce the shRNA in the pLKO Tet ON vector</td>
<td>CGCGGTTCAGTCTAGAGACGTTCG TTACTGAGATGGTGGTTTCTGAGAATGAAACGTCTC</td>
</tr>
<tr>
<td>sh3AMD B01</td>
<td>sh3 AMD bottom</td>
<td>To introduce the shRNA in the pLKO Tet ON vector</td>
<td>ATTACAAAGAGGTTCTCAGAGAGCT GTTACTGAGATGGTGGTTTCTGAGAATGAAACGTCTC</td>
</tr>
<tr>
<td>AC.AMD 01</td>
<td>HABMSXNC. for</td>
<td>Liner for LNCX; Hill-AgeI-BglII-MluI-SalI-XhoI-NotI-ClaI</td>
<td>AGTTACCGTGATAGCTCAAGCCTG TCGACCGTGAGCAGCAGC</td>
</tr>
<tr>
<td>AC.AMD 02</td>
<td>HABMSXNC. rev</td>
<td>Liner for LNCX; Hill-AgeI-BglII-MluI-SalI-XhoI-NotI-ClaI</td>
<td>CATGCGTGACGCTCAGGTCGA CAGCCCTAGCTACGTACCGTA</td>
</tr>
<tr>
<td>AC.AMD 07</td>
<td>BamHI.Nhel.MYC.AMD1.for</td>
<td>to amplify AMD1/mutants with a N-terminal MYC tag</td>
<td>GATCGGATCCGTCGACAGCTCAAM GCGTAATCTGGAAGACGTCTC</td>
</tr>
<tr>
<td>AC.AMD 10</td>
<td>BamHI.SalI.H A. rev</td>
<td>to amplify AMD1/mutants with C-terminal HA</td>
<td>GATCGGATCCGTCGACAGCTCAAM GCGTAATCTGGAAGACGTCTC</td>
</tr>
<tr>
<td>3336</td>
<td>AMD1.S298A. qc. for</td>
<td>to mutate S298 in AMD1</td>
<td>aaatgtcgcacagtgcgtgGCcccccagaaag afgaaggttttaagc</td>
</tr>
<tr>
<td>3337</td>
<td>AMD1.S298A. qc. rev</td>
<td>to mutate S298 in AMD1</td>
<td>gcttaaaacccttaatctttgcggGGCagc aagcactgtgcagcacttt</td>
</tr>
<tr>
<td>3338</td>
<td>AMD1.S298D. qc. for</td>
<td>to mutate S298 in AMD1</td>
<td>aaatgtcgcacagtgcgtgGAccccagaaga gaaggttttaagc</td>
</tr>
<tr>
<td>3339</td>
<td>AMD1.S298D. qc. rev</td>
<td>to mutate S298 in AMD1</td>
<td>gcttaaaacccttaatctttgcggGTCagcaagc acgtgcagcacttt</td>
</tr>
</tbody>
</table>

**LNCX-neo (HCX):**

Retroviral expression vector LNCX-neo was opened using HindIII-ClaI (Fermentas/Thermo). A multiple cloning site was created by inserting a double-stranded synthetic oligo pair into the HindIII-ClaI site, to create LNCX-neo (HCX). For the annealing, 5µl of each oligo (100 µM stock) (Metabion) were added to a 50µl reaction, including 200 mM NaCl, 10 mM Tris-HCl pH 7.9, 20mM MgCl₂ (2X NEB Buffer 3). The reaction was added to a preheated thermoblock (95 °C), allowed to
incubate for 5 min, and then the thermoblock was switched off, allowing slow cooling to room temperature. Finally, ~100 ng of linearized vector was ligated to 1µl of annealed oligos, in a reaction of 10 µl, with 2 µl of 5x T4 DNA ligase buffer and 1µl of T4 DNA ligase (Invitrogen). After 1h of incubation at RT, ligation was transformed into competent XL-10 Gold E. coli and selected on Amp plates. Positive colonies were screened by PCR, confirmed by restriction digest and Sanger sequencing.

**LNCX-MYC-AMD1(WT)-HA:**

A retroviral expression construct for N-terminal MYC- and C-terminal HA-tagged AMD1 was created. Primer AC.AMD07 and AC.AMD08 were used to amplify the AMD1 ORF using high-fidelity PCR (KAPA Biosystems). The resulting amplicon (~1kb) was digested with BamH1-Sal1, and cloned into LNCX-neo (HCX) Bgl2-Sal1.

**LNCX-MYC-AMD1(S298A)-HA (phospho-dead mutant):**

These mutants were created by 2-step overlap extension PCR. Briefly, oligos AC.AMD07 and mutagenic oligos 3337 (or 3339) were used to create a 5' amplicon, while mutagenic oligos 3336 (or 3338) and AC.AMD10 were used to create a 3' amplicon, using AMD1(WT) ORF as a template. Amplicons were gel-purified, mixed, elongated using 10 cycles of melting/annealing/extension, without amplification. Outer primers AC.AMD07 and AC.AMD10 were added and PCR with amplification was carried out for 25 cycles. The resulting composite amplicons were cleaned up, digested with BamH1-Sal1, gel-purified, and then cloned into LNCX-neo (HCX) Bgl2-Sal1. Colonies were screened by restriction digest and positives confirmed by Sanger sequencing.

**II.2.2 Virus production and target cell line infection**

Virus production was performed by employing a packaging cellline and the target cellline in which the transgene was aimed to be introduced.

The general protocol was similar for both lentivirus and retrovirus production (Fig. M7):

- **Day1:**
  - Morning: Packaging cells were seeded at high density (4x10^6 cells/100mm plate)
  - Afternoon: Packaging cells were transfected

- **Day2:** Packaging cells’ media was changed to fresh culture-media and target cell line was seeded.

- **Day3:** Target cells were first infected with virus containing supernatant (SN) from packaging cells and fresh media was added to these cells for further virus production
Day4: Second infection of target cells was performed with virus containing SN and packaging cells were discarded. For infection, SN from packaging cells was filtered with 0.45µm filters and 4mL of fresh media were added to a total of 13mL. Protamine sulfate (Stock 8mg/ml) was added to the mixture (1:1000 dilution) to increase infection efficiency.

Day5: Target cells were submitted to selection with the corresponding antibioticin each case.

Figure M7. Schematic showing the experimental design followed for virus production.

II.2.2.1 Transient transfection in HEK293 cells

Virus production was performed by transient transfection of Human Embryonic Kidney 293 cells (HEK293). In transient transfection, the exogenous DNA is not inserted into the genome, and hence, it is diluted in subsequent cellular divisions.

Cells were transfected with packaging vectors and the vector of interest (transfer vector), by calcium phosphate method, to produce viral particles. DNA was first diluted in miliQ-water and then CaCl₂ was added to a final concentration of 125 mM. This DNA solution was then mixed with same volume of a 2x HEPES-Buffered Solution (HBS) [50mM HEPES, 280mM NaCl, 10mM KCl, 1.5mM Na₂HPO₄, 2H₂O, 12mM dextrose, pH=7.05] in the presence of oxygen to facilitate the formation of calcium phosphate crystals. These crystals form pores in the cytoplasmic membrane allowing exogenous DNA entrance. 4x10⁶ HEK293 cells were seeded for each transfection and culture media was changed to fresh media 16h post-transfection to induce viral particle production. Then, the viral particles produced were used to infect target cell lines for genetic modification.
II.2.2.2 Lentivirus production and target cell-line infection

Lentivirus production was performed in HEK293FT cells transfected with packaging vectors and the vector carrying the transgene (Fig M8). We used lentiviral infection to over-express GNMT and to silence AMD1 in PCa cell lines. Depending on the back-bone vector containing our gene or shRNA of interest, second generation or third generation packaging vectors were employed.

![Image](M8)

Figure M8. Representative image showing packaging system and lentivirus production in HEK293 cells.

II.2.2.2.1 Second Generation Lentivirus production

GNMT and PTEN (WT and C124S mutant) were introduced in a doxycycline inducible TRIPZ vector. TRIPZ vectors are not compatible with third generation packaging systems. Thus, a second generation strategy was followed to produce the virus. Second generation lentiviral vectors consist of three plasmids normally: the transfer vector, containing all the cis-acting sequences required and the transgene to be delivered, and two packaging vectors psPAX2 and pVSV-G, which provide the trans-acting factors (Fig. M9). The separation of cis-acting and trans-acting sequences reduces the probability of recombination producing replication-competent viral particles. In this particular case, due to the TRIPZ backbone of the GNMT and PTEN bearing vector, as aforementioned, a pTAT vector was needed to help in transcription (See Table M10).

![Image](M9)

Figure M9. Informative image showing the fragmentation of the lentiviral genome into a second generation packaging system.
Second generation lentivirus production was performed following standard protocol mentioned in II.2.1. Target cell-lines (PC3, DU145, LNCaP and 22RV1) were submitted to puromycin (2ug/mL) selection for 48-72h.

Table M10: Information regarding the specific vectors employed for second generation lentivirus production.

<table>
<thead>
<tr>
<th>Vector Name</th>
<th>Role</th>
<th>Encoding sequences</th>
<th>Function</th>
<th>Origin</th>
<th>Amount transfected</th>
</tr>
</thead>
<tbody>
<tr>
<td>psPAX2</td>
<td>Packaging vector</td>
<td>Gag-Pol</td>
<td>integrase, reverse transcriptase, and structural proteins</td>
<td>Dr. James D. Sutherland</td>
<td>1.66µg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RRE</td>
<td>Rev-responsive element</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rev</td>
<td>Enhancer of unspliced viral genomic RNA nuclear export</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pVSV-G</td>
<td>Packaging vector</td>
<td>VSV-G</td>
<td>Envelope protein</td>
<td>Dr. James D. Sutherland</td>
<td>1.66µg</td>
</tr>
<tr>
<td>pTAT</td>
<td>Helper vector</td>
<td>TAT</td>
<td>Enhances transcription efficiency</td>
<td>Dr. James D. Sutherland</td>
<td>1.66µg</td>
</tr>
<tr>
<td>HA-GNMT-TRIPZ</td>
<td>Transfer vector</td>
<td>GNMT</td>
<td>Gene to over-express</td>
<td>Dr. James D. Sutherland</td>
<td>5µg</td>
</tr>
<tr>
<td>TRIPZ-YFP-PTEN-WT</td>
<td>Transfer vector</td>
<td>PTEN-WT</td>
<td>Gene to over-express</td>
<td>Dr. James D. Sutherland</td>
<td>5µg</td>
</tr>
<tr>
<td>TRIPZ-YFP-PTEN-C124S</td>
<td>Transfer vector</td>
<td>PTEN-C124S</td>
<td>Mutant to over-express</td>
<td>Dr. James D. Sutherland</td>
<td>5µg</td>
</tr>
</tbody>
</table>

II.2.2.2 Third Generation Lentivirus production

Third generation virus (Fig. M10) were generated for constitutive and inducible silencing of AMD1 in DU145 and PC3 cells. A set of five short-hairpin RNA (shRNA) sequences against AMD1 in a pLKO backbone were purchased from SIGMA (MISSION® shRNA Bacterial Glycerol Stock).

Figure M10. Informative image showing the fragmentation of the lentiviral genome into a third generation packaging system.

The set of shRNAs was validated and two efficient shRNAs were selected for further experiments. One of those two selected sequences was then cloned into a doxycycline inducible pLKO backbone in collaboration with Dr. Sutherland. pLKO vectors are compatible with third generation lentivirus production. Third generation lentivirus require three packaging vectors (pRRE, pREV, pVSV-G; which decreases recombination probability and makes them more secure to handle than second generation ones) and transfer vector (See Figure M10,11 and Table M11).
**Materials and Methods**

**Figure M11.** Illustrative image explaining the third generation lentiviral production in HEK283 cells and posterior infection of target cells.

Table M11: Information regarding the specific vectors employed for third generation lentivirus production

<table>
<thead>
<tr>
<th>Vector Name</th>
<th>Role</th>
<th>Encoding sequence</th>
<th>Function/Sequence</th>
<th>Origin</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>pRRE</td>
<td>Packaging vector</td>
<td>Gag-Pol</td>
<td>Integrate, reverse transcriptase, and structural proteins</td>
<td>Dr. James D. Sutherland</td>
<td>1.66µg</td>
</tr>
<tr>
<td>pREV</td>
<td>Packaging vector</td>
<td>Rev</td>
<td>Rev-responsive element</td>
<td>Enhancer of unspliced viral genomic RNA nuclear export</td>
<td>Dr. James D. Sutherland</td>
</tr>
<tr>
<td>pVSV-G</td>
<td>Packaging vector</td>
<td>VSV-G</td>
<td>Envelope protein</td>
<td>Dr. James D. Sutherland</td>
<td>1.66µg</td>
</tr>
<tr>
<td>sh3 AMD1- pLKO</td>
<td>Transfer vector</td>
<td>shRNA against AMD1</td>
<td>CCGGGGCTCTCCAAGAGACGGTTCCATTCTCGAGAATGAAACGTCTCTGGAGAC</td>
<td>SIGMA TRCN0000078 462</td>
<td>5µg</td>
</tr>
<tr>
<td>sh4 AMD1- pLKO</td>
<td>Transfer vector</td>
<td>shRNA against AMD1</td>
<td>CCGGGCCCATAAGATGATGTCTCTACTCTCAAGTATGAAACACTACTATGGGTTTTTG</td>
<td>SIGMA TRCN0000078 458</td>
<td>5µg</td>
</tr>
<tr>
<td>sh3 AMD1 pLKO TeT ON</td>
<td>Transfer vector</td>
<td>shRNA against AMD1</td>
<td>CCGGGGCTCTCCAAGAGACGGTTCCATTCTCGAGAATGAAAC</td>
<td>Dr. James D. Sutherland</td>
<td>5µg</td>
</tr>
</tbody>
</table>

Adapted from http://www.invivogen.com/review-lentiviral-vectors
II.2.2.2.3 Constitutive Silencing of AMD1

First attempts to silence AMD1 were performed with SN infection as explained in II.2.1.2. However, due to the high silencing efficiency and the aggressive phenotype (high percentage of dead) observed upon AMD1 silencing, freshly infected cells were required per experiment, because stable growth of AMD1 silenced cells was not viable.

To optimize the timing per infection, virus was submitted to concentration procedures. Concentrated virus aliquots were generated following the time schedule mentioned in Fig. M7. until day 3, in which the SN was collected, filtered and fresh media was added to HEK293FT cells. 3 volumes of clarified supernatant were combined with 1 volume of Lenti-X Concentrator and, after gently mixing it by inversion, it was incubated at 4ºC until next day SN collection. On day 4, same procedure was repeated and SN was incubated at 4ºC for 1-3 hours. SN from both days were mixed and centrifuged at 1500G for 45 minutes at 4ºC. After centrifugation, SN was discarded and the pellet was resuspended in 400µl of PBS and aliquoted in 20uL aliquots, based on previous experience. Once the virus was concentrated, target cells were seeded on day 1 in the morning, infected with an aliquot in the afternoon, infected for the second time on day 2 and submitted to puromycin (2ug/mL) selection on day 3 for three days. In this ways infection protocol was shortened from 5 days to 3 days.

II.2.2.2.4 Inducible AMD1 silencing

Inducible silencing of AMD1 was performed by SN infection with a third generation system following the timing aformentioned in II.2.1. Target cells were submitted to selection pressure with puromycin (2ug/mL). Packaging and transfer vector information is mentioned in II.2.1.2.2. (See Table M10).

II.2.2.3 Retrovirus production and target cell-line infection

Retrovirus production was performed transfecting HEK293 Ampho cells. These cells derive from HEK 293 cells, but were generated to stably express the viral gag-pol and env genes (Fig. M12), allowing rapid production of high-titer replication-incompetent amphotropic retrovirus. Thus, for retrovirus generation these packaging cells were transfected with the transfer vector only (Fig. M13, right), following the time-line specified in II.2.1. Target DU145 cells were submitted to G418 (Geneticin) selection (starting from 200ug/mL and scaling the dose to 1mg/mL to reach total selection) during 3-4 weeks, because puromycin was used to maintain stable expression of the viral genes in HEK293 Ampho cell generation. Retrovirus mediated transduction was performed to over-express wild-type and phospho-mutant (S298A) AMD1 in DU145 cells (Table M12).
Materials and Methods

Figure M1: Informative image showing the fragmentation of the retroviral genome into the packaging system.

Adapted from https://www.addgene.org/viral-vectors/retrovirus/retro-guide/

Figure M12: Informative image showing the fragmentation of the retroviral genome into the packaging system.

Table M12: Information regarding the specific vectors employed for retrovirus production.

<table>
<thead>
<tr>
<th>Vector Name</th>
<th>Role</th>
<th>Encoding sequences</th>
<th>Function</th>
<th>Origin</th>
<th>Amount transfected</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNCX Neo (HCX) HABMSXNC linker</td>
<td>Transfer vector</td>
<td>Empty vector</td>
<td>Control cells</td>
<td>Dr. James D. Sutherland</td>
<td>5µg</td>
</tr>
<tr>
<td>LNCX-MYC-AMD1-HA</td>
<td>Transfer vector</td>
<td>AMD1-WT</td>
<td>Gene to over-express</td>
<td>Dr. James D. Sutherland</td>
<td>5µg</td>
</tr>
<tr>
<td>LNCX-MYC-AMD1S298A-HA</td>
<td>Transfer vector</td>
<td>AMD1-S298A</td>
<td>Mutant to over-express</td>
<td>Dr. James D. Sutherland</td>
<td>5µg</td>
</tr>
</tbody>
</table>

Adapted from https://www.addgene.org/viral-vectors/retrovirus/retro-guide/

Figure M13: Informative image showing different retroviral packaging methods.

Adapted from https://www.addgene.org/viral-vectors/retrovirus/retro-guide/
II.2.3 Cellular analysis

II.2.3.1 Cell-growth analysis by crystal violet staining

Cells were seeded in 12 well-plates (5000-8000 cells/well) for days 0, 2, 4 and 6 or 0, 1, 2 and 3 (depending on the experiment). Each plate was washed with 10% PBS, fixed with 10% formalin and stored at 4°C for further processing of all plates at the same time. Once fixed (> 15 minutes with formalin), cells were stained with crystal violet (0.1% crystal violet, 20%) for 40 minutes. After washing (4x dH₂O) and air drying the plates, precipitates were dissolved with 10% acetic acid for 30 minutes and absorbance was measured in 96-well-plates by spectrophotometer at 595 nm.

II.2.3.2 Anchorage-independent growth (Soft agar)

Anchorage independent growth is considered an aggressiveness parameter, utilized to characterize cellular phenotypes in vitro. For cell plating in anchorage independent conditions, 6 well-plates were previously coated with a lower layer of 0.6% agar (SeaKem LE agarose, Lonza)/medium mixture (3mL/well) and stored at 4°C for at least 30 minutes to let the agar solidify. Previous to the upper layer seeding, cells (3000-5000 cells/well) were suspended in a 0.3% low melting agar/medium mixture and 1.5mL/well were plated. Low melting agar allows to maintain the agar/cell mixture liquified at lower temperature, to avoid harming cells. Plates were stored at 4°C (around 20 mins) to allow the solidification of upper layer and then incubated at 37°C in a humidified atmosphere of 5% CO₂ for 3-4 weeks, until colony detection.

II.2.3.3 Foci formation assay

Foci formation assay measures the clonogenic capacity of transformed cells (Alvarez et al., 2014), by means of number of foci formed at very low seeding cellular density. To perform these experiments, 500 cells/well were seeded in 6well/plates in adherence and incubated at 37°C in a humidified atmosphere of 5% CO₂ for 10 days. Plates were then fixed with 10% formalin solution at 4°C for at least 15 minutes, washed with PBS and stained with crystal violet (0.1% crystal violet, 20% methanol) for 40 minutes. After washing (4 x dH₂O) and air drying, plates were scanned to obtain digitalized images for foci counting. After scanning the plates, crystal violet precipitates were dissolved in 10% acetic acid for 30 minutes and absorbance was measured in 96 well-plates by spectrophotometer at 595 nm, for cell number quantification.
II.2.3.4  DNA synthesis rate analysis by bromo deoxyurdine (BrdU)

One of the most commonly used techniques to analyze cell proliferation is the incorporation of the thymidine pyrimidine analogue BrdU (5-bromodeoxyuridine) into newly replicated DNA, based on the direct correlation between DNA replication and cell division.

II.2.3.4.1  BrdU Incorporation

This analogue when added in culture media gets incorporated into DNA, during DNA replication process (Darzynkiewicz and Juan, 2001). Since monoclonal antibodies were developed to target incorporated BrdU into DNA (Gratzner, 1982), BrdU has been extensively used to estimate cell proliferation by immunofluorescence. In this thesis work BrdU was used in asynchronic cultures. Cells were seeded onto coverslips and once adhered BrdU was added to culture media to a final concentration of 0.2µg/mL and incubated for 3-4h at 37ºC. After incubation cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) solution in PBS for 15 minutes. Cells were washed twice to eliminate remaining PFA and coverslips were stored in PBS at 4ºC until processing.

II.2.3.4.2  BrdU exposure and detection by immunofluorescence (IF)

BrdU needs to be exposed to detect it with monoclonal antibodies. To this end, coverslips were incubated with HCl 2Nfor 5 minutes and quickly washed twice with PBS to further neutralize the acid with Borax (Sodium tetraborate 0.1M, pH8.5) for two minutes. Cells were permeabilized with Triton X100 0.1% for 5 minutes and 10% goat serum was employed as blocking reagent for 30 minutes at RT. Primary antibody against BrdU (BD Pharmingen™, Cat# 555627) was incubated at 1:100 dilution overnight at 4ºC. The next day, secondary anti-mouse antibody (labelled with Alexa Fluor® 594 dye) was incubated at 1:1000 dilution in 10% goat serum for 1h in the dark. Finally, cells were stained with DAPI (1:1000 dilution in PBS) for nuclear staining and coverslips were mounted onto slides with home-made Mowiol. The slides were stored at 4ºC in the dark until analysis with the upright fluorescent microscope Axio Imager D1 (Carl Zeiss).

II.2.3.5  Cell cycle analysis

Propidium Iodide (PI) is an intercalating fluorescent agent extensively used for cell cycle analysis (Krishan, 1975). Harvested cells were suspended in 1mL of PBS and fixed drop by drop with 2.5 mL of absolute ethanol (70% final ethanol concentration). Samples were incubated overnight at -20ºC for fixation. Next, cells were centrifuged and suspended in 200-500µL of PI staining solution [RNase 25ug/ml (stock 1mg/ml), Triton X-100 0.05%, PI: 1 µg/ml (stock 1mg/ml)]. Samples were incubated for 20-40 minutes at 37ºC and analyzed by flowcytometry.
II.2.4 Molecular Assays

Cells were seeded for a final density of around 70-80% in 6 well plates. Plates were washed with PBS and processed or snap-frozen in liquid-nitrogen for later protein or RNA extraction, unless otherwise specified.

II.2.4.1 Gene expression analysis

II.2.4.1.1 RNA extraction and retrotranscription

RNA was extracted using NucleoSpin® RNA isolation kit from Macherey-Nagel (ref: 740955.240C) according to manufacturer’s protocol and concentration was determined by Nanodrop ND-1000 Spectrophotometer. 1µg of the obtained RNA was used for complementary DNA (cDNA) synthesis using qScript cDNA Supermix from Quanta (ref. 95048). Resulting cDNA was diluted 1/6-1/30 in fresh mQ water (depending on the expression levels of each gene) and 1µL was used for RT-QPCR reaction.

II.2.4.1.2 Real time quantitative PCR (RT-Q-PCR)

RT-QPCR was performed using Viia7 system from Life Technologies’. The RT-QPCRs were performed according to the following program: 2min at 50°C and 10min at 95°C (Hold Stage) followed by 40 cycles of 15sec at 95°C (denaturation) and 1min for 60°C (annealing and elongation). Polyamine pathway related enzyme gene expression was analyzed with primers and probes from Universal Probe Library from Roche. The Universal Probe Library Assay Design Center is available on-line in: http://lifescience.roche.com/shop/en/mx/overviews/brand/universal-probe-library. This tool allows the design of primers and assigns the respective probe needed for each reaction in order to build a TaqMan assay. Methionine cycle-related enzyme gene expression was analyzed by SYBRGreen Technology and primers were kindly provided by Dr. Woodhoo (CIC bioGUNE). For the analysis of reference house-keeping genes (Gapdh, GAPDH and β-ACTIN) Taqman Probes were used. Two different master mixes were used to catalyze the reaction: FastStart Universal Probe Master (Roche ref. 04914058001) and TaqMan® Universal Master Mix II (Life Technologies ref. 4440046). For quantification of changes in gene expression, Comparative Ct method was selected. See Table M13 for specific primer sequences and references.
Table M13: Table detailing the specific primer sequences and probe numbers from Universal Probe Library from Roche, specific primers for SYBR technology and references of Taqman technology probes used for RT-QPCRs.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Species</th>
<th>Technology</th>
<th>Forward 5´-3´</th>
<th>Reverse 5´-3´</th>
<th>Probe</th>
</tr>
</thead>
<tbody>
<tr>
<td>SpmS</td>
<td>Mouse</td>
<td>UPL Roche</td>
<td>CAGCACGCTGAGCTTCAA</td>
<td>CCAGGTGTCAGCATGACTCTG</td>
<td>#68</td>
</tr>
<tr>
<td>SpdS</td>
<td>Mouse</td>
<td>UPL Roche</td>
<td>TCCAGTGGAGATAGTGGAG</td>
<td>CCCAGTGGAGATAGTGGAG</td>
<td>#78</td>
</tr>
<tr>
<td>Amd1</td>
<td>Mouse</td>
<td>Taqman UPL Roche</td>
<td>GACGCAATCAATCAGCTAGC Mm04207265</td>
<td>TGGGTCAGCTCAGCTCATCA</td>
<td>#47</td>
</tr>
<tr>
<td>Odc1</td>
<td>Mouse</td>
<td>UPL Roche</td>
<td>GCTAAGTCAGCTCTGAGGA</td>
<td>AGCTGCTCACTGTTCTGAT</td>
<td>#80</td>
</tr>
<tr>
<td>Sat1</td>
<td>Mouse</td>
<td>UPL Roche</td>
<td>TCTGAAAGATCCTGCTGAGAG</td>
<td>CACTGCTCAGCGGAGACT</td>
<td>#110</td>
</tr>
<tr>
<td>Paox</td>
<td>Mouse</td>
<td>UPL Roche</td>
<td>ACCGTTCCGGAGTATACAGT</td>
<td>TCGGTAACTGTCTGAGCC</td>
<td>#26</td>
</tr>
<tr>
<td>Sloc3a2</td>
<td>Mouse</td>
<td>UPL Roche</td>
<td>CAAAGTGCGACATCCAGGCTG</td>
<td>AGCTGCCAGGTACATCTGCT</td>
<td>#81</td>
</tr>
<tr>
<td>Cbs</td>
<td>Mouse</td>
<td>SYBR</td>
<td>CTTCAGGGACATCCCAGGCTG</td>
<td>AGCTGCCAGGTACATCTGCT</td>
<td></td>
</tr>
<tr>
<td>Cth</td>
<td>Mouse</td>
<td>SYBR</td>
<td>GAGCAAGTGGAGCTCAGTGG</td>
<td>GCTTCTTCTTCAGGCAAGAGG</td>
<td></td>
</tr>
<tr>
<td>Mthr</td>
<td>Mouse</td>
<td>SYBR</td>
<td>CAGGTACCTTCGAGAAGCTCT</td>
<td>GAGACCTGTGAAGCACATCC</td>
<td></td>
</tr>
<tr>
<td>Ms</td>
<td>Mouse</td>
<td>SYBR</td>
<td>CTTCAGGGACATCCCAGGCTG</td>
<td>AGCTGCCAGGTACATCTGCT</td>
<td></td>
</tr>
<tr>
<td>Sahh</td>
<td>Mouse</td>
<td>SYBR</td>
<td>CTCAGGCAATCTTCATTCAGC</td>
<td>CGCCAGCACTGCTGATAAAC</td>
<td></td>
</tr>
<tr>
<td>Bnmt</td>
<td>Mouse</td>
<td>SYBR</td>
<td>GAGCCCTCCAGGAGCTCAGAC</td>
<td>CTTGCCAGTGGACAGGAGG</td>
<td></td>
</tr>
<tr>
<td>Pend</td>
<td>Mouse</td>
<td>SYBR</td>
<td>AGTTCTCTGTCCCTCCATCG</td>
<td>AGTTCTCTGTCCCTCCATCG</td>
<td></td>
</tr>
<tr>
<td>Mat2a</td>
<td>Mouse</td>
<td>SYBR</td>
<td>CTTCCTTCAGGAGCACTGCT</td>
<td>CTTCCTTCAGGAGCACTGCT</td>
<td></td>
</tr>
<tr>
<td>Mat2b</td>
<td>Mouse</td>
<td>SYBR</td>
<td>CCAGGTGCCAGCATTAATGAG</td>
<td>AGCTGCTGACCTGACCTGCT</td>
<td></td>
</tr>
<tr>
<td>Gntt</td>
<td>Mouse</td>
<td>SYBR Taqman</td>
<td>AGGCCCCTCTCCAGGAGC</td>
<td>AGCTACAAAGGCGTGTTGCTT</td>
<td>#81</td>
</tr>
<tr>
<td>Gntmt 338</td>
<td>Mouse</td>
<td>SYBR Taqman</td>
<td>AAAGGATGGCTCTTCCCTCC</td>
<td>GTGCTGACGTAGCCTGG</td>
<td></td>
</tr>
<tr>
<td>Sardh</td>
<td>Mouse</td>
<td>SYBR Taqman</td>
<td>GACAAAAGGACAGCCTGATGG M 4657 m</td>
<td>GCAGATGCTGTGATGG</td>
<td></td>
</tr>
<tr>
<td>Gapdh</td>
<td>Mouse</td>
<td>Taqman</td>
<td>Mm99999915_g1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMD1</td>
<td>Human</td>
<td>UPL Roche Taqman</td>
<td>CAGACCTCTATATGATGACCTGA Hs00750876s1</td>
<td>TCAGGTGACGAACTTCCACTCT</td>
<td>#72</td>
</tr>
<tr>
<td>ODC1</td>
<td>Human</td>
<td>UPL Roche Taqman</td>
<td>AAAACATGGGAGCTTCACTC</td>
<td>TCGAATTGCTGAGTGGAG</td>
<td>#3</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Human</td>
<td>Taqman</td>
<td>Hs02758991_g1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-ACTIN</td>
<td>Human</td>
<td>Taqman</td>
<td>Hs09999903_m1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

II.2.4.2 Protein expression analysis

II.2.4.2.1 Protein extraction

Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer (See Table M14 for recipe) for protein extraction, based on predicted protein molecular weights smaller than 200KDa. Lysates were rocked at 4°C for 20 minutes, centrifuged at 13500 rpm for 10 minutes and the supernatant was recovered. Protein concentration was quantified with Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific Cat# 23225), and lowest protein concentration in the sample set was used as reference for normalization. Samples were prepared in Laemmli sample buffer.
### II.2.4.2.2 Western Blotting (WB)

Protein lysates were boiled at 95°C for 5 minutes for denaturalization, resolved in NuPAGE® Novex® 4-12% Bis-Tris Midi Protein gels (ref: WG1403BOX) at 180V for 1h 20mins in MES Buffer 1X or MOPS Buffer 1X and transferred to nitrocellulose membranes at 100V for 1h 45mins. The membranes were blocked with 5% non-fat milk prepared in Tris-buffered saline solution containing 0.01% Tween-20 (TBS-T) and primary antibodies were incubated at 4°C over-night (o/n). See table M15 for references of antibodies used for Western Blotting.

<table>
<thead>
<tr>
<th>Antibody (Clone)</th>
<th>Reference</th>
<th>Species</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD1</td>
<td>Proteintech 11052-1-AP</td>
<td>Rabbit</td>
<td>1:1000</td>
</tr>
<tr>
<td>AKT54773 (D9E)</td>
<td>Cell Signaling Technology #4060</td>
<td>Rabbit</td>
<td>1:1000</td>
</tr>
<tr>
<td>AKT</td>
<td>Cell Signaling Technology #9272</td>
<td>Rabbit</td>
<td>1:1000</td>
</tr>
<tr>
<td>RpS65240/244</td>
<td>Cell Signaling Technology #2215</td>
<td>Rabbit</td>
<td>1:1000</td>
</tr>
<tr>
<td>RpS654D2</td>
<td>Cell Signaling Technology #2317</td>
<td>Mouse</td>
<td>1:1000</td>
</tr>
<tr>
<td>PTEN(6H2.1)</td>
<td>CASCADEABM-2052</td>
<td>Mouse</td>
<td>1:1000</td>
</tr>
<tr>
<td>c-MYC (D3N8F)</td>
<td>Cell Signaling Technology #13987</td>
<td>Rabbit</td>
<td>1:1000</td>
</tr>
<tr>
<td>HA-tag (16B12)</td>
<td>COVANCE</td>
<td>Mouse</td>
<td>1:1000</td>
</tr>
<tr>
<td>β-ACTIN</td>
<td>SIGMA A5316</td>
<td>Mouse</td>
<td>1:1000</td>
</tr>
<tr>
<td>HSP90</td>
<td>Cell Signaling Technology #4874</td>
<td>Rabbit</td>
<td>1:1000</td>
</tr>
<tr>
<td>α-TUBULIN</td>
<td>?</td>
<td>-</td>
<td>1:1000</td>
</tr>
<tr>
<td>Secondary Rabbit ab</td>
<td>Jackson ImmunoResearch</td>
<td>Rabbit</td>
<td>1:4000</td>
</tr>
<tr>
<td>Secondary Mouse ab</td>
<td>Jackson ImmunoResearch</td>
<td>Mouse</td>
<td>1:4000</td>
</tr>
</tbody>
</table>

### II.2.4.2.3 Protein Immunoprecipitation (IP) Assay

Protein immunoprecipitation was performed to analyze AMD1 synthesis rate and for the phosphoproteomics study of AMD1 phosphorylation sites. Cell plates were washed with ice cold PBS (3 ml/p60; 5mL/p100; 10mL/p150) directly after removing medium and placed on a bed of ice. Cells were scrapped with RiPA lysis buffer and protein extraction and quantification was...
performed as explained in II.2.3.2.1. 1mg of protein incubated diluted in a total volume of 800µL using pre-cold IP buffer (See table M16 for recipe) for immunoprecipitation with the primary antibody. For endogenous AMD1 precipitation, anti-AMD1 antibody (11052-1-AP, Proteintech) and Protein A/G agarose beads (PierceTM Thermo, Cat# 20421) were utilized, while exogenous AMD1 was immunoprecipitated with agarose HA-beads (A2095 SIGMA). Beads were centrifuged (30 seconds at 10000rpm at 4°C) and washed with IP buffer (800µL) five times. After last washing step beads were dried with capillary tips and suspended in 2x Laemmli sample buffer for elution by boiling them at 95°C for 5 minutes. Bead supernatants were loaded in a bis-acrylamide gel for migration.

Table M16: Reagent concentrations used to prepare immunoprecipitation buffer.

<table>
<thead>
<tr>
<th>Stock [ ]</th>
<th>For 50 mL</th>
<th>Final [ ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris pH 7.6</td>
<td>2 M</td>
<td>1 mL</td>
</tr>
<tr>
<td>EDTA pH 8</td>
<td>0.5 M</td>
<td>0.1 mL</td>
</tr>
<tr>
<td>MgCl2</td>
<td>1 M</td>
<td>50 uL</td>
</tr>
<tr>
<td>NaCl</td>
<td>5 M</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>Triton-100</td>
<td>10 %</td>
<td>500 uL</td>
</tr>
<tr>
<td>NaF, Na Orthovanadate, β-GP</td>
<td>100 mM</td>
<td>500 uL/each</td>
</tr>
<tr>
<td>Protease Inhibitor Cocktail</td>
<td>1 pill</td>
<td></td>
</tr>
</tbody>
</table>

II.2.4.2.4 AMD1 translation rate by $^{35}$S-Met labelling

For AMD1 synthesis with radio-labelling assay, PC3 and DU145 cells were treated with either vehicle (dimethylsulfoxide (DMSO)) or Rapamycin (20 nM) for 20h in 60mm (PC3) and 100 mm (DU145) dishes. To asses AMD1 synthesis, cells were starved for 40 min from methionine and cystine and radio-labelled for 30 min with a $^{35}$S-Met/Cys mix (Cat# NEG772002MC EasyTag™ EXPRESS$^{35}$S Protein Labeling Mix, $^{35}$S-, 2 mCi (74 MBq), Stabilized Aqueous Solution) before lysis. Protein lysates were incubated with protein A/G agarose beads (30 uL) for 1h to pre-clear non-specific binding to the beads. Precleared lysates were then incubated with anti-AMD1 polyclonal antibody (11052-1-AP, Proteintech) overnight at 4°C in 400 µL of RIPA buffer. Next, samples were incubated with protein A/G agarose beads for 1h and following immunoprecipitation bead washing steps were performed as explained in II.2.3.2.3. Lysate migration was performed in a NuPAGE™ (Novex™ 4-12% Bis-Tris Protein Gels, 1.0 mm, 12-well, Life Technologies) precast gel, in parallel with Input samples as a control of total AMD1 levels and rapamycin effect. After migration, the gel was submitted to fixation in a trichloroacetic acid (TCA) solution [10 % TCA, 10 % acetic acid, and 30 % ethanol] for 30 minutes and to signal amplification in sodium salicylate (1 M) for 1h. The gel was then dried (Model 583 gel dryer, BIORAD) and exposed to a film at -80°C for at least 96h (Fig. M12).

II.2.4.2.5 Polysome Profiling

Distribution of mRNAs across sucrose gradients was performed as described earlier (Fumagalli et al., 2012), except for minor modifications.
II.2.4.2.5.1 Sample extraction

Briefly, 3.5x10^6 DU145 cells were plated in 150mm plates to ensure a final density no higher than 50-60%. After 24h, cells were treated with either vehicle (DMSO) or rapamycin (20 nM) for 8 hours. After treatment, cycloheximide (CHX) was added to the medium at 37°C for 5 min at a concentration of 100 µg/mL. Cells were washed twice with cold PBS supplemented with CHX (100 µg/mL), scraped on ice and pelleted by centrifugation at 3000 rpm for 3’. Cell pellets were suspended in 250 µl of fresh hypotonic lysis buffer [1.5 mM KCl, 2.5 mM MgCl2, 5mM Tris HCl pH7.4, 1 mM dithiothreitol (DTT), 1% sodium deoxycholate, 1 % Triton X-100, 100 µg/ml CHX] supplemented with protease inhibitors Cocktail (Roche) and RNase inhibitor (New England Biolabs) at a concentration of 100 U/ml and left on ice for 5 minutes. Cell lysates were cleared of debris and nuclei by centrifugation for 5 minutes at 13000 rpm and 4°C, and the polysomal lysate in supernatant was transferred to new tubes. Protein concentrations were determined by BCA assay and aliquots of 900 µg-1.5 mg protein in 200 µL (same protein amount and volume among conditions per experiment) were prepared. Aliquots were snap frozen in liquid nitrogen, stored at -80°C and shipped to Dr. Thomas laboratory in IDIBELL for polysome profiling by Dr. Antonio Gentilella.

Figure M12. Schematic of the protocol followed to analyze AMD1 protein synthesis rate.
II.2.4.2.5.2 Sample processing

500 μg of lysate were loaded on 10-50% sucrose linear gradients containing 80 mM NaCl, 5 mM MgCl2, 20 mM Tris HCl pH7.4, 1 mM DTT, 10 U/ml RNase inhibitor with a BIOCOMP gradient master. Gradients were centrifuged on a SW40 rotor for 3 hours at 35000 rpm. Gradients were analyzed on a BIOCOMP gradient station and collected in 12 fractions ranging from light to heavy sucrose. Fractions were supplemented with SDS at a final concentration of 1% and placed for 10 min at 65°C. To each fraction was added 1ng of firefly luciferase mRNA, followed by phenol-chloroform extraction and precipitation with isopropanol. Purified RNAs from each fraction were reverse-transcribed and subjected to RT-QPCR. mRNA quantification was normalized to firefly mRNA.

II.2.4.2.6 Phosphoproteomics

DU145 cells stably expressing Myc-AMD1-HA were plated in 2-3 150mm plates per condition to ensure a final density no higher than 50-60% and sufficient protein amount to immunoprecipitate ectopic AMD1 and detect the corresponding band by Sypro-Ruby (Invitrogen, S12000) gel staining. Cells were treated for 8 hours with rapamycin (20nM) and Torin-1 (250nM) prior to immunoprecipitation.

II.2.4.2.6.1 Sample Preparation

Cells were washed with PBS on a bed of ice and lysed in 300μL RIPA lysis buffer per plate. Plates were scrapped and protein extraction was performed as explained in II.2.3.2.1. Ectopic AMD1 was immunoprecipitated as detailed in II.2.3.2.3. Specifically, the IP was performed in a total volume of 1mL with 40μL of HA-beads (A2095 SIGMA) for 1hour rolling at 4°C. Beads were washed 5 times with IP Buffer and immunoprecipitate was prepared in 80 µL 2xLaemmli by boiling the samples at 95°C for 5 min. After migrating samples in a 10% Sodium Dodecyl Sulfate Polyacrylamide MiniGel, the gel was fixed in fixing solution [10% acetic acid and 30% ethanol, fresh prepared] for 30 min and stained overnight with Sypro-Ruby (Invitrogen, S12000) under agitation in the dark. Next, the gel was rinsed in unstaining solution and water several times prior to image acquisition in theTyphoon Trio scanner (Variable Mode imager) (GE Healthcare life sciences).

The bands were unstained with several washes of 40% acetonitrile (ACN) in 50 mM ammonium bicarbonate. Then the proteins were reduced with 15 mM tris(2-carboxyethyl)phosphine (TCEP) in 50 mM ammonium bicarbonate for 30 min at room temperature and alkylated with 55mM for 30 min in the dark. Proteins were digested overnight at 37°C with trypsin. The resulting peptides were desalted and concentrated using homemade reversed phase micro-columns filled with Poros Oligo R3 beads (Life Technologies). The samples were dried using the Speed-Vac and dissolved in 22 µL of loading buffer (0.1% formic acid).
II.2.4.2.6.2 LC-MS/MS analysis

LC-MS/MS was performed by Pilar Ximenez and Javier Muñoz at CNIO. Peptides were separated by reversed-phase chromatography using a nanoLC Ultra system (Eksigent), directly coupled with a LTQ-Orbitrap Velos instrument (Thermo Fisher Scientific) via nanoelectrospray source (ProxeonBiosystem). Peptides were loaded onto the column (Dr. Maisch, ReproSil-Pur C18-AQ GmbH 2.4 µm, 500x0.075 mm), with a previous trapping column step (NS-MP-10 BioSphere C18 5 µm 120 Å 360/100 µm, L=20 mm, Nanoseparations), during 10 min with a flow rate of 2.5 µl/min of loading buffer (0.1% formaldehyde, FA). Elution from the column was made with a 60 min linear gradient (buffer A: 4 % ACN, 0.1 % FA; buffer B: 100 % ACN, 0.1 % FA) at 250 nL/min. The peptides were directly electrospayed into the mass spectrometer using a PicoTip emitter (360/20 OD/ID µm tip ID 10 µm, New Objective), a 1.4 kV spray voltage with a heated capillary temperature of 325°C and S-Lens of 60 %. Mass spectra were acquired in a data-dependent manner, with an automatic switch between MS and MS/MS scans using a top 5 method with a threshold signal of 800 counts. MS spectra were acquired with a resolution of 60000 (FWHM) at 400 m/z in the Orbitrap, scanning a mass range between 350 and 1500 m/z. Peptide fragmentation was performed using collision induced dissociation (CID/CAD) and fragment ions were detected in the linear ion trap. The normalized collision energy was set to 35%, the Q value to 0.25 and the activation time to 10 ms. The maximum ion injection times for the survey scan and the MS/MS scans were 500 ms and 100 ms respectively and the ion target values were set to 1E6 and 5000, respectively for each scan mode.

II.2.4.2.6.3 Data analysis

Data analysis was performed by Pilar Ximenez and Javier Muñoz at CNIO. Raw files were analyzed either by Proteome Discoverer (version 1.4.1.2) or by MaxQuant (Cox and Mann, 2008) (version 1.5.3.30) against a forward-reverse concatenated human database (UniProtKB/SwissProt 20,187 sequences), including common contaminants. Carbamidomethylation of cysteines was considered as fixed modification whereas oxidation of methionines and phosphorylation on serine, threonine and tyrosine residues were set as variable modifications in both Sequest HT and Andromeda search engine (v2.2). Sequest HT, in conjunction with Percolator provided the list of proteins for Proteome Discoverer. Minimal peptide length was set to 6 amino acids and a maximum of two missed-cleavages were allowed. Peptides were filtered at 1% FDR (False Discovery Rate). For protein assessment in MaxQuant, at least one peptide provided by Andromeda search engine(Cox et al., 2011) with a FDR = 1% was required. Other parameters were set as default. Results at peptide label were exported to excel for further analysis. Extracted ion Chromatograms (XIC) of the identified phosphopeptides were manually obtained from Xcalibur (version 2.2). In order to normalize the XICs to the total protein amount, absolute intensities from MaxQuant were considered.
II.2.4.3 In-House targeted metabolomic approaches

All samples were seeded in 6-well plates, unless otherwise specified, to a final density of no more than 80% of confluence, adjusting seeding cell numbers per condition to reach similar final density. At the experimental end-point, cells were washed three times with ammonium carbonate pH=7.4 (adjusted with acetic acid and sodium hydroxide), prepared in High-Performance Liquid Chromatography (HPLC) water, snap frozen in liquid nitrogen and stored at -80°C until processing.

II.2.4.3.1 One carbon Metabolism and Polyamine Pathway analysis by LC/MS in vitro

Cell samples were shipped in frozen plates to Agios Pharmaceuticals, where metabolites were extracted and processed by LC/MS as specified in I.2.5.2.

II.2.4.3.2 dcSAM and polyamine quantification in vitro

Frozen plates were processed by the metabolomics platform in CIC bioGUNE to extract the metabolites and analyze them by UPLC-MS as specified in I.2.5.3.

II.2.4.3.3 MFA in vitro

Seeded cells were treated with either vehicle (DMSO) or rapamycin (20nM) in fresh medium for 30 hours. After the treatment, cells were washed with methionine free (Gibco, Cat. # 21013-024) medium (with dialyzed FBS or no serum) and incubated with U-13C5-L-methionine (30 µg/mL) resuspended in same methionine-free medium (with dialyzed FBS or no serum) for 15 min to detect metabolites related to methionine cycle and 2 hours to detect metabolites related to polyamine synthesis pathway.
III STATISTICAL ANALYSIS

All experiments were performed a minimum of three times (biological replicates), except for the exploratory experiments, such as metabolomics by ToF-MS, LC/MS, UPLC-MS or preclinical trials with mice, that were done once, but with independent biological replicates (n≥3).

Values in histograms represent average value, while values in plot graphs show individual values, with a line representing the mean in parametric analyses or the median in non-parametric analyses. The error bars represent the standard error (Std Er) in the parametric analyses, while they depict the interquartile range in non-parametric analyses. The confidence interval (CI) established for the statistical analysis was 95% (α=0.05).

When comparing datasets from cell culture origin, a normal distribution was assumed and the statistic used for the analysis was paired or unpaired Student T-test, depending on the existence of dependency among samples. However, when analyzing differences among datasets from murine or human origin, a Gaussian distribution could not be assumed and thus, non-parametric Mann Whitney U-test was chosen for the analysis. Two-tailed analysis were the choice for experiments with non-predicted result, while one-tailed analysis was performed for hypothesis driven validations.
Results & Discussion I
I Integrative metabolic study to uncover metabolic alterations underlying prostate cancer (PCa)

The first aim of this thesis work was to uncover the metabolic alterations underlying the pathogenesis of PCa in order to understand the metabolic requirements of cancer cells.

HYPOTHESIS
Prostate cancer harbors metabolic alterations relevant to the pathogenesis of the disease

In the last fifteen years, multiple studies have attempted to tackle this question by developing and applying metabolomics technologies to cancer models. These efforts have allowed to establish that the metabolome (the compendium of low-molecular weight intermediates produced by cellular biochemical reactions) (Oliver et al., 1998) is intrinsically different in normal and cancer cells, as well as among different cancer types (Liesenfeld et al., 2013). After the genomic and proteomic eras, metabolomics is considered the closest approach to understand cellular phenotypes (Liesenfeld et al., 2013).

Several metabolomics studies have been performed on cancer patient specimens, to elucidate key molecular alterations underlying tumorigenesis that would in turn help to find early diagnostic biomarkers (Ren et al., 2015). However, there is intrinsic noise in these analyses, coming from the complexity of human samples and inter-individual variability. This highlights the challenge of defining consistent and relevant altered pathways. In turn, metabolic studies identifying novel metabolic biomarkers remain controversial, such as sarcosine for prostate cancer diagnosis (Sreekumar et al., 2009). To avoid such heterogeneity, in this project we decided to take advantage of our Pten prostate-specific knockout genetic engineered mouse model (GEMM) (Pten\textsuperscript{pc\textsuperscript{-}}), that faithfully recapitulates the pathogenesis of the human disease, for a profound metabolic study.

In order to better understand the development of the disease, we analyzed tissue from three different prostate lobes (the ventral, VP; the anterior, AP, and the dorsolateral, DLP) and two different ages, three and six month-old mice, as representative of early (prostate intraepithelial neoplasia - PIN - lesions) and late (prostate invasive carcinoma - PCa) disease, respectively (Fig. R1).

With these representative samples we performed an integrative metabolomics study by combining the power of untargeted metabolomics, the resolution of targeted metabolomics and the dynamism of isotope-labeled metabolite tracing.
Results & Discussion

Figure R1. General experimental design of in vivo experiments. *Pten*^pc−/−^ mice were compared to *Pten*^pc+/+^ mice at three (when mice develop PIN lesions) and six (when mice develop PCa) months of age. The three different lobes (VP, AP and DLP) of mouse prostate were extracted and snap-frozen in liquid N$_2$ for metabolomics analysis.

A. High-throughput Flow Injection-Time-of-Flight Mass Spectrometry (Fi-ToF-MS)

We first decided to perform an untargeted metabolic study by Time-of-Flight Mass Spectrometry (ToF-MS) to have an overall idea of the metabolic alterations that the loss of *Pten* could trigger during prostate tumorigenesis. We therefore measured hundreds of ionized peptides in an unbiased way (Hypothesis-generating approach) (Fig. R2A).

In this technique, the flow injection, omitting the usual chromatography, allows to analyze more than 1400 samples a day, making possible the analysis of all the samples of the study in a day to avoid the variability derived from measurements performed in different days. Furthermore, ToF-MS enables the detection and identification of metabolites, based on their mass to charge ratio (m/z). However, this technique only provides a semi-quantitative measurement of the altered metabolites (Fuhrer et al., 2011).
Figure R2. Experimental design of the integrative metabolomic study. The first study was approached by untargeted ToF-MS analysis (A). The second study was performed by targeted quantitative LC/MS analysis (B). Finally, results were corroborated by a dynamic U-13C5-labeled methionine tracing experiment.

B. Liquid Chromatography / Mass Spectrometry (LC/MS)

Based on the data obtained by FI-ToF-MS, we then decided to perform a hypothesis driven targeted metabolic experiment by LC/MS (Fig. R2B). With this strategy, we aimed at confirming the previous observations and obtaining a more accurate quantification. Thus, in this approach we only included the altered pathways and related routes detected by ToF-MS, hence decreasing the number of metabolites analyzed, and in accordance with the separation limit of the
Chromatography (Fuhrer et al., 2011). Nevertheless, LC/MS shows very high specificity and quantitative reproducibility (Patti et al., 2012), what has promoted its use as a main option of choice for numerous metabolic studies (Liesenfeld et al., 2013). This second approach provided us with important accurate information and quantification of altered metabolites in PCa. However, these data were limited by its static nature. Due to the dynamic nature of metabolism, we perceived that these results were insufficient to understand the biochemical cues that drive those alterations (Zamboni et al., 2015). In order to overcome this limitation, we sought to apply metabolite tracing (Fig. R2C), a technique that allows the interpretation of dynamic metabolic data (Feng et al., 2012).

C. In vivo $^{13}$C labeling Metabolic Flux Analysis (MFA) by LC/MS

The purpose of labeling a metabolite of interest with $^{13}$C is to trace the fate of carbons derived from that metabolite in the metabolic pathway of choice. In this work we designed an in vivo non-stationary MFA experiment, which focuses on the kinetics of the labeled isotope propagation before reaching isotopic equilibrium (Zamboni et al., 2015) (Fig. R2C). In this way, we have not only the measurement of the concentration of each metabolite by LC/MS, but also information about the flux from a particular metabolite into the related pathways. The fluxes provide directionality to the metabolic analysis, and the combination of $^{13}$C vs. $^{12}$C abundance for a carbon in a metabolite, informs about the reaction that originates the molecule. These knowledge is crucial in order to understand the mechanisms for metabolic regulation and in disease vs. healthy settings provides very valuable information in order to ascertain potential therapeutic targets (Zamboni et al., 2015).

I.1.1 ToF-MS metabolomics.

As mentioned in the description of the general experimental design followed for the integrative metabolomics study (Fig. R2), the first analysis was performed using FI-ToF-MS. In this first untargeted metabolomics experiment we analyzed prostate tissues from VP, AP and DLP lobes of Pten $^{pc+/+}$ and Pten $^{pc^{-/-}}$ mice at the age of three and six months in order to have representative time points of early (PIN) and advanced (PCa) disease.

At first glance, data represented in volcano plots showed multiple increased (Fold Change (FC)>1.5; p-value<0.05) and decreased (FC<1.5; p-value<0.05) ions, corresponding to altered metabolites (Fig. R3A). Furthermore, the number of altered metabolites increased as the disease progressed. However, that increase was variable among the prostate lobes: VP showed a 13.1% (61 significantly altered ions/3Mo; 69 significantly altered ions/6Mo) increase in altered metabolites in the Pten $^{pc^-}$ mice compared to Pten $^{pc+/+}$ (Table S1), while we could observe a 25% (80 significantly altered ions /3Mo; 100 significantly altered ions/6Mo) (Fig. R3B) increase in the DLP and a further increase of a 110% (60significantly altered ions/3Mo; 126 significantly altered
ions/6 Mo) (Fig. R3C) in the AP. These results suggest different metabolic impact of Pten deletion and prostate tumorigenesis in the different lobes.

We identified 156 total metabolites (Fig. R3), based on their mass-to-charge ratio. From those, 130 were significantly altered in Pten pc−/− mice compared to Pten pc+/+ , in at least one of the lobes and time points. Such a numerous amount of alterations made it complicated to identify at a glance the metabolic pathways relevant to the disease. Thus, to further understand the implication of the deregulated metabolites observed, we analyzed the data by an enrichment analysis. This computational method identified several altered metabolic pathways in the different lobes of Pten pc−/− mice. Thus, data was represented as percentage of altered metabolites (Fig. R4).

In coherence with our previous observations, VP seemed to follow different disease evolution compared to AP and DLP, by means of altered pathway number. Indeed, no significant hits arose at three months of age in this lobe and only three metabolic pathways stood out as significantly altered at six months (Fig. R4A). These results could be explained by the different histological features of the three mouse prostate lobes and the higher similarity between DLP and AP. VP is composed of a flat monolayer of luminal cells, DLP shows a slightly stratified simple epithelium and AP is the lobe with the most marked papillary structure (Shappell et al., 2004). Based on the previous observations and the differential histological structure, we decided to focus in AP and DLP lobes for consistency for further analysis. Among the top hits, we observed consistent alterations in pathways related to amino acids (aa) (threonine, Thr/T; cysteine, Cys/C; glutamate, Glu/E; glutamine, Gln/Q; branched chain aa and Urea cycle), sugar (amino sugars) and mitochondrial metabolism (TCA, electron transport chain, ETC; oxidative phosphorylation, OXPHOS; and reactive oxygen species, ROS) (Fig. R3A,B). We then decided to consider pathways robustly altered in at least three of the four experimental settings:

### I.1.1.1 Tricarboxylic Acid Cycle (TCA)

The Warburg effect establishes that cancer cells exhibit a preference for glycolysis as source of energy and metabolic intermediates, alternatively to the TCA, even in the presence of oxygen (Vander Heiden et al., 2009; Warburg, 1956b). In this respect, despite the fact that mutations in TCA enzymes have been associated to tumorigenesis, it has been found that these metabolic alterations stem primarily from the deregulation of oncogenes or tumor suppressors (Desideri et al., 2015). The enrichment analysis of the ToF-MS data (Fig. R4, in orange) revealed alterations in TCA related metabolites, such as a decrease in succinyl-CoA levels, which correlated with a less oxidative phenotype (Cardaci et al., 2012; Torrano et al., 2016). However, many other alterations where related to less TCA-specific metabolites, such as nicotinamide adenine dinucleotide (NAD) or quinone.
Results & Discussion

Figure R3. ToF-MS study unraveled increasing number of metabolic alterations through PCa development. Volcano plots representing each decreased (blue dots) or increased (red dots) ion detected by ToF-MS (FC>1.5 and FC<1.5; p-value<0.05) in VP (A), AP (B) and DLP (C) lobes at three months of age (left column) and six months of age (right column). Y axis represents negative Log10 of the adjusted p-values. X axis represents Log2 (Fold change) percentage of altered metabolites.

- % of significantly decreased metabolites
- % of significantly increased metabolites
The Warburg effect was originally attributed to mitochondrial dysfunction and ROS production, although a causal effect remains unclear (Senyilmaz and Teleman, 2015). Other lines of research in the lab are focused in the regulation of this metabolic pathway (Torrano et al., 2016).

### I.1.1.2 Amino Sugar Synthesis Pathway

Another top hit of the ToF-MS enrichment analysis was the amino sugar synthesis pathway or hexosamine biosynthetic pathway (HBP) (Fig. R4, in purple). N-acetylglucosamine (GlcNAc) was among the top altered metabolites in this group. GlcNAc is covalently bound to the hydroxyl group of serine (Ser, S) or Thr residues in proteins by the O-GlcNAc transferase (OGT), a post-translational modification process called O-Glc-N-acylation. Cancer cells have higher glucose uptake (Vander Heiden et al., 2009; DeBerardinis et al., 2008; Warburg, 1956b) which favors the synthesis of GlcNAc and consequent O-Glc-N-acylation. Indeed, the latter has been suggested as a nutrient sensor and metabolic regulator (Hanover et al., 2010; Jóźwiak et al., 2014). Hyper-O-Glc-N-acylation and/or increased OGT expression have been related to different cancer type pathogenesis in multiple publications in the last five years (Ma and Vosseller, 2013), which is in line with our data. This pathway was first reported to increase breast cancer aggressiveness (Gu et al., 2010), but was later demonstrated to participate in various other cancer types, including PCa (Lynch et al., 2012) and pancreatic cancer (Guillaumond et al., 2013).

### I.1.1.3 Branched Chain Amino Acid (BCAA) Metabolism

BCAA (Fig. R4, in light grey) are leucine (Leu, L), isoleucine (Ile, I) and valine (Val, V), and they compose around the 35% of essential amino acids in muscle proteins (O’Connell, 2013). BCAAs are first transaminated by the enzyme branched chain aminotransferase to produce branched chain ketoacids (BCKA) (O’Connell, 2013). This first reaction requires α-KG for the transamination, producing Glu in the reaction, which links BCAA metabolism to the previously mentioned TCA, also altered in our data.

mTORC1, a master nutrient sensor, depends on amino acid signals to become fully active (Bar-Peled and Sabatini, 2014). Furthermore, it has been reported that Sestrin-2, a protein that interacts with GATOR-2 complex to inhibit mTORC1, is a Leu sensor, what makes this aminoacid (one of the three BCAAs) necessary for mTORC1 activation (Wolfson et al., 2015). These data reveal a close relationship between BCAAs and mTORC1 signaling pathway, which confers coherence to our data. However, Val was the only altered specific signal among BCAA in the ToF-MS data and the changes were very mild and inconsistent to make any conclusion.

### I.1.1.4 Serine, Glycine (Gly) and one-carbon (1C) Metabolism

Ser and Gly (G) metabolism was the most altered pathway in our analysis (Fig. R4, in wine-red). Importantly, it remained altered in both lobes and the alteration was conserved along the two stages of the disease.
Figure R4. ToF-MS enrichment analysis uncovered alterations in amino sugar synthesis pathway, BCAA metabolism, TCA and Ser and Gly metabolism in PCa pathogenesis. Enrichment analysis of the ToF-MS data at three and six months of age in VP (A), AP (B) and DLP (C). The data is represented as percentage of altered metabolites.

Ser and Gly fuel 1C metabolism, composed of two cyclic pathways, namely folate and Met cycle. The two routes are coupled through the production of methyl-tetrahydrofolate (m-THF), which donates one carbon to homocysteine (HCys) to generate methionine (Met, M). The name of this pathway refers to the fact that these two cycles are fueled with a carbon residue from Ser and Gly that afterwards can be followed from one metabolite to another, reaction by reaction. Those carbon donors can be incorporated from the extracellular environment, can be synthesized de novo (from glucose) in the case of Ser or from other metabolites in the case of Gly (such as choline, betaine, dimethylglycine and sarcosine). The metabolic pathways involving Ser, Gly and 1C metabolism have been related to tumorigenesis in multiple studies (Locasale, 2013). However,
Results and Discussion I

carbons incorporated into 1C metabolism can be further followed through many other related pathways as the trans-sulphuration pathway, which is linked to Met cycle through HCs; or the synthesis of polyamines through the decarboxylation of S-adenosylmethionine (SAM). For polyamine synthesis, another carbon source coming from the urea cycle is needed, ornithine (Pegg, 2009a).

From the 130 differentially altered metabolites upon Pten loss, 107 appeared to be significantly increased or decreased in two of the experimental settings, meaning that were altered in AP and DLP at three or six months of age, or were altered at both stages of the disease in AP or DLP. From those 107 metabolites, 80 showed alterations in three of the four experimental settings, meaning that were altered in both lobes, but either AP or DLP did not show the alteration at one of the timepoints. Finally, 49 of the significantly altered metabolites showed consistent changes in location (both prostate lobes) and time points of the disease, as shown by the Venn diagram in Fig. R5A.

In order to identify a pathway of relevance through the pathogenesis of the disease, we decided to focus on those consistently altered 49 metabolites for further analysis (highlighted in Fig. R5B Waterfall). Among those 49 metabolites, the highest decrease was observed in 3-Hexenedioic acid. This metabolite is an unsaturated dicarboxylic acid inversely correlated with fatty acid oxidation (FAO) (Jin and Tserng, 1989), which is coherent with the relevance of FAO in various cancerous settings (Wu et al., 2014; Carracedo et al., 2013; Liu, 2006).

On the other hand, three metabolites related to polyamine synthesis pathway were the top increased metabolites: decarboxylated SAM (dcSAM), N1-Acetylspermine and N1-Acetylspermidine. dcSAM comes from decarboxylation of SAM, the master methyl donor in the cell belonging to Met cycle. dcSAM provides carbons for polyamine synthesis (Locasale, 2013). N1-Acetylspermine and N1-Acetylspermidine are acetylated forms of polyamines, a product of their catabolism by the enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT1), a key regulator of polyamine levels (Pegg, 2008).

In conclusion, these data suggest an increase in polyamine-related metabolites, from one of the essential substrates for their synthesis (dcSAM) to their catabolized form, the acetylated-polyamines. Polymamines have been widely associated to proliferation, although the mechanism underlying their role in cancer remains to be elucidated (Gerner and Meyskens, 2004b). Thus, with this data, we focused our efforts on studying alterations in 1C-metabolism and polyamine pathway in prostate cancer pathogenesis. To further confirm these data with a more accurate quantification of these metabolites we addressed in a second step of our integrative metabolic design by LC/MS, as explained in Fig. R2.
RESULTS & DISCUSSION

Figure R5. The inclusion criteria established narrowed the number of consistently altered metabolites. A-B, VENN diagram (anterior prostate (AP) and dorsolateral prostate (DLP), A) and Waterfall pathway enrichment (AP and DLP, B) from the analysis of altered metabolites in TOF-MS metabolomic analysis carried out in Pten^{pc/-} vs. Pten^{pc+/+} mouse prostate samples at the indicated age (n=4-5). Values in (B) represent the average of the Log (Fold change) of the two lobes and two time points (3 and 6 months of age) per metabolite.

SECTION SUMMARY

- The untargeted metabolomic study by FI-ToF-MS revealed alterations in TCA, amino sugar synthesis pathway, BCAA metabolism and Ser, Gly and 1C Metabolism in Pten^{pc/-} mice compared to Pten^{pc+/+} at both stages of the disease.
- From the integration of alterations in both AP and DLP prostate lobes and time-points we could identify 49 consistently altered metabolites, among which polyamine pathway related metabolites were predominantly increased.
I.1.2 LC/MS metabolomic study to quantify metabolic alterations in PCa

I.1.2.1 LC/MS metabolomics in murine samples

For the LC/MS study, we included polyamines and related pathways in the set of analysis. As previously mentioned, we analyzed AP and DLP tissues of Pten<sup>pc<sup>+</sup></sup/+ and Pten<sup>pc<sup>-</sup></sup>/− mice at three and six months of age.

I.1.2.1.1 Branched chain amino-acid metabolism

The ToF-MS analysis showed an enrichment in BCAA metabolism in three of the four conditions (six months AP, three months DLP and six months DLP) of the experimental design (Fig. R4B,C). Interestingly, valine (BCAA) levels measured by LC/MS were slightly but significantly decreased, while leucine and isoleucine (also BCAAs) showed the same trend although without reaching statistical significance, in Pten<sup>pc<sup>-</sup></sup>/− mice AP at three months of age. No significant alteration was observed in the rest of conditions (Fig. R6A,B). There are different potential explanations for this lack of coherence. Firstly, some of the metabolites that arose in the BCAA enrichment could have been misidentified. Secondly, other metabolites implicated in BCAA metabolism could be the responsible of the enrichment rather than the three BCAAs themselves. Lastly, although the altered metabolites in Pten<sup>pc<sup>-</sup></sup>/− mice seemed to be enriched in BCAA metabolism, those alterations could be quantitatively not significant and relevant enough to appear in the LC/MS analysis.

I.1.2.1.2 Urea cycle

Although excluded for consideration in our ToF-MS analysis, Urea cycle and arginine (Arg, R) metabolism showed significant alterations by LC/MS. Ornithine levels were consistently increased, whereas Arg levels were significantly decreased at three months of age in both lobes and showed the same tendency at six months of age (Fig. R6A, B). These data suggest a decrease in Arg in favor of ornithine production, the substrate for ornithine decarboxylase 1 (ODC1), to further produce the polyamine putrescine (Put).

I.1.2.1.3 Methionine cycle

Met cycle metabolites also showed clear alterations in the LC/MS analysis, confirming the data obtained by ToF-MS. Met levels were only slightly decreased in Pten<sup>pc<sup>-</sup></sup>/− mice AP at three months of age (Fig. R6A), while they remained unaltered in the rest of conditions. Notwithstanding, SAM levels were consistently increased in both lobes and time-points, whereas we could observe a less consistent (due to variability among samples) but clear decrease of SAH levels (Fig. R6A, B). SAH levels did not correlate with the increased sarcosine levels. However, this increase could be explained by the increase in Gly, one of the substrates of the reaction, catalyzed by GNMT, to produce sarcosine. The increase in Gly, together with the increase in betaine observed in Pten<sup>pc<sup>-</sup></sup>/− mice prostates at six months of age compared to Pten<sup>pc<sup>+</sup></sup>/+, could also be the reflect of higher
Results and Discussion: Aim III

metabolites in mice treated with either dose of SAM486A compared to vehicle-treated mice (Fig. R53). Put levels were dramatically increased in both treatment regimens. The increase in Put correlated with the alterations observed in ornithine and Arg, both metabolites of the urea cycle implicated in the synthesis of Put. These results indicate that SAM486A induces a robust increase in putrescine synthesis, presumably acting on ODC1 activity. The fact that the changes in Put occur in the absence of a consistent reduction in dcSAM strongly suggests that this event is not due to the intricate compensatory mechanisms of polyamine synthesis, but rather to some direct effect of the compound on Put synthesis. Our data was in line with previous in vitro studies (Regenass et al., 1994; Svensson et al., 1997), preclinical trials (Dorhout et al., 1995a, 1995b) and with some of the mentioned phase I and phase II clinical trials (Millward et al., 2005; Siu et al., 2002), in which SAM486A treatment caused an increase in Put. The authors in these studies argued that the increase in putrescine was due to a compensatory mechanism rising from the decrease in dcSAM. However, although SAM486A treatment was able to decrease Spd and Spm levels in the in vitro studies and in the preclinical leukemia trials, none of them had any data about dcSAM levels. According to the clinical trials, PA levels showed in most cases very high inter-patient variability and inconsistency. It should be noted that the analysis of PA pools in those cases was done in peripheral blood leucocytes, and not in the target tissue (Eskens et al., 2000). Only in one phase I trial were able to confirm a decrease from pre-treatment to post-treatment analysis of dcSAM levels in a biopsy of a melanoma patient with apparently very high initial levels of dcSAM (Siu et al., 2002). In that particular patient, they were also able to detect decreased Put/Spd ratio and a reduction in Spm levels. Interestingly in the phase II melanoma trial reductions in Spd levels were also achieved (Millward et al., 2005), suggesting tumor type-specific efficacy of the treatment.

In our preclinical trial, SAM486A 2mg/Kg dose was not able to alter the levels of PA pools or dcSAM (Fig. R53 left). However, the higher dose caused an increase in the putrescine/Spd ratio and a mild but significant decrease in Spm levels. In the same line, dcSAM levels showed a tendency to decrease (Fig. R53 right).

Polyamine synthesis is tightly regulated through multiple feedback mechanisms. We speculate that SAM486A might retain structural similarities with SAM and dcSAM to interfere with ODC1 regulation, leading to an activation of putrescine synthesis. Our results suggest that local dose reached in the tumor tissue is sufficient to activate ODC1, but it does not inhibit AMD1 efficiently, as shown in the metabolomics analysis. Further research is needed in order to define whether such an off-target effect could hamper the therapeutic efficacy of SAM486A and explain the poor therapeutic efficacy observed in the preclinical and clinical trials with the compound.
III.2.3 Analysis of AMD1 levels in a clinical trial of RAD001

Our data demonstrated that regulation of AMD1 by mTORC1 is preserved in vivo in mice and that AMD1 levels can be modulated upon mTORC1 inhibition with Everolimus (RAD001). To further study the extent of our findings, we sought to validate our data in human specimens from a clinical trial with RAD001. Thanks to the collaboration with Dr. Baselga and Dr. Tabernero’s laboratory at Vall D’Hebron Hospital, we had access to pre- and post-treatment biopsy samples from cancer patients with advanced solid tumors treated with either daily (5 or 10 mg) or weekly (20 or 50 mg) administration (Fig. R54A) of RAD001 (Tabernero et al., 2008).

Paired pre- and post-treatment biopsies were processed by IHC to assess AMD1 immunoreactivity and analyze changes upon RAD001 treatment. To quantify AMD1 protein expression, an H-Scoring was performed. Strikingly, 62% of the patient biopsies analyzed exhibited a decrease in AMD1 levels upon RAD001 treatment in the tumor (Fig. R54B), as appreciable in the decreased immunoreactivity of AMD1 in the post-treatment staining of biopsies (Fig. R54C, lower panels) compared to pre-treatment samples (Fig. R54C, upper panels).

To further analyze whether AMD1 levels were differently altered in the RAD001 treatment regimens, we evaluated differential AMD1 immunoreactivity for each regime. Interestingly, AMD1 levels were significantly decreased only in patients treated with low doses of Everolimus (a maximum cumulative dose of 35mg/week; 5mg/day or 20mg/week), but not in response to high dose regimens (a minimum cumulative dose of 50mg/week; 10mg/day or 50mg/week) (Fig. R55A). Strikingly, the Everolimus regime resulting in AMD1 reduction was the only capable of impacting tumor cell proliferation, assessed by Ki67 staining (Fig. R55B).

Analysis of the phosphorylation level of molecular markers of mTOR pathway showed that phosphorylation of all markers downstream mTOR (S6\textsuperscript{235/236}, S6\textsuperscript{240/244}, 4EBP\textsuperscript{T70} and eukaryotic initiation factor 4G, eIF4G\textsuperscript{S205/208}) was significantly inhibited at the time-points analyzed irrespective of the Everolimus regime (Fig. R55C). This data suggests that AMD1 is a more sensitive biomarker of therapeutic efficacy for mTORC1 than other targets evaluated. AKT

SECTION SUMMARY
- Methionine deficient diet resulted insufficient to revert the metabolic alterations observed in Pten\textsuperscript{PC	extsubscript{-/-}} mice and did not show therapeutic advantage, compared to regular Chow diet fed mice.
- Pharmacological AMD1 inhibition with SAM486A in vivo showed no efficacy in decreasing dcSAM levels, and lacked therapeutic potential.
phosphorylation, which stands upstream mTOR, showed trend to upregulation upon high dose administration (Tabernero et al., 2008). This upregulation is caused by a negative feedback loop inducing upstream insulin-like growth factor 1 receptor (IGF-1R) signaling, which in term would result in AKT activation (O’Reilly et al., 2006; Tabernero et al., 2008). This feedback loop would also explain higher polyamine content upon re-phosphorylation of AKT (Rajeeve et al., 2013) and the rationale for the attenuation of the clinical activity of this agent.

In conclusion, our data led us to hypothesize that the effect on AMD1 upon mTORC1 inhibition is responsible of the reduced cancer cell proliferation and thus, unveil AMD1 as an important marker to monitor in mTOR-targeting therapies.
Figure R55. Impact of pharmacological mTORC1 inhibition with RAD001 on AMD1 levels in a clinical trial. **A**, Differential AMD1 immunoreactivity (quantified as H-score post-treatment – H-score pre-treatment) in each dose regime (5-10 mg/day or 20-50 mg/week). **B**, Differential AMD1 (left panel) or Ki67 (right panel) immunoreactivity (quantified as differential H-score) according to combined low dose regimens (5 mg/day or 20 mg/week) or combined high dose regimens (10 mg/day or 50 mg/week). **C**, Differential H-scores of molecular biomarkers (phospho-AKT, phospho-RpS6, phospho-4EBP1 and phospho-eIF4G) for mTOR pathway inhibition according to combined dose regimens mentioned in **B**.

**SECTION SUMMARY**

- Regulation of AMD1 levels upon mTORC1 inhibition (Rapamycin, RAD001 or Everolimus *in vivo*) is preserved in human specimens and associated to its anti-proliferative activity, enforcing the relevance of this enzyme for therapeutic purposes.
CONCLUSION III

- Genetic and pharmacological modulation of AMD1 underscored the therapeutic potential of targeting this enzyme
- Methionine restriction alone and pharmacological AMD1 inhibition with SAM486A in vivo did not show any therapeutic benefit against PCa development, arguably due to reduced pathway inhibitory effects
- AMD1 downstream mTORC1 might be a critical component of the cytostatic effect of mTORC1 inhibitors

EXPERIMENTAL IMPROVEMENTS AND FUTURE PERSPECTIVES

- The polyamine rescue experiment could be validated by overexpressing AMD1 ectopically and then performing AMD1 silencing with an shRNA that targets endogenous, but not exogenous AMD1, mimicking in that way endogenous polyamine depletion and further polyamine addition.
- Methionine restriction beyond 0.15% would be more appropriate to evaluate the impact of nutritional manipulation in PCa
- Combination of SAM486A treatment with DFMO (ODC1 inhibitor) could prevent the increase of putrescine and increase the therapeutic benefit in pre-clinical trials
I THE REVOLUTION OF OMICS: MILESTONES AND REMAINING CHALLENGES IN CANCER RESEARCH

Omics development and cancer research

Large-scale profiling methods have been innovatively employed to elucidate metabolic pathways implicated in tumor initiation, progression and metastasis (Benjamin et al., 2012). The last of the “omics”, metabolomics, has transformed cancer research (Klupczyńska et al., 2015). Previously developed “omics”, such as genomics, transcriptomics or proteomics, offered valuable information about the expression levels of oncogenes or tumor-suppressors, which led to the discovery of altered signaling pathways that play relevant roles in cancer pathogenesis (Stratton et al., 2009; Hanash and Taguchi, 2010). However, the information provided by these large-scale profiling methods was limited to the quantification of gene alterations and transcript or protein levels, which do not necessarily correlate with the enzymatic activities, reaction rates and, in general, metabolic dynamics (Holmes et al., 2008). Metabolomics conferred the capacity of measuring metabolite pools, which provide faithful information about substrate, intermediate and product amounts of the biochemical reactions that sustain cellular metabolism (Patti et al., 2012). Furthermore, this data can provide a speculative idea of the regulation status of involved metabolic enzymes. Consequently, metabolomics is considered the OMIC that most closely relates to the phenotype (Klupczyńska et al., 2015).

The technological blooming of instrumentation offered a broad variety of metabolomic techniques, from untargeted screenings to targeted MFA. Steady-state metabolomics provide valuable information regarding deregulated metabolic pathways. However, this type of metabolomics offers a static view, a snapshot of the metabolome, providing cues about the altered biochemical reactions in a particular moment (Zhao and Yang, 2015). The challenge of capturing the dynamic essence of metabolism was achieved by the development of metabolic flux techniques (Zamboni et al., 2015). Non-stationary metabolic flux analysis provides reaction rate information and directionality based on the $^{13}$C/$^{12}$C labeling ratio, and recapitulates more closely the dynamism of metabolism (Wiechert and Nöh, 2013).

In this work we combined untargeted (ToF/MS), targeted (LC-MS) and MFA metabolomics in an integrative metabolomics study to faithfully uncover, narrow down and validate the most relevant metabolic alterations underlying PCa pathogenesis in murine and human specimens. This approach allowed us to characterize a metabolic wiring showing increased flux from methionine cycle towards polyamine metabolic pathway in PCa. Importantly, the metabolic routes identified by ToF/MS in the murine prostates, were then validated by LC/MS and MFA employing murine, human and cell line samples to elucidate the extent and relevance of this metabolic switch in PCa.
Challenges and future prospects of metabolomics in eukaryotes

Despite the informative potential of metabolomics and the valuable information obtained by this approach, the technology exhibits limitations and faces challenges in the analysis of samples of eukaryotic origin. Contrary to prokaryotic cells, eukaryotic cells are compartmentalized into specialized organelles, with compartment-specific and shared metabolic activities (Wahrheit et al., 2011). Furthermore, cells have achieved sophisticated mechanisms to separate zones inside each compartment, as liquid-liquid phase separation, leading to membraneless compartmentalization (Aguzzi and Altmeyer, 2016). Compartmented subcellular structure results in numerous cellular metabolic microenvironments (Wahrheit et al., 2011), which allow the isolation and regulation of the numerous reactions that take place within a cell. However, compartmentalization has a price: the development of communication mechanisms to transmit signals and exchange material among the different organelles (Prinz, 2014). In turn, subcellular compartmentalization remarkably complicates the interpretation of metabolic networks from whole cell lysates (Niklas et al., 2010). Most current techniques obviate this variable and measure average labeling and metabolite levels of all mixed compartments in a cell (Buescher et al., 2015).

These facts are in support of our results. Indeed, although increased entrance (dcSAM) and exit (ac-polyamines) metabolites were detected, polyamine pools did not show consistent alterations, but rather remained fairly constant throughout the different experimental approaches addressed. In a metaphoric comparison, we could imagine polyamine reservoir as a water tank with continuous enter/exit flux, where an increased influx will be immediately compensated with a proportional efflux. In a biological context where the influx is increased (in our case Pten loss), the metabolomics data would reveal as increased influx and efflux metabolites, without major changes in the total pool of the central metabolites. Our hypothesis was reinforced by the metabolic flux experiments. The dynamic essence of this technique provided us the opportunity to demonstrate the increased production of dcSAM with carbons being incorporated into polyamines and subsequently into their acetylated derivatives (Fig. D2). Thus, our results highlight the relevance changes in polyamine influx and efflux, rather than total polyamine pools. Compartmentalization is particularly relevant when studying polyamine dynamics. Polyamines have been suggested to exhibit vesicle sequestration upon cell internalization through yet undefined mechanisms (Poulin et al., 2011). Importantly, quick polyamine through yet undefined mechanisms (Poulin et al., 2011). Importantly, quick polyamine import/export capacity from these putative vesicles could explain the rapid regulation of polyamine levels in response to exogenous alterations. Moreover, most polyamines are found in RNA-bound complexes (Igarashi and Kashiwagi, 2010). These two factors combined imply that the free polyamine pool is minor relative to total polyamine amounts. In turn, changes in free polyamines that are negligible when measuring total polyamine pool size, could exert profound effects in cell biology.
Figure D1. Schematic representation of polyamine pools according to the observed in Pten pc−/− mice and upon AMD1 inhibition with SAM486A.

Figure D2. Schematic representation of the hypothesis postulating increased flux through polyamine pathway in prostate cancer. The representation reflects the importance of altered enter and exit fluxes despite unaltered total polyamine pools.
The considerations postulated herein might be of vital importance for therapies targeting polyamine metabolism. Indeed, despite the promising results \textit{in vitro} and \textit{in vivo} models, drugs targeting polyamine synthesis enzymes, such as DFMO (ODC1) or SAM486A (AMD1) failed to show clear antitumoral benefit in clinical trials (Millward et al., 2005; Vlastos et al., 2005; Pless et al., 2004; Siu et al., 2002; Paridaens et al., 2000; Eskens et al., 2000; Loprinzi and Messing, 1992; Horn et al., 1987). The lack of therapeutic efficacy of these and other polyamine pathway modulators could be explained in part by the aforementioned data. By targeting \textit{de novo} polyamine synthesis, these drugs should alter free polyamine levels. However, it is plausible that these pools are rapidly equilibrated by polyamine export from sequestrating vesicles. Following this rationale, polyamine pathway-targeting therapies might need to be rethought. Probably, specific therapies targeting polyamine vesicle sequestration upon internalization would show higher benefit.

The possibility of measuring metabolites in a compartment-dependent manner could profoundly change our understanding of polyamine pathway regulation. In this work we have demonstrated that AMD1 is regulated by mTORC1. This serine-threonine kinase complex is reported to localize to the lysosome (Sancak et al., 2010). Based on these data, it is tempting to speculate that AMD1 could temporarily localize to the lysosome to be subject to mTORC1-dependent regulation.

II THE INTERPLAY OF mTORC1 SIGNALING AND POLYAMINE METABOLISM IN CANCER AND BEYOND

The crosstalk between signaling and metabolism in cancer

Most oncogenes and tumor suppressor genes discovered during the genomics era encode proteins implicated in signal transduction (Ward and Thompson, 2012). In the last decade of the twentieth century, cancer research focused on characterizing the oncogenic or tumor suppressive nature of genes based on gain or loss of function analysis with genetic tools. Traditionally, these genes have been attributed the capacity to support the acquisition of cancer hallmarks (Hanahan and Weinberg, 2000). However, increasing evidence reveal and alternative scenario, where oncogenes and tumor suppressors are essential mediators of the metabolic reprogramming, leading to the possibility of metabolic regulation as the ancient function of many of these genes (Ward and Thompson, 2012). In the same line, downstream aberrantly activated oncogenic signals, cell metabolism is reprogrammed to comply with anabolic needs. Nevertheless, metabolism also remolds the signaling network through the control of the epigenetic landscape (Pavlova and Thompson, 2016). This renewed understanding of cancer hallmarks implies an exquisite crosstalk between signaling and metabolism. In this sense, we provide a direct link between one of the master sensors that integrates and interprets growth signals, mTORC1, and a
metabolic route essential for cell proliferation and survival, the polyamine pathway. In support of our data, other metabolic enzymes related to polyamine synthesis and catabolism have previously been reported to be under the regulation of oncogenes and tumor suppressor genes. Indeed, the other rate limiting enzyme in polyamine synthesis, ODC1, is an established direct target of the oncogene c-MYC (Bello-Fernandez et al., 1993; Peña et al., 1993). Moreover, this decarboxylase cooperates with the oncogene H-RAS in fibroblast transformation \textit{in vitro} (Shantz and Pegg, 1998) and in skin carcinogenesis \textit{in vivo} (Smith et al., 1998). Likewise, the catabolistic enzyme SSAT1 has been shown to lie under the control of the oncogene K-RAS (Ignatenko et al., 2004).

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure_d3.png}
\caption{Scheme depicting the anabolic processes regulated downstream mTORC1, including AMD1 regulation and polyamine production.}
\end{figure}

mTORC1 promotes growth and proliferation depending on the nutrient and energy status of the cell (Howell and Manning, 2011). This complex induces anabolic metabolism by orchestrating several biosynthetic pathways. Under energy and nutrient-availability conditions, mTORC1 blocks autophagy by inhibiting a protein complex containing the kinases ULK1/2, which is essential for the autophagic process (Yecies and Manning, 2011; Neufeld, 2010). However, mTORC1 is also capable of directly regulating the synthesis of macromolecules, such as proteins, lipids and nucleic acids (Dibble and Manning, 2013a). The implication of mTORC1 in protein synthesis regulation is the best characterized of its functions. Indeed, this master regulator controls not only cap-dependent translation through phosphorylation of its targets 4EBP1 and S6K, but also protein degradation to ensure protein homeostasis (Zhang et al., 2014; Ma and Blenis, 2009). mTORC1 is also implicated in the regulation of lipid homeostasis. In fact, this protein complex induces lipid synthesis and storage, while inhibiting processes that imply lipid consumption (Ricoult and Manning, 2013). In the same line, mTORC1 induces purine synthesis, through the regulation of folate cycle (Ben-Sahra et al., 2016), as well as, \textit{de novo} pyrimidine production by direct phosphorylation of carbamoyl-phosphate synthetase 2 (CAD) by its
downstream target S6K (Ben-Sahra et al., 2013). In this work we have described a previously unidentified branch under the control of mTORC1 (Fig. D3). Based on our preliminary data, this regulatory pathway would stem from direct phosphorylation of AMD1, although ongoing validation experiments are warranted to validate this assumption. If our hypothesis is confirmed, AMD1 would be a direct target immediately downstream mTORC1, together with 4EBP1 and S6K. The regulation of AMD1 by mTORC1 is of vital importance since connects a signaling cascade and a metabolic pathway, both relevantly implicated in such an essential cellular process as proliferation (Dibble and Cantley, 2015; Miller-Fleming et al., 2015). Importantly, this connection also integrates polyamines and the synthesis of macromolecules. Polyamines induce adipogenesis (Hyvönen et al., 2013; Ishii et al., 2011) and bind to DNA and RNA affecting their structure and stability (Iacomino et al., 2012; Igarashi and Kashwagi, 2010). Furthermore, Spd is essential for eIF5A hypusination, a post-translational modification required for its activation and subsequent correct mRNA translation elongation (Park et al., 2009; Cooper et al., 1982). In conclusion, we have identified a mTORC1-AMD1-PAs axis, which enriches the metabolic landscape downstream mTORC1.

**Signaling-metabolism crosstalk beyond cancer**

The fact that polyamine pathway enzymes are so tightly regulated under the control of oncogenes and tumor suppressors underscores the relevance of these molecules in cancer and, potentially, in physiology. We show that mTORC1 regulates polyamine synthesis to support proliferation. Indeed, both mTORC1 signaling and polyamines are involved in relevant processes throughout our lifespan. This perspective well correlates with new perspectives on aging, which define this vital process as "any change in an organism over time", thus aging being synonymous of change rate (Bowen and Atwood, 2004). In view of this, the developmental processes occurring in mammals sequentially through lifespan could reasonably be separated into a "positive phase", from conception to adulthood; followed by a "negative phase", senescence, from adulthood to death (Scalabrino and Ferioli, 1984).

Embryonic development and tissue growth are processes that imply high proliferation and change rates ("positive phase"). In this context, mTORC1 is of vital importance. In fact, germline deletion of mTOR components showed that both mTORC1 and mTORC2 are essential during embryogenesis, although mTORC1 is primordial at early stages of the development, whereas mTORC2 plays its decisive role at midgestation (Guertin et al., 2009). In fact, mTOR is critical for gastrulation and tissue growth during organogenesis (Land et al., 2014). Interestingly, polyamines are essential during embryonic development. Knockout of both polyamine biosynthetic enzymes (AMD1 and ODC1) lead to embryonic lethality at early stages of development (Nishimura et al., 2002; Pendeville et al., 2001). In the same line, polyamines play a relevant role during pregnancy, especially during first half of development (Sooranna et al., 1998). These data support a role for mTORC1-AMD1-PAs in early life stages.
The connection of this axis might result less certain in later stages of life, when proliferation requirements are reduced. Experimental evidence suggest that mTOR controls aging through the regulation of several downstream processes (Blagosklonny and Hall, 2009). Researchers in the gerontology field support the notion of non-programmed aging, which hypothesizes that aging is the consequence of the incorrect inactivation of the growth program (Blagosklonny, 2013). Aging impacts on the entire organism, through the accumulation of damage in molecules, cells and tissues over time. Tissue dysfunction in aging has been correlated with a switch in cellular status, from reversible G0 quiescence to irreversible G0 senescence, a proliferation block driven by mTOR (Demidenko and Blagosklonny, 2008) and named "geroconversion". This process leads to hypertrophic cells, due to active mTOR signaling despite cell-cycle inhibition (Blagosklonny, 2014). Importantly, both mTORC1 specific and dual mTORC1 and mTORC2 inhibitors have been demonstrated to efficiently prevent geroconversion, preserving proliferative potential (Leontieva et al., 2015; Sousa-Victor et al., 2015; Demidenko et al., 2009). However, polyamine levels show a sustained inverse correlation with ageing, although there is certain tissue specificity. (Nishimura et al., 2006; Scalabrino and Ferioli, 1984). For instance, spermidine and spermine levels decrease with age in mice (Nishimura et al., 2006) and humans (Pucciarelli et al., 2012). Strikingly, in this study nona/centenarian people showed an enrichment in Spd and Spm concentrations relative to total polyamines, suggesting that maintaining these polyamines in aging contribute to longevity (Pucciarelli et al., 2012). This evidence supports the notion that polyamines are required for the extension of lifespan.

**Figure D4. Interplay between PI3K-mTORC1 signaling and polyamine levels. A-B, Crosstalk throughout proliferation-related processes in lifespan (A) and cancer (B).**
In the search for anti-aging strategies, genetic or pharmacological inhibition of mTOR was found to extend lifespan in yeast, nematodes, flies, and mice (Harrison et al., 2009; Powers et al., 2006; Kaeberlein et al., 2005; Kapahi et al., 2004; Jia et al., 2004; Vellai et al., 2003). In turn, rapamycin and its derivatives (Rapalogs) have become the best-supported candidates as anti-aging therapeutics. Likewise, exogenous Spd supplementation was demonstrated to increase the lifespan of yeast, flies, worms, human immune cells and to decrease oxidative stress in aging mice. In this study Eisenberg and coworkers showed that Spd addition caused general hypoaepitelylation of histone H3 and induced autophagy by promoting acetylation of autophagy-related autophagy related 7 (ATG7) gene promoter (Eisenberg et al., 2009). Thus, polyamines, and especially Spd, have aroused as anti-aging molecules, which can be supplemented in food or water to increase their levels in the organism (Minois, 2014). Rapamycin also shares with Spd multiple potential mechanisms by which it exerts its anti-aging effect, such as regulation of cell growth, autophagy induction and anti-inflammatory mechanisms. Nonetheless, despite its encouraging effects rapamycin, it seems unlikely that this drug will be approved for preventive use, due to its side effects (Lamming et al., 2013).

Our data demonstrate a direct regulation of AMD1 downstream mTORC1, which led us to speculate that this axis also operates throughout development and aging. This might be true until the axis is disconnected from proliferation. Nevertheless, in conditions where proliferation is sustained, such as cancer, the axis might be preserved, as we observed in PCa. In conclusion, the analogous activities of PI3K signaling and polyamines, are observed in several facets of life. Elucidating this complex relationship would help us better understand physiological processes at the cellular and systemic level, and could reveal novel therapeutic avenues for pathological alterations related to cell growth and senescence.

### III AMD1 AS A PREDICTIVE BIOMARKER AND TARGET IN PROSTATE CANCER

The combination of established clinical-pathological acquaintance with state-of-the-art molecular profiling to achieve diagnostic, prognostic and therapeutic strategies is termed precision medicine (Mirnezami et al., 2012). In this regard, genomic technologies have inspired this stratification approach, whereas other high throughput technologies that provide better information about the phenotype of the tumor remain underdeveloped in this area of research (Friedman et al., 2015). In the particular case of PCa, precision medicine is yet far from becoming a reality. Indeed, stratification of PCa patients depends on very general parameters, such as PSA, Gleason Score and TNM classification, and targeted therapy is limited to the inhibition of androgen signaling. Therefore, novel stratification markers and targeted therapies are needed to treat the disease once first line therapy (surgery or radiotherapy) fails. This fact underscores the need for reliable and reproducible prognostic biomarkers to discriminate patients that would benefit from early adjuvant treatment from those requiring more aggressive therapy (Sedelaar and Schalken, 2015). Patient derived tumor xenograft (PDTX) models, which maintain the molecular, genetic and
histological heterogeneity of the tumor of origin, might represent excellent platforms to predict clinical efficacy based on potential biomarkers (Cho et al., 2016; Tentler et al., 2012).

In this project we have shown that the rapamycin-derivative Everolimus is capable of decreasing AMD1 levels in vivo. Interestingly, a decrease in AMD1 immunoreactivity exhibits better association to a decrease in tumor cell proliferation than the rest of mTORC1 activity readout proteins (Tabernero et al., 2008), that remained inhibited regardless of Everolimus regime and therapeutic effects. Thus, we hypothesize that AMD1 might be a key contributing factor to the cytostatic effect triggered by Everolimus. This fact would be of relevance to predict therapeutic efficacy, and underscore the relevance of AMD1 as a potential predictive biomarker for response to mTORC1 inhibition-based therapies.

Genetic and pharmacological inhibition of AMD1 in vitro and in xenograft models demonstrated the therapeutic potential of targeting this metabolic enzyme for PCa treatment. However, in contrast to previous studies showing and antitumoral effect of SAM486A in xenograft models (Dorhout et al., 1995a, 1995b), pharmacological inhibition of AMD1 in vivo failed to support an antitumoral effect in our PCa model. This drug reached the prostate, but was unable to efficiently decrease neither dcSAM, nor polyamine levels. For yet unclear reasons, SAM486A led to a dramatic induction of putrescine levels (Fig. R53). One plausible explanation for this effect is that SAM486A would not reach prostate cancer cells at sufficient concentration to exert its pharmacological activity. In this regard, the emerging field of drug nanoencapsulation might provide advantageous alternatives. Nanoparticles (NP) possess unique properties, such as nanoscopic size, large surface-to-volume ratio, the capacity to encapsulate large payloads and a modifiable external surface. These characteristics provide them with advantages over bulk drugs: the possibility of adding targeting-ligands on their surface, efficient navigation through the often hostile microenvironments in the body, the capability of co-transporting multiple drugs, controlled release of the drug and increased cellular uptake (Davis et al., 2008). Furthermore, NPs offer the possibility of targeting them to specific organelles to achieve maximal therapeutic benefit, with minimal side-effects (Biswas and Torchilin, 2014). Thus, encapsulation of SAM486A into nanoparticles would allow directly targeting the drug to the prostate and would facilitate its incorporation, thereby enhancing the probabilities of achieving an effective therapeutic concentration. This approach could potentiate the efficacy of this drug.

Our data reflects another alternative for targeting AMD1, mTORC1 inhibition. We have shown that mTORC1 inhibition with rapamycin and Torin-1 effectively decreases AMD1 protein levels and dcSAM production in vitro and in vivo. We propose that Everolimus could show therapeutic benefit in patients with high AMD1 levels. Importantly, Everolimus-based combinatorial therapy might increase treatment efficacy, decrease the emergence of resistance and avoid therapy-induced metastasis (Nastiuk and Krolewski, 2016). Despite the discouraging results in the latest attempts to test rapamycin for combination therapies in prostate cancer clinical trials (Vaishampayan et al., 2015; Nakabayashi et al., 2012), the elucidation of AMD1 as...
the plausible downstream effector of mTORC1 raises the alternative of combining Everolimus with another polyamine pathway inhibitor, such as the ODC1 inhibitor, difluoromethylornithine (DFMO). Previous studies in which DFMO in combination with SAM486A showed beneficial effect against leukemic xenografts support this hypothesis. In summary, we believe AMD1 shows predictive capacity for mTORC1 inhibition-based therapies and represents a potential target for combination therapies in PCa.
Conclusions
The results obtained throughout this thesis work confirm our initial hypothesis and demonstrate that oncogenic events trigger the deregulation of metabolism in prostate cancer. The results are summarized as follows:

- *Pten* loss induces a metabolic switch from methionine cycle towards polyamine synthesis pathway in murine and human prostate cancer.

- *Gnmt* loss as a single or compound genetic event is not relevant for disease initiation.

- AMD1 increase upon *Pten* loss induces the metabolic switch observed in prostate cancer.

- AMD1 is under the control of mTORC1.

- We propose the direct phosphorylation of proAMD1 by mTORC1 as the mechanism of regulation, leading to stabilization of the proenzyme and subsequent processing.

- Genetic and pharmacological inhibition of AMD1 exhibits therapeutic potential.

**GENERAL CONCLUSION**

The results obtained in this thesis work demonstrate that the oncogenic loss of *Pten* induces the metabolic deregulation in prostate cancer, through the increase of AMD1. Furthermore, we propose a mechanism of AMD1 regulation downstream mTORC1, which opens new alternatives to target this enzyme.


<table>
<thead>
<tr>
<th>ion</th>
<th>mz</th>
<th>assigned metabolite</th>
</tr>
</thead>
<tbody>
<tr>
<td>m3121</td>
<td>355.1572</td>
<td>4-O-Acetylphenothiazine // HMDB01284: (H/) // 355.1572 (100)</td>
</tr>
<tr>
<td>m3136</td>
<td>188.1765</td>
<td>Nt-Acetylperidione // HMDB00376: (H+) // 188.1765 (100)</td>
</tr>
<tr>
<td>m3140</td>
<td>245.2397</td>
<td>Nt-Acetylperidione // HMDB01188: (H+) // 245.2397 (40)</td>
</tr>
<tr>
<td>m3153</td>
<td>113.0405</td>
<td>(S)-Uric acid // HMDB00105: (H+) // 135.0410 (100)</td>
</tr>
<tr>
<td>m3157</td>
<td>144.9860</td>
<td>Methylpropargylamine // HMDB01184: (H/) // 144.9860 (100)</td>
</tr>
<tr>
<td>m4145</td>
<td>453.2972</td>
<td>3,3-Di-tert-butyl-4-hydroxyphenylacrylate // HMDB02954: (H/) // 453.2972 (100)</td>
</tr>
<tr>
<td>m4156</td>
<td>345.0746</td>
<td>Threonine monophosphate // HMDB01666: (H+) // 345.0746 (100)</td>
</tr>
<tr>
<td>m3040</td>
<td>349.1120</td>
<td>Riboflavin reduced // HMDB01575: (H+) // 349.1120 (100)</td>
</tr>
<tr>
<td>m3049</td>
<td>341.1205</td>
<td>Succinyladenosine // HMDB00293: (H+) // 341.1205 (100)</td>
</tr>
<tr>
<td>m3053</td>
<td>341.1205</td>
<td>Succinyladenosine // HMDB00293: (H+) // 341.1205 (100)</td>
</tr>
<tr>
<td>m3057</td>
<td>341.1205</td>
<td>Succinyladenosine // HMDB00293: (H+) // 341.1205 (100)</td>
</tr>
<tr>
<td>m1131</td>
<td>277.0405</td>
<td>Ascorbic acid // HMDB00042: (H+) // 277.0405 (100)</td>
</tr>
<tr>
<td>m759</td>
<td>147.1398</td>
<td>L-Leucine // HMDB000118: (H-) // 147.1398 (100)</td>
</tr>
<tr>
<td>m144</td>
<td>98.8980</td>
<td>Phosphohydrazine // HMDB02163: (H-) // 98.8980 (100)</td>
</tr>
</tbody>
</table>

**Supplementary table. Time of Flight analysis of murine prostate tissue from Pten wt or prostate deficient mice at 3 months (X3M) or 6 months (X6M) in AP and DLP lobes.**

<table>
<thead>
<tr>
<th>ion</th>
<th>mz</th>
<th>assigned metabolite</th>
</tr>
</thead>
<tbody>
<tr>
<td>m3121</td>
<td>355.1572</td>
<td>4-O-Acetylphenothiazine // HMDB01284: (H/) // 355.1572 (100)</td>
</tr>
<tr>
<td>m3136</td>
<td>188.1765</td>
<td>Nt-Acetylperidione // HMDB00376: (H+) // 188.1765 (100)</td>
</tr>
<tr>
<td>m3140</td>
<td>245.2397</td>
<td>Nt-Acetylperidione // HMDB01188: (H+) // 245.2397 (40)</td>
</tr>
<tr>
<td>m3153</td>
<td>113.0405</td>
<td>(S)-Uric acid // HMDB00105: (H+) // 135.0410 (100)</td>
</tr>
<tr>
<td>m3157</td>
<td>144.9860</td>
<td>Methylpropargylamine // HMDB01184: (H/) // 144.9860 (100)</td>
</tr>
<tr>
<td>m4145</td>
<td>453.2972</td>
<td>3,3-Di-tert-butyl-4-hydroxyphenylacrylate // HMDB02954: (H/) // 453.2972 (100)</td>
</tr>
<tr>
<td>m4156</td>
<td>345.0746</td>
<td>Threonine monophosphate // HMDB01666: (H+) // 345.0746 (100)</td>
</tr>
<tr>
<td>m3040</td>
<td>349.1120</td>
<td>Riboflavin reduced // HMDB01575: (H+) // 349.1120 (100)</td>
</tr>
<tr>
<td>m3049</td>
<td>341.1205</td>
<td>Succinyladenosine // HMDB00293: (H+) // 341.1205 (100)</td>
</tr>
<tr>
<td>m3053</td>
<td>341.1205</td>
<td>Succinyladenosine // HMDB00293: (H+) // 341.1205 (100)</td>
</tr>
<tr>
<td>m3057</td>
<td>341.1205</td>
<td>Succinyladenosine // HMDB00293: (H+) // 341.1205 (100)</td>
</tr>
<tr>
<td>m1131</td>
<td>277.0405</td>
<td>Ascorbic acid // HMDB00042: (H+) // 277.0405 (100)</td>
</tr>
<tr>
<td>m759</td>
<td>147.1398</td>
<td>L-Leucine // HMDB000118: (H-) // 147.1398 (100)</td>
</tr>
<tr>
<td>m144</td>
<td>98.8980</td>
<td>Phosphohydrazine // HMDB02163: (H-) // 98.8980 (100)</td>
</tr>
<tr>
<td>m/z</td>
<td>Name</td>
<td>Description</td>
</tr>
<tr>
<td>-----</td>
<td>-------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>231.175</td>
<td>N-Acetyl-b-glucosaminylamine Cytidine monophosphate N-acetylneuraminic acid</td>
<td></td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.4652 0.0643</td>
<td>1.0000 0.0000 0.0000 1.0000 -1.5496 0.0000 1.0000 -1.6417 0.0000 1.0000 -1.6838 0.0000</td>
</tr>
<tr>
<td>243.0274</td>
<td>Hexosyl cytosine phosphate</td>
<td>HMDB01255-(-H2O.H(+) 243.0274 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.6757 0.3877</td>
<td>1.0000 -1.4158 0.0000 1.0000 -1.0751 0.0000 1.0000 -1.5560 0.0000 1.0000 -1.9885 0.0000</td>
</tr>
<tr>
<td>354.0202</td>
<td>N-Succinyl-2-amino-6-ketogluric acid</td>
<td>HMDB01256-(H+) 354.0202 63</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.8073 0.0692</td>
<td>1.0000 -1.6165 0.0000 1.0000 -1.9924 0.0000 1.0000 -1.9885 0.0000 1.0000 -1.9885 0.0000</td>
</tr>
<tr>
<td>390.0282</td>
<td>4-Hydroxyphenylacetylglutamine</td>
<td>HMDB03017-(-H2O.H(+) 390.0282 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.5656 0.3312</td>
<td>1.0000 -1.5394 0.0000 1.0000 -1.4397 0.0000 1.0000 -1.5527 0.0000 1.0000 -1.6003 0.0000</td>
</tr>
<tr>
<td>492.9931</td>
<td>2-Hydroxynaphthalene</td>
<td>HMDB00557-(-H+ 492.9931 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.5538 0.4776</td>
<td>1.0000 -1.3615 0.0000 1.0000 -1.0014 0.0000 1.0000 -1.5834 0.0000 1.0000 -2.1360 0.0000</td>
</tr>
<tr>
<td>540.0287</td>
<td>Methylmalonyl-CoA</td>
<td>HMDB00085-(H/Na.H(+) 540.0287 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.5454 0.3971</td>
<td>1.0000 -1.5381 0.0000 1.0000 -1.0222 0.0012 1.0000 -1.6333 0.0000 1.0000 -1.9894 0.0000</td>
</tr>
<tr>
<td>582.0895</td>
<td>4-Hydroxyphenylacetylur runnable</td>
<td>HMDB00161-(-H2O.H(+) 582.0895 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.5550 0.4328</td>
<td>1.0000 -1.9625 0.0000 1.0000 -0.9941 0.0000 1.0000 -1.7774 0.0000 1.0000 -1.6380 0.0000</td>
</tr>
<tr>
<td>73.0288</td>
<td>Pyruvic acid</td>
<td>HMDB00167-(-H2O.H(+) 73.0288 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.7552 0.3295</td>
<td>1.0000 -1.6941 0.0000 1.0000 -1.5529 0.0000 1.0000 -1.8233 0.0000 1.0000 -2.0402 0.0000</td>
</tr>
<tr>
<td>183.0504</td>
<td>3-Methyluric acid</td>
<td>HMDB001973-(-H+ 183.0504 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.8332 0.3210</td>
<td>1.0000 -1.5959 0.0000 1.0000 -1.5560 0.0000 1.0000 -2.1519 0.0000 1.0000 -2.1090 0.0000</td>
</tr>
<tr>
<td>183.0504</td>
<td>3-Methyl-D-ribose</td>
<td>HMDB001973-(-H+ 183.0504 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.8332 0.3210</td>
<td>1.0000 -1.5959 0.0000 1.0000 -1.5560 0.0000 1.0000 -2.1519 0.0000 1.0000 -2.1090 0.0000</td>
</tr>
<tr>
<td>183.0504</td>
<td>3-Methyl-L-ribose</td>
<td>HMDB001973-(-H+ 183.0504 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.8332 0.3210</td>
<td>1.0000 -1.5959 0.0000 1.0000 -1.5560 0.0000 1.0000 -2.1519 0.0000 1.0000 -2.1090 0.0000</td>
</tr>
<tr>
<td>183.0504</td>
<td>L- Iditol</td>
<td>HMDB001973-(-H+ 183.0504 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.8332 0.3210</td>
<td>1.0000 -1.5959 0.0000 1.0000 -1.5560 0.0000 1.0000 -2.1519 0.0000 1.0000 -2.1090 0.0000</td>
</tr>
<tr>
<td>298.0977</td>
<td>Methyluric acid</td>
<td>HMDB001973-(-H+ 298.0977 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.5454 0.3971</td>
<td>1.0000 -1.5381 0.0000 1.0000 -1.0222 0.0012 1.0000 -1.6333 0.0000 1.0000 -1.9894 0.0000</td>
</tr>
<tr>
<td>511.1162</td>
<td>8-Hydroxyoctadecenoic acid</td>
<td>HMDB001973-(-H+ 511.1162 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.6757 0.0001</td>
<td>1.0000 -1.4158 0.0000 1.0000 -1.0751 0.0000 1.0000 -1.5560 0.0000 1.0000 -1.9885 0.0000</td>
</tr>
<tr>
<td>511.1162</td>
<td>8-Hydroxyoctadecenoic acid</td>
<td>HMDB001973-(-H+ 511.1162 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.6757 0.0001</td>
<td>1.0000 -1.4158 0.0000 1.0000 -1.0751 0.0000 1.0000 -1.5560 0.0000 1.0000 -1.9885 0.0000</td>
</tr>
<tr>
<td>511.1162</td>
<td>8-Hydroxyoctadecenoic acid</td>
<td>HMDB001973-(-H+ 511.1162 100)</td>
</tr>
<tr>
<td>4.0000</td>
<td>-1.6757 0.0001</td>
<td>1.0000 -1.4158 0.0000 1.0000 -1.0751 0.0000 1.0000 -1.5560 0.0000 1.0000 -1.9885 0.0000</td>
</tr>
<tr>
<td>Compound</td>
<td>HMDB ID</td>
<td>Charge</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------</td>
<td>--------</td>
</tr>
<tr>
<td>Proline betaine</td>
<td>320.0444</td>
<td>0</td>
</tr>
<tr>
<td>NAD</td>
<td>306.0468</td>
<td>0</td>
</tr>
<tr>
<td>L-Palmitoylcarnitine</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Diadenosine tetraphosphate</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Molybdopterin-AMP</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>dADP</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Solanesyl-PP</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>L-Serine</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>dGMP</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>dCYP</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>dATP</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>3'Carboxy-1-hydroxypyridinium</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>diaminopimelate</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Phosphorylcholine</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>5C-aglycone</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Epsilon-(gamma-Glutamyl)-lysine</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Acetylmannosamine</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>3'-O-Methyladenosine</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Lacto-N-biose I</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Tryptophanol</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>Acetylcholine</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>3-O-Methyl-2,4-dihydroxybutanol</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>400.3444</td>
<td>320.0468</td>
<td>0</td>
</tr>
<tr>
<td>384.1488</td>
<td>320.0468</td>
<td>0</td>
</tr>
</tbody>
</table>

Page 6 of 11
<table>
<thead>
<tr>
<th>M/z</th>
<th>Retention Time</th>
<th>Compound Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>m1413</td>
<td>203.2424</td>
<td>Spermine</td>
</tr>
<tr>
<td>m1413</td>
<td>203.2424</td>
<td>O-4-deoxy-l-galactopyranosyl(1→2)-O-6-deoxy-l-galactopyranosyl(1→2)-O-2-deoxy-D-Galactose</td>
</tr>
<tr>
<td>m4772</td>
<td>530.2008</td>
<td>HMDB01256:.H(+)</td>
</tr>
<tr>
<td>m4772</td>
<td>530.2008</td>
<td>2-deoxy-D-Galactose</td>
</tr>
<tr>
<td>m105</td>
<td>89.1076</td>
<td>Putrescine</td>
</tr>
<tr>
<td>m105</td>
<td>89.1076</td>
<td>HMDB01414:.H(+)</td>
</tr>
<tr>
<td>m651</td>
<td>140.9953</td>
<td>Acetylphosphate</td>
</tr>
<tr>
<td>m651</td>
<td>140.9953</td>
<td>HMDB01494:.H(+)</td>
</tr>
<tr>
<td>m4911</td>
<td>543.4860</td>
<td>7,7,8,8,11,11,12,12-Hexahydro-y,y-Carotene</td>
</tr>
<tr>
<td>m4911</td>
<td>543.4860</td>
<td>Phytofluene</td>
</tr>
<tr>
<td>m3550</td>
<td>399.1471</td>
<td>S-Adenosylmethionine</td>
</tr>
<tr>
<td>m5550</td>
<td>613.1583</td>
<td>Oxidized glutathione</td>
</tr>
<tr>
<td>m758</td>
<td>147.0765</td>
<td>7,8,8,11.11.12.12-Hexahydro-y,y-Carotene</td>
</tr>
<tr>
<td>m758</td>
<td>147.0765</td>
<td>HMDB02172:.H(+)</td>
</tr>
<tr>
<td>m473</td>
<td>137.0243</td>
<td>Taurine</td>
</tr>
<tr>
<td>m350</td>
<td>399.1471</td>
<td>S-Adenosylmethionine</td>
</tr>
<tr>
<td>m657</td>
<td>509.3881</td>
<td>Reduced Vitamin K (phylloquinone)</td>
</tr>
<tr>
<td>m510</td>
<td>613.1583</td>
<td>Oleate</td>
</tr>
<tr>
<td>m2741</td>
<td>318.2966</td>
<td>Phytosphingosine</td>
</tr>
<tr>
<td>m2752</td>
<td>319.2575</td>
<td>Allopregnanolone</td>
</tr>
<tr>
<td>m2752</td>
<td>319.2575</td>
<td>Alloepipregnanolone</td>
</tr>
<tr>
<td>m2752</td>
<td>319.2575</td>
<td>Epipregnanolone</td>
</tr>
<tr>
<td>m2752</td>
<td>319.2575</td>
<td>Epimetendiol</td>
</tr>
<tr>
<td>m2752</td>
<td>319.2575</td>
<td>3a-Hydroxy-5b-pregnane-20-one</td>
</tr>
<tr>
<td>m2752</td>
<td>319.2575</td>
<td>2,6-dimethylheptanoyl carnitine</td>
</tr>
<tr>
<td>m2752</td>
<td>319.2575</td>
<td>HMDB06320:.NH4(+)</td>
</tr>
</tbody>
</table>

This table represents the retention times and compound descriptions for various metabolites detected in the analyzed sample. The values provided are in milligrams per liter (mg/L) and represent the concentration of each compound detected in the sample.
<table>
<thead>
<tr>
<th>m/z</th>
<th>Retention Time</th>
<th>Compound Description</th>
</tr>
</thead>
</table>
# Teklad Global 14% Protein Rodent Maintenance Diet

## Product Description

2014 is a fixed formula, non-autoclavable diet manufactured with high quality ingredients and designed to promote longevity and normal body weight in rodents. 2014 does not contain alfalfa or soybean meal, thus minimizing the occurrence of natural phytoestrogens. Typical isoflavone concentrations (daidzein + genistein aglycone equivalents) range from non-detectable to 20 mg/kg. Exclusion of alfalfa reduces chlorophyll, improving optical imaging clarity. Absence of animal protein and fish meal minimizes the presence of nitrosamines. Also available certified (2014C) and irradiated (2014). For autoclavable diet, refer to 2014S (Sterilizable).

## Ingredients

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheat middlings, ground wheat, ground corn, corn gluten meal, calcium carbonate, soybean oil, dicalcium phosphate, iodized salt, L-lysine, vitamin E acetate, DL-methionione, magnesium oxide, choline chloride, manganese oxide, ferrous sulfate, menadione sodium bisulfite complex (source of vitamin K activity), zinc oxide, copper sulfate, niacin, calcium pantothenate, calcium iodate, pyridoxine hydrochloride, riboflavin, thiamin mononitrate, vitamin A acetate, vitamin B₁₂ supplement, folic acid, cobalt carbonate, biotin, vitamin D₃ supplement.</td>
<td></td>
</tr>
</tbody>
</table>

## Macronutrients

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crude Protein</td>
<td>14.3</td>
</tr>
<tr>
<td>Fat (ether extract)</td>
<td>4.0</td>
</tr>
<tr>
<td>Carbohydrate (available)</td>
<td>48.0</td>
</tr>
<tr>
<td>Crude Fiber</td>
<td>4.1</td>
</tr>
<tr>
<td>Neutral Detergent Fiber</td>
<td>18.0</td>
</tr>
<tr>
<td>Ash</td>
<td>4.7</td>
</tr>
<tr>
<td>Energy Density</td>
<td>2.9 (12.1 kcal/g)</td>
</tr>
<tr>
<td>Calories from Protein</td>
<td>20</td>
</tr>
<tr>
<td>Calories from Fat</td>
<td>13</td>
</tr>
<tr>
<td>Calories from Carbohydrate</td>
<td>67</td>
</tr>
</tbody>
</table>

## Minerals

<table>
<thead>
<tr>
<th>Mineral</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium</td>
<td>0.7</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>0.6</td>
</tr>
<tr>
<td>Sodium</td>
<td>0.1</td>
</tr>
<tr>
<td>Potassium</td>
<td>0.6</td>
</tr>
<tr>
<td>Chloride</td>
<td>0.3</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.2</td>
</tr>
<tr>
<td>Zinc</td>
<td>70 mg/kg</td>
</tr>
<tr>
<td>Manganese</td>
<td>100 mg/kg</td>
</tr>
<tr>
<td>Copper</td>
<td>15 mg/kg</td>
</tr>
<tr>
<td>Iodine</td>
<td>6 mg/kg</td>
</tr>
<tr>
<td>Iron</td>
<td>175 mg/kg</td>
</tr>
<tr>
<td>Selenium</td>
<td>0.23 mg/kg</td>
</tr>
</tbody>
</table>

## Amino Acids

<table>
<thead>
<tr>
<th>Amino Acid</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspartic Acid</td>
<td>0.9</td>
</tr>
<tr>
<td>Glutamic Acid</td>
<td>2.9</td>
</tr>
<tr>
<td>Alanine</td>
<td>0.9</td>
</tr>
<tr>
<td>Glycine</td>
<td>0.7</td>
</tr>
<tr>
<td>Threonine</td>
<td>0.5</td>
</tr>
<tr>
<td>Proline</td>
<td>1.2</td>
</tr>
<tr>
<td>Serine</td>
<td>0.7</td>
</tr>
<tr>
<td>Leucine</td>
<td>1.4</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>0.6</td>
</tr>
<tr>
<td>Valine</td>
<td>0.7</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>0.7</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>0.4</td>
</tr>
<tr>
<td>Methionine</td>
<td>0.3</td>
</tr>
<tr>
<td>Cystine</td>
<td>0.3</td>
</tr>
<tr>
<td>Lysine</td>
<td>0.7</td>
</tr>
<tr>
<td>Histidine</td>
<td>0.4</td>
</tr>
<tr>
<td>Arginine</td>
<td>0.8</td>
</tr>
<tr>
<td>Tryptophan</td>
<td>0.2</td>
</tr>
</tbody>
</table>

## Vitamins

<table>
<thead>
<tr>
<th>Vitamin</th>
<th>IU/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A&lt;sup&gt;e, f&lt;/sup&gt;</td>
<td>6.0</td>
</tr>
<tr>
<td>Vitamin D&lt;sub&gt;₃&lt;/sub&gt;&lt;sup&gt;e, g&lt;/sup&gt;</td>
<td>0.6</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>120</td>
</tr>
<tr>
<td>Vitamin K&lt;sub&gt;₃&lt;/sub&gt; (menadione)</td>
<td>20</td>
</tr>
<tr>
<td>Vitamin B₁ (thiamin)</td>
<td>12</td>
</tr>
<tr>
<td>Vitamin B₂ (riboflavin)</td>
<td>6</td>
</tr>
<tr>
<td>Niacin (nicotinic acid)</td>
<td>54</td>
</tr>
<tr>
<td>Vitamin B₆ (pyridoxine)</td>
<td>10</td>
</tr>
<tr>
<td>Pantothenic Acid</td>
<td>17</td>
</tr>
<tr>
<td>Vitamin B₁₂ (cyanocobalamin)</td>
<td>0.03</td>
</tr>
<tr>
<td>Biotin</td>
<td>0.26</td>
</tr>
<tr>
<td>Folate</td>
<td>2</td>
</tr>
<tr>
<td>Choline</td>
<td>1030</td>
</tr>
</tbody>
</table>

## Fatty Acids

<table>
<thead>
<tr>
<th>Fatty Acid</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>C16:0 Palmitic</td>
<td>0.5</td>
</tr>
<tr>
<td>C18:0 Stearic</td>
<td>0.1</td>
</tr>
<tr>
<td>C18:1ω9 Oleic</td>
<td>0.7</td>
</tr>
<tr>
<td>C18:2ω6 Linoleic</td>
<td>2.0</td>
</tr>
<tr>
<td>C18:3ω3 Linolenic</td>
<td>0.1</td>
</tr>
<tr>
<td>Total Saturated</td>
<td>0.6</td>
</tr>
<tr>
<td>Total Monounsaturated</td>
<td>0.7</td>
</tr>
<tr>
<td>Total Polyunsaturated</td>
<td>2.1</td>
</tr>
</tbody>
</table>

## Other

<table>
<thead>
<tr>
<th>Other</th>
<th>mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol</td>
<td>--</td>
</tr>
</tbody>
</table>

---

<sup>a</sup> Ether extract is used to measure fat in pelleted diets, while an acid hydrolysis method is required to recover fat in extruded diets. Compared to ether extract, the fat value for acid hydrolysis will be approximately 1% point higher.

<sup>b</sup> Carbohydrate (available) is calculated by subtracting neutral detergent fiber from total carbohydrates.

<sup>c</sup> Neutral detergent fiber is an estimate of insoluble fiber, including cellulose, hemicellulose, and lignin. Crude fiber methodology underestimates total fiber.

<sup>d</sup> Energy density is a calculated estimate of metabolizable energy based on the Atwater factors assigning 4 kcal/g to protein, 9 kcal/g to fat, and 4 kcal/g to available carbohydrate.

<sup>e</sup> Indicates added amount but does not account for contribution from other ingredients.

<sup>f</sup> 1 IU vitamin A = 0.3 µg retinol

<sup>g</sup> 1 IU vitamin D = 25 ng cholecalciferol

For nutrients not listed, insufficient data is available to quantify.

Nutrient data represent the best information available, calculated from published values and direct analytical testing of raw materials and finished product. Nutrient values may vary due to the natural variations in the ingredients, analysis, and effects of processing.

---

Teklad Diets are designed and manufactured for research purposes only.
AIN-76A Semi-Purified Diet with 0.15% L-Methionine

Storage conditions are particularly critical to TestDiet® products, due to the absence of antioxidants or preservative agents. To provide maximum protection against possible changes during storage, store in a dry, cool location. Storage under refrigeration (2°C) is recommended.

Storage conditions are particularly critical to TestDiet® products, due to the absence of antioxidants or preservative agents. To provide maximum protection against possible changes during storage, store in a dry, cool location. Storage under refrigeration (2°C) is recommended. Maximum shelf life is six months. (If long term studies are involved, storing the diet at -20°C or colder may prolong shelf life.) Be certain to keep in air tight containers.

Product Forms Available*  
1/2” Pellet  
52501

*Other Forms Available On Request

INGREDIENTS (%)  

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corn Starch</td>
<td>43.4600</td>
</tr>
<tr>
<td>Sucrose</td>
<td>20.0000</td>
</tr>
<tr>
<td>Corn Oil</td>
<td>8.0000</td>
</tr>
<tr>
<td>Dextrin</td>
<td>5.0000</td>
</tr>
<tr>
<td>Powdered Cellulose</td>
<td>5.0000</td>
</tr>
<tr>
<td>Glutamic Acid</td>
<td>3.5600</td>
</tr>
<tr>
<td>AIN-76 Mineral Mix</td>
<td>3.5000</td>
</tr>
<tr>
<td>Glycine</td>
<td>2.3300</td>
</tr>
<tr>
<td>L-Lysine Hydrochloride</td>
<td>1.4400</td>
</tr>
<tr>
<td>L-Phenylalanine</td>
<td>1.1600</td>
</tr>
<tr>
<td>L-Leucine</td>
<td>1.1200</td>
</tr>
<tr>
<td>AIN-76A Vitamin Mix</td>
<td>1.0000</td>
</tr>
<tr>
<td>L-Isoleucine</td>
<td>0.8200</td>
</tr>
<tr>
<td>L-Valine</td>
<td>0.8200</td>
</tr>
<tr>
<td>L-Threonine</td>
<td>0.8200</td>
</tr>
<tr>
<td>L-Histidine HCI-H2O</td>
<td>0.3300</td>
</tr>
<tr>
<td>Choline Bitartrate</td>
<td>0.2000</td>
</tr>
<tr>
<td>L-Tryptophan</td>
<td>0.1800</td>
</tr>
<tr>
<td>L-Methionine</td>
<td>0.1500</td>
</tr>
</tbody>
</table>

MINERALS

<table>
<thead>
<tr>
<th>Mineral</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium</td>
<td>0.52</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>0.40</td>
</tr>
<tr>
<td>Potassium</td>
<td>0.36</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.05</td>
</tr>
<tr>
<td>Sodium</td>
<td>0.13</td>
</tr>
<tr>
<td>Chloride</td>
<td>0.73</td>
</tr>
<tr>
<td>Fluoride</td>
<td>0.00</td>
</tr>
<tr>
<td>Iron</td>
<td>37</td>
</tr>
<tr>
<td>Zinc</td>
<td>29</td>
</tr>
<tr>
<td>Manganese</td>
<td>59</td>
</tr>
<tr>
<td>Copper</td>
<td>6.0</td>
</tr>
<tr>
<td>Cobalt</td>
<td>0.0</td>
</tr>
<tr>
<td>Iodide</td>
<td>0.21</td>
</tr>
<tr>
<td>Chromium</td>
<td>2.0</td>
</tr>
<tr>
<td>Molybdenum</td>
<td>0.00</td>
</tr>
<tr>
<td>Selenium</td>
<td>0.11</td>
</tr>
</tbody>
</table>

VITAMINS

<table>
<thead>
<tr>
<th>Vitamin</th>
<th>IU/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A</td>
<td>4.0</td>
</tr>
<tr>
<td>Vitamin D-3</td>
<td>1.0</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>50.0</td>
</tr>
<tr>
<td>Vitamin K</td>
<td>0.50</td>
</tr>
<tr>
<td>Thiamin</td>
<td>6.0</td>
</tr>
<tr>
<td>Riboflavin</td>
<td>6.0</td>
</tr>
<tr>
<td>Niacin</td>
<td>30</td>
</tr>
<tr>
<td>Pantothenic Acid</td>
<td>15</td>
</tr>
<tr>
<td>Folic Acid</td>
<td>2.0</td>
</tr>
<tr>
<td>Pyridoxine</td>
<td>5.8</td>
</tr>
<tr>
<td>Biotin</td>
<td>0.2</td>
</tr>
<tr>
<td>Vitamin B-12</td>
<td>10</td>
</tr>
<tr>
<td>Choline</td>
<td>1,000</td>
</tr>
<tr>
<td>Ascorbic Acid</td>
<td>0.0</td>
</tr>
</tbody>
</table>

FEEDING DIRECTIONS

Feed ad libitum. Plenty of fresh, clean water should be available at all times.

CAUTION: Perishable - store properly upon receipt. For laboratory animal use only; NOT for human consumption.

4/8/2011

TestDiet®  
www.testdiet.com
Contributed publications
Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN

Aitziber Ugalde-Olano a,1, Ainara Egia b,1, Sonia Fernández-Ruiz c,1, Ana Loizaga-Iriarte d,1, Patricia Zuñiga-García c,1, Stephane Garcia e, Félix Royo c,1, Isabel Lacasa-Viscasillas d, Erika Castro b, Ana R. Cortazar d, Amaia Zabala-Letona c, Natalia Martín-Martín c, Amaia Arruabarrena-Aristorena c, Verónica Torran-Moya c, Lorea Valcárcel-Jiménez c, Pilar Sánchez-Mosquera c, Alfredo Caro-Maldonado c, Jorge González-Tampan d, Guido Cachi-Fuentes d, Elena Bilbao d, Rocio Montero d, Sara Fernández a,b, Edurne Arrieta b, Kerman Zorroza b, Mireia Castillo-Martín g, Violeta Serra h,i, Eider Salazar b, Nuria Macías-Cámara c, Jose Tabernero h,i, Jose Baselga h,i, Carlos Cordón-Cardo g, Ana M. Aransay c,f, Amaia Del Villar b, Juan L. Iovanna e, Juan M. Falcón-Pérez c,f,k, Miguel Unda d,2, Roberto Bilbao b,2, Arkaitz Carracedo c,k,l,*2

a Department of Pathology, Basurto University Hospital, 48013 Bilbao, Spain
b Basque Biobank, Basque Foundation for Health Innovation and Research-BIOEF, Barakaldo, Spain
c CIC bioGUNE, Bizkaia Technology Park, 801 Building, 48160 Derio, Spain
d Department of Urology, Basurto University Hospital, 48013 Bilbao, Spain
e Centre de Recherche en Carcérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, Marseille, France
f Centeno de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberhe), Spain
g Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
h Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain
i Experimental Therapeutics Group, Vall d’Hebron University Hospital, Barcelona, Spain
j Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
k Ikerbasque, Basque Foundation for Science, Bilbao, Spain
l Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bilbao, Spain

ARTICLE INFO

Article history:
Received 3 October 2014
Received in revised form 9 February 2015
Accepted 10 February 2015
Available online 16 February 2015

Keywords:
PTEN
Prostate cancer
Fresh tissue
Molecular biology

ABSTRACT

Prostate cancer is among the most frequent cancers in men, and despite its high rate of cure, the high number of cases results in an elevated mortality worldwide. Importantly, prostate cancer incidence is dramatically increasing in western societies in the past decades, suggesting that this type of tumor is exquisitely sensitive to lifestyle changes. Prostate cancer frequently exhibits alterations in the PTEN gene (inactivating mutations or gene deletions) or at the protein level (reduced protein expression or altered sub-cellular compartmentalization). The relevance of PTEN in this type of cancer is further supported by the fact that the sole deletion of PTEN in the murine prostate epithelium recapitulates many of the features of the human disease. In order to study the molecular alterations in prostate cancer, we need to overcome the methodological challenges that this tissue imposes. In this review we present protocols and methods, using PTEN as proof of concept, to study different molecular characteristics of prostate cancer.

© 2015 Published by Elsevier Inc.

1. Introduction

Prostate cancer (PCa) is among the deadliest forms of cancer (WHO), and represents the third cause of death by cancer in men (www.globocan.iarc.fr). The tumor suppressor PTEN is among the most mutated and lost tumor suppressors in PCa [1]. Up to 70% of PC as harbor loss of PTEN at presentation. This
tumor suppressor is located at the top of a highly oncogenic signaling pathway, the PI-3 Kinase (PI-3K) cascade, which contains many other oncogenes and tumor suppressors [2]. In addition, regulatory feedback loops stem from the PTEN/PI-3K pathway to ensure cell homeostasis, which decrease the efficacy of single agent therapies [2,3].

PTEN down-regulation is not restricted to genetic events, and regulation of its transcription, translation and stability can play an important role. PTEN is frequently lost in heterozygosity, whereas mostly advanced cancers exhibit complete loss of the tumor suppressor. Interestingly, the prostate epithelium is exquisitely sensitive to the reduction in PTEN levels. This concept has been formally proven in mice through the use of genetic interference, which allows a partial reduction of the expression of the interfered allele [4,5]. While PTEN heterozygous mice present PIN lesions in the prostate with long latency [6], PTEN hypomorphic mice show progression of the prostate lesions to invasive cancer at higher penetrance [5]. Importantly, while a gradual decrease of PTEN promotes prostate cancer progression, acute and complete PTEN-loss elicits the activation of a fail-safe senescence response, which is driven by the up-regulation of the tumor suppressor p53 [7]. This novel type of senescence is genuinely distinct from the classic oncogene-induced senescence [8]. Importantly, genetic or environmental events regulating this process may be key players in the progression of prostate cancer and therefore attractive targets for anti-cancer therapy [9,10].

All these evidence point to the need of studying PTEN-dependent pathways in prostate cancer. However, the technical challenges related to the study of this type of tumor require special attention, and hence, in this review we aim at describing a series of methodologies to study prostate cancer biology, with a reference to the pathway aforementioned.

2. Methods and results

2.1. Preparation of well-diagnosed prostate cancer specimens for molecular studies

Cancerous lesions in the prostate, unlike in other tissues, are difficult to identify macroscopically. This poses a challenge when the aim is to obtain well-diagnosed frozen tissue. To overcome this limitation, we have set up together with the Basque Biobank and Basurto University Hospital (OSH-Basurto, Bilbao, Spain), in collaboration with the Dept. of Pathology at Mount Sinai, a procedure to obtain this type of specimen.

2.2. Key materials

- A biopsy punch (Miltex Ref. 33–34).

Due to the characteristics of prostate cancer, we established a procedure by which fresh tissue obtained from radical prostatectomy is sliced into left and right lobe (after delimiting the margins of the surgical piece with ink and fixing the ink with acetic acid). All prostate specimens were obtained upon informed consent and with evaluation and approval from the corresponding ethics committee (CEIC code OHEUN11–12 and OHEUN14–14). From each lobe, the dermatologic punch is employed to harvest 8 tissue cylinders of 4 mm diameter. The site of the punches is selected blindly due to the lack of macroscopic alterations associated to cancerous lesions. However, we did notice that the expertise of the pathologist does influence the rate of success in harvesting cylinders with cancer. Of note, this approach prevents from damaging the capsule and a drop of eosin on the site of tissue harvest can help monitoring the histological alterations surrounding the area for diagnostic purposes. Tissue cylinders are then divided longitudinally with a scalpel and dedicated to snap-freeze (in liquid nitrogen or isopentane at −80 °C) and to paraffin embedding for diagnostic purposes (procedure in Fig. 1A–D). Due to the width of the cylinder (4 mm diameter), the diagnosed tissue fraction will closely represent the histological properties of the frozen adjacent tissue. In Fig. 1E, hematoxylin/eosin staining of whole tissue sections from cylinders with different tumor abundance are shown, together with a zoom that shows the correct preservation of the histological properties of the sections. Importantly, this protocol allows us to closely estimate the tumor abundance that we have in the frozen tissue piece, hence solving an otherwise challenge in the acquisition of frozen material. The material obtained from this approach is sufficient to carry out different molecular biology studies, including RNA preparation (described below), protein extraction and metabolite profiling (data not shown).

2.3. Molecular biology analysis from frozen tissue: tips for good quality RNA preparation

Preparation of RNA of high quality from prostate cancer specimens remains a challenge, primarily due to the abundance of RNAses and proteases in the prostate and prostatic fluid. A variety

![Fig. 1. Preparation of well-diagnosed fresh frozen biopsies. (A–D) Preparation of the punch biopsy (A) and excision with scalpel (B), identification of the harvest point in surgical piece with eosin (C) and longitudinal separation of the punch with scalpel (D). (E) Histological features of punch biopsies with different abundance of tumoral tissue, whole section hematoxylin/eosin staining is shown together with a zoom to show the histological features of the piece.](image-url)
of protocols have been proposed to maximize the quality and yield from biopsies of different origin [11–14] (see also protocols from Prostate Cancer Biorepository Network; SOP N:006 http://www.prostatebiorepository.org). While real time PCR is a low-demanding approach in terms of RNA integrity, the latest OMIC technologies, including RNA sequencing, require material in optimal conditions.

To define the technical needs of an appropriate RNA extraction strategy, we have tested one main technical implementation (the use of phenolic extraction agents) and one variable (the presence of ink and acetic acid in the preparation).

2.4. Key materials

- Trizol (Life Technologies/Invitrogen Ref. 15596-018).
- Total RNA extraction kit (NucleoSpin® miRNA Ref. 740971.10/50/250).

The protocol is the following, where the alternative procedure with and without Trizol is underlined (the Trizol-based implementation is described in the user manual of the NucleoSpin® miRNA kit):

1. RNAse inhibition and tissue thawing (a minimal amount of tissue of 10 mg is sufficient for the procedure). RNA later ICE (Life Technologies Ref. AM7030) is used to ensure the maximal inhibition of RNAses and the optimization of tissue homogenization afterwards. The protocol is based on transferring frozen tissue (stored dry at −80°C) to RNA later ICE (also at −80°C) and thawing the tissue at −20°C overnight.

2. Regular lysis buffer. Tissue is transferred to the recommended volume of NucleoSpin® miRNA lysis buffer.

Trizol-based lysis. Tissue is transferred to 400 µL volume of Trizol. Additional 400 µL are added after homogenization.

3. Homogenization. 5–6 beads/tube (Ceramic Bead Tubes 2.8 mm, Cat.: 13114-50; MO BIO Laboratories). Homogenization is carried out in Precellys in two cycles of 6000 rpm and 30 s.

4. RNA extraction. Following the manufacturer's instructions.

RNA extraction. Following homogenization, we add 160 µL of Chloroform, mix by vortex, incubate 3 min and centrifuge 15 min at 12,000 g in tabletop centrifuge. The supernatant (350–400 µL) is transferred to a new tube and mixed with 1 mL of MX buffer. After vortex, the product is loaded in the column and the same process indicated in point 4 is followed.

The results obtained from frozen tissues with a stabilizing agent (RNA later ICE), a total RNA extraction kit, and with or without Trizol implementation are shown in Fig. 2. RNA stabilizing agents and the standard non-phenol based lysis buffer is not sufficient to prevent the RNA from degrading (Fig. 2A), while Trizol implementation results in total RNA of optimal quality for transcriptomic studies (Fig. 2B, RNA Integrity Number – RIN – values in Fig. 2C). Of note, although small RNAs have not been monitored in this procedure, the kit presented herein would allow for their isolation.

On the other hand, we have evaluated with an independent phenol-based RNA extraction kit (Absolutely RNA miRNA KIT. Cat. 400814, Agilent) whether the presence of ink and acetic acid from the margins of the non-tumoral prostate tissue could influence RNA quality. To this end, we selected biopsies containing increasing amounts of these contaminants (Fig. 2D). The presence of these agents did not impact the quality of RNA, as quantified by Agilent Bioanalyzer (Fig. 2E). We further studied if despite yielding good quality RNA, ink and acetic acid could interfere with...
the retrotranscription and real time quantitative PCR process. We predicted that if the ink/acetic acid interferes with the retrotranscription or real time PCR, we would observe an increase in the Ct values of the genes studied in the high ink conditions. However, evaluation of PTEN expression with two independent Taqman probes (PTEN 48: Universal Probe library [Roche] #48; primer F: ggggagaagggcagagac Primer R: tccacagtttcacaggtgc; PTEN 60: Universal Probe library [Roche] #60; primer F: gcacaagggcctttcctgatgc Primer R: cgcctctgactgggaatagt) and GAPDH (REF. Life Technologies Hs02758991_g1) as housekeeping gene clearly showed a lack of correlation between the amount of ink and any alteration in gene expression (Fig. 2F). In summary, phenol-based RNA extraction coupled to column-based purification significantly improves RNA quality and the presence of ink/acetic acid in the tissue sample does not influence RNA preparation, retrotranscription, or real time PCR amplification.

2.5. Monitoring PTEN expression in prostate cancer: an immunohistochemical (IHC) procedure

Immunodetection of PTEN could become critical in the coming years to stratify patients and define the best therapeutic strategies [15,16]. Therefore, good standardized IHC procedures need to be established. Lotan et al. recently established an immunohistochemical protocol for PTEN [17]. We have employed a different clone from Cell Signaling Technology PTEN (138G6) and we have established a sensitive and specific IHC protocol for research purposes.

2.6. Key material

– Rabbit monoclonal PTEN antibody, clone 138G6 (Cell Signaling Technology, Ref. 9559).

Antigen retrieval was performed with Tris–EDTA (pH 9) in microwave (4 min). H₂O₂ was used to block the endogenous peroxidase, followed by blocking with goat serum and primary antibody (1:100) incubation overnight at 4 °C. Goat anti-rabbit IgG antibody (1:1000) was incubated at room temperature for 30 min. IHC detection was performed with the ABC Kit from Vector Laboratories. This protocol with DAB-based development results in specific detection of PTEN, which was setup in DU145 (PTEN positive) and PC3 (PTEN negative) xenograft-derived formalin fixed, paraffin embedded (FFPE) slides. Sections were counterstained with hematoxylin.

With this protocol, tumors with known PTEN status (described above) were correctly identified (Fig. 3A and B). We also stained human biopsies consisting of benign hyperplasias and prostate cancer. We could identify PTEN positive epithelia in the hyperplasia cases as well as prostate cancer biopsies with and without detectable PTEN immunoreactivity (Fig. 3C). Of note, we observed that often the stromal component exhibited greater PTEN expression than the adjacent epithelial tissue (see asterisks in Fig. 3). In summary, we present here a protocol that is valuable for the detection of PTEN in human specimens for research purposes.

2.7. Extracellular vesicle isolation from urine samples of prostate cancer patients

Due to the close proximity of the prostate to the urinary tract, urine-mediated diagnosis of prostate cancer has remained an attractive concept. Extracellular vesicles (EVs) have been described to contain mRNA, protein and metabolites that could be selectively loaded [18]. Importantly, EVs have been identified in urine and cancerous alterations in the bladder have been shown to impact on their composition, suggesting that they could serve as a source for non-invasive biomarker identification. Since current non-invasive prostate cancer biomarkers have been proven to have limitations [19–21], urine EVs might provide a future source of novel biomarkers. Here, we describe the current protocol for urine EV isolation we are employing (a setup carried out by the group of Dr. Falcón-Pérez).

2.8. Key material

– Ultracentrifuge.

Urine EVs can be isolated through this methodology starting from 50 mL of urine. Urine is centrifuged in a tabletop centrifuge

![Fig. 3. An immunostaining protocol for PTEN in human prostate cancer specimens. (A and B) Representative immunohistochemical images (200×) of PTEN expressing (DU145) and PTEN deficient (PC3) human tumor xenografts. Asterisks indicate stromal cells. (C) Representative micrographs (200×) of PTEN staining in benign hyperplasia tissue (BPH) and prostate cancer (PCa) biopsies with PTEN high and low immunoreactivity, arrows indicate epithelial cells and asterisk depict stromal area.](Image)
PTEN has been recently reported to be secreted [23,24], and PTEN protein abundance in blood exosomes has been suggested to reflect status of the tumor suppressor in the prostate tumor ([25]). Hence we sought to ascertain to which extent the transcript abundance of PTEN would be altered in urine EVs from prostate cancer patients. The results revealed that both PTEN and GAPDH were present in all EV preparations analyzed at a similar abundance regardless of the benign of the tumoral status. This result was in discordance with PTEN protein expression, since the urine samples analyzed include cases that we identified as negative for PTEN immunoreactivity (displayed in Fig. 3). This lack of differences could be due to two main factors: first, the content of EVs in urine might be strongly influenced by bladder cells, perhaps more than by prostate cells. Second, PTEN is down-regulated at multiple levels, through mutations, deletions, but also through post-transcriptional regulation, which would not necessarily impact on the transcript levels.

3. Discussion

In this methods manuscript, we present approaches that allow us to study the biology of prostate cancer. While much work remains to be carried out in order to understand the molecular changes in this disease, we believe that the technological improvements that we present herein could serve as the basis to ensure the acquisition of (i) fresh and well diagnosed prostate cancer tissue, (ii) RNA of high quality for OMIC studies, (iii) immunostaining methodology to ascertain the expression of PTEN in human tissues and (iv) isolation of urine EVs for molecular studies.

The interaction between pathologists, uro-oncologists and basic scientists is fundamental in order to reach clinically relevant conclusions in prostate cancer research. The fresh tissue preparation procedure that we present has proven to be sustainable in a hospital with biobanking support and, importantly, to preserve the integrity of the surgical material for diagnostic purposes. Unpublished evidence also suggest that the area/volume ratio of the biopsy is directly proportional to the quality of the RNA obtained, and it is therefore plausible that the dimensions of these punch biopsies will allow molecular studies of the highest quality requirements. It is worth noting that the surgical material in our studies was obtained from robotic surgeries, where the warm ischemia period (the time the surgical piece stays excised and inside the patient) is of 60–80 min, while the cold ischemia (the time elapsed from the extraction of the piece to the snap-freeze of the punch biopsy) is at least of 30 min. These ischemic periods do not alter the RNA quality of the biopsy (which we consider a good readout of tissue integrity) and can be achieved in any urology and pathology service.

Importantly, the molecular studies described herein can greatly benefit from the analysis of public databases. In the recent years, bioinformatic platforms have been developed in order to aid in the analysis of publicly available genomic, epigenomic, transcriptomic and proteomic studies. These platforms now allow quick browsing through tens of studies (which imply thousands of samples) looking at a gene or pathway of interest. Two outstanding examples of this effort are Oncomine (www.oncomine.org) [26] and cbioportal (www.cbioportal.org) [27,28]. These sites allow the researcher to get information about the status of a gene or genes of interest in a given cancer, the mutational landscape throughout different cancers, the epigenetic modifications regulating its expression and the clinical variables associated with its expression. Therefore, these platforms can serve both as a

![Fig. 4](image-url). A method to harvest RNA from urine EVs. (A) Experimental procedure of the EV isolation from urine samples. (B) Representative image by cryo-Transmission Electron Microscopy (TEM) of the isolated EVs with this approach (scale represents 100 nm). (C) Abundance of PTEN (with two probes) and GAPDH transcript in urine EVs by real time quantitative PCR.
discovery starting point or a clinical validation end point. In summary, a good balance between experimental approaches with human cancer specimens and data mining studies can maximize the relevance of the conclusions met by the researcher.

Acknowledgments

Apologies to those whose related publications were not cited due to space limitations. We thank Paolo Nuciforo, Maurizio Scaltriti and Pau Castell for technical advice. David Gil and Sandra Delgado from electron microscopy CIC bioGUNE platform for their technical assistance in the cryo-TEM analysis of EVs. The work of AC is supported by the Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (EtorTek), Health (2012111086) and Education (P2012-03), Marie Curie (277043), Movember Foundation (GAP1), ISCIII (PT13/00031) and ERC (336343). N.M.-M. is supported by the Spanish Association Against Cancer (AECC). A.A.-A and L.V.-J are supported by the Basque Government. RB is supported by ISCIII (PI13/00031) and Education (PI2012-03), Marie Curie (277043), Fernandez-Botero (2012111086) and Education (PI2012-03), Marie Curie (277043), Fernández-Botero (2012111086) and Education (PI2012-03), Marie Curie (277043). A.E. is supported by MICINN (PTA2011-5805-I).
ORIGINAL ARTICLE

Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of L-asparaginase in childhood ALL cells


L-asparaginase (ASNase), a key component in the treatment of childhood acute lymphoblastic leukemia (ALL), hydrolyzes plasma asparagine and glutamine and thereby disturbs metabolic homeostasis of leukemic cells. The efficacy of such therapeutic strategy will depend on the capacity of cancer cells to adapt to the metabolic challenge, which could relate to the activation of compensatory metabolic routes. Therefore, we studied the impact of ASNase on the main metabolic pathways in leukemic cells. Treating leukemic cells with ASNase increased fatty-acid oxidation (FAO) and cell respiration and inhibited glycolysis. FAO, together with the decrease in protein translation and pyrimidine synthesis, was positively regulated through inhibition of the RagB-mTORC1 pathway, whereas the effect on glycolysis was RagB-mTORC1 independent. As FAO has been suggested to have a pro-survival function in leukemic cells, we tested its contribution to cell survival following ASNase treatment. Pharmacological inhibition of FAO significantly increased the sensitivity of ALL cells to ASNase. Moreover, constitutive activation of the mammalian target of rapamycin pathway increased apoptosis in leukemic cells treated with ASNase, but did not increase FAO. Our study uncovers a novel therapeutic option based on the combination of ASNase and FAO inhibitors.

Leukemia (2016) 30, 209–218; doi:10.1038/leu.2015.213

INTRODUCTION

L-asparaginase (ASNase) is an essential component in the treatment of childhood acute lymphoblastic leukemia (ALL).\(^1\) Intensified use of ASNase increases event-free survival in children with ALL by 10–15%.\(^2,3\) ASNase has the potential to be used in other types of cancers besides childhood ALL – at present, it is already used in the treatment protocol of adult T-ALL and lymphomas.\(^4,5\) There are also ongoing in vitro studies on its use in solid tumors (brain, prostate and ovarian cancers).\(^5,6\) Although ASNase has been in clinical use for the treatment of childhood ALL for several decades, our knowledge of mechanisms behind its therapeutic effect is still incomplete. ASNase catalyzes deamination of asparagine (Asn) and glutamine (Gln).\(^11,12\) Intracellular Asn is typically produced by Asn synthetase (ASNS). The cytotoxic effect of ASNase on leukemic cells was traditionally explained by the lower activity of ASNS in leukemic cells compared with healthy cells.\(^13,14\) However, recent studies reported that basal ASNS expression does not predict resistance to ASNase among ALL patients.\(^15–18\) and has no biological or clinical consequences in ALL patients.\(^19\) These findings indicate that the mechanism of action of ASNase is more complex and cannot be explained by the expression of a single gene.

Proliferating cancer cells are characterized by considerably different metabolic requirements compared with normal differentiated cells.\(^20,21\) Cancer cell metabolism is therefore studied with a focus on potential therapeutic targets. As metabolic modulators are widely used for pathologies beyond cancer, drug repurposing has become a very appealing concept in the field, as exemplified by metformin, an antidiabetic that has been newly investigated for its inhibitory effect on cancer progression.\(^22–24\) By deaminating Asn and Gln, ASNase obviously also perturbs metabolism, but these metabolic consequences have not yet been described. The main sensor of amino-acid deprivation is mammalian target of rapamycin (mTOR), which has been associated with the activity of ASNase.\(^25\) Moreover, it has been shown that Gln depletion can efficiently inhibit downstream mTOR signaling in acute myeloid leukemia and ovarian cancer cells.\(^26,27\) Under nutrient-rich conditions, mTORC1 promotes cell growth by stimulating biosynthetic pathways. Meanwhile, cellular catabolism, such as autophagy, is inhibited. Signaling via mTOR also influences a wide range of metabolic mechanisms\(^28–31\) and the impact of ASNase on the downstream mTOR targets that are involved in metabolic processes has not yet been studied thoroughly. This study for the first time describes the profound effect of ASNase on the
metabolism of lymphoid leukemic cells that is driven by mTOR. The characterization of these cellular processes reveals novel potential targets for the treatment of ALL to enhance the effects of chemotherapy and improve clinical outcome in patients.

MATERIALS AND METHODS

Cell culture

REH (human B-cell precursor leukemia, etis variant 6/ runt-related transcription factor 1 (ETV6/RUNX1, TEL/AML1) - positive); NALM-6 (human B-cell precursor leukemia, TEL/platelet derived growth factor receptor beta 1 (PDGFRB1); (TEL/PDGFRB1) - positive) and RS4;11 (human B-cell precursor leukemia, mixed-lineage leukemia/AFA/FMR2 family, member 1 (AFA); MLL/AF4-positive) cell lines were purchased from German Collection of Microorganisms and Cell Cultures (DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and cultivated according to the producer’s instructions. Cell lines were negative for mycoplasma contamination.

Patient samples

Bone marrow samples from untreated children initially diagnosed with B-cell precursor ALL were collected from the Czech Pediatric Hematology Centers. Within 24 h after aspiration, mononuclear cells were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Chalfont St Giles, UK). Ethical committee approved the study no. NT12429. All samples were obtained with the informed consent of the children’s parents or guardians. Isolated blasts were maintained in Roswell Park Memorial Institute media with 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA) and insulin-transferrin-sodium selenite supplement (Sigma-Aldrich, St Louis, MO, USA). The characteristics of the patients whose samples were used for western blot analysis (1–3), Annexin V/4,6-diamidino-2-phenylindole ( Annexin V/DAPI) staining (4–8) and measurement of respiration (9–11) are listed in Supplementary Table 1.

Isolation of B lymphocytes

Human B-Cell Enrichment Cocktail (Stemcell Technologies, Vancouver, BC, Canada) was used according to the manufacturer’s instructions to isolate B cells from the buffy coat of healthy donors. B cells were incubated in Roswell Park Memorial Institute media supplemented with 10% fetal bovine serum, interleukin-21 (50 ng/ml) and interleukin-2 (50 ng/ml) (Sigma-Aldrich). B cells were isolated from three healthy donors.

Electrophoresis and western blotting

Protein lysates were prepared as previously described.19 Proteins (10–40 μg per well) were resolved by NuPAGE Novex 4–12% Bis-Tris Gels (Life Technologies) and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The membrane was blocked overnight with primary antibodies listed in Supplementary Table 2. The bound antibodies were detected with the appropriate secondary antibodies (Bio-Rad) conjugated with horseradish peroxidase and visualized using enhanced chemiluminescence reagent followed by exposure to X-ray film (Kodak, Rochester, NY, USA). Rapamycin (Sigma-Aldrich) served as a positive control of mTORC1 inhibition. Densitometry was performed using Image J software. The densitometry value was normalized against the value for β-actin.

RNA extraction, complementary DNA synthesis and quantitative real-time PCR

Total cellular RNA was extracted using the RNeasy mini-kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions and converted to complementary DNA using the iScript complementary DNA synthesis kit (Bio-Rad). The c-Myc transcript was detected using the Power SYBR Green PCR Master Mix (Life Technologies). The primer sequences of c-Myc are listed in Supplementary Table 3. β2 microglobulin served as a house-keeping gene. PCR reactions were performed in a LightCycler 480 real-time PCR machine (Roche Diagnostics GmbH, Mannheim, Germany).

Assessment of cell death

Cells were treated with ASNase (Medac GmbH, Hamburg, Germany), etomoxir (Sigma-Aldrich) or both and apoptosis was quantified by Annexin V-FITC (Exbio Praha, a.s., Czech Republic) and DAPI (Life Technologies) or propidium iodide (PI) (Miltenyi Biotec, Bergisch Gladbach, Germany) staining using flow cytometer. Measurements were performed in triplicate.

Combination index (CI) calculation

CI values were calculated using CompuSyn software (www.combusyn.com). The calculation of dose-effect relationship for each drug we used was done via serial dilution. CI was calculated from serial dilution of ASNase and each dose of etomoxir. CI was used to express synergism (CI < 1), additive effect (CI = 1) or antagonism (CI > 1).25

Assessment of autophagic flux

Cells were treated with ASNase and baflopinomycin (Sigma-Aldrich) for 6, 12 and 24 h. Autophagic flux was quantified by western blotting.

Detection of de novo intermediates of pyrimidine synthesis by UPLC-ToF-MS

The cells were seeded to fresh media and incubated overnight. Next we treated the cells with ASNase (4 IU/ml) for 24 h. Five million of cells were harvest for each condition and washed in phosphate-buffered saline. Dried cell pellets were resuspended in 500 μl of a methanol/water (50/50; v/v%) mixture containing 10 mM acetic acid. After precipitation of the protein content, the supernatant was evaporated. The dried pellets were resuspended in 150 μl of water/acetonitrile/formic acid (39.9/60.1/0.1 v/v/v %) and centrifuged. The results extracting were injected into the LC-MS system using ACQUITY UPLC with Acquity UPLC amide column 1.7 μm (2.1 × 100 mm) and ToF MS, SYNAPT G2 (Waters Corporation, Milford, MA, USA). Retention time for uridine monophosphate and uridine was 2.95 and 1.68 min, respectively. The limit of detection of those compounds: uridine monophosphate 0.5 μM, uridine 0.05 μM. The measurement was performed in three independent experiments.

High performance liquid chromatography analysis

High performance liquid chromatography analysis of amino acids was performed using Waters AccQ-Tag Chemistry Package (WAT052875) on two pump Beckman Coulter Gold chromatograph with Merck-Hitachi F-1080 fluorescence detector (ex.250 nm, em. 395 nm). Data were collected and evaluated with DataApex CSW32 chromatography software.

Glucose-uptake measurement

Cells were washed twice with Krebs-Ringer-4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 136 mM NaCl, 4.7 mM KCl, 1.25 mM MgSO4, 1.25 mM CaCl2), resuspended in 900 μl of Krebs-Ringer-4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer and incubated for 15 min at 37 °C. Next, we added 100 μl of 10 × START solution (1 mM 2-deoxyglucose, 5 μCi/ml [3H]-2-deoxyglucose, PerkinElmer Life Sciences, Waltham, MA, USA) and incubated the cells for 10 min at 37 °C. Cells were washed with phosphate-buffered saline, collected by centrifugation, and the cell pellet was solubilized in 1 ml of 0.03% sodium dodecyl sulphate for 10 min at 37 °C. Radioactivity was measured using a 1900TR liquid scintillation analyzer (Packard). The measurement was performed in four independent experiments.

Extracellular lactate

Extracellular lactate was measured using the Lactate Kit (Trinity Biotech, Bray, Ireland) according to the manufacturer’s directions. Changes in lactate production were normalized to the protein content. The measurement was performed in five independent experiments.

FAO measurement

Cells were incubated for 4 h in culture medium containing 100 μM palmitic acid, 1 mM carnitine and 1.7 μCi [9,10(2H)-3H]palmitic acid (GE Healthcare) in the presence or absence of etomoxir (100 μM, Sigma-Aldrich), and the medium was collected to analyze the amount of released [3H]-H2O that was formed during the cellular oxidation of [2H]-palmitate.24–26 Medium was precipitated with 10% TCA, and supernatants were neutralized with 6 M NaOH and loaded onto ion exchange columns packed with DOWEX 1 × 2-400 resin (Sigma-Aldrich). [3H]-H2O was eluted with water and quantitated by liquid scintillation counting. The oxidation of [2H]-palmitate
was normalized to the protein content, as determined using a DC Protein Assay (Bio-Rad). Non-mitochondrial FAO and background signal (FAO measured in samples after incubation with etomoxir) was extracted, and mitochondrial FAO (etomoxir counts extracted from total counts) was presented in nCi/mg protein/h. The measurement was performed in four independent experiments.

Respiration

The endogenous respiration of intact cells was measured in the culture medium at 37 °C using Oxygraph-2k-respirometer (OROBOROS Instruments Corporation, Innsbruck, Austria). Respiratory rates were determined in both coupled and uncoupled states; the latter after titration of the uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (Sigma-Aldrich). Inhibition by ATP synthase inhibitor oligomycin (Sigma-Aldrich) was used to verify dependence of coupled respiration on mitochondrial F,F1-ATP synthase. The following concentrations of cells and respiratory inhibitors were applied: 0.4 mg/ml cells, 1 μM oligomycin, 200–300 μM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone and 0.5 μM antimycin A (respiratory chain inhibitor; Sigma-Aldrich). The measurement was performed in four (REH, NALM-6) and three (healthy B lymphocytes, BCP-ALL) independent experiments.

NAD+ / NADH ratio

The ratio of oxidized and reduced form of nicotinamide adenine dinucleotide (NAD+/NADH) was measured using the NAD+/NADH Glo assay (Promega, Madison, WI, USA) according to the manufacturer's protocol. The ratio was measured in three independent experiments.

Lentiviral RagB cell models

We have used Flag pLJM1 RagB wild-type (RagB wt; Addgene plasmid 19313) and Flag pLJM1 RagB 99L (Addgene plasmid 19315) lentiviral constructs (Addgene, Cambridge, MA, USA). Lentiviral particles were produced as previously described37 and used for the transduction of NALM-6 cells. Positive clones were selected by puromycin resistance and observed signiﬁcantly increased FAO in these cell lines, which blocks the fusion of autophagosomes with lysosomes, leading to an accumulation of autophagosomes.41 This result suggests a decrease in the balance of available substrates. Indeed, we detected a signiﬁcant increase in the NAD+/NADH ratio in ALL cell lines following ASNase treatment (Supplementary Figure S7).

RESULTS

ASNase treatment extensively alters cellular metabolism

As ASNase disrupts nutrient homeostasis, we studied its effect on key metabolic pathways in leukemic cells. Effect of applied ASNase dosage (RS4;11: 0.5 IU/ml; REH, NALM-6: 4 IU/ml) chosen according to the pharmacokinetics of ASNase35 was conﬁrmed as a change in extracellular amino-acid levels by high-performance liquid chromatography (Supplementary Figure S1). First, we focused on the impact of ASNase on FAO. We incubated REH, NALM-6 and RS4;11 B-precursor leukemic cells with ASNase for 18 h and measured the activity of FAO. ASNase treatment signiﬁcantly increased FAO in these cell lines (Figure 1a). The effect of etomoxir on FAO in ALL cell lines is shown in Supplementary Figure S2. Next, we determined the effect of ASNase on glucose metabolism in REH and NALM-6 cells and observed that ASNase treatment signiﬁcantly reduced glucose uptake in both cell lines (Figure 1b). This was accompanied by decreased lactate production in NALM-6 cells (Supplementary Figure S3). Lactate production in RS4;11 was also signiﬁcantly reduced after ASNase treatment. There were no observable changes in REH cells; however, the basal lactate level was substantially lower in REH cells compared with NALM-6 (data not shown). Furthermore, we determined the levels of the glycolysis regulator c-Myc and glucose transporter type 1 (GLUT1). As shown in Supplementary Figure S4, ASNase signiﬁcantly decreased c-Myc messenger RNA expression in ALL cell lines with a concomitant decrease in the protein levels of c-Myc and GLUT1. Consistent with these results observed in ALL cell lines, we detected decreased c-Myc protein levels also in some primary ALL cells following ASNase treatment (Supplementary Figure S4).

Both FAO and glucose oxidation yield NADH, which is then oxidized by mitochondrial respiratory chain. In the subsequent experiment we therefore investigated the impact of ASNase on the mitochondrial respiration in ALL cells. ASNase signiﬁcantly increased basal oxygen consumption (routine respiration) of REH cells (P = 0.0276) (Figure 1c and Supplementary Figure S5). In the uncoupled state, which serves as a measure of the maximum capacity of the respiratory chain, we observed a signiﬁcant increase in oxygen consumption in ALL cell lines (Figure 1c and Supplementary Figure S5). More interestingly, we observed signiﬁcant increase of the spare respiratory capacity (uncoupled/coupled respiration) in REH and NALM-6 cell lines treated with ASNase (Figure 1d). The increase of spare respiratory capacity was borderline signiﬁcant (P = 0.062) in RS4;11 cell line. We found a similar increase in the spare respiratory capacity also in the primary ALL cells on ASNase treatment (Figure 1d). In contrast, this was not the case for the control B lymphocytes isolated from peripheral blood of healthy subjects (Figure 1d), indicating that the effect of ASNase is speciﬁc to leukemic cells. The increase in the respiratory capacity was not accompanied by a change in the content of oxidative phosphorylation proteins (Supplementary Figure S6), meaning that it likely represents a shift in the balance of available substrates. Indeed, we detected a signiﬁcant increase in the NAD+/NADH ratio in ALL cell lines following ASNase treatment (Supplementary Figure S7).

ASNase modulates pyrimidine synthesis and autophagy via mTORC1 inhibition

Our previous experiments have shown that ASNase treatment affects key metabolic pathways in ALL cells. Based on the sensitivity of mTORC1 to amino-acid levels and the evidence that ASNase treatment inhibits mTORC1 signaling,25 we hypothesized that the effect of ASNase on metabolism is driven through mTORC1. First, we conﬁrmed the effect of ASNase on main mTORC1 targets. We detected dephosphorylated p-P70S6K and p-S6 in ALL cell lines and some primary ALL samples treated with ASNase (Figure 2a and Supplementary Figure S8). Furthermore, we detected dephosphorylated carbamoyl phosphate synthase II (p-CAD), suggesting a decrease in the de novo synthesis of pyrimidines (Figure 2a).40 Similar effect on p-CAD status was also observed using speciﬁc mTOR inhibitor rapamycin (Figure 2a). We also measured the intermediates of de novo pyrimidine synthesis using UPLC-ToF-MS in REH and NALM-6 cells treated with ASNase. In concordance with the dephosphorylation of p-CAD, we observed signiﬁcantly decreased synthesis of uridine monophosphate and uridine in REH and NALM-6 cells treated with ASNase (Figure 2b). Another mechanism that may be activated on mTORC1 inhibition is autophagy. To investigate whether ASNase treatment augments autophagic flux, we detected the conversion of the marker of autophagosome, microtubule-associated protein light chain 3 (LC3), LC3-I to LC3-II, by western blot. Treatment with ASNase induced a time-dependent increase in the expression of LC3-II in the NALM-6 cell line (Figure 2c), indicating that ASNase activates autophagy. Consistent with increased autophagic flux following treatment with ASNase, there was a time-dependent decrease in the level of p62 (selective substrate of autophagy).

LC3-II accumulation following ASNase treatment was intensified in the NALM-6 cell line after treatment with bafilomycin A1 (Figure 2c). Bafilomycin A1 is an inhibitor of the vacuolar ATPase, which blocks the fusion of autophagosomes with lysosomes, leading to an accumulation of autophagosomes.41 This result confirms that the observed increase in LC3-II after ASNase treatment was due to increased autophagic flux and not because of decreased degradation of lipidated LC3.
ASNase acts through the RagB-mTORC1 pathway. Next, we investigated the mechanism whereby ASNase inhibits the mTORC1 pathway. The activation of mTORC1 in the presence of amino acids is mediated by the Rag GTPases (guanosine-5’-triphosphatases) A, B, C and D. A key event in the amino-acid-dependent activation of mTORC1 is the conversion of RagA or RagB from a guanosine-5’-diphosphate (GDP) to guanosine-5’-triphosphate (GTP)-bound state.31,37,42 To determine whether ASNase inhibits mTORC1 by the same mechanism as general amino-acid deprivation, we established RagB wt and RagB mutant (RagB 99L) cells (Figure 3). The mutation of RagB causes constitutive activation of mTORC1 by permanent conversion to GTP and localization of mTOR in the vesicle compartments regardless of amino-acid deprivation.31 The resistance of the mTOR pathway inhibition to amino-acid deprivation by ASNase treatment was confirmed in RagB 99L. There was no change in p-S6 level in the RagB 99L cells, whereas ASNase treatment inhibited p-S6 protein in RagB wt cells. Concordantly, p-CAD protein was inhibited more extensively in RagB wt cells than in RagB 99L cells (Figure 3a). Importantly, the ability to enhance FAO was impaired in RagB 99L cells exposed to ASNase (Figure 3b). These results suggest that the effect of ASNase on protein translation, de novo pyrimidine synthesis and FAO is mediated through the RagB-mTORC1 pathway. By contrast, c-Myc expression was decreased in both RagB wt and RagB 99L cells (Figure 3a). Consistent with this result, there was a significant decrease in the level of extracellular lactate in RagB 99L cells (Supplementary Figure S9), indicating that ASNase inhibits glycolysis in a RagB-mTORC1-independent manner. To test whether c-Myc inhibition following ASNase treatment is mTORC1 independent, we detected the c-Myc protein level in REH and NALM-6 cells treated with the mTORC1 inhibitor rapamycin.

Figure 1. Effect of ASNase on the metabolism of leukemic cells. (a) ALL cell lines were cultured for 18 h with or without ASNase and the rate of fatty-acid oxidation was assessed. The concentration of ASNase was 4 IU/ml (REH, NALM-6) and 0.5 IU/ml (RS4;11). The experiment was performed in quadruplicate. (b) ALL cell lines were cultured overnight with or without ASNase (4 IU/ml). Changes in glucose uptake were measured by the accumulation of [3H]-2-deoxyglucose in cells. (c) ALL cell lines (d) healthy B lymphocytes and BCP-ALL patient samples were cultured with or without ASNase for 24 h. The dose of ASNase was 4 IU/ml for all samples except of RS4;11 (0.5 IU/ml). The endogenous respiratory rates were determined in both coupled and uncoupled states (the latter after titration of the uncoupler FCCP) and also after the addition of oligomycin. The spare respiratory capacity was calculated. The following concentrations of cells and respiratory inhibitors were applied: 0.4 mg/ml cells, 1 μM oligomycin, 200–300 nM FCCP. Asterisks represent significant changes. ***P < 0.001; **P < 0.01; *P < 0.05.
Contrary to the effects of ASNase, inhibition of mTORC1 by rapamycin did not cause a substantial decrease in c-Myc (Supplementary Figure S10). These results suggest that ASNase inhibits protein translation and DNA synthesis directly through RagB-mTORC1, and inhibition of the mTORC1 pathway also causes enhancement of FAO. However, glycolysis seems to be regulated through a different mechanism.

Inhibition of FAO increases the cytotoxic effect of ASNase in ALL cells

The activation of FAO has been suggested to exert a pro-survival function in leukemic cells under nutrient stress conditions. We tested whether the increase of FAO upon ASNase treatment allows leukemic cells to cope with metabolic stress. We treated REH and NALM-6 cells with the FAO inhibitor etomoxir, ASNase, or both drugs, and measured its effect on the viability of the cells. The concentrations of etomoxir were 25, 50, 100, 200, and 400 μM. The range of etomoxir was chosen according to previous publications. Pharmacological inhibition of FAO in combination with ASNase increased apoptosis in REH and NALM-6 cells. As shown in Figure 4a, CI for etomoxir with ASNase were < 1, indicating synergistic mode of action in both cell lines. Complete data on the effect of both drugs are shown in Supplementary Figure S11. The most effective concentrations of etomoxir in the combination with ASNase were 100 and 200 μM. Importantly, similar results were obtained in primary diagnostic ALL patient samples co-treated with ASNase and etomoxir. Etomoxir increased the cytotoxic effect of ASNase in ex vivo conditions in four out of five diagnostic BCP-ALL patient samples (Figure 4b). These results reveal that increased FAO is crucial for the survival of ALL cells treated with ASNase. Moreover, cells with the inability to induce FAO (RagB 99L) were significantly more sensitive to ASNase compared with RagB wt cells, shown by the cleavage of PARP (Figure 3a) and the assessment of apoptosis by Annexin V/DAPI staining (Figure 4c).

Figure 2. Effect of ASNase on mTORC1 targets. (a) ALL cell lines were cultured for 24 h with or without ASNase (4 IU/ml). Levels of phospho-CAD and CAD proteins were measured by immunoblotting, with β-actin used as a loading control. Rapamycin (Rapa; 10 nM) served as a positive control of mTORC1 inhibition. Phospho-S6 and phospho-CAD proteins were measured in ASNase-treated cells (4 IU/ml; 24 h) from three different patients by immunoblotting, using β-actin as a loading control. (b) ALL cell lines were cultured for 24 h with or without ASNase (4 IU/ml). Uridine monophosphate (UMP) and uridine levels were measured using UPLC-ToF-MS. (c) NALM-6 cells were cultured with or without ASNase (4 IU/ml) in the presence or absence of bafilomycin A (BafA1, 100 nM) for 6, 12 and 24 h to analyze autophagic flux. LC3 I/II and p62 protein levels were measured by immunoblotting, with β-actin used as a loading control. Asterisks represent significant changes.

**P < 0.01; *P < 0.05.
Altogether, our results revealed enhanced cytotoxic effect of ASNase owing to FAO inhibition.

Distinct effect of Asn and Gln on mTOR downstream targets and FAO activity

At last, we examined the individual roles of Gln and Asn on cellular processes. We cultured ALL cell lines under four different conditions: complete media, media without Asn, media without Gln and complete media treated with ASNase. In REH and NALM-6, p-S6 and c-Myc protein levels were decreased after cultivation in media without Asn or Gln but the effect of Gln depletion was more pronounced in NALM-6 cells. On the other hand, in RS4;11 we detected a substantial reduction of p-S6 and c-Myc in the cells cultured in media without Asn. Apoptosis detected by cleaved PARP was not increased by depletion of any amino acid in NALM-6 cells. On the other hand, in RS4;11 we detected a substantial reduction of p-S6 and c-Myc in the cells cultured in media without Asn. Apoptosis detected by cleaved PARP was not increased by depletion of any amino acid in NALM-6 cells. On the other hand, in RS4;11 the rate of fatty-acid oxidation was measured. The experiment was performed in quadruplicate. Asterisks represent significant changes. *P < 0.05.

DISCUSSION

ASNase was incorporated into the treatment protocol for childhood ALL in 1970. Despite the successful use of this drug for decades, the mechanism underlying its cytotoxic effect remains surprisingly obscure. ASNase depletes two extracellular amino acids, Asn and Gln. The depletion of amino acids changes nutrient availability and consequently influences metabolic signaling. Metabolic pathways in malignant cells can be rewired depending on the cellular availability of the nutrients and thus participate in the mechanisms of drug resistance. This study, for the first time, presents evidence that ASNase triggers extensive metabolic reprogramming in leukemic cells and reveals the adaptive activation of pro-survival metabolic pathways following ASNase treatment. Our data show increased levels of FAO, inhibition of glycolysis and elevated respiratory activities after ASNase treatment. FAO serves as a source of NADH, FADH2 and acetyl-CoA.
feeding the Krebs cycle and mitochondrial oxidative phosphorylation. Utilization of FAO for energy provision is thus important for the growth and survival of cancer cells under both normal and metabolic stress conditions.36,46–50 The metabolic rescue role of FAO has been described in different tumors such as diffuse large B-cell lymphoma, multiple myeloma and glioblastoma.50–52 Moreover, FAO can contribute to chemoresistance.51,52 Pharmacological inhibition of FAO showed a therapeutic benefit in combination with chemotherapy in mouse models of human myeloid leukemia, suggesting that the shift

Figure 4. Effect of FAO inhibition on ASNase-mediated cytotoxicity. (a) REH and NALM-6 cells were treated with ASNase (1, 2, 4, 8 and 16 IU/ml) in combination with etomoxir (Eto1, 100 μM; Eto2, 200 μM) for 24 h. The percentage of cell death was determined by Annexin V/PI staining followed by FACS analysis. Combination indexes (CI) were obtained by entering the resulting specific death values into the CompuSyn program. Fraction affected (FA; Percentage of Annexin V/PI positive cells)-CI plots indicate that the combinations of ASNase with etomoxir are synergistic (CI < 1). (b) Leukemic blasts isolated from the bone marrow of patients with ALL were cultivated with or without ASNase (4 IU/ml) in the presence or absence of the FAO inhibitor etomoxir (Eto1, 100 μM; Eto2, 200 μM) for 24 h. (c) RagB wt and RagB 99L NALM-6 cells were cultivated with or without ASNase (4 IU/ml) for 24 h. The percentage of cell death was determined by Annexin V/DAPI staining followed by FACS analysis. Values represent the mean of triplicate measurements. Asterisks represent significant changes. ***P < 0.001; **P < 0.01; *P < 0.05.
toward FAO could be a target for the treatment of hematological malignancies. In this study, we combined ASNase and the FAO inhibitor etomoxir in the treatment of childhood ALL samples for the first time. Our experiments showed an increase in FAO after ASNase treatment, providing a rationale for the combination treatment. Etomoxir-sensitized leukemic cells to ASNase in two leukemic cell lines in vitro as well as under ex vivo conditions when treating BCP-ALL patient samples. These data support the pro-survival effect of FAO in the treatment of ALL cells with ASNase and demonstrate the potential of this combination treatment. Previous studies have described a negative association between mTOR and FAO and a positive relation of mTOR upregulation with fatty-acid synthesis. Our results show that ASNase inhibited mTORC1 through RagB (Ras-related GTPase), which is a mediator of amino-acid signaling. Importantly, in the presence of ASNase, RagB mutant cells with the constitutively activated mTOR pathway exhibited a reduction of FAO compared with the significant FAO elevation observed in RagB wt cells. Accordingly, RagB mutant cells were significantly more sensitive to ASNase than RagB wt cells. These results demonstrate that RagB-mTOR inhibition senses metabolic stress, which induces FAO. We hypothesize that the limited elevation of FAO after ASNase treatment in RagB mutant cells was not sufficient to protect these cells from amino-acid deprivation.

As ASNase treatment inhibited mTORC1, we focused on the downstream targets of mTORC1 that are involved in cellular metabolism. ASNase treatment inhibited protein translation and pyrimidine synthesis in ALL cells as part of the apoptotic process. Concurrently, leukemic cells treated with ASNase increased autophagy as has been already shown in other cancer types. Autophagy may serve to maintain intracellular metabolic homeostasis through the degradation of unfolded or aggregated proteins and organelles. Thus, autophagy may serve as another rescue mechanism by producing amino acids or even fatty acids that restore the nutrient balance disrupted by ASNase. Glycolysis was yet another metabolic pathway affected by ASNase. ASNase inhibited c-Myc, but it is not clear if this was a direct effect or a feedback loop resulting from the inhibition of glycolysis. Of particular note is our finding that treatment with ASNase increases spare respiration exclusively in leukemic cells. Increase in respiration may reflect increased flux of nutrients that can be oxidized by mitochondria. Although this could be both FAO-dependent and FAO-independent, the observed increase in FAO (involving the whole pathway from uptake of palmitate from culture media to its final oxidation to water) argues that at least substantial part of these fatty acids originated from extracellular environment and was oxidized by mitochondria. The increased ratio of NAD+/NADH measured after ASNase treatment further supports the increased mitochondrial oxidation of reducing equivalents.

The role of individual amino acids in these cellular processes is cell line specific. The tested leukemic cell lines differ in their sensitivity to ASNase and also in ASNS protein level. RS4;11 cells are the most sensitive with undetectable ASNS protein, REH cells are intermediate sensitive and have higher ASNS protein levels, and NALM-6 cells are the most resistant of the studied cell lines with higher ASNS protein level. Most importantly, we did not see any differences in the effect of ASNase in ALL cell lines on mTOR targets and metabolic processes. Next, we propose that the higher the sensitivity, the deeper the cells’ dependence on Asn.

Figure 5. Effect of Asn and Gln depletion on ALL cells. (a) ALL cell lines were incubated in complete RPMI media (Ctrl), RPMI media without Asn (–ASN), RPMI media without Gln (–GLN) or complete RPMI media with ASNase for 24 h. The concentration of ASNase was 4 IU/ml (REH, NALM-6) and 0.5 IU/ml (RS4;11). Levels of phospho-S6, S6, phospho-CAD, CAD, c-Myc, cleaved PARP (cl.PARP), ASNS proteins were measured by immunoblotting, with β-actin used as a loading control. (b) ALL cell lines were incubated in complete RPMI media (Ctrl), RPMI media without Asn (–ASN), RPMI media without Gln (–GLN) or complete RPMI media with ASNase for 18 h and the rate of fatty-acid oxidation was assessed. Asterisks represent significant changes. ***P < 0.0001; **P < 0.05.
In other words, the cells’ dependence on Asn is inversely proportional to the ASNS protein expression. Accordingly, the rescue effect of Asn was pronounced in sensitive cells (REH) after ASNaSe treatment, whereas in NALM-6 cells both amino acids displayed rescue properties. Our data support previous finding presenting that glutaminase activity of ASNaSe is not essential in antitumor effect of ASNS-negative cancer cells.59

In conclusion, our results demonstrate that ASNaSe has a strong effect on the bioenergetics and biosynthesis in leukemic cells. Our data further show that increased FAO has a pro-survival effect on leukemic cells. Moreover, our results also suggest that pharmacological blocking of FAO sensitizes leukemic cells to ASNaSe treatment. Metabolic changes similar to those described here in acute leukemia cells are rather frequent among other cancer subtypes; therefore, using ASNaSe in combination with etomoxir may represent a treatment option not only for ALL but also for other types of cancers.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported by the Grant Agency of the Ministry of Health of the Czech Republic (NT124299) (IH, JS, JT), NT12370-S (TM); The Charles University Grant Agency (532513) (IH, JS, JT), (14-21095P) (KV); UNCE 204025/2012 (KV, PN); Ministry of Health, Czech Republic, (00064203 University Hospital Motol, Prague, Czech Republic) (IH, JS, JT, KP); Czech Science Foundation (P302/12/G01) (MJZ); 15-26848A (JS, JT); MSMT Navrat grant LK21307 (MAJ); the Grant Agency of the Czech Republic (14-36804G) (TM); the Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etorerk), health (2012111086 and education (P12012-03), Marie Curie (277043, Movember, ISCIII (PI10/01484, PI13/00031) and ERC (336343: AC); The Basque Government of education (AAA).

REFERENCES
L-asparaginase alters metabolism of leukemic cells
I Hermanova et al


Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)
PTEN mediates Notch-dependent stalk cell arrest in angiogenesis

Helena Serra1,*, Iñigo Chivite1,*, Ana Angulo-Urarte1, Adriana Soler1, James D. Sutherland2, Amaia Arruabarrena-Aristorena2, Anan Ragab3, Radiance Lim4, Marcos Malumbres5, Marcus Fruttiger6, Michael Potente4, Manuel Serrano5, Àngels Fabra7, Francesc Viñals8,9, Oriol Casanovas8, Pier Paolo Pandolfi10, Anna Bigas11, Arkaitz Carracedo2,12,13, Holger Gerhardt3,14 & Mariona Graupera1

Coordinated activity of VEGF and Notch signals guides the endothelial cell (EC) specification into tip and stalk cells during angiogenesis. Notch activation in stalk cells leads to proliferation arrest via an unknown mechanism. By using gain- and loss-of-function gene-targeting approaches, here we show that PTEN is crucial for blocking stalk cell proliferation downstream of Notch, and this is critical for mouse vessel development. Endothelial deletion of PTEN results in vascular hyperplasia due to a failure to mediate Notch-induced proliferation arrest. Conversely, overexpression of PTEN reduces vascular density and abrogates the increase in EC proliferation induced by Notch blockade. PTEN is a lipid/protein phosphatase that also has nuclear phosphatase-independent functions. We show that both the catalytic and non-catalytic APC/C-Fzr1/Cdh1-mediated activities of PTEN are required for stalk cells’ proliferative arrest. These findings define a Notch–PTEN signalling axis as an orchestrator of vessel density and implicate the PTEN-APC/C-Fzr1/Cdh1 hub in angiogenesis.
Vessel sprouting is a central mechanism of blood vessel growth and it relies on the induction of specialized endothelial cell (EC) populations, each accounting for distinct functions. At the very front of the sprouts, tip cells provide guidance and migrate towards gradients of vascular endothelial growth factor (VEGF)-A, but rarely proliferate. Instead, trailing stalk cells located at the base of the sprout proliferate, establish adherent and tight junctions and form the vascular lumen.

The tip cell phenotype is usually associated with high levels of Delta-like 4 (Dll4), which activate Notch in neighbouring stalk cells, preventing them from becoming a new tip cell. Notch signalling is initiated by receptor–ligand recognition between adjacent cells. This interaction results in two sequential proteolytic events that release the Notch intracellular domain (NICD). Subsequently, NICD translocates to the nucleus, where it forms a complex with the transcriptional factor Rbpj/Cbf1 and the Mastermind-like proteins to drive target gene expression. Activation of Notch in ECs leads to cell cycle arrest both in vitro and in vivo. However, it is still unclear how Notch exerts its negative effects on EC proliferation, and the transcriptional programme that triggers stalk cell function is not understood. Furthermore, it is not clear how stalk cells are ultimately released from this arrest to provide sufficient cell numbers for the sprout to elongate and stabilize.

PTEN (phosphate and tensin homologue deleted on chromosome TEN) is a dual lipid/protein phosphatase, which is often underexpressed in cancer. The main activity of PTEN is to dephosphorylate the lipid phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) at the 3´-position, thereby counterbalancing class I phosphoinositide 3-kinase (PI3K) signalling that mediates growth, cell division, survival, migration and metabolism. Genetic studies in mice and zebrafish point to a restrictive role of PTEN in angiogenesis. Mice lacking PTEN specifically in ECs exhibit cardiac failure and severe haemorrhages due to defects of the myocardial wall and impaired mural cell coverage of blood vessels. Mutant zebrafish embryos lacking functional PTEN show enhanced angiogenesis; whether this is due to a cell-autonomous effect of PTEN in ECs or is simply a consequence of increased VEGF levels is unclear. Importantly, the specific functions of PTEN in endothelial behaviour and vascular patterning remain unknown.

In most cells and tissues, PTEN localizes to the cytoplasm and the nucleus. There is evidence to suggest that PTEN has nuclear, non-lipid phosphatase-dependent functions. Interestingly, PTEN localization is cell cycle-dependent, with higher levels of nuclear PTEN during the G0–G1 phase than during the S phase. This is in line with the observation that nuclear PTEN negatively regulates cell cycle progression. Indeed, in late mitosis and G1, nuclear PTEN enhances the E3 ligase activity of APC/C by facilitating the association of APC/C with its activator Fzr1/Cdh1 (encoded by the Fzr1 gene), with no requirement of its phosphatase activity. The APC/C-Fzr1/Cdh1 complex controls G1 progression by targeting several proteins for degradation, including mitotic cyclins (Cyclin-A), mitotic kinases (Aurora Kinase A (Aurora A) and Polo-like kinase 1 (Plk1)), proteins involved in chromosome segregation and DNA replication (Gemmin; ref. 25). Despite the large body of molecular evidence, the role and relevance of nuclear PTEN in physiology is poorly understood.

Here we report that endothelial PTEN regulates stalk cell proliferation during vessel development. Our data further identify PTEN as a key mediator of the antiproliferative responses of Notch. We show that Dil4/Notch signalling arrests stalk cell proliferation by inducing expression of PTEN to balance stalk cell numbers and coordinate patterning. On PTEN deletion, Notch signalling fails to arrest early stalk cells and result in defective sprout length and patterning. Our results strongly indicate that both catalytic and non-catalytic activities of PTEN contribute to this function, providing evidence for an important in vivo physiological function for the PTEN-APC/C-Fzr1/Cdh1 axis.

**Results**

**PTEN negatively regulates vascular density in angiogenesis.** To study the EC-autonomous role of PTEN in sprouting angiogenesis, we crossed PteniC-PteniC mice with PdgfbCreER<sup>22</sup> transgenic mice that express a tamoxifen-activatable Cre recombinase in ECs (further referred to as Pten<i>flx/flx</i>/Pten<i>flx/flx</i>/EC) and assessed postnatal retinal angiogenesis. 4-hydroxytamoxifen (4-OHT) was administrated in vivo at postnatal day 1 (P1) and P2, followed by analysis of the retinal vasculature at different time points. Comparing whole-mount-stained retinas of control (Pten<i>flx/flx</i>/EC) to Pten<i>flx/flx</i>/Pten<i>flx/flx</i>/EC mice at P5 revealed a mild increase in vessel width (Supplementary Fig. 1a–g). By P7, loss of PTEN resulted in excessive branching and substantially increased vessel width (Fig. 1a–d), a phenotype that was further exacerbated at P10 (Fig. 1h,i). Pten<i>flx/flx</i>/Pten<i>flx/flx</i>/EC P7 retinas showed efficient recombination of the Cre-reporter R26-R and deletion of PTEN in the retinal endothelium (Supplementary Fig. 1h,i), with an increase in staining for phosphoS6 (pS6), a marker of PI3K-negative effects on EC proliferation, and the transcriptional activation of Notch in ECs (Supplementary Fig. 1f). The tip cell phenotype is usually associated with high levels of Delta-like 4 (Dll4), which activate Notch in neighbouring stalk cells, preventing them from becoming a new tip cell. Notch signalling is initiated by receptor–ligand recognition between adjacent cells. This interaction results in two sequential proteolytic events that release the Notch intracellular domain (NICD). Subsequently, NICD translocates to the nucleus, where it forms a complex with the transcriptional factor Rbpj/Cbf1 and the Mastermind-like proteins to drive target gene expression. Activation of Notch in ECs leads to cell cycle arrest both in vitro and in vivo. However, it is still unclear how Notch exerts its negative effects on EC proliferation, and the transcriptional programme that triggers stalk cell function is not understood. Furthermore, it is not clear how stalk cells are ultimately released from this arrest to provide sufficient cell numbers for the sprout to elongate and stabilize.

In most cells and tissues, PTEN localizes to the cytoplasm and the nucleus. There is evidence to suggest that PTEN has nuclear, non-lipid phosphatase-dependent functions. Interestingly, PTEN localization is cell cycle-dependent, with higher levels of nuclear PTEN during the G0–G1 phase than during the S phase. This is in line with the observation that nuclear PTEN negatively regulates cell cycle progression. Indeed, in late mitosis and G1, nuclear PTEN enhances the E3 ligase activity of APC/C by facilitating the association of APC/C with its activator Fzr1/Cdh1 (encoded by the Fzr1 gene), with no requirement of its phosphatase activity. The APC/C-Fzr1/Cdh1 complex controls G1 progression by targeting several proteins for degradation, including mitotic cyclins (Cyclin-A), mitotic kinases (Aurora Kinase A (Aurora A) and Polo-like kinase 1 (Plk1)), proteins involved in chromosome segregation and DNA replication (Gemmin; ref. 25). Despite the large body of molecular evidence, the role and relevance of nuclear PTEN in physiology is poorly understood.

Here we report that endothelial PTEN regulates stalk cell proliferation during vessel development. Our data further identify PTEN as a key mediator of the antiproliferative responses of Notch. We show that Dil4/Notch signalling arrests stalk cell proliferation by inducing expression of PTEN to balance stalk cell numbers and coordinate patterning. On PTEN deletion, Notch signalling fails to arrest early stalk cells and result in defective sprout length and patterning. Our results strongly indicate that both catalytic and non-catalytic activities of PTEN contribute to this function, providing evidence for an important in vivo physiological function for the PTEN-APC/C-Fzr1/Cdh1 axis.

**Next, we sought to address whether regulated elevation in PTEN expression in vivo would oppose the phenotype induced by loss of PTEN. To this end, we used super-PTEN transgenic mice (PTENTG<sup>28</sup>, a mouse model that allows moderate organismal elevation of PTEN levels (two-fold over WT littermates), with no changes in the number of sprouts per 100 μm of leading endothelial membrane were found in Pten<i>flx/flx</i>/Pten<i>flx/flx</i>/EC mice confirmed that effective depletion of PTEN protein in mECs was achieved 96 h following 4-OHT administration (Supplementary Fig. 1k,l). To further characterize the cell-autonomous role of PTEN in ECs, we therefore focused on the P7 time point. No differences in radial expansion (Fig. 1e) and in the number of sprouts per 100 μm of leading endothelial membrane were found in Pten<i>flx/flx</i>/Pten<i>flx/flx</i>/EC when compared with control retinas (Fig. 1f). Instead, the length of the sprouts was significantly reduced in the Pten<i>flx/flx</i>/Pten<i>flx/flx</i>/EC retinal vasculature compared with controls (Fig. 1g). The hyperplastic phenotype observed on PTEN loss was validated in an independent cellular system based on embryoid body (EB) formation, in which clusters of embryonic stem cells respond to VEGF by forming vascular tubes. Compared with wild type (WT), PTEN null EBs showed increased sprout width and length (Supplementary Fig. 2a–d), with no differences in the number of sprouts (Supplementary Fig. 2e).
PTEN regulates endothelial stalk cell number. Previous data have shown that constitutive targeting of PTEN in ECs results in altered mural cell coverage19. Instead, immunostaining with desmin, a retinal pericyte marker30, did not reveal any obvious defect in mural cell coverage in PTEN\textsubscript{iΔEC/iΔEC} retinas compared with control, consistent with the lack of sprouting defects on PTEN loss (Supplementary Fig. 3f).

Analysis of PTEN\textsubscript{iΔEC/iΔEC} retinas stained with a nuclear endothelial marker (Erg) revealed increased EC numbers in the angiogenic vasculature (Fig. 2a,b). Conversely, elevated PTEN expression resulted in reduced EC numbers at the sprouting front (Fig. 2c,d). We sought to validate whether these differences relate to changes in EC proliferation. Surprisingly, no difference in the number of proliferative ECs located in the subfront retinal area,
Figure 2 | PTEN negatively regulates stalk cell proliferation. (a) IB4 (blue) and Erg (red) staining of control and PTEN^ΔEC/ΔEC littermate retinas at P7. Islets show higher magnification of selected regions shown to the right. (b) Quantification of EC nuclei per unit area assessed by Erg positivity in control and PTEN^ΔEC/ΔEC P7 retinas (n=4). (c) IB4 (blue) and Erg (red) staining of WT and PTEN^TG littermate retinas at P7. Islets show higher magnification of selected regions shown to the right. (d) Quantification of EC nuclei per unit area assessed by Erg positivity in WT and PTEN^TG P7 retinas (n=8). (e) IB4 (blue), Erg (red) and Edu (green) staining of control and PTEN^ΔEC/ΔEC P7 retinas. Islets show higher magnification of selected regions shown below. Arrows indicate Edu-positive ECs in the sprouting front. (f) Quantification of Edu-positive cells per unit area assessed in control and PTEN^ΔEC/ΔEC P7 retinas (n=7). (g) Quantification of number of Edu-positive cells located at the sprouting front expressed per vascular front length in control and PTEN^ΔEC/ΔEC P7 retinas (n=7). (h) IB4 (blue), Erg (red) and Edu (green) staining of WT and PTEN^TG littermate retinas at P7. Islets show higher magnification of selected regions shown below. Arrows indicate Edu-positive ECs in the sprouting front. (i) Quantification of Edu-positive cells per unit area assessed in WT and PTEN^TG P7 retinas (n=4). (j) Quantification of number of Edu-positive cells located at the sprouting front expressed per vascular front length in WT and PTEN^TG retinas (n=4). Scale bars, 20 μm (a,c,e,h). Error bars are s.e.m. *P<0.05 and **P<0.01 were considered statistically significant. Statistical analysis was performed by nonparametric Mann–Whitney test.
behind the sprouting front, was found on either loss (Fig. 2e,f) or gain of PTEN function (Fig. 2h,i). This is unexpected, given that in the growing vasculature ECs with high turnover are located in this subfront area (Supplementary Fig. 4a,b). To test whether PTEN regulated proliferation of ECs in other retinal locations, we focused on the first line of cells located at the sprouting front where proliferating cells are rarely observed (Supplementary Fig. 4a,b). Interestingly, a 40% increase in proliferation in PTEN<sup>EC/i</sup> retina (Fig. 2g) or 60% reduction in PTEN<sup>TG</sup> retinas (Fig. 2i) compared with control retinas was observed in ECs at the front. These data point towards a selective role of PTEN in restricting EC proliferation in cells located at the sprouting front.

**PTEN executes Notch-dependent cell cycle arrest.** Given that the impact of PTEN loss or overexpression in vivo on proliferation are restricted to the sprouting front that is highly Notch-dependent<sup>3</sup>, we hypothesized that a functional connection exists between these two signalling pathways. Activation of Notch in mECs, both in vivo and in vitro, resulted in cell cycle arrest, shown by reduced 5-bromo-2’-deoxyuridine (Brdu) incorporation (Supplementary Fig. 4c,d and Fig. 3a) and downregulation of cell cycle regulators including Cyclin D and A, Plk1, Aurora A and Geminin (Fig. 3b). Interestingly, genetic manipulation of PTEN levels in ECs altered the antiproliferative response to Notch activation (Fig. 3c,e). PTEN<sup>AECAEC</sup> mECs failed to stop proliferation on Notch activation (Fig. 3c,d), whereas PTEN<sup>TG</sup> mECs showed a 50% increase in the cell cycle arrest response (Fig. 3e,f). Consistent with a role of PTEN in regulating the cell cycle arrest, higher PTEN levels in ECs in vivo corresponded to nonproliferative cells (Supplementary Fig. 4e,f). Our results suggest that PTEN is necessary for the growth-suppressive activity of Notch signalling in ECs and imply that the PTEN loss-of-function phenotype is the result of an impaired response to Dll4 stimulation.

Because PTEN is required for the Notch-dependent regulation of endothelial proliferation, we tested whether PTEN expression is regulated by Notch. Bioinformatic analysis of the PTEN locus identified the presence of three Rbpj motifs that are conserved in both the human and mouse PTEN gene (Fig. 3g). We used chromatin immunoprecipitation (ChIP) analysis on human ECs to determine the recruitment of NICD protein to the PTEN promoter after 2 h of incubation with Dll4. PTEN promoter occupancy was determined using real-time quantitative PCR (qPCR) probes that amplify seven regions spanning from −2,380 to −590 relative to the transcription initiation site. Our analysis revealed NICD occupancy in the −1,492 region, which contains one of the three predicted Rbpj-binding sites (Fig. 3g). We next validated the functional significance of Rbpj binding to the promoter in luciferase reporter assays. Indeed, analysis of PTEN promoter activity showed activation in response to Dll4 (Fig. 3h) and on overexpression of the intracellular domain of the Notch receptor (NICD; Fig. 3i). Importantly, enhanced PTEN promoter responsiveness to Dll4 was abrogated by the γ-secretase inhibitor dibenzazepine (DBZ; Fig. 3i). Western blot experiments confirmed that Dll4 stimulation results in elevated protein levels of PTEN in human ECs and mECs (Fig. 3j,k). Using lungs as highly vascularized tissue, we validated that overactivation of Notch signalling by inhibiting the Notch ligand, Jagged 1 (Jag1)<sup>11</sup>, resulted in higher PTEN expression levels (Fig. 3i). Taken together, these results demonstrate that PTEN is a target gene of Notch signalling in ECs, which becomes induced by Dll4 stimulation.

**PTEN is required for Notch function in vivo.** We sought to confirm the Notch/PTEN functional interaction in vivo. We took advantage of endothelial Jag1 inactivation, which results in reduced EC proliferation and decreased vascular branching due to overactivation of Notch signalling<sup>11</sup>. We hypothesized that, if the regulation of the angiogenic process by Notch requires the increase in PTEN function, loss of PTEN would prevent the phenotype of Jag1 deletion. We tested this hypothesis in inducible endothelial-cell-specific PTEN<sup>AECAEC</sup> and Jag1<sup>AECAEC</sup> double mutants. The vasculature of Jag1<sup>AECAEC</sup> retinas showed reduced endothelial proliferation and reduced vessel width, confirming previous reports (Fig. 4a–g and Supplementary Fig. 5a)<sup>11</sup>. However, concomitant PTEN deletion abrogated the phenotype observed in Jag1<sup>AECAEC</sup> retinas (Fig. 4a–g), while the phenotype of PTEN loss remained unaffected by Jag1 deletion (the increase in endothelial proliferation at the sprouting front). Next, we validated our hypothesis in the PTEN<sup>TG</sup> mice by blocking Notch activation with the γ-secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetly)-L-alanyl]-S-phenylglycine t-butyl ester) that strongly enhances angiogenesis partially due to increased EC proliferation.<sup>9</sup> Remarkably, DAPT-induced increase in vascular density at the angiogenic front was abolished by increased levels of PTEN (Fig. 4h,i,j,m,n and Supplementary Fig. 5b). However, elevated levels of PTEN did not prevent the enhanced sprouting caused by DAPT (Fig. 4i,k,l), further indicating that PTEN is not required for Notch-dependent tip/stalk selection.

**Dual function of PTEN in angiogenesis.** To gain insight into the biological mechanism underlying the role of PTEN in sprouting angiogenesis, we investigated the contribution of phosphatase-dependent and -independent activities of PTEN at the organismal and cellular levels. We observed a compartmentalization of PTEN in the nucleus and cytoplasm in cultured control cells (Fig. 5a), whereas PTEN<sup>AECAEC</sup> mECs showed nuclear staining with some residual positivity in the cytoplasm. PTEN depletion in mECs resulted in increased Akt phosphorylation and in accumulation of the E3 ubiquitin ligase APC/C-Fzr1/Cdh1 complex substrates Aurora A, Plk1 and Geminin (Fig. 5b). Control mECs treated with 4-OHT did not show any of the aforementioned changes (Fig. 5c). In contrast, mECs isolated from PTEN<sup>TG</sup> lungs showed reduced Akt phosphorylation and reduced accumulation of E3 ubiquitin ligase APC/C-Fzr1/Cdh1 complex substrates compared with WT cells (Fig. 5d).

To investigate whether increased levels of the APC/C-Fzr1/Cdh1 targets were only a consequence of increased PI3K activity, we tested the impact of GDC-0941 (a pan-class I PI3K inhibitor that blocks p110α, p110β, p110δ and p110γ; ref. 31). While pretreatment with GDC-0941 abrogated Akt activation in PTEN<sup>AECAEC</sup> mECs (Fig. 5e), it did not modify the levels of Aurora A and Geminin (Fig. 5e), further corroborating that the function of PTEN promoting the APC/C-Fzr1/Cdh1 activity is independent of its ability to inhibit PI3K signalling through its lipid phosphatase activity<sup>22</sup>.

As our data indicate that the principal function of PTEN in sprouting angiogenesis is to regulate EC proliferation, we tested to what extent phosphatase-dependent and -independent activities of PTEN participate in this regulation. In vitro isolated PTEN<sup>AECAEC</sup> and PTEN<sup>TG</sup> mECs showed increased and decreased BrdU incorporation, respectively (Fig. 5f and Supplementary Fig. 6a,b). Inhibition of PI3K activity and Aurora kinase, one of the main targets of APC/C-Fzr1/Cdh1 (ref. 22), partially rescued normal proliferation rate in PTEN<sup>AECAEC</sup> mECs (Fig. 5f and Supplementary Fig. 6a). A synergistic effect was observed on pretreatment with both GDC-0941 and VX680, further implying a dual function of PTEN in this process. Next, we complemented PTEN-depleted ECs with either WT...
Figure 3 | Notch limits EC proliferation by upregulating PTEN levels. (a) Quantification of in vitro proliferation of mECs and HUVECs plated for 24 h in vehicle or Dll4-coated dishes, pulsed with BrdU for 2 h and subjected to immunostaining analysis. At least 100 cells per condition were counted (n = 4). (b) Immunoblot analysis of mECs and HUVECs plated for 24 h in vehicle or Dll4-coated plates using the indicated antibodies (n = 3). Molecular weight marker (kDa) is indicated. (c,e) Quantification of in vitro proliferation by Ki67 immunofluorescence of control and PTEN−/−/ΔEC (c) and WT and PTENTG mEC (e) plated for 24 h in vehicle or Dll4-coated plates. Overall 100 cells per condition were counted (n = 4). (d) Control and PTEN−/−/ΔEC or (f) WT and PTENTG mEC were plated for 24 h in vehicle or Dll4-coated dishes, followed by immunoblot analysis using the indicated antibodies. The quantification of the relative immunoreactivity of each protein normalized to β-actin is represented as the mean of four different experiments in d,f. Molecular weight marker (kDa) is indicated. (g) ChIP with the anti-NICD antibody from HUVECs and the analysis of the PTEN locus by qPCR. A pool of two independent experiments is shown. (h,i) PTEN-luciferase reporter assays were performed in HUVECs with a 2,666-bp PTEN promoter construct (pGL3 PTEN Hind III-NotI). (h) Cells were plated for 6 h in vehicle or Dll4-coated dishes and (i) HUVECs were transfected with VS-NICD (n = 3). (j,k) Immunoblot analysis of PTEN in lung mECs (j) and in HUVECs (k) plated for 8 or 24 h in vehicle or Dll4-coated plates (n = 4). Molecular weight marker (kDa) is indicated. Error bars are s.e.m. *P < 0.05 and **P < 0.01 were considered statistically significant. ns, not statistically significant. Statistical analysis was performed by nonparametric Mann-Whitney test.
Next, we tested the differential contribution of each of these functions in vivo, by first analysing the retinas of PTEN^WT, phosphatase-inactive (C124S; PTEN^C124S; refs 32,33) or nuclear-excluded (K13,289E; PTEN^K13,289E) PTEN (ref. 22). Expression of PTEN^WT, PTEN^C124S and PTEN^K13,289E abrogated the increase in EC proliferation (Fig. 5g and Supplementary Fig. 6c) of PTEN null ECs, albeit most prominently seen with PTEN^WT. All together, these data indicate that phosphatase-dependent and -independent activities of PTEN are important to regulate EC proliferation.

Figure 4 | PTEN interacts with Notch in vivo to negatively control stalk cell proliferation. (a) Whole-mount visualization of blood vessels by IB4 staining of control, Jag1^iEC/ΔEC, PTEN^ΔEC/ΔEC and PTEN^ΔEC/ΔEC, Jag1^ΔEC/ΔEC littermates at P7. (b–g) Quantitative analysis of the retinas shown in a. Retinas from five independent litters were pooled for quantification. (b) Vascular branch points (n ≥ 4). (c) Vessel width (n ≥ 4). (d) Number of sprouts per vascular front length (n ≥ 4). (e) Spout length from the tip to the base of the sprout (n ≥ 4). (f) Quantification of number of Ki67-positive cells located at the vascular front expressed per sprouting front length (n ≥ 4). (g) Quantification of number of Edu-positive cells located at the vascular front expressed per sprouting front length (n ≥ 4). (h) Whole-mount visualization of blood vessels by IB4 staining of WT and PTENTG P7 retinas treated with vehicle or DAPT (100 mg kg⁻¹). (i–n) Quantitative analysis of the retinas shown in h. Retinas from three independent litters were pooled for quantification. (i) Vascular branch points per unit area (n ≥ 4). (j) Vessel width (n ≥ 4). (k) Number of sprouts per vascular front length (n ≥ 4). (l) Sprout length from the tip to the base of the sprout (n ≥ 4). (m) Quantification of endothelial nuclei per unit area assessed by Erg positivity (n ≥ 4). (n) Quantification of number of Ki67-positive cells located at the vascular front expressed per sprouting front length (n = 6). Scale bars, 100 μm (a,h). Error bars are s.e.m. *P<0.05, **P<0.01 and ***P<0.001 were considered statistically significant. Statistical analysis was performed by nonparametric Mann–Whitney test.
sprouting angiogenesis by inhibiting Aurora kinase. Strikingly, the phenotype of PTEN\textsuperscript{AE/C\textsubscript{EC}/AE\textsubscript{EC}} was abrogated by Aurora kinase inhibition (Fig. 6e–h), which is consistent with the role of the phosphatase-independent activity of PTEN in sprouting angiogenesis \textit{in vivo}. This was further corroborated by genetic conditional and inducible deletion of \textit{Fzr1} in ECs. Complete depletion of \textit{Fzr1/Cdh1} protein was achieved 48 h post incubation with 4-OHT (Supplementary Fig. 7b,c). Therefore, pups were treated with 4-OHT at P5 and P6, followed by analysis of the retinal vasculature at P7. The retinas of \textit{Fzr1\textsuperscript{i\textsubscript{Fzr1/Cdh1}} mECs were infected with PTEN WT, PTENC124S or PTENK13,289E, treated with 4-OHT for 72 h, plated for 48 h in the presence of doxycycline, pulsed with BrdU for 2 h and subjected to immunostaining analysis. Data shown are the means of six independent experiments. Error bars are s.e.m. \textdagger P<0.05 and *P<0.01 were considered statistically significant. Statistical analysis was performed by nonparametric Mann–Whitney test.

**Discussion**

Here we report that PTEN in ECs is required in a cell-autonomous and dose-dependent manner for the control of vascular density and vessel growth, but is dispensable for the regulation of the sprouting activity of tip cells. We show that endothelial PTEN restricts vascular growth by limiting stalk cell proliferation during sprouting angiogenesis. An important conclusion from this study is that PTEN is not required in all ECs to regulate proliferation \textit{in vivo}, as shown in cultured ECs (our data and ref. 19). Instead, our results indicate that the consequence of PTEN loss or overexpression is restricted specifically to the zone of the vasculature that is highly Notch-dependent. Constitutive targeting of PTEN in ECs leads to embryonic lethality due to aberrant angiogenesis\textsuperscript{19}. Although these studies have established that PTEN regulates EC proliferation, the analysis of vasculature in Tie2Cre-PTEN\textsubscript{flox/flox} embryos did
not allow unravelling precisely how PTEN regulates sprouting angiogenesis. Furthermore, Hamada et al. were unclear of whether the aberrant vasculature, which results on PTEN loss, was a consequence of aberrant PTEN signalling in ECs or simply a consequence of an altered pro-angiogenic cytokine profile. Similarly, zebrafish studies have shown that loss of PTEN leads to increased VEGF levels and in turn vessel hyperplasia, highlighting indeed that PTEN also regulates angiogenesis in a paracrine manner. Another difference between Hamada et al. and our study is that constitutive loss of PTEN in ECs also results in altered mural cell coverage, while induced loss of postnatal endothelial PTEN does not. These discrepancies suggest that PTEN may differently regulate angiogenesis in different vascular beds.

Activation of Notch leads to cell cycle arrest. In this study, we identify PTEN as a critical mediator of Notch antiproliferative response in stalk cells. If PTEN is not expressed in ECs, stalk cells become insensitive to the antiproliferative signals of Notch and exhibit unrestricted expansion, hence perturbing sprout length and pattern and eventually resulting in profound hyperplasia. Interestingly, our results also reveal that stalk cells located further away from the...
front are insensitive to changes in PTEN expression. Given that these stalk cells at the subfront area are highly proliferative, our data support the existence of two biological states for stalk cells. A first state in which stalk cells must remain arrested to ensure the correct patterning of the sprout, and a second state in which cells enter the cell cycle to expand the plexus. These two states are likely the consequence of dynamic changes in Notch signalling, with high Notch activity in early nonproliferative stalk cells and low Notch activity in the late proliferative stalk cells. Our data predict a rise and fall in PTEN levels that will accompany the early quiescent and late proliferative phases, respectively. This is supported by the observation that, in WT cultured ECs, higher PTEN levels are seen 8h post stimulation with Dll4 compared with 24h post stimulation. Furthermore, co-staining of PTEN and 5-ethyl-2'-deoxyuridine (Edu) in the growing vasculature showed that Edu-negative cells express higher levels of PTEN than Edu-positive cells, supporting the notion that PTEN protein levels rise to guarantee cell cycle arrest. Whether high PTEN cells correspond to high Notch signalling still needs to be determined. Most et al. speculated that early and late stalk cell behaviours might be orchestrated by oscillation in Notch activity. The authors proposed that Id proteins, members of HLH proteins, govern these two states by releasing the negative autoregulatory loop of Hes1 (ref. 35). While our results are consistent with the idea of two states, they identify PTEN as the key mediator of early stalk cell function in response to Notch.

Why and how Notch exerts a unique negative regulation in the endothelium while driving proliferation in virtually every other cell type and in cancer has been a mystery3,36. Our data show that PTEN negatively regulates cell cycle progression in ECs through conserved pathways. Critically, what our results illustrate is a novel interaction between Notch and PTEN in ECs. We find that Notch stimulates PTEN transcription in the endothelium, an effect that is required for Notch-mediated cell cycle arrest. Interestingly, in cell types where Notch stimulates cell cycle progression, PTEN is transcriptionally repressed by Notch/Hes36–38. The PTEN gene locus contains both Rbpj- and Hes-binding sites, suggesting that binding to one or another is what determines the final biological output.

In line with the observation that PTEN restricts stalk cell proliferation, endothelial gain and loss of PTEN proliferation phenotypes are reminiscent of gain and loss of Notch function in stalk cells9–11. However, in response to Notch signalling PTEN appears to only regulate EC proliferation while it is not required for tip and stalk specification. This is shown by the observation that Notch mutants not only show aberrant proliferation phenotypes in the nascent plexus but also sprouting defects9,11, while PTEN mutants only show vascular density defects. In the same line, increased levels of PTEN protect angiogenic ECs treated with DAPT from uncontrolled proliferation but fail to prevent excessive tip cell numbers. Conversely, a recent study has shown that inhibitors of the VEGFR3 kinase activity rescue the hypersprouting phenotype of Notch loss-of-function mutants, without reducing EC proliferation39. Taken together, these data suggest that Notch regulates tip cell numbers and stalk cell proliferation independently through VEGFR3 and PTEN pathways, respectively.

The predominant activity of PTEN is the dephosphorylation of PtdIns(3,4,5)P3 and thus the counteraction of class I PI3K-mediated functions13,15. However, PTEN also exhibits PtdIns(3,4,5)P3-independent functions, including protein phosphatase14 and non-catalytic activities13,15. In this context, PTEN can be found in the nucleus where it regulates DNA stability and cell cycle progression22,40. Several reports have highlighted the relevance of nuclear PTEN in disease22,41–43. To date, the physiological relevance of nuclear PTEN in vivo remains elusive. Our results reveal that both lipid phosphatase-dependent and non-catalytic activities of PTEN regulate stalk cell proliferation during sprouting angiogenesis. Inhibition of class I PI3K activity with GDC-0941 or Aurora kinase with VX680 significantly abrogates the phenotype observed on PTEN loss. However, the observation that pretreatment with either GDC-0941 or VX680 is not able to completely rescue the hyperplasia phenotype of PTENnull ECs recapitulates the phenotype observed on endothelial loss of PTEN, reinforcing the importance of nuclear PTEN facilitating the APC/C-Fzr1/Cdh1 function. Taken together, our study provides in vivo evidence that nuclear PTEN is not only involved in disease such as cancer or cerebral ischaemia22,41–43 but is also critical to regulate a fundamental physiological process such angiogenesis.

**Figure 7** | Schematic model of the role of PTEN in Dll4/Notch-mediated stalk cell cycle arrest. (a) Activation of Notch by Dll4 induces expression of PTEN, which through its lipid phosphates activity and its nuclear function as a scaffold of the APC/C-Fzr1/Cdh1 blocks stalk cell proliferation. (b) On PTEN loss, Notch signalling fails to arrest stalk cells and result in defective sprout length and patterning.
We and others have previously shown that inhibition of class I PI3K isomerase in vivo does not lead to blockade of EC proliferation22,24–46. Although contradictory, these observations may reflect that PI3K principally regulates EC proliferation independently of its lipid phosphatase activity22. In line with this, our data also reveal that the regulation of APC/C-Fzr1/Cdh1 by Pten seems to play a major role in response to Notch signalling in angiogenesis. This is shown by the altered APC/C-Fzr1/Cdh1 target expression under conditions of Pten loss and Notch activation. This observation, together with the fact that Notch stimulation in ECs results in phosphorylation of Akt24,48, suggest that Notch stimulates Pten nuclear translocation. These findings would be in agreement with the notion that higher nuclear Pten levels are found during G0–G1 phase than during the S phase23,24. Further experiments are needed to elucidate how Pten accumulates in the nucleus on Notch activation.

The unique direction of the coupling of Notch and Pten in the endothelium (Fig. 7), and the highly selective effects on the active vascular front raise the prospect that targeting this interaction and perturbation of Pten signalling may be used therapeutically to render EC quiescence and therefore to promote a normalization effect. Clinically, our results imply that stimulating both arms of Pten function in ECs could render a more quiescence phenotype of highly proliferative tumour ECs22–49. However, inhibition of P13K in the tumour stroma not only results in reduced EC proliferation but also in reduced vascular function47. It is thus tempting to speculate that promoting nuclear Pten may offer more selectivity towards a tight control of EC proliferation.

Methods

Reagents.
Sources and catalogue numbers of antibodies were as follows: Cell Signaling Technology: Pten (9595s), pS473-Akt (#4060) and pser240/244-S6 (#61965-026); BD Pharmingen: p27 (#562440), cyclin-D1 (#556470), Brdu (#437580) and Aurora A kinase (#610939); NeoMarkers: Ki67 (#RM-9106-S); Abcam: NICD (ab225726), desmin (ab15200) and Pten (ab32199); Santa Cruz Biotechnology: VE-cadherin (sc-6458), geminin (sc-31051), cyclin-A (sc-53230), hes1 (sc-25392) and erb (sc-353); Millipore: Plk1 (#06-813) and Fzr1/Cdh1 (#CC43); Sigma-Aldrich: β-actin (A5441) and α-tubulin (T6074). Isocitrate GS-IB4 and secondary antibodies conjugated to Alexa 488, Alexa 568 and Alexa 633, and Click-it Edu Alexa 488 and 647 Imaging Kit were from Molecular Probes. Human Dll4 were used accordingly.

Embryoid bodies.
ES cells were cultured and EBs were generated, as previously described22. Briefly, ES cells were regularly cultured on a layer of irradiated DR4 mouse embryonic fibroblast in DMEM glutamax (Life Technologies, #61965-026) in the presence of 20% fetal bovine serum, Hepes (30 mM), sodium pyruvate (1.5 mM), monothiolipase (1.5%) and leukemia inhibitory factor (Chemicon#ESG1107, 123 units ml⁻¹). For vascular sprouting assays, cells were cultured for two passages without feeders, depleted of leukaemia inhibitory factor and left in suspension as hanging drops. Four days after, the formed EBs were transferred to a polymerized collagen gel with the addition of 60 ng ml⁻¹ VEGF (Peprotech). The medium was changed once daily and 5 days and every day thereafter. Overall, 70,000 WT ES cells and 10,000 PTEN⁻/⁻ ES cells were plated to generate EB. PTEN⁻/⁻ ES cells were provided in ref. 53.

Isolation and stimulation of mEsCs.
Mouse lungs were digested with Dispase (Life Technologies, #17105-041; 4 units ml⁻¹) for 1 h at 37°C, followed by positive selection with antimonious vascular endothelial-cadherin (Pharmingen, #555289) antibody coated with magnetic beads (Dynal Biotech, #110-35). Cells were seeded on a 12-well plate, and were coated with gelatin (0.5%) in DMEM/F12 containing 10% FCS. mECs were plated to generate EB. PTEN⁺/⁺ and PTEN⁻/⁻ ES cells were plated to generate EB.

In vitro measurement of mEC cell proliferation.
Overall, 10⁴ mECs were plated in a 24-well plate for 48 h before the experiment of the beginning, BrdU (10 μM) was added to the medium. For Ki67 staining, cells were plated for 24 h in DM14-coated dishes. Cells were fixed in 4% PFA for 10 min at RT, permeabilized for 10 min with TBS-T (25 mM Tris HCl pH 7.4, 150 mM NaCl, 0.5% Triton X-100), blocked with TBS containing 2% BSA and incubated with primary antibodies BrdU (1:100) or Ki67 (1:50) at 4°C on ice for 60 min. The following day, cells were washed three times with TBS and incubated with Alexa conjugated secondary antibodies for 1 h at RT. For Di4 stimulation, mouse Di4 (500 μg ml⁻¹) was immobilized by coating culture dishes for 1 h at RT, followed by seeding mECs for 6, 8 or 24 h. Mouse and human Di4 were used accordingly.

Plasmids and transfections.
peK5-MyC-PTEN, CI24S pEGFP-PFN-PTEN-wt and pEGFP-PFN-PTEN-K13,289E expressing human WT, lipid phosphate-inactive and nuclear-excluded PTEN mutants, respectively, were provided in ref. 22. All three mutants were subcloned to an N-terminal yellow fluorescent protein into a modified lentiviral vector TRIPZ. Lentiviral particles were prepared by transfecting HEK299FT cells with the TRIPZ vector of interest and the packaging vectors pPAX, VSV-G and pTAT. Viral particles in the supernatant were concentrated with Lenti-X-concentrator (Clontech). mECs of P2 or P3 from PdgfbCreER2, Ptenflx/flx were infected with lentivirus expressing WT Pten, Pten (CI24S) or Pten (K13,289E) in the presence of virapilus transduction enhancer (Applied Biological Material #6998). Infection, mECs were plated at

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8935

© 2015 Macmillan Publishers Limited. All rights reserved.
a density of $4 \times 10^4$ per well of 12-well plate and infected with viruses from 293FT cells 48 h after transfection. After 48 h post infection, mECs were re-plated and treated with 4-OHT (5 μM) to induce gene deletion for 72 h. Next, 10^6 mECs were plated in 24-well plate for 48 h in the presence of doxycycline (4 μM); 2 h before the termination of the experiment, BrdU (10 μM) was added to the medium. Cells were then fixed in 4% PFA for 10 min at RT, permeabilized for 10 min with TBS-T (25 mM Tris HCl pH 7.4, 150 mM NaCl, 0.5% Triton X-100), blocked with TBS-T-containing 2% BSA and incubated with primary antibodies BrdU (1:100) at 4°C ON. The following day, cells were washed three times with TBS-T and incubated with Alexa-conjugated secondary antibodies for 2 h at RT. DAPI was added in the final wash. Specimens were mounted in Mowiol. Cells were visualized in a Nikon-80i microscope.

MTS viability assay. mECs were cultured in 96-well plate (2,000 cells per 100 μl culture medium per well) in the presence of the test compounds (GDC-0941 (1 μM) and VX680 (0.5 μM)) or the respective controls for 48 h, followed by MTS assay (Promega, #G5421).

Protein extraction and immunoblotting. mECs, human umbilical vascular ECs (HUVECs) (Lanza #CC-2519) and lungs were lysed in 50 mM Tris HCl pH 7.4, 5 mM EDTA, 150 mM NaCl, 50 mM NaF and 1% Triton X-100 supplemented with 2 mM N-ethyl, N’-nitro-1,1-2-naphtylethylene (NEM), 1 mM pepstatin, 1 mM leupeptin, 1 mM phenylmethylsulfonylfluoride and 1 mM sodium orthovanadate, followed by clearance of lysates using microcentrifugation. Supernatants were resolved on a 10% SDS–PAGE gel, transferred on nitrocellulose membranes and probed with the indicated antibodies. Detection was performed by enhanced chemiluminescence. Uncropped immunoblots and larger blot areas are presented in Supplementary Fig. 8.

Luciferase assays. Reporter assays in HUVECs were performed with the Dual Luciferase Assay System (Promega, #E1910) and a LUMAT LB 9507 luminometer (BERTHOLD Technologies). HUVECs were grown to 60–70% confluence in culture medium per well of 12-well plate and infected with virus from 293FT manufacturers’ protocol. To induce Notch activity with Dll4, transfected HUVECs were re-plated on Dll4-coated dishes 6 h after plasmid infection. Luciferase activity was measured after an additional 24 h. To inhibit Notch signalling, cells were pretreated for at least 1 h before stimulating with Dll4 with 0.08 μM DBZ ((S,S)-2-[2-(3,5-Difluorophenyl)acetylamino]-N-(5-methyl-6-oxo-6,7-dihydro-1,2,4-benzoxazin-3(4H)-yl)propanamide).

ChIP assay. To analyse the binding sites for RBP on the selected PTEN proximal promoter, we used the Genomatix software. For analysis, the gene bank sequence was used for genomic DNA, which contains the promoter sequence AF066618.1. Three putative RBP-binding sites located at −1,914, −1,992 and −1,132 positions relative to transcription initiation site(−1) were identified. ChIP assay was performed as previously described. Briefly, chromatin was isolated from HUVECs stimulated for 2 h with vehicle or Dll4 (500 ng ml−1). Crosslinked chromatin was sonicated for 10 min, and medium-sized powders (10 000–10 000) were digested with a Bioruptor (Diagenode) and precipitated with anti-NCID or control IgG. After crosslinkage reversal, DNA was used as a template for PCR. qPCR was performed with SYBR Green I Master (Roche, #04.887.352.001) in the LightCycler480 system. Primers used are described in Supplementary Table 1.
Acknowledgements

We thank Ramon Parsons (The Mount Sinai Hospital, NY, US) for pGL3 PTEN HindIII-Notl construct and Lluís Espinosa (IMIM, Barcelona), Alba Martínez (Research Laboratory, Catalan Institute of Oncology, IDIBELL, Barcelona) and Magali Castells (Vascular Signalling laboratory, IDIBELL) for support with experiments. This work was supported by research grants SAF2010-15661 and SAF2013-46542-P from MICINN (Spain), 2014-SGR-725 from the Catalan Government, from the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme FP7/2007-2013/ (REA grant agreement 317250) and Ajuts Joves Investigadors from IDIBELL to M.G., and SAF2013-49022 and RDI12/0036/0054 to A.B. Personal support was from PPI of the Spanish Ministry of Education (A.G.), IDIBELL (H.S.) and Ramon y Cajal fellow of the Spanish Ministry of Education (M.G. and O.C.). The work of A.C. is supported by the Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etorreka), health (201211086) and education (PI2012-03), Marie Curie (277463), Movember, ISCIII (PI10/01484, PI11/00031) and EBC (336343). The work of M.P. is supported by the Max Planck Society, the Deutsche Forschungsgemeinschaft (SFB 834) and an ERC Starting Grant (ANGIOMET). H.G. is supported by Cancer Research UK, the Lister Institute of Preventive Medicine, the Leducq Network Grant ARTEMIS, BIRAX and an ERC starting grant Reshape 311719.

Author contributions


Additional information

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Serra, H. et al. PTEN mediates Notch-dependent stalk cell arrest in angiogenesis. Nat. Commun. 6:7935 doi: 10.1038/ncomms8935 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer

Felix Royo\textsuperscript{1,2,*}, Patricia Zuñiga-Garcia\textsuperscript{1,*}, Verónica Torrano\textsuperscript{1,*}, Ana Loizaga\textsuperscript{3,*}, Pilar Sanchez-Mosquera\textsuperscript{1}, Aitziber Ugalde-Olano\textsuperscript{4}, Esperanza González\textsuperscript{1}, Ana R. Cortazar\textsuperscript{1}, Laura Palomo\textsuperscript{1}, Sonia Fernández-Ruiz\textsuperscript{1}, Isabel Lacasa-Viscasillas\textsuperscript{3}, María Berdasco\textsuperscript{5}, James D. Sutherland\textsuperscript{1}, Rosa Barrio\textsuperscript{1}, Amaia Zabala-Letona\textsuperscript{1}, Natalia Martín-Martín\textsuperscript{1}, Amaia Arruabarrena-Aristorena\textsuperscript{1}, Lorea Valcarcel-Jimenez\textsuperscript{1}, Alfredo Caro-Maldonado\textsuperscript{1}, Jorge Gonzalez-Tampan\textsuperscript{3}, Guido Cachi-Fuentes\textsuperscript{3}, Manel Esteller\textsuperscript{5}, Ana M. Aransay\textsuperscript{1,2}, Miguel Unda\textsuperscript{3}, Juan M. Falcón-Pérez\textsuperscript{1,2,6,Ω}, Arkaitz Carracedo\textsuperscript{1,6,7,Ω}

\textsuperscript{1}CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain
\textsuperscript{2}Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
\textsuperscript{3}Department of Urology, Basurto University Hospital, Bilbao, Spain
\textsuperscript{4}Department of Pathology, Basurto University Hospital, Bilbao, Spain
\textsuperscript{5}Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
\textsuperscript{6}Ikerbasque, Basque Foundation for Science, Bizkaia, Spain
\textsuperscript{7}Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bizkaia, Spain

*These authors contributed equally to this work
ΩThese authors contributed equally to this work

Correspondence to: Arkaitz Carracedo, e-mail: acarracedo@cicbiogune.es
Juan M. Falcón-Pérez, e-mail: jfalcon@cicbiogune.es

Keywords: extracellular vesicles, exosomes, prostate cancer, urine biomarkers

Received: August 18, 2015    Accepted: November 26, 2015    Published: January 12, 2016

ABSTRACT

Extracellular vesicles (EV) are emerging structures with promising properties for intercellular communication. In addition, the characterization of EV in biofluids is an attractive source of non-invasive diagnostic, prognostic and predictive biomarkers. Here we show that urinary EV (uEV) from prostate cancer (PCa) patients exhibit genuine and differential physical and biological properties compared to benign prostate hyperplasia (BPH). Importantly, transcriptomics characterization of uEVs led us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV from PCa patients. Tissue and cell line analysis strongly suggested that the status of CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the prostate tumor. CDH3 was negatively regulated at the genomic, transcriptional, and epigenetic level in PCa. Our results reveal that uEVs could represent a non-invasive tool to inform about the molecular alterations in PCa.

INTRODUCTION

In the recent years, the search of biomarkers in urine has focused on the characterization of urinary extracellular vesicles (uEVs), trying to overcome the complexity and variation of this biofluid [1, 2]. Under the denomination of uEVs, there is a complex mixture of vesicles, including exosomes, microvesicles and apoptotic bodies [3, 4]. Although there are no clear markers to distinguish them, exosomes are defined as small membrane vesicles with a diameter of 40–150 nm formed by inward budding of the membrane of late endosomes resulting in the formation of multivesicular bodies (MVB) filled of intraluminal vesicles. Then, some of these (MVB) fuse to the plasma membrane releasing in this manner the exosomes to the extracellular milieu [5]. Microvesicles or ectosomes refer to plasma membrane shedding vesicles of 0.1–1 μm [6]. Apoptotic bodies are assumed to be of bigger size [7]. uEVs are released by several tissues along the urinary tract and their cargo varies depending on their origin [8].
Evidence of the presence of uEVs belonging to prostate has been already reported [9, 10] and the cargo includes proteins of prostate origin such as prostate-specific membrane antigen (PSMA) [11]. Proteomic analysis of uEVs in PCa patients has been recently carried out with promising results as a source of biomarkers [12] and the use of microRNAs as markers for this disease have been also extensively reported and reviewed [13]. Most of the studies to date focus on the comparative analysis of healthy and PCa patients. This raises the question of the existence of biomarkers that can discriminate PCa from BPH [14], a pathology that has been shown to interfere with well established biomarkers such as prostate-specific antigen (PSA) [15]. In the present work, we aimed at identifying PCa biomarkers within uEVs through the analysis of the uEV transcriptome. We selected transcripts with a presence-absence pattern in BPH and PCa, and we extensively validated the candidate transcript encoded by the Cadherin 3, type 1 gene (CDH3). Importantly, we corroborated this observation in a miniaturized assay that could facilitate the translation of the results into the clinic. Finally, the analysis of mRNA in prostate tumor tissue from patients revealed alterations in this gene, coherent with genomic transcriptional and epigenetic changes, all pointing at the inhibition of CDH3 in PCa.

Overall, our results support that analysis of uEVs could present a non-invasive method to evaluate and monitor changes, all pointing at the inhibition of CDH3 in PCa.

**RESULTS**

**Characterization of uEVs from BPH and PCa patients**

As a first approach, we analyzed the physical characteristics of uEVs from patients with BPH and PCa by comparing more than 23–30 independent preparations from each group (Supplementery Table S1). In order to validate the ultracentrifugation procedure [16] for isolation of uEVs, the presence of double membrane vesicles by cryo-electron microscopy (Figure 1A) and EV markers by western blot [28] was confirmed (Supplementary Figure S1). We next analyzed uEV size and number in urine of BPH and PCa patients. Nanoparticle-tracking analysis (NTA) was performed in samples before and after ultracentrifugation. NTA-estimated particle number was comparable before and after urine ultracentrifugation. Although no statistically significant differences were found, NTA analysis revealed a trend to a different size distribution of the uEVs, with a lower abundance of small vesicles (0–100 nm) and a greater abundance of large (150–200 nm) and very large (250–350 nm) vesicles in PCa when compared with BPH (Figure 1D).

Further to this characterization, we analyzed the changes in cargo in BPH and PCa. RNA concentration per vesicle was comparable in BPH and PCa uEVs (0.017 ± 0.006 ng RNA per million uEVs in BPH and 0.0046 ± 0.0005 ng RNA per million uEVs in PCa; mean ± s.e.m.; n = 9–10; Mann Whitney U p = 0.13). Similarly, we did not observe significant differences in protein concentration (0.041 ± 0.01 µg protein per million uEVs in BPH and 0.019 ± 0.003 µg protein per million uEVs in PCa; mean ± s.e.m.; n = 9–10; Mann Whitney U p = 0.18).

**Transcriptomic analysis of PCa and BPH uEVs**

We next aimed at identifying molecular alterations in uEV cargo from PCa patients. It has been recently reported that these particles present a genuinely differential proteome in patients harboring PCa [12]. However, little is known about the transcript content of uEVs and the potential of these molecules to inform about the biological characteristics of PCa, especially when comparing to patients with BPH. To address this question, we extracted RNA of uEVs from BPH and PCa patient samples. First, we observed lack of overt changes in overall RNA size distribution (Figure 2A). Next, we labeled and hybridized BPH and PCa uEV-derived RNA into whole genome Illumina gene expression microarrays. The results showed the detection (detection p-value < 0.01) of 1336 unique transcripts in the two groups analyzed (presence in 50% of the cases in either group was defined as positive, Supplementery Table S3), 1010 in BPH and 956 in PCa (Figure 2B). Venn analysis revealed an overlap of 47.1% from total unique transcripts in BPH and PCa (Figure 2B). We performed a further step in candidate transcript selection by identifying genes that were selectively detected in one of the two biological settings (BPH or PCa, in at least 75% of the cases). Illumina platform provides information about the probability of a probe to present a signal that is different to background noise, for which purpose we established a confidence interval of...
99% (p < 0.01). The list of differentially detected probes is shown in Figure 2C. In addition, we took advantage of the microarray analysis in order to define housekeeping genes that would have similar abundance in uEVs from BPH and PCa patients. To this end, starting from normalized signal values, we defined genes with no differential abundance (p-value > 0.95 and fold change no greater than ± 5%; Supplementary Table S4). From this analysis, we selected two transcripts, Eukaryotic Elongation Factor 1A1 (EEF1A1) and Ribosomal Protein L6 (RPL6), that we monitored in subsequent studies. In addition, we also included Glyceraldehyde Phosphate Dehydrogenase (GAPDH) as a housekeeping gene supported by prior studies of our group [16].

Validation of uEV biomarkers of PCa

To ascertain the potential of candidate uEV transcripts, we performed qRTPCR from an independent set of ultracentrifuge-purified uEV retrotranscribed RNA (using an average of 1.5e7 uEVs per reaction). Firstly, the abundance of housekeeping transcripts (RPL6, EEF1A1, GAPDH) was strongly correlated (Supplementery Figure S2A), reinforcing the notion of their value as housekeeping transcripts. The use of these controls allowed us to identify 4 cases with lack of amplification in all three transcripts, which was considered an exclusion criterion for the analysis. Secondly, the evaluation of 10 transcripts of interest (From Figure 2C) revealed that two candidates, Cadherin 3, type 1 (CDH3) and CKLF-Like MARVEL Transmembrane Domain

Figure 1: Physical characterization of uEVs from PCa and BPH samples. (A) Representatives cryo-TEM micrographs of uEVs isolated from BPH and PCa urine samples. Bar, 100 nm. n = 3. (B and C) Box-plots showing number (B) or size (C) of particles isolated from each group, indicating the mean and s.e.m. (n = 23 for BPH and 30 for PCa). (D) Size distribution of the particles isolated from each preparation (Mean ± s.e.m. is depicted, n = 23 for BPH and 30 for PCa). Statistic test: Student t test.
Containing 3 (CMTM3), exhibited the predicted behavior in the validation dataset (Figure 2D). These two transcripts were predominantly detected in BPH uEVs, whereas the detection rate was below 30% in PCa uEVs. Of note, we confirmed that these transcripts were contained in uEVs, since they exhibited resistance to RNase treatment (Supplementary Figure S2B).

Our results demonstrate that we can identify transcripts with differential abundance in PCa uEVs, employing 50 mL of urine and using an ultracentrifugation-based method for uEV isolation [16]. However, biomarker identification requires miniaturization of the assay with the consequent scaling down of the starting material. To refine our detection method, we employed a commercial exosomal RNA purification procedure (Norgen Biotek) in an independent set of samples that allowed us to reduce urine volume to 10 mL. We then performed qRT-PCR from Norgen-purified retrotranscribed RNA. We evaluated the expression level of the two best candidates, CMTM3 and CDH3. As shown before, the two housekeeping transcripts employed (GAPDH and RPL6) exhibited a strong and significant correlation (Supplementary Figure S2C).

Interestingly, this purification method precluded detection of CMTM3, while recapitulated the reduction in CDH3 with higher sensitivity using normalization against RPL6 (0.69 ± 0.1; mean ± s.e.m.; p = 0.055) and GAPDH (0.65 ± 0.08; mean ± s.e.m.; p = 0.01) (Figure 2E).

Taken together, our transcriptomic analysis reveals that CDH3 abundance is reduced in PCa uEVs and sets the basis for PCa biomarker search based on uEV transcript analysis.

**uEVs are indicators of PCa alterations**

Our results convincingly show that CDH3 abundance is reduced in uEVs from PCa patients. On the basis of these results, we hypothesized that the alteration observed in uEVs might be a reflection of transcriptomic changes in the prostate tumor.

In order to confirm our hypothesis, we studied the expression of CDH3, in a set of BPH and PCa tissue specimens. The results of CDH3 expression analysis demonstrated that it was significantly decreased in tissue from patients with PCa compared to BPH (0.52 ± 0.12; mean ± s.e.m.; p = 0.018), in full coherence with our observation in uEVs (Figure 3A). Of note, these results could lead to the notion that the association between transcriptomic tumor cell landscape and exosome RNA cargo correlate at high frequency. However, prior studies from our lab showed that known cancer genes, such as PTEN, do not exhibit a direct correlation between uEVs mRNA abundance and PTEN tumor alterations [16], suggesting a selective process in cargo loading into uEVs.

Next, we ascertained the potential extrapolation of this observation to other biological contexts, such as a panel of benign prostate cells and metastatic prostate cancer cell lines and large human PCa datasets. Interestingly, the expression of CDH3 in prostate cell lines revealed a down-regulation of the transcript in metastatic cancer cell lines (black), compared to benign-immortalized cells (grey) (0.17 ± 0.07; mean ± s.e.m.) (Figure 3B). Importantly, this observation was confirmed in two datasets where the expression of PCa specimens was compared to biopsies from healthy patients [24, 25] (Figure 3C) and was in full agreement with a previous report [29].

We also monitored the expression levels of other transcripts identified in uEVs. On the one hand, CMTM3 expression, which was shown to be down-regulated in the ultracentrifugation uEVs (but not detected with Norgen extraction method), showed a significant reduction in PCa compared with BPH tissues, but this result was not reproduced in publicly available PCa datasets and exhibited only a modest trend in PCa cell lines (Supplementary Figure S3A–S3C). On the other hand, our housekeeping genes RPL6 and EEF1A1 showed no consistent alterations throughout the same analytical layout (Supplementary Figure S3A–S3C).

We next ask whether the reduction of CDH3 expression observed in PCa could be extrapolated to other urogenital cancers. Data mining analysis was performed in bladder and renal cancer datasets (www.oncomine.org, [30]). Although there was certain consistency in the alteration of CDH3 expression within the same tumor type, the directionality of the alterations was not preserved among the different tumor types (Supplementary Figure S3D).

In order to address whether gene expression alterations in CDH3 could be translated in a decrease in the protein expression, we took advantage on publicly available initiatives for immunoreactivity analysis. Proteinatlas (www.proteinatlas.org, [31–35]) allows the visualization of immunohistochemistry (IHC) staining in a wide array of tissues. There was data available for CDH3 staining with high quality IHC-specific antibodies. Importantly, the staining in normal prostate epithelia corroborated the staining of basal prostate epithelial cells, in agreement with reports in this and other epithelial tissues [29, 36, 37] (Figure 3E, middle panel and Supplementary Figure S3F).

As predicted, CDH3 expression was decreased in PCa specimens. This result was particularly evident in tumor samples with adjacent non-neoplastic tissue (Figure 3D). Interestingly, CDH3 sub-cellular distribution was altered in tumor cells, with a predominant loss of membrane immunoreactivity (Figure 3D).

We next asked the molecular cues leading to the down-regulation of CDH3 in PCa. On the one hand, we studied the genomic and epigenetic changes occurring in CDH3 locus. The genomic analysis showed frequent shallow deletions of CDH3 in four independent PCa datasets (Figure 4A, [24, 25, 38, 39]). Moreover, epigenetic analysis of CDH3 promoter indicated increased methylation in PCa and a correlation between the methylation status of the locus and the transcript abundance. 


(Figure 4B, 4C; [38, 39]), in line with a previous report [29]). On the other hand, we evaluated the association of CDH3 expression with well-known upstream regulators. Tp63 is a basal prostate epithelial marker which is down-regulated in PCa specimens [40–42], and that has been reported to regulate CDH3 expression [43]. We found a strong correlation between the mRNA expression of Tp63 and CDH3 in prostate specimens, which suggests that transcriptional regulation of this cadherin downstream p63 is at play in PCa (Figure 4D). Altogether, our results indicate that genomic loss, transcriptional regulation and promoter methylation contribute to the down-regulation of CDH3 in PCa.

**DISCUSSION**

Extracellular vesicles including exosomes have been detected and characterized in urine [2, 44, 45]. These vesicles vary in composition and are associated with different diseases [12, 46]. Importantly, recent evidence suggests that PCa might exhibit alterations in the composition of uEVs [12, 47, 48]. The majority of...
Figure 3: CDH3 expression is reduced in PCa specimens. (A) CDH3 expression in tissue biopsies from BPH and PCa. CDH3 expression relative to GAPDH is shown. $n = 14$ for BPH and $n = 15$ for PCa. (B) CDH3 expression in a panel of metastatic prostate cancer cell lines (black bars) and benign immortalized prostate cell lines (grey bars) relative to beta-Actin. $n = 3$. (C) CDH3 expression in two PCa datasets (Taylor PCa $n = 150$, normal $n = 29$; Grasso PCa $n = 76$, normal $n = 12$). (D) Representative images of immunohistochemical detection of CDH3 protein in PCa. Middle panel corresponds to a normal area and right panel to high grade PCa (HG PCa). Data source: Human Protein Atlas. Statistic test: Mann Whitney $U$ test (A), Student $t$ test (C).
the studies are carried out comparing healthy individuals with PCa patients. It is worth noting that there is an increasing incidence of BPH in association with age [14], and the interference that this might introduce to biomarker identification is poorly understood. To address this question, we have performed a transcriptomics analysis comparing the mRNA content of uEVs from patients with BPH or PCa. The results reveal that urine from these two groups have significant alterations in vesicle number. Little is known about alterations in EV production in different pathologies as compared to the nature of its cargo and this aspect warrants further investigation. Importantly, we found a markedly different transcriptomics profile in uEVs from BPH and PCa. We were able to reduce a whole genome analysis (which revealed 1336 transcripts detected in uEV preparations) to two candidate transcripts (CMTM3 and CDH3) with decreased abundance in PCa. Interestingly, the miniaturization of the assay employing an alternative purification method revealed that CMTM3 detection is sensitive to the approach used. This suggests that the detection of uEV transcripts might be affected by the uEV purification protocol and calls for further refinement and characterization of the selectivity and specificity of the uEV isolation methods.

Placental cadherin (P-Cad or CDH3) has been widely studied in cancer [37, 49–59]. This protein regulates cell-cell adhesion processes and cellular differentiation. Interestingly, both oncogenic and tumor suppressive activities of this gene have been described in tissue-specific manner [37, 49–59]. We observe that CDH3 mRNA levels are down-regulated in PCa. This is coherent with preliminary observations at the protein level. It has been suggested that CDH3 is down-regulated and exerts tumor suppressive functions in hepatocellular carcinoma [50] and a prior study reported changes of CDH3 in PCa [29]. Our data suggest that CDH3 may be exerting tumor suppressive activities in PCa.

Figure 4: Evaluation of the molecular events accounting for CDH3 down-regulation in PCa. (A) Analysis of the genomic alterations in CDH3 locus in four PCa databases (Taylor n = 93, Grasso n = 61, TCGA n = 258, Broad n = 56). (B and C) Promoter methylation analysis from TCGA database evaluating methylation in CDH3 locus (B) n = 49 for normal tissue, n = 101 acinar PCa and n = 196 for PCa) and the correlation between methylation status and CDH3 mRNA expression (C) n = 294). (D) Correlation analysis between CDH3 and Tp63 expression in two independent datasets. (Grasso, n = 49; Taylor, n = 131; primary tumors). Statistic test: Student’s t Test (B); Pearson’s coefficient (R) (C, D).
We show that the regulation of CDH3 expression in PCa occurs at multiple levels. On the one hand, genomic and epigenetic analysis strongly suggests that deletion and methylation of the locus accounts for changes in expression. On the other hand, we find potential regulations at the level of upstream transcriptional regulators. Prior studies showed that CDH3 is a basal epithelial cell marker [29, 37]. Interestingly, Tp63, an upstream regulator of CDH3 [36], presents similar behavior to our gene of interest. Tp63 localizes to basal epithelial cells and is down-regulated in PCa [40–42, 60]. Our correlation analysis in public PCa supports the notion that p63 is a transcriptional upstream regulator of CDH3.

Of note, immunoreactivity analysis has provided preliminary evidence of mis-localization of CDH3 in PCa cells compared to non-tumoral counterparts. Interestingly, this alteration is also observed in other cancers and is associated to poor prognosis [59].

Altogether, our data show multiple means of regulation (genomic loss, DNA methylation, transcriptional regulation, and protein mis-localization) that could potentially lead to the alteration of CDH3 function in PCa.

The function of EVs in cell communication and cancer aggressiveness has emerged in the past years [61, 62]. While their use as source of biomarkers is under intense investigation, there is limited evidence about their potential role as readouts of the tumoral genetic alterations [9]. This study informs about the properties of uEVs to reflect genetic alterations in the tumor of origin. We find that the decrease in abundance of CDH3 in uEVs is coherent with mRNA changes in the prostate tumor cells. This data opens new avenues in the non-invasive characterization of genetic alterations in PCa using uEVs, with the consequent potential for patient stratification.

**MATERIALS AND METHODS**

**Patient samples and cell lines analysis**

All urine samples were obtained from the Basque Biobank for research (BIOEF, http://www.biobancovasco.org, Basurto University Hospital) upon informed consent and with evaluation and approval from the corresponding ethics committee (CEIC code OHEUN11-12 and OHEUN14-14). Inclusion criteria: For BPH patients, samples were obtained from cases with normal PSA, with symptomatic alterations (polyuria, distress), and that were scheduled for surgery. For PCa cases, samples were obtained from patients with primary localized cancer diagnosed de novo and that were scheduled for radical prostatectomy. Urine (40–100 ml) was collected by spontaneous urination between 8–10 AM, in fasting conditions. Patient information, tumor characteristics and urine volume is described in Supplementry Table S1. For prostate tissue specimens, samples were prepared and diagnosed as described in [16]. Cell lines were cultured as described in [17] and RNA was harvested in conditions of exponential growth.

**Urine extracellular vesicle purification**

uEV isolation by ultracentrifugation was performed as described in [16]. Briefly, urine was centrifuged at 2000 × g for 5 min to remove cell debris and filtered through 0.22 μm pore-filter before frozen at −80°C. For uEV isolation sample was thawed and subjected to two sequential centrifugations of 11500 × g for 30 min and second 118000 × g for 90 minutes. The pellet containing uEVs was resuspended in 150 μl of cold PBS and frozen for later processing. RNase treatment was not performed unless otherwise specified.

**Western blot**

Western blot was performed as described [18], using CD26 (Abcam, Cambridge, UK), CD63 (clone H5C6; from Developmental Studies Hybridoma Bank, Iowa, US), CD13 (clone 3D8; from Santa Cruz Biotechnology Inc.), FLT1 (clone 18; from BD Biosciences) and AQP2 (Sigma-Aldrich) antibodies.

**Transmission electron microscopy (TEM) analysis**

For cryo-electron microscopy, uEV preparations were directly adsorbed onto glow-discharged holey carbon grids (100 Holex carbon film of Cu with mess 200; Quantifoil®, Germany). Grids were blotted at 95% humidity and rapidly plunged into liquid ethane with the aid of VITROBOT (Maastricht Instruments BV, The Netherlands). Vitrified samples were imaged at liquid nitrogen temperature using a JEM-2200FS/CR transmission cryo-electron microscope (JEOL, Japan) equipped with a field emission gun and operated at an acceleration voltage of 200 kV.

**Size analysis and size distribution**

Size distribution within uEV preparations was analyzed by nanoparticle-tracking analysis (NTA) by measuring the rate of Brownian motion using a NanoSight LM10 system (Malvern, U.K.), which is equipped with a fast video capture and particle-tracking software. NTA post-acquisition settings were kept constant for all samples, and each video was analyzed to give the mean, mode, and median vesicle size, as well as an estimation of the concentration [19]. For each preparation, two videos of 30 seconds each were taken. For each video, at least 200 tracks were completed in post-capture tracking analysis.
Transcriptomic analysis

Total RNA isolation from uEV was achieved by RNeasy columns (Qiagen, Inc). The integrity, size and quantification were evaluated in RNA Pico Chips (Bioanalyzer; Agilent Technologies). For transcriptomic analysis of mRNA-associated uEVs, Illumina whole genome (HumanHT-12_V4.0; DirHyb, nt) method was used as reported [20]. cRNA synthesis was obtained out of 2–25 ng of Total RNA, with TargetAmp™ Nano-g™ Biotin-aRNA Labeling Kit for the Illumina® System (Epicentre, Cat# TAN07924) and subsequent amplification, labelling and hybridization were performed according to “Whole-Genome Gene Expression Direct Hybridization” Illumina Inc.’s protocol, except the hybridization cRNA concentration, which was 285 ng instead of the standard 750 ng. Raw expression data were background-corrected, log2-transformed and quantile-normalized using the lumi R package [21], available through the Bioconductor repository. Probes with a “detection p-value” lower than 0.01 in at least one sample were regarded as detected.

Retrotranscription and quantitative real time PCR analysis

To extract RNA from uEVs isolated by ultracentrifugation, we employed miRCURY™ RNA Isolation Kit Cell & Plant (Exiqon). In average, 1.5e7 vesicles were used per retrotranscription reaction. In addition, a set of samples was extracted by Norgen Biotek Exosomal RNA purification kit, following the manufacturers’ instructions. For cell lines, RNA was extracted using NucleoSpin® RNA isolation kit from Macherey-Nagel (ref: 740555.240C). cDNA was synthesized from 0.1–1 µg of RNA using Superscript III (Life Technologies) following the manufacturer’s recommendations. For prostate tissue samples, RNA was extracted as reported in [16]. Quantitative Real Time PCR (Taqman qRTPCR) was performed as previously described [18]. Universal Probe Library (Roche) primers and probes employed are detailed in Supplementary Table S2. β-ACTIN (Hs99999903_m1) and GAPDH (Hs02758991_g1) housekeeping assays were from Applied Biosystems and used as reported [20]. cRNA synthesis was obtained out of 2–25 ng of Total RNA, with TargetAmp™ Nano-g™ Biotin-aRNA Labeling Kit for the Illumina® System (Epicentre, Cat# TAN07924) and subsequent amplification, labelling and hybridization were performed according to “Whole-Genome Gene Expression Direct Hybridization” Illumina Inc.’s protocol, except the hybridization cRNA concentration, which was 285 ng instead of the standard 750 ng. Raw expression data were background-corrected, log2-transformed and quantile-normalized using the lumi R package [21], available through the Bioconductor repository. Probes with a “detection p-value” lower than 0.01 in at least one sample were regarded as detected.

DNA methylation

Raw intensity CDH3 DNA methylation was extracted from The Cancer Genome Atlas dataset (https://tcga-data.nci.nih.gov/tcga/) based on Illumina’s 450K methylation array. Data analysis from normal tissues (n = 49), prostate carcinoma (n = 196) and acinar prostate carcinoma (n = 101) were included. A three step-based normalization procedure was performed using the lumi [21] package available for Bioconductor [22], under the R statistical environment [23], consisting in color bias adjustment, background level adjustment and quantile normalization across arrays, as specified in [21]. Methylation level (β-value) for each of the 485, 577 CpG sites was calculated as the ratio of methylated signal divided by the sum of methylated and unmethylated signals plus 100. After normalization step, probes related to X and Y chromosomes were removed as well as those containing a SNPs with a frequency > 1% (1000 Genome project) in the probe sequence or interrogated CpG site.

Bioinformatics analysis and statistics

The following statistical analysis were employed: Database normalization: all the datasets used for the data mining analysis were downloaded from GEO and subjected to background correction, log, transformation and quartile normalization. In the case of using a pre-processed dataset, this normalization was reviewed and corrected if required.

For CDH3 genomic data, analysis from PCa patients with copy number alteration information in Taylor [24], Grasso [25], Broad/Cornell [26] and Robinson [27] et al. datasets was extracted from cbioportal.org.

Correlation analysis

Pearson correlation test was applied to analyze the relation between paired genes. From this analysis, Pearson’s coefficient (R) indicates the existing linear correlation (dependence) between two variables X and Y, giving a value between +1 and −1 (both included), where 1 is total positive correlation, 0 is no correlation, and −1 is total negative correlation. The p-value indicates the significance of this R coefficient.

Statistical analysis

Data represent mean ± s.e.m. of pooled experiments unless otherwise stated. For data mining analysis, ANOVA test was used for multi-component comparisons. Student T test or Mann Whitney U test for two-group parametric or non-parametric comparisons, respectively. The confidence level used for all the statistical analyses was of 0.95 (alpha value = 0.05). Two-tail statistical analysis was applied for experimental design without predicted result and one-tail for validation experiments.

ACKNOWLEDGMENTS AND FUNDING

Apologies to those whose related publications were not cited due to space limitations. We thank David Gil and Sandra Delgado from electron microscopy CIC bioGUNE platform for their technical assistance in the cryo-TEM analysis of EVs. We are thankful to the Basque Biobank
for research (BIOEF), for the acquisition, maintenance and distribution of urine samples. The work of AC is supported by the Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etortek), Health (2012111086) and Education (PI2012–03), Marie Curie (277043), Movember Foundation (GAP1), ISCIII (PI10/01484, PI13/00031) and ERC (336343). The work of JF-P is supported by ISCIII (PI12/01604). RB is supported by MINECO (BFU2014-52282-P, BFU2011-25986) and Basque Government (PI2012/42). N.M-M. is supported by the Spanish Association Against Cancer (AECC). A.A-A and L.V-J are supported by the Basque Government of education.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES


60. Team RDC. R: A Language and Environment for Statistical Computing. (Vienna, Austria Vienna, Austria). 2011.


The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

Veronica Torrado\textsuperscript{1,18}, Lorea Valcarcel-Jimenez\textsuperscript{1,18}, Ana Rosa Cortazar\textsuperscript{1}, Xiaojing Liu\textsuperscript{2}, Jelena Urosevic\textsuperscript{3}, Mireia Castillo-Martín\textsuperscript{4,5}, Sonia Fernández-Ruiz\textsuperscript{1}, Giampaolo Morciano\textsuperscript{6}, Alfredo Caro-Maldonado\textsuperscript{1}, Marc Guiu\textsuperscript{3}, Patricia Zúñiga-García\textsuperscript{1}, Mariona Graupera\textsuperscript{1}, Anna Bellmunt\textsuperscript{1}, Pahini Pandya\textsuperscript{1}, Mar Lorente\textsuperscript{6}, Natalia Martín-Martín\textsuperscript{1}, James David Sutherland\textsuperscript{1}, Pilar Sanchez-Mosquera\textsuperscript{1}, Laura Bozal-Basterra\textsuperscript{1}, Amaia Zabala-Letona\textsuperscript{1}, Amaia Arruabarrena-Aristorena\textsuperscript{1}, Antonio Berenguer\textsuperscript{10}, Nieves Embade\textsuperscript{1}, Aitziber Ugalde-Olano\textsuperscript{13}, Isabel Lacasa-Viscasillas\textsuperscript{12}, Ana Loizaga-Iriarte\textsuperscript{12}, Miguel Anda-Urzáiz\textsuperscript{12}, Nikolaus Schultz\textsuperscript{12}, Ana Maria Aransay\textsuperscript{1,14}, Victoria Sanz-Moreno\textsuperscript{1}, Rosa Barrio\textsuperscript{1}, Guillermo Velasco\textsuperscript{9}, Paolo Pinton\textsuperscript{4}, Carlos Cordon-Cardo\textsuperscript{1}, Jason W. Locasale\textsuperscript{2,19}, Roger R. Gomis\textsuperscript{3,15,19} and Arkaitz Carracedo\textsuperscript{1,16,17,20}

Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α-ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.

The metabolic switch in cancer encompasses a plethora of discrete enzymatic activities that must be coordinately altered to ensure the generation of biomass, reductive power and the remodelling of the microenvironment\textsuperscript{1-5}. Despite the existence of mutations in metabolic enzymes\textsuperscript{6}, it is widely accepted that the main trigger for metabolic reprogramming is the alteration in cancer genes that remodel the signalling landscape\textsuperscript{2}. Numerous reports provide evidence that pathways regulating one or a few enzymes within a metabolic pathway in cancer. However, the means of coordinated regulation of complex metabolic networks remain poorly documented.

Master transcriptional co-regulators of metabolism control a variety of genes that are in charge of remodelling the metabolic landscape, and their impact in cellular and systemic physiology has been studied for decades. It is worth noting that these co-regulators,
Figure 1 PGC1A is downregulated in prostate cancer. (a) Frequency of alterations (differences greater than twofold versus mean expression of nontumoral biopsies) in the expression of 23 master co-regulators of metabolism in a cohort of 150 PCA patients. *P < 0.05, statistically different expression of the indicated gene in PCA (n = 150) versus normal (n = 29) patient specimens (according to Supplementary Fig. 1A). (b) Gene expression levels of PGC1A, PGC1B and HDAC1 in up to four additional PCA data sets (N, normal; PCa, prostate cancer). Sample sizes: Tomlins et al.23 (N, 23; PCa, 52); Grasso et al.21 (N, 12; PCa, 76); Lapointe et al.18 (N, 9; PCa, 17); and Varambally et al.22 (N, 6; PCa, 13). (c) Association of the indicated genes with disease-free survival (DFS) in two PCA data sets (low: first quartile distribution; high: fourth quartile distribution. Sample sizes: TCGA provisional data; primary tumours n = 240; Taylor et al., primary tumours n = 131. (d) PGC1A expression in normal prostate (N), primary tumour (PT) and metastatic (Met) specimens in the Taylor and Lapointe data sets18,22. Sample sizes: Taylor (N, 29; PT, 131; Met, 19) and Lapointe (N, 9; PT, 13; Met, 4). (e) Incidence of PGC1A shallow deletions in three independent data sets (Robinson et al., Taylor et al. and Grasso et al.). Points outlined by circles indicate statistical outliers. Error bars represent minimum and maximum values. P, P value. Statistical tests: two-tailed Student’s t-test (a,b), Kaplan–Meier estimator (c) and ANOVA (d).

through their capacity to interact and regulate diverse transcription factors, exhibit a unique capacity to control complex and extensive transcriptional networks, making them ideal candidates to promote or oppose oncogenic metabolic programs.

The tumour suppressor PTEN is a negative regulator of cell growth, transformation and metabolism4–9. PTEN and its main downstream pathway, PI(3)K, have been extensively implicated in prostate cancer (PCA) pathogenesis and progression10–12. This tumour suppressor is progressively lost through the progression of PCA, and complete loss of PTEN is predominant in advanced disease and metastasis8. Genetically engineered mouse models (GEMMs) recapitulate many of the features of PCA progression. However, the molecular and
A bioinformatics screen identifies PGC1A as a metabolic co-regulator associated with prostate cancer progression

We approached the study of PCa metabolism applying criteria to ensure the selection of relevant master regulators that contribute to the metabolic switch. We focused on transcriptional co-regulators of metabolism that were consistently altered in several publicly available PCa data sets, and were associated with reduced time to recurrence and disease aggressiveness. We first evaluated the expression levels of the metabolic co-regulators in a study comprising 150 PCa specimens and 29 non-pathological prostate tissues (or controls), and the analysis revealed 10 co-regulators in the set of available PCa data sets, and we associated with reduced time to recurrence and disease aggressiveness. We first evaluated the expression levels of the metabolic co-regulator associated with prostate cancer progression.

RESULTS

A bioinformatics screen identifies PGC1A as a metabolic co-regulator associated with prostate cancer progression

We approached the study of PCa metabolism applying criteria to ensure the selection of relevant master regulators that contribute to the metabolic switch. We focused on transcriptional co-regulators of metabolism that were consistently altered in several publicly available PCa data sets, and were associated with reduced time to recurrence and disease aggressiveness. We first evaluated the expression levels of the metabolic co-regulators in a study comprising 150 PCa specimens and 29 non-pathological prostate tissues (or controls), and the analysis revealed 10 co-regulators in the set of study with significant differential expression in PCa compared with non-neoplastic prostate tissue (Fig. 1a and Supplementary Fig. 1A).
We next extended this observation to four additional data sets in which there were available data for non-tumoral and PCa tissues. Only the alteration in PPARγ1 (PPARγ1A), PPARγ2 (PPARγ1B) and HDAC1 expression was further confirmed in most or all sets (Fig. 1b and Supplementary Fig. 1B). Among these, PGC1α was the sole co-regulator with altered expression associated with Gleason score (Supplementary Fig. 1C,D) and disease-free survival (Fig. 1c).

To rule out the possibility that cellular proliferation could contribute to the alteration of metabolic regulators, we carried out an additional analysis in which we compared the expression of PGC1α in PCa versus a benign hyper-proliferative condition (benign prostate hyperplasia or BPH). The results corroborated that the decrease in PGC1α expression is associated with a cancerous state rather than with a proliferative condition (Supplementary Fig. 1E).

We observed that the expression of PGC1α was progressively decreased from primary tumours to metastasis (Fig. 1d and Supplementary Fig. 1F). Strikingly, genomic analysis revealed shallow deletions of PGC1A exquisitely restricted to metastatic PCa specimens, (Fig. 1e), in full agreement with the notion that there is a selective pressure to reduce the expression of this transcriptional co-activator as the disease progresses.

From our analysis, PGC1α emerges as the main master metabolic co-regulator altered in PCa, with an expression pattern reminiscent of a tumour suppressor.

PGC1α deletion in the murine prostate epithelium promotes prostate cancer metastasis

PGC1α has been widely studied in the context of systemic metabolism, whereas its activity in cancer is just beginning to be understood. To ascertain the role of PGC1α in PCa in vivo, we conditionally deleted this metabolic co-regulator in the prostate epithelium, alone or in combination with loss of the tumour suppressor Pten (Fig. 2a–d and Supplementary Fig. 2A,B). Pgc1α deletion alone or in the context of Pten heterozygosity did not result in any differential tissue mass or histological alteration, which led us to conclude that it is not an initiating event (Fig. 2b,d). However, compound loss of both Pten and Pgc1α resulted in significantly larger prostate mass (Fig. 2c), together with a remarkable increase in the rate of invasive cancer (Fig. 2d). Histological analysis of the prostate revealed the existence of vascular invasion in double-mutant mice (DKO), but not in Pten deleted (Pten-KO) prostates (Supplementary Fig. 2C). PGC1α regulates the inflammatory response, which could influence and contribute to the phenotype observed. However, we did not observe significant differences in the infiltration of polymorphonuclear neutrophils and lympho-plasmacytic infiltrates in our experimental settings (Supplementary Fig. 2D). PGC1α has been shown to induce angiogenesis in coherence with the induction of vascular endothelial growth factor (VEGF)-A expression. Pgc1α status in our GEMMs did not alter VEGF-A expression and microvessel density (Supplementary Fig. 2E,F). We therefore excluded the possibility that regulation of angiogenesis or inflammation downstream of PGC1α could drive the phenotype characterized in this study.

PCa GEMMs faithfully recapitulate many of the features of the human disease. A reduced number of mouse models with clinically relevant mutations show increased metastatic potential. Strikingly, histopathological analysis of our mouse model in the context of Pten loss revealed that DKO mice—but not Pten-KO counterparts—presented evidence of metastasis, which was estimated in 44% to lymph nodes and 20% to liver (Fig. 2e,f and Supplementary Fig. 2G). Metastatic dissemination was in agreement with the observation of pan-cytokeratin (panCK)- and androgen receptor (AR)-positive PCa cell deposits in the lymph nodes of DKO mice (Fig. 2g). Of note, 33% of Pten-KO mice presented small groups of panCK-positive cells in lymph nodes (without metastatic lesions; Supplementary Fig. 2H), suggesting that even if these cells are able to reach the lymph nodes, they lack capacity to establish clinical metastasis.

Interestingly, bone analysis revealed disseminated groups (but not clinical metastasis) of panCK-positive cells in DKO but not in Pten-KO mice (Supplementary Fig. 2I–K). Analysis of a small cohort of Pten+/−; Pgc1α−/− mice demonstrated that heterozygous loss of Pgc1α is sufficient to promote aggressiveness, vascular invasion and metastasis (Supplementary Fig. 2L–N). This observation supports the notion that single-copy loss of PGC1A (as observed in metastatic human PCa specimens, Fig. 1e) could be a key contributing factor to the metastatic phenotype.

The cooperative effect observed in our mouse model between loss of Pten and Pgc1α was supported by the direct correlation of the two transcripts in patient specimens and the association of PGC1A downregulation with PTEN genomic loss (TCGA provisional data, Supplementary Fig. 2O).

In summary, our results in GEMMs and patient data sets formally demonstrate that the downregulation of PGC1α in PCa is an unprecedented causal event for the progression of the disease and its metastatic dissemination.

PGC1α suppresses prostate cancer growth and metastasis

To characterize the prostate tumour suppressive activity of PGC1α, we first evaluated its expression level in well-established PCa cell lines. Using previously reported PGC1α-positive and -negative melanoma cells, we could demonstrate that PCa cell lines lack detectable expression of the transcriptional co-activator at the protein level. In agreement with this notion, PGC1α silencing in these cells failed to impact on the expression of its well-established targets (Supplementary Fig. 3A). Importantly, through the analysis of publicly available data sets, we could demonstrate that the transcript levels of PGC1A in metastatic cell lines are comparable to those observed in human metastatic PCa specimens and vastly reduced compared with PGC1α-positive melanoma cells (Fig. 3a and Supplementary Fig. 3B). Despite our efforts to optimize the detection of the protein with different commercial antibodies, we could not identify an immunoreactive band that would correspond to PGC1α, in contrast with other reports. Yet, we cannot rule out that in non-basal conditions, stimulation of other factors such as AR or 5′ AMP-activated protein kinase (AMPK) could lead to the upregulation and allow detection of PGC1α in PCa cells.

Owing to the lack of PGC1α detection in PCa cellular systems, we aimed at reconstituting the expression of this gene to levels achievable in the cancer cell lines previously reported. By means of lentiviral delivery of inducible Pgc1α and doxycycline titration, we reached expression levels of this protein in three PCa cell lines (AR-dependent—LnCaP—and independent—PC3 and DU145).
Figure 3 PGC1α exhibits tumour and metastasis suppressive activity in PCa cell lines. (a) Analysis of PGC1α expression by quantitative qPCR (top histogram) and western blot in a panel of prostate cancer cell lines (technical duplicates are shown), using melanoma cell lines as positive (MeWo) and negative (HT114, HS294T and A375) controls (n=3, independent experiments). (b) Representative experiment of PGC1α expression in PC3, DU145 and LnCaP cell lines after treatment with 0.5 μg ml⁻¹ doxycycline (Dox) (similar results were obtained in three independent experiments). (c) Relative cell number quantification in Pgc1α-expressing (+Dox, pink) and -non-expressing (−Dox, black) cells. Data are represented as cell number at day 6 relative to −Dox cells (n=12 in PC3; n=7 in DU145; n=3 in LnCaP, independent experiments). (d,e) Effect of Pgc1α expression on anchorage-independent growth (d; n=3, independent experiments) and BrdU incorporation (e; n=3, independent experiments) in PC3 cells. (f) Evaluation of tumour formation capacity in xenotransplantation experiments (n=7 mice; two injections per mouse). (g) Schematic representation of metastasis assay through intra-cardiac (IC) injection. (h,i) Evaluation of metastatic capacity of Pgc1α-expressing PC3 cells using IC xenotransplant assays (n=8 mice for −Dox and n=6 for +Dox). Luciferase-dependent signal intensity (upper panels) and metastasis-free survival curves (lower panels) of PCa cells in lungs (h) and limbs (i) were monitored for up to 28 days. Representative luciferase images are presented, referring to the quantification plots. In hind limb photon flux analysis, the average signal from two limbs per mouse is presented. Images (i) and (ii) depict tibia or lung photon flux images from specimens that are proximal to the median signal in −Dox and +Dox, respectively. (j) Schematic representation of bone metastasis assay through intra-tibial (IT) injection. (k) Evaluation of the metastatic capacity of Pgc1α-expressing PC3 cells using IT xenotransplant assays (n=7 mice). Photon flux quantification at 20 days (upper panel) and incidence of metastatic lesions at the end point (lower panel). Representative luciferase images are presented, referring to the quantification plots. For photon flux analysis, the average signal from two limbs per mouse is presented. For incidence analysis, mice with at least one limb yielding luciferase signal >50,000 units were considered metastasis-positive. Images (i) and (ii) depict tibia photon flux images from specimens that are proximal to the median signal in −Dox and +Dox, respectively. +Dox, Pgc1α-expressing conditions; −Dox, Pgc1α-non-expressing conditions; BrdU, bromodeoxyuridine; a.u., arbitrary units. Error bars represent s.e.m. (c–e) or minimum and maximum values (h,i,k). Statistical tests: two-tailed Student’s t-test (c–e), one-tailed Mann–Whitney U-test (h,i,k (upper panels)), log-rank test (f,h,i (lower panels)) and Fisher’s exact test (k, lower panels). *P<0.05, **P<0.01, ***P<0.001. Statistics source data for Fig. 3k are provided in Supplementary Table 9. Unprocessed original scans of blots are shown in Supplementary Fig. 8.
PGC1α induces a metabolic transcriptional program. (a) KEGG (Kyoto Encyclopaedia of Genes and Genomes) analysis of the transcriptional program regulated by PGC1α. The dotted line indicates \( P < 0.05 \). (b–d) Validation of microarray by quantitative rPCR in PC3 TRIPZ-HA-Pgc1α cells (b, \( n = 3 \) for TP53INP2, SOD2, NNT, GSTM4, ETFDH, GOT1, CLYBL, SUCLA2, MPC1, MPC2, ACAT1 and ACSL4; \( n = 4 \) for ATP1B1, ISCU, SDHA, IDH3A and ACADM; independent experiments; data are normalized to the −Dox condition, represented by a black dotted line), xenograft samples (c, −Dox \( n = 11 \) tumours; +Dox \( n = 6 \) tumours) and prostate tissue samples from Pten-KO and DKO mice (d, \( n = 7 \) mice). +Dox, Pgc1α-induced conditions; −Dox, Pgc1α-non-expressing conditions; Pten-KO, Pten−/−; Pgc1a−/−; DKO, Pten−/−, Pgc1a−/−. ROS, reactive oxygen species; ETC, electron transport chain; TCA, tricarboxylic acid cycle; Pyr, pyruvate; FA, fatty acid. Error bars indicate s.e.m. (b) or interquartile range (c,d). Statistical tests: one-tail Student’s t-test (b); one-tail Mann–Whitney U-test (c,d). \( P < 0.05 \), \( ** P < 0.01 \), \( *** P < 0.001 \).

PGC1α induces a metabolic transcriptional program. (a) KEGG (Kyoto Encyclopaedia of Genes and Genomes) analysis of the transcriptional program regulated by PGC1α. The dotted line indicates \( P < 0.05 \). (b–d) Validation of microarray by quantitative rPCR in PC3 TRIPZ-HA-Pgc1α cells (b, \( n = 3 \) for TP53INP2, SOD2, NNT, GSTM4, ETFDH, GOT1, CLYBL, SUCLA2, MPC1, MPC2, ACAT1 and ACSL4; \( n = 4 \) for ATP1B1, ISCU, SDHA, IDH3A and ACADM; independent experiments; data are normalized to the −Dox condition, represented by a black dotted line), xenograft samples (c, −Dox \( n = 11 \) tumours; +Dox \( n = 6 \) tumours) and prostate tissue samples from Pten-KO and DKO mice (d, \( n = 7 \) mice). +Dox, Pgc1α-induced conditions; −Dox, Pgc1α-non-expressing conditions; Pten-KO, Pten−/−; Pgc1a−/−; DKO, Pten−/−, Pgc1a−/−. ROS, reactive oxygen species; ETC, electron transport chain; TCA, tricarboxylic acid cycle; Pyr, pyruvate; FA, fatty acid. Error bars indicate s.e.m. (b) or interquartile range (c,d). Statistical tests: one-tail Student’s t-test (b); one-tail Mann–Whitney U-test (c,d). \( P < 0.05 \), \( ** P < 0.01 \), \( *** P < 0.001 \).

PGC1α determines the oncogenic metabolic wiring in prostate cancer

PGC1α regulates gene expression through the interaction with diverse transcription factors26. To define the transcriptional program associated with the tumour suppressive activity of PGC1α, we performed gene expression profiling from Pgc1α-expressing versus non-expressing PC3 cells. We identified 174 probes with significantly altered signal encoding genes predominantly related to functions such as mitochondrial catabolic programs and energy-producing processes26,44 (Supplementary Table 1 and Fig. 4a), which we validated by quantitative real-time PCR (rtPCR) (Fig. 4b–d and Supplementary Fig. 4).

To demonstrate that the tumour suppressive activity of PGC1α was indeed accompanied by a global metabolic rewiring, we carried out integrative metabolomics. We analysed cell line, xenograft and GEMM tissue extracts using liquid-chromatography high-resolution mass spectrometry (LC–HRMS). LC–HRMS metabolomics and subsequent biochemical assays confirmed that oxidative processes such as fatty acid β-oxidation (Fig. 5a–d and Supplementary Fig. 5A–C and
Figure 5 Pgc1α induces a catabolic metabolic program. (a–c) Untargeted LC–HRMS analysis of differential abundance in metabolites involved in fatty acid catabolism in Pgc1α-expressing PC3 cells (a, n=4, independent experiments), xenografts (b, −Dox n=8 tumours; +Dox n=4 tumours) and GEMMs (c, Pten KO n=3 mice; DKO n=5 mice). (d) Evaluation of the dehydrogenation of tritiated palmitate (readout of fatty acid β-oxidation) in Pgc1α-expressing PC3 cells (n=6, independent experiments). (e) Effect of Pgc1α expression on the abundance of tricarboxylic acid cycle (TCA) intermediates measured by LC–HRMS in PC3 cells (n=4, independent experiments). (f) Effect of Pgc1α expression on TCA intermediates (mass isotope abundance) after stable 13C-U6-glucose labelling in PC3 cells (n=3, independent experiments). (g) Oxygen consumption rate (OCR) in PC3 Pgc1α-expressing cells (n=7, independent experiments). (h) Basal mitochondrial ATP production in PC3 cells following Pgc1α expression (n=20 for −Dox and n=10 for +Dox conditions, independent experiments). (i) LC–HRMS quantification of ATP abundance in xenografts (left panel, −Dox n=8 tumours; +Dox n=4 tumours) and GEMMs (right panel, Pten-KO n=3 mice; DKO n=5 mice). (j) Effect of Pgc1α expression on palmitate paired mass isotope abundance after stable 13C-U6-glucose labelling in PC3 cells (n=3, independent experiments). (k) Schematic representation of the main findings of the study. Pyr, pyruvate; AcCoA, acetyl CoA; OAA, oxaloacetate; Mal, malate; Fum, fumarate; Succ, succinate; Cit, citrate; ETC, electron transport chain; FA, fatty acids. a.u., arbitrary unit. Error bars indicate s.e.m. (a,d–h), i or interquartile range (b,c,i). Statistical tests: two-tailed Student’s t-test (a,d–h); one-tail Mann–Whitney U-test (b,c,i). •P < 0.05, ••P < 0.01, •••P < 0.001.

Supplementary Tables 2–5) and tricarboxylic acid cycle (TCA, Fig. 5e and Supplementary Fig. 5D) were increased in response to Pgc1α expression. To quantitatively define the use of glucose in the TCA cycle, we carried out stable 13C-U6-glucose isotope labelling. This experimental approach provided definitive evidence of the increased oxidation of glucose in the mitochondria in Pgc1α-expressing cells (Fig. 5f). This metabolic wiring was consistent with elevated oxygen consumption (basal and ATP-producing) and ATP levels following Pgc1α expression (Fig. 5g–i and Supplementary Fig. 5E–I and Supplementary Tables 2–5).

We next reasoned that over-activation of mitochondrial oxidative processes would lead to decreased anabolic routes. On the one hand,
we monitored the incorporation of carbons from $^{13}$C–$^{15}$N-glucose into fatty acids (through the export of citrate from TCA to the cytoplasm and conversion to acetyl CoA that is used for de novo lipid synthesis). Interestingly, we found a significant decrease in $^{13}$C incorporation into palmitate (reflected as $^{13}$C carbon pairs) when Pgc1α was expressed (Fig. 5 and Supplementary Fig. 5). On the other hand, we monitored lactate production as a readout of aerobic glycolysis or ‘the Warburg effect’, which has been associated with the anabolic switch. As predicted, Pgc1α-expressing cells exhibited reduced extracellular lactate levels (Supplementary Fig. 5K). Of note, lactate production and respiration were unaltered by doxycycline challenge in non-transduced PC3 cells (Supplementary Fig. 5L,M). Taken together, our data provide a metabolic basis for the tumour suppressive potential of PGC1α in PCa, according to which this metabolic co-regulator controls the balance between catabolic and anabolic processes (Fig. 5k).

An ERRα-dependent transcriptional program mediates the prostate tumour suppressive activity of PGC1α

We next aimed to identify the transcription factor that mediated the activity of PGC1α, and hence we performed a promoter enrichment analysis. The results revealed a predominant abundance in genes regulated by ERRα (Fig. 6a). We corroborated these results with Gene Set Enrichment Analysis (GSEA; normalized enrichment score = 2.02; nominal P value = 0.0109). This transcription factor controls a wide array of metabolic functions, from oxidative processes to mitochondrial biogenesis. We have shown that PGC1α is indeed capable of regulating functions attributed to ERRα, such as mitochondrial oxidative metabolism (Figs 4 and 5 and Supplementary Figs 4 and 5). In addition, we observed that Pgc1a expression led to increased mitochondrial volume (Supplementary Fig. 6A). To ascertain the extent to which the growth inhibitory and anti-metastatic activity of PGC1α required its ability to interact with ERRα, we took advantage of a mutant variant of the co-activator (PGC1α<sup>L2L3M</sup>) that is unable to interact with this and other nuclear receptors. The expression of PGC1α<sup>L2L3M</sup> in PC3 cells (Supplementary Fig. 6B) failed to upregulate target genes, to reprogram oxidative metabolism, to inhibit cell growth, and, importantly, to suppress bone metastasis in intra-tibial xenografts (Fig. 6b–f and Supplementary Fig. 6C). To further discriminate between PGC1α functions that depend on ERRα or other nuclear receptors, we undertook a targeted silencing approach, and we transduced Pgc1a-inducible PC3 cells with an ERRα-targeting or a scramble short hairpin RNA (shRNA; Supplementary Fig. 6D). In coherence with the L2L3M mutant data, ERRα silencing partially blunted the effects of Pgc1α on gene expression and cell growth (Fig. 6g and Supplementary Fig. 6H). In vivo, silencing of ERRα in the presence of the ectopically expressed transcriptional co-activator resulted in a significant increase in bone metastasis incidence from 40% (in Pgc1α-expressing cells transduced with scramble shRNA) to full penetrance (Fig. 6h). Of note, the requirement of ERRα for the effect of PGC1α was recapitated <i>in vitro</i> with a reverse agonist of the transcription factor, namely XCT790 (Supplementary Fig. 6F–I).

It is worth noting that other metabolic pathways have been suggested to sustain the metastatic phenotype. Oxidative stress has been shown to limit metastatic potential in breast cancer and melanoma. PGC1α regulates the expression of antioxidant genes, and the enhancement of mitochondrial metabolism can lead to the production of reactive oxygen species (ROS; Fig. 4b and Supplementary Table 1). We therefore tested whether ROS production was modified in our experimental settings and if it could contribute to the phenotype observed. Mitochondrial and cellular ROS production were not consistently altered by Pgc1α expression <i>in vitro</i> (Supplementary Fig. 6I). In addition, lipid peroxidation (which serves as a readout of ROS production) was unaffected in our xenograft study (Supplementary Fig. 6K). These results are coherent with the inability of antioxidants to rescue the proliferative defect elicited by Pgc1α (Supplementary Fig. 6L).

Our data provide a molecular mechanism by which ERRα activation downstream of PGC1α promotes a metabolic rewiring that suppresses PCa proliferation and metastasis.

A PGC1α–ERRα transcriptional signature harbours prognostic potential

We have shown that reduced PGCIα expression in PCa exhibits prognostic potential (Fig. 1c). As our data demonstrate that transcriptional regulation downstream of ERRα is key for the tumour suppressive activity of this co-activator, we reasoned that the association of PGC1α with aggressiveness and disease-free survival should be recapitated when monitoring ERRα target genes (Fig. 7a). We started the analysis from the list of genes positively regulated by Pgc1α in our cellular system (153 genes, Fig. 7b). As predicted, the analysis in two independent patient data sets confirmed that the average signal of the PGC1α gene list was positively correlated with time to PCa recurrence (Fig. 7c). In addition, we observed a decrease in the expression of the aforementioned gene list associated with disease initation and progression (Supplementary Fig. 7A). Importantly, comparable results were obtained when we performed the analysis with the subset of ERRα-target genes within the PGC1α gene set (73 genes, Supplementary Table 6 and Fig. 7b,d and Supplementary Fig. 7B). We next sought to curate the gene list to consolidate a prognostic PGC1α–ERRα gene set. We therefore focused on genes that exhibited a strong correlation with PGCIα in patient data sets. We selected genes that were significantly correlated with the co-activator ($R > 0.2; p < 0.05$) in at least three out of five studies. The results unveiled a PGC1α transcriptional signature in patients consisting of 17 genes, most of which exhibited decreased expression in PCa versus BPH, and were further downregulated in metastatic disease (Supplementary Table 7 and Supplementary Fig. 7c,d). Nearly 60% of these genes were regulated by ERRα (10 genes out of 17) and were selected for further analysis as a PGC1α–ERRα curated gene set (Supplementary Table 7). The results revealed reduced PGCIα–ERRα curated gene set expression as the disease progressed (Fig. 7e). We next analysed the association of the PGC1α–ERRα curated gene set with disease recurrence. To this end, we compared patients harbouring primary tumours with ERRα curated gene set average signal values in the first quartile (Q1, termed signature-positive) versus the rest (Q2–Q4). Patients with signature-positive tumours exhibited reduced disease-free survival in two independent data sets (Fig. 7f). A hazard ratio of 4.2 (Taylor) and 17.8 (TCGA) was defined for signature-positive patients, whereas signature-negative individuals presented reduced risk of recurrence, with a hazard ratio...
Figure 6 An ERRα-dependent transcriptional program mediates the tumour suppressive activity of PGC1α. (a) Promoter enrichment analysis of the PGC1α transcriptional program. The red dotted line indicates P = 0.05. (b–d) Effect of PGC1α WT (WT) or PGC1α L2L3M (L2L3M) induction on the expression of the indicated genes (b, quantitative RT-PCR; n = 8 for IDH3A; n = 4 for ATP1B1; n = 3 for ACAT1, ISC-U, GOT1 and ACADM genes, independent experiments; data are normalized to each –Dox condition, represented by a black dotted line), relative cell number by crystal violet (c, n = 7, independent experiments) and oxygen consumption rate (d, OCR, n = 5, independent experiments). (e,f) Evaluation of the metastatic capacity of PGC1α WT (WT)-expressing (upper panels) or PGC1α L2L3M (L2L3M)-expressing (lower panels) cells using intra-tibial xenotransplant assays (e, photon flux quantification; WT, n = 6 mice; L2L3M, n = 7 mice, two hind limbs per mouse; f, incidence of metastatic lesions presented as histograms). Representative luciferase images are presented referring to the quantification plots. For photon flux analysis, average signal from two limbs per mouse is presented. For incidence analysis, mice with at least one limb yielding luciferase signal >50,000 units were considered metastasis-positive. (g) Relative cell number quantification following ERRα silencing in PGC1α-expressing PC3 cells. Data are represented as cell number at day 4 relative to –Dox cells (n = 3, independent experiments). (h) Evaluation of metastatic capacity of PGC1α-expressing PC3 cells transduced with SC shRNA or ERRα shRNA using intra-tibial implantation for 14 days (n = 8 mice; two injections per mouse; incidence of metastatic lesions presented as histograms). For photon flux analysis (left panel), average signal from two limbs per mouse is presented. For incidence analysis (right panel), mice with at least one limb yielding luciferase signal >50,000 units were considered metastasis-positive. +Dox, PGC1α-induced conditions; –Dox, PGC1α-non-expressing conditions. NS, not significant; SC, Scramble; OCR, oxygen consumption rate. Error bars represent s.e.m. (b–g) or minimum and maximum values (e,h). Statistical tests: one-tailed Student’s t-test (b–d,g); one-tailed Mann–Whitney U-test (e,h (left panel)); Fisher’s exact test (f,h (right panel)). * or 1P < 0.05, ** or 1P < 0.01, *** or 1P < 0.001. Asterisks indicate statistical difference between –Dox and +Dox conditions and dollar symbols between PGC1α WT and PGC1α L2L3M or SC shRNA and ERRα shRNA. Statistics source data for Fig. 6e,h are provided in Supplementary Table 9.
Figure 7 The PGC1α transcriptional program is associated with prostate cancer recurrence. (a) Schematic summary of the ERRα-dependent regulation of the PGC1α transcriptional metabolic program and its association with PCA progression. Dashed PGC1α outline represents a decrease in abundance. (b) Venn diagram showing the distribution of PGC1α target genes, ERRα target genes (from Supplementary Table 6) and genes correlated with PGC1A expression in PCA patient specimens (from Supplementary Table 7). (c,d) Correlation between time to recurrence and the average signal of the genes within the PGC1α-upregulated gene set (c) or the PGC1α-dependent ERRα-upregulated gene set (d) in the indicated data sets (Taylor: n = 27; TCGA: n = 240). Each dot corresponds to an individual patient specimen. (e) Representation of the average signal of the genes within the PGC1α-ERRα curated gene set (Supplementary Table 7) in normal tissue (N; Taylor n = 29 and Grasso n = 12), primary tumour (PT; Taylor n = 131 and Grasso n = 49) and metastasis specimens (Met; Taylor n = 19 and Grasso n = 27), in two independent data sets. Each dot corresponds to an individual patient specimen. (f) Association of the PGC1α-ERRα signature with disease-free survival in the indicated patient data sets (Taylor n = 131; TCGA provisional data set n = 240). Q1 indicates patients with signature signal within the first quartile of primary tumours (Q1) in the corresponding data set. HR, hazard ratio. Error bars indicate interquartile range. Statistical tests: Pearson’s coefficient (R) (c,d), ANOVA (e), Student’s t-test (e) and Kaplan–Meier estimator (f). **P < 0.01; *P > 0.05. Asterisk indicates statistical difference versus N; hash indicates statistical difference versus PT.

of 0.23 (Taylor) and 0.05 (TCGA). Furthermore, the frequency of patients with signature-positive signal values was absent or low in the normal prostate group and further increased in metastasis compared with primary tumours (Supplementary Fig. 7E). Taken together, ERRα-regulated metabolic transcriptional program is associated with the activity of PGC1α in PCA. This interplay is conserved in patient specimens and defines a gene signature that harbours prognostic potential.

DISCUSSION

In this study we provide a comprehensive analysis of master transcriptional co-regulators of metabolism in PCA. Through the use of human data mining analysis, GEMMs and cellular systems, our study presents evidence demonstrating that PGC1α exerts a tumour suppressive activity opposing PCA metastasis. Interestingly, three out of ten significantly altered co-regulators (PGC1A, PGC1B and NRIP1, Fig. 1a) in the Taylor22 PCA data set (two out of three consistently altered throughout databases, Fig. 1b) converge in the regulation of a common transcriptional metabolic program, led by ERRα (ref. 44), and that is associated with the phenotype observed in this study. These data strongly suggest that such pathway is of critical importance for the control of aggressiveness properties in PCA. Indeed, our results demonstrate that a gene set composed of ERRα target genes that are under the control of PGC1α expression is progressively downregulated in PCA and metastatic disease, and presents prognostic potential for the identification of patients at risk of early recurrence.
The study of the tumour suppressive potential of Pgc1α in mouse models allowed us to characterize a clinically relevant PCa GEMM presenting enhanced metastatic dissemination. Pgc1α is added to the shortlist of genetic events that drive metastasis in this model13–16, and the first to be explicitly linked to the regulation of the metabolic switch. Overall, our finding is of importance for the future study of the requirements for PCa metastasis and therefore for therapeutic purposes.

The sole alteration of PGC1α expression in PCa has a profound impact on the oncogenic metabolic switch20. These data are in line with the reported activities of this protein in metabolism and mitochondrial biogenesis26. Of note, despite the widely accepted fact that the reported metabolic switch20 has comparable consequences in all cancer scenarios, the study of PGC1α in other tumour types has also revealed a selective pressure towards oxidative processes27–29. Previous work from others and us defined PGC1α signalling as a selective advantage for breast cancer and melanoma cells4,27–29,31. The contribution of this co-activator to cellular proliferation differs between tumour types and experimental systems, promoting growth in melanoma28 but irrelevant to breast cancer cells29. Interestingly, in breast circulating tumour cells, PGC1α expression supports metastatic capacity30. The molecular pathways regulating these diverse biological features converge in the activation of ERα and peroxisome proliferator-activated receptors (PPAR). Whereas PPAR activation mediates the increase in fatty acid β-oxidation4, ERα is responsible for the overall increase in oxidative metabolism and mitochondrial biogenesis41. Similarly, the activation of an antioxidant transcriptional program has been suggested to contribute to anoikis and cancer cell dissemination in a PGC1α-dependent and independent manner27,28,49,52. In PCa, however, we demonstrate that the oxidative metabolic program elicited by PGC1α prevents tumour growth and metastatic dissemination, in the absence of overt changes in ROS production, inflammatory response or angiogenic signals. These findings support the notion that the optimal metabolic wiring for tumour growth and metastasis might differ depending on the tumour type, the mutational landscape of the tumour and, potentially, the microenvironment. This would lead to opposite activities of PGC1α depending on the cancer setting, from metastatic promoter26 to metastasis suppressor (as we demonstrate in the present work).

In summary, our study identifies PGC1α as a master regulator of PCa metabolism that opposes the dissemination of the disease. Therefore, a PGC1α-regulated ERα-dependent transcriptional program might open new avenues in the identification of metabolic transcriptional signatures that can be exploited for patient stratification and the use of metabolism-modulatory therapies.
ARTICLES

METHODS

Reagents. [3-4(2,4-Bis-trifluoromethylbenzoxyl)-3-methoxyphenyl]-2-cyano-N-(3-trifluoromethoxy-1,3,5-triazidazole-2-)acrylamide (XC7 990, etomoxi (ETO), doxycycline hylate (Dox), oligomycin, N-acetyl-cysteine (NAC) and manganese (III) tetrakis (4-benzoic acid)porphyrin chloride (MTRAP) were purchased from Sigma.

Cell culture. Human prostate carcinoma cell lines LnCaP, DU145 and PC3 were purchased from Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, who provided an authentication certificate. None of the cell lines used in this study were found in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. Cells were transduced with a modified TRIPZ (Dharmacon) doxycycline-inducible lentiviral construct in which the RFP and miR30 region was replaced by HA–Flag–Pgc1a (WT) (ref. 51) or lentiviral construct in which the RFP and miR30 region was replaced by Flag–Pgc1a (ref. 51) or lentiviral shRNA construct targeting PGC1A (TRCN000001166) and ESRA (TRCN0000022180) were purchased from Sigma and a scramble shRNA (hairpin sequence: 5’-CCCGCA ACAAGATGAAAAACGACACTGAGTTGTTTCCTTCTTGTG-3’) was used as the control. For ESRA shRNAs, the puromycin resistance cassette was replaced by the hygromycin cassette from pLKO.1 Hygro (Addgene Ref. 24150) using BamHI and KpnI sites. Melanoma lines were provided by M. D. Boyano10 and A. Buqué and purchased from ATCC. Cell lines were routinely monitored for mycoplasma contamination and quarantined while treated if positive.

Animals. All mouse experiments were carried out following the ethical guidelines established by the Biosafety and Welfare Committee at CIC bioGUNE and The Institutional Animal Care and Use Committee of IRB Barcelona. The procedures employed were carried out following the recommendations from AAALAC. Xenograft experiments were performed as previously described14, injecting 10⁶ cells per condition in two flanks per mouse. PC3 TRIPZ–HA–Pgc1a cells were injected in each flank of nude mice and 24 h post-injections mice were fed with chow or doxycycline diet (Research diets, D1210402). GEMM experiments were carried out as reported in a mixed background14,15,26 (where the founder colony was cross-bred for at least 3 generations before the expansion of experimental cohorts to ensure a homogenous mixed background). The Pten conditional knockout alleles have been described elsewhere11. Prostate epithelium-specific deletion was effected by the P–Cre14. Mice were fasted for 6 h before tissue collection (9:00–15:00) to prevent metabolic alterations due to immediate food intake.

For intra-tibial and intra-cardiac injections BALB/c nude male mice (Harlan) of 9–11 weeks of age were used. Before the injections, PC3 TRIPZ–HA–Pgc1a (WT, L2L3M, SC shRNA, ERK0 shRNA) cell lines were pre-treated for 48 h with PBS or doxycycline (0.5 mg ml⁻¹). Mice injected with cells treated with doxycycline were also pre-treated for 48 h with 1 mg ml⁻¹ of doxycycline in drinking water. After the injection, this group of mice was left on continuous doxycycline treatment (1 mg ml⁻¹ in drinking water). Before the injections mice were anaesthetized with a mixture of ketamine (80 mg kg⁻¹) and xylazine (8 mg kg⁻¹). For intra-tibial injections, 1 × 10⁶ cells were resuspended in a final volume of 5 µl of cold PBS and injected as described previously24. For intra-cardiac injections 2 × 10⁵ cells were resuspended in a final volume of 100 µl of cold PBS and injected as described previously. After the injections, tumour development was followed on a weekly basis by BLI using the IVIS-200 imaging system from Xenogen. Quantification of bioluminescent images was done with Living Image 2.60.1 software. The development of metastasis was confirmed by examining in vivo or ex vivo (following necropsy) bioluminescent images of organs of interest (metastasis positivity in lesion incidence analysis was defined as tubias with luciferase signals greater than 50,000 units). When comparing cell lines independently transduced with the luciferase-expressing vector (Fig. 6h), photon flux values per limb were presented as normalized signal (correlated by basal signal, obtained within 24 h after injection). Normalized photon flux = (day 1 signal/day 0 signal) × 1,000. For metastasis-free survival curves, a metastatic event was scored when the measured value of bioluminescence bypassed 1/10 of the day 0 value.

Patient samples. All samples were obtained from the Basque Biobank for research (BIOE; Basurto University Hospital) on informed consent and with evaluation and approval from the corresponding ethics committee (CEEC code OHEUN11-12 and OHEUN14-14).

Cellular, molecular and metabolic assays. Cell number quantification with crystal violet16 was performed as referenced. Soft agar assays were performed as previously described (INSERT REF 60) seeding 5,000 cells per well in 6-well plates.

Western blot was performed as previously described20. Antibodies used: PGC1α (H300; Santa Cruz Biotechnology sc-13067; dilution 1:1,000); ERα (E1G1F; Cell Signaling no. 13826; dilution 1:1,000); β-actin (clone AC-74; Sigma no. A 5316; dilution 1:2,000); GAPDH (clone 14C10; Cell Signaling no. 2218; dilution 1:1,000); HSP90 (Cell Signaling; no. 4874; dilution 1:1,000).

RNA was extracted using the NucleoSpin RNA isolation kit from Macherey-Nagel (ref: 749055-240C). For patients and animal tissues a Trizol® protocol was used as described previously. For all cases, 1 µg of total RNA was used for cDNA synthesis using qScript cDNA Supermix from Quanta (ref. 95048). Quantitative real-time PCR (rtPCR) was performed as previously described. Universal Probe Library (Roche) primers and probes employed are detailed in Supplementary Table 8. β-ACTIN (H9999993_m1; Mm0607939_s1) and GAPDH (Hs00278991_g1, Mm9999915_g1) housekeeping assays from Applied Biosystems showed similar results (all quantitative rtPCR data presented were normalized using GAPDH/Gapdh).

Fatty acid oxidation was performed as previously described20. Lactate production was measured as referenced using the Trinity Biotech lactate measurement kit.

Oxygen consumption rate (OCR) was measured with an XF24 extracellular flux analyzer (Seahorse Biosciences). Briefly, 50,000 cells per well were seeded in an XF24 plate, and OCR measurements were normalized to cell number analysed by crystal violet. Cells were initially plated in 10% PBS DMEM media for 24 h, and 1 h before measurements, the medium was changed to serum- and bicarbonate-free DMEM, with glutamine and glucose (10 mM). Mitochondrial stress test was carried out using the following concentration of injected compound: oligomycin (1 µM).

For mitochondrial ATP assays, 50,000 PC3 and DU145 cells were plated onto 13-mm coverslips and transfected with a mitochondrional-targeted luciferase chimera (mtLuciferase). Cells were perfused in the luminometer at 37°C with KRB solution containing 25 µM luciferin and 1 mM CaCl₂ and supplemented with 5.5 mM glucose. Under these conditions, the light output of a coverslip of transfected cells was in the range of 5,000–20,000 c.p.s. for the luciferase construct versus a background lower than 100 c.p.s. Luminescence was entirely dependent on the presence of luciferin and was proportional to the perfused luciferin concentration between 20 and 200 c.p.s.

Mitochondrial morphology was assessed by using a cDNA encoding mitochondrial matrix-targeted DsRed (mDsRed). Cells were seeded onto 24-mm diameter coverslips (thickness between 0.16–0.19 mm) (Thermo Scientific) and 24 h later cells were transfected with 2 µg mDsRed (Lipofectamine LTX reagent; Invitrogen). mDsRed expression was assessed 36 h later. All of the acquisitions were performed with a confocal Nikon Eclipse T; system and fluorescent images were captured using NisElements 3.2.

Lipid peroxidation based on MDA detection was assayed in xenograft samples following the manufacturer’s instructions (MAK085 Sigma-Aldrich).

ROS production was determined by Mitoxo and DCF staining as previously described24.

Histopathological analysis. After euthanasia, histological evaluation of a haematoxylin and eosin (H&E)-stained section from formalin-fixed paraffin-embedded tissues of the following organs was performed: prostate gland, lymph nodes, long bones from lower limbs and other solid organs such as lungs and liver.

Following the consensus reported previously25, prostate gland alterations were classified into four categories: gland within normal limits; high-grade prostatic intraepithelial neoplasia (HPGIN); HGPIN with focal micro-invasion; and invasive carcinoma. Lymphovascular invasion was assessed in all cases where micro-invasion or invasive carcinoma were observed.

Lymph node metastasis and the presence of groups of PCa cells in bone marrow were determined after haematoxylin–eosin (H&E)-stained sections from formalin-fixed paraffin-embedded tissues of the following organs was performed: prostate gland, lymph nodes, long bones from lower limbs and other solid organs such as lungs and liver.

Following the consensus reported previously25, prostate gland alterations were classified into four categories: gland within normal limits; high-grade prostatic intraepithelial neoplasia (HPGIN); HGPIN with focal micro-invasion; and invasive carcinoma. Lymphovascular invasion was assessed in all cases where micro-invasion or invasive carcinoma were observed.

To assess the inflammatory component in the prostate tissues we performed a semi-quantitative analysis in the glandular and the stromal areas separately for each tissue compartment: polymorphonuclear neutrophils versus lympho-plasmacytic infiltrates. Then we performed a quantification of these cells using the following scoring system: 0—no inflammatory cells, 1—few cells, 2—moderate amount of cells and 3—high amount of cells. Scores in between were also determined as 0.5, 1.5 and 2.5. If both types of cell were present in one compartment, we chose the highest as the final score.

Proliferation was assessed in paraffin-embedded xenograft samples by using Ki67 antibody (MA5-14520, Thermos Scientific). Microvessel density was determined and quantified in GEMMs and xenograft samples by the immunodetection of CD31 (rabbit anti-CD31; Ref. ab28364 Abcam).
Metabolomics. Liquid-chromatography high-resolution mass spectrometry (LC-HRMS) metabolomics and stable isotope \(^{13}\)C-\(\text{U-}\)glucose labelling was performed as reported previously\(^{64}\)-\(^{66}\). Briefly, for LC-HRMS metabolomics, PC3 TRIPZ-\(\text{HA–\text{Flag–Pgc1a}}\) cells treated or untreated for 72 h with 0.5 \(\mu\text{g mL}^{-1}\) doxycycline were plated at 500,000 cells per well in 6-well plates, and grown maintaining the doxycycline regime for 42 h before collection. For stable isotope \(^{13}\)C-\(\text{U-}\)glucose labelling experiments, 24 h after seeding cells were washed and exposed to media with serum, without glucose and pyruvate and supplemented 2 mM \(^{12}\)C-\(\text{U-}\)glucose. After a further 16 h, cells were washed and another \(^{13}\)C-\(\text{U-}\)glucose pulse was performed for 2 h before collection.

Transcriptomic analysis. For transcriptomic analysis in PC3 TRIPZ-\(\text{HA–\text{Flag–Pgc1a}}\) cells, the illumina whole-genome \text{-HumanHT-12_V4.0 (DirHyb, nt)} method was used as reported previously\(^{65}\).

Promoter enrichment analysis was assessed with the Transcription Factors (TFs) data set from MSigDB (The Molecular Signature Database; \url{http://www.broadinstitute.org/gsea/mSigdb/collections.jsp}). The TFs data set contains genes that share a transcription factor-binding site defined in the TRANSFAC (version 7.4, \url{http://www.gene-regulation.com}) database. Each of these gene sets was annotated by a TRANSFAC record. A hypergeometric test was used to detect enriched data set categories.

The GSEA was performed using the GenePattern web tool from the Broad Institute (\url{http://genepattern.broadinstitute.org}). The list of PGC1\(\alpha\)-upregulated genes ranked by their fold change was uploaded and analysed against a list of ERR target genes\(^{66}\). The number of permutations carried out was 1,000 and the threshold was 0.05.

Bioinformatic analysis. For database normalization, all of the data sets used for the data mining analysis were downloaded from GEO, and subjected to background correction, log transformation and quartile normalization. In the case of using a pre-processed data set, this normalization was reviewed and corrected if required.

Frequency of alteration of metabolic co-regulators (Fig. 1 and Supplementary Fig. 1A): expression levels of the selected co-regulators were obtained from the data set reported by Taylor et al.\(^{61}\). A matrix containing signal values and clinical information was prepared to ascertain the up- or downregulation. We computed the relative expression of an individual gene and tumour to the expression distribution in a reference population (patients without prostate tumour or metastasis). The relative expression of an individual gene and tumour to the expression distribution in a reference population (patients without prostate tumour or metastasis). The relative expression of an individual gene and tumour to the expression distribution in a reference population (patients without prostate tumour or metastasis). The relative expression of an individual gene and tumour to the expression distribution in a reference population (patients without prostate tumour or metastasis). The relative expression of an individual gene and tumour to the expression distribution in a reference population (patients without prostate tumour or metastasis). The relative expression of an individual gene and tumour to the expression distribution in a reference population (patients without prostate tumour or metastasis).

For quartile analysis in disease-free survival, patients’ biopsies from primary tumours were organized into four quartiles according to the expression of the gene of interest in two data sets. The recurrence of the disease was set as the event of interest. The Kaplan–Meier estimator was used to perform the test as it takes into account right-censoring, which occurs if a patient withdraws from a study. On the plot, small vertical tick marks indicate losses, where a patient’s survival time has been right-censored. With this estimator we obtained a survival curve, a graphical representation of the occurrence of the event in the different groups, and a \(P\) value that estimates the statistical power of the differences observed.

For PGC1\(\alpha\) genomic analysis, data from prostate cancer patients with copy number alteration information in Taylor\(^{22}\), Grasso\(^{23}\) and Robinson\(^{24}\) et al. data sets were extracted from chiplot.org. Percentage of shallow deletions of primary tumours and metastatic patients was calculated separately.

For correlation analysis, the Pearson correlation test was applied to analyse the relationship between paired genes. From this analysis, Pearson’s coefficient (\(R\)) indicates the existing linear correlation (dependence) between two variables \(X\) and \(Y\), giving a value between +1 and −1 (both included), where 1 is total positive correlation, 0 is no correlation, and −1 is total negative correlation. The \(P\) value indicates the significance of this \(R\) coefficient.

Statistics and reproducibility. No statistical method was used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Unless otherwise stated, data analysed by parametric tests are represented by the mean ± s.e.m. of pooled experiments and median ± interquartile range for experiments analysed by non-parametric tests. \(n\) values represent the number of independent experiments performed, the number of individual mice or patient specimens.

For each independent \textit{in vitro} experiment, at least three technical replicates were used (exceptions: in western blot analysis technical replicates are presented, in untargeted metabolomics two technical replicates were used and for \(^{13}\)C-\(\text{U-}\)glucose labelling one technical replicate was used) and a minimum number of three experiments were performed to ensure adequate statistical power. For data mining analysis, ANOVA test was used for multi-component comparisons and Student’s \(t\)-test for two component comparisons. In the \textit{in vitro} experiments, normal distribution was confirmed or assumed (for \(n < 5\)) and Student’s \(t\)-test was applied for two-component comparisons. For \textit{in vivo} experiments, as well as for experimental analysis of human biopsies (from Basurto University Hospital) a non-parametric Mann–Whitney exact test was used, without using approximate algorithms to avoid different outcomes of statistics packages\(^{64}\). To this end, we applied the formulae described\(^{65}\) for small-sized groups and Graphpad Prism for large-sized groups. In the statistical analyses involving fold changes, unequal variances were assumed. For contingency analysis, Fisher’s exact test was used for two-group comparison (metastasis incidence) and Chi Square when analysing more than two groups (analysis of PGC1\(\alpha\)-ERR\(\alpha\) signature frequency in PCA human specimens). The confidence level used for all the statistical analyses was 95% (alpha value = 0.05).

Two-tailed statistical analysis was applied for experimental design without predicted result, and one-tail for validation or hypothesis-driven experiments.

Accession numbers and data sets. Primary accessions: the transcriptomic data generated in this publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE75193.

Referenced accessions: Grasso et al.\(^{21}\), GEO: GSE39898; Lapointe et al.\(^{18}\), GEO: GSE39933; Taylor et al.\(^{22}\), GEO: GSE21032; Tomlins et al.\(^{25}\), GEO: GSE6099; Varambally et al.\(^{26}\), GEO: GSE3325.
Supplementary Figure 1 A. Expression of 23 metabolic co-regulators in Taylor\(^1\) dataset (N: normal; PCa: prostate cancer). B. Expression of 7 metabolic co-regulators from figure 1a in four additional prostate cancer datasets (N: normal; PCa: prostate cancer). In Varambally\(^2\) dataset gene expression levels are presented in \(\log_2\). In Tomlins\(^3\), Grasso\(^4\) and Lapointe\(^5\) datasets gene expression levels are presented in median centred \(\log_2\). C-D, Association of \(\text{PGC1A}\) expression with Gleason score in TCGA provisional data\(^6,7\) (C) and Taylor\(^1\) datasets (D). E, Analysis of \(\text{PGC1A}\) expression in benign prostatic hyperplasia (BPH) and PCa specimens from Basurto University Hospital cohort (qRTPCR, BPH n= 14 patient specimens and Cancer n=16 patient specimens). F, \(\text{PGC1A}\) expression in normal prostate (N), primary tumour (PT) and metastatic (Met) specimens in Grasso\(^4\) dataset. Points outlined by circles indicate statistical outliers (A, C, D and F). Error bars represent minimum and maximum values (A, B, C, D and F) or median with interquartile range (E). Statistic test: two-tailed Student T test (A, B), two-tailed Mann Whitney U test (E) and ANOVA (C, D and F).
Supplementary Figure 2 A. Analysis of Pten and Pgc1a gene expression in GEMMs of the indicated genotype (Pten wt, Pgc1a wt n=3 mice; Pten p/-, Pgc1a p/- n=7 mice; Pten p/c-, Pgc1a p/c- n=6 mice; Pten p/c-, Pgc1a p/c- n=12 mice; data is normalized to Gapdh expression). B. Age comparison between experimental cohorts (n as in Figure 2d). C. Quantification of prostate tissue with histological vascular invasion signs in Pten KO (2 mice) and DKO mice (9 mice) (limited to mice with invasive signs). D, Histological analysis of inflammatory signs (stromal and glandular infiltration) in Pten KO and DKO mice (Pten KO, n=7 mice; DKO n=12 mice). E, Quantification of Vegfa mRNA expression in Pten KO and DKO mice (Pten KO, n=7 mice; DKO, n=6 mice; data is normalized to Gapdh expression). F, Quantification of microvessel density (MVD) (dot plot, bars represent median with interquartile range). P = p-value. Statistic tests: one-tailed Mann-Whitney U test (A, B), two-tailed Mann-Whitney U test (D, E and F), ANOVA (O, right panel); Pearson’s coefficient (O, left panel). *p < 0.05, **p < 0.001.

© 2016 Macmillan Publishers Limited. All rights reserved
Supplementary Figure 3 A, mRNA expression of PGC1A, ACO2 and HADHA by qRT-PCR in PC3 cells transduced with scramble shRNA (shSC) or PGC1A-targeting shRNA (shPGC1A) (n=3). B, PGC1A expression in normal (N, n=29), primary tumour (PT, n=131), metastasis (Met, n=19) specimens and metastatic cell lines. Data is shown as Log2 mRNA expression. C, Densitometry of PGC1α protein expression in MeWo (endogenous) and PC3 TRIPZ-HA-Pgc1α (ectopic) cell lines, relative to β-Actin (n=3, independent experiments). D, Effect of Pgc1α induction (+Dox) on ACO2 mRNA expression in PC3 (n=4, independent experiments), DU145 (n=7, independent experiments) and LnCaP cells (n=3, independent experiments). E-F, Effect of Pgc1α expression on anchorage-independent growth (E, n=3, independent experiments) and BrdU incorporation (F, n=3, independent experiments) in DU145 cells. G, Effect of Pgc1α expression on cell cycle progression in PC3 cells (n=4, independent experiments). H, Effect of doxycycline treatment (0.5µg/ml) on cell growth of non-transduced PC3 cells (n=3, independent experiments). I-J, Pgc1α protein expression and cell proliferation by Ki67 immunoreactivity in xenograft samples from Fig. 3f (-Dox n=14 tumours, +Dox n=6 tumours). K, mRNA expression of ACO2 and HADHA in xenograft samples from Fig. 3f. (-Dox n=9 tumours, +Dox n=6 tumours). L-M, Analysis of VEGFA mRNA expression upon Pgc1α induction in PC3 cells (L, n=4, independent experiments) and xenograft samples (M, -Dox n=9 tumours and +Dox n=6 tumours). N, Quantification of microvessel density (MVD) in xenograft samples (-Dox n=9 tumours and +Dox n=7 tumours). Right panels show representative CD31 staining micrographs. Error bars indicate s.e.m (A, C, D, E, F, G, H, L) and median with interquartile range (J, K, M, N). Statistic tests: two-tailed Student T test (A, C, D, E, F, G, H, L) and one-tailed Mann-Whitney U test (J, K, M, N). *p < 0.05, **p < 0.01, ***p < 0.001.
**Supplementary Figure 4 A-B.** Validation of the microarray by qRTPCR in DU145 (n=4, independent experiments) and LnCaP (n=3, independent experiments) TRIPZ-HA-Pgc1a cells. Gene expression values relative to -Dox cells are represented (reference -Dox gene expression values are indicated with a dotted line). **C.** mRNA expression of PGC1α target genes in doxycycline-treated (0.5µg/ml) non-transduced PC3 cells (n=3, independent experiments). Error bars represent s.e.m. Statistic test: One tail Student T test. *p < 0.05, **p < 0.01, ***p < 0.001.
**Supplementary Figure 5**

A. Analysis of differential abundance in metabolites involved in fatty acid catabolism by untargeted LC-HRMS in DU145 TRIPZ-HA-Pgc1α cells (n=4, independent experiments). B-C Evaluation of the dehydrogenation of 3H-palmitate (readout of β-oxidation) in DU145 cells upon Pgc1α expression (B, n=3, independent experiments) and, in doxycycline-treated (0.5µg/ml) non-transduced PC3 cells (C, n=3, independent experiments). Values relative to - Dox cells are presented. D, Effect of Pgc1α expression on citrate abundance measured by LC-HRMS metabolomics in DU145 cells (n=4, independent experiments). E-F, ATP-producing OCR (upon complex V inhibition by oligomycin injection) in PC3 (E, n=3, independent experiments) and DU145 (F, n=3, independent experiments) cells upon Pgc1α expression. G, Basal mitochondrial ATP production in DU145 cells upon Pgc1α expression (n=10, independent experiments). H-I, LC-HRMS quantification of ADP (H) and AMP (I) abundance in PC3 Pgc1α (n=4, independent experiments), DU145 Pgc1α (n=4, independent experiments), xenografts (-Dox n=8 tumours; +Dox n=4 tumours) and GEMMs (Pten KO n=3 mice; DKO n=5 mice). J, Quantification of area under the curve (AUC, relative to Dox) of Palmitate labelling from 13C-U6-Glucose in PC3 TRIPZ-HA-Pgc1α cells (data related to Fig. 5j, n=3, independent experiments). K, Determination of extracellular lactate in PC3 TRIPZ-HA-Pgc1α cells (n=3, independent experiments). L-M, Lactate production (L) and OCR (M) in doxycycline-treated (0.5µg/ml) non-transduced PC3 cells (n=3, independent experiments). Error bars represent s.e.m., except xenograft and GEMM data in H-I, that represent median with interquartile range. Statistic tests: two tailed Student T test (A, B, C, D, E, F, G, H (PC3 and DU145), I (PC3 and DU145), J, K, L, M) and one tailed Mann Whitney U test (H (Xenografts and GEMMs), I (Xenografts and GEMMs)). *p < 0.05, **p < 0.01, ***p < 0.001.
Supplementary Figure 6  A, Analysis of mitochondrial morphology (mitochondrial volume) in PC3 cells upon Pgc1α expression (n=5, independent experiments). B, Expression of PGC1α and PGC1α L2L3M in PC3 cells after treatment with 0.5 μg/ml doxycycline (Dox) (a representative experiment with technical replicates is presented, similar results were obtained in three independent experiments). C, Basal mitochondrial ATP production in PC3 cells after treatment with 0.5 μg/ml doxycycline (Dox) (a representative experiment with technical replicates is presented, similar results were obtained in three independent experiments). D, Expression of Pgc1α and ERRα in doxycycline-treated PC3 TRIPZ-HA-Pgc1α cells transduced with sh-scramble (shSC) or shERRα (a representative experiment with technical replicates is presented, similar results were obtained in three independent experiments). E, mRNA expression of PGC1α target genes in doxycycline-treated PC3 TRIPZ-HA-Pgc1α cells transduced with shSC or shERRα (n=4 for ACAT1 and n=5 for IDH3A, ATP1B1, ISCU, GOT1 and ACADM; independent experiments). F-I, mRNA expression of Pgc1α target genes (F, n=3 for ACAT1 and n=4 for ATP1B1 and IDH3A; independent experiments), cell number (G, n=4, independent experiments), basal oxygen consumption (H, n=3, independent experiments) and basal mitochondrial ATP production (I, n= 7 for -Dox + XCT790; n=8 the rest; independent experiments) in vehicle (Veh) or XCT790-treated Pgc1α-inducible PC3 cells. J, Evaluation of cellular (DCF) and mitochondrial-specific (Mitosox) ROS production in Pgc1α-expressing PC3 (left panel; n=4, independent experiments) and DU145 (right panel; n=6, independent experiments) cells. K, Evaluation of lipid peroxidation in xenograft tissues from Fig. 3f (-Dox n=4 tumours; +Dox n=5 tumours). L, Effect of the indicated antioxidant treatments on cell number (relative to day 0) of Pgc1α-expressing PC3 cells (n=3, independent experiments). DCF: 2',7'-dichlorodihydrofluorescein. n.s.: not significant. Error bars represent s.e.m. (A, C, E, F, G, H, I, J, L) or median with interquartile range (K). Statistic tests: two tailed Student T test (A, C, E, F, G, H, I, J, L) or one tailed Student T test (comparison between +Dox conditions in C, E, F, G, H, I) and two tailed Mann-Whitney U test (K). */$ p < 0.05, **/$$ p < 0.01, $$$/$$$ p < 0.001. Asterisks indicate statistic between -Dox and +Dox conditions (unless represented otherwise) and dollar symbol between either, vehicle (Veh) and XCT790-treated Pgc1α-expressing cells, shSC and shERRα-transduced Pgc1α-expressing cells or Pgc1αWT and Pgc1αL2L3M.
**SUPPLEMENTARY INFORMATION**

**Supplementary Figure 7 A-B**, Representation of the average signal of genes within the PGC1α-upregulated gene set (A) (Fig. 7b, blue circle) and within the PGC1α-dependent ERRα-upregulated gene set (B) (Fig. 7b, yellow circle, Table S6) in the indicated datasets in normal (N; Taylor n=29 and Grasso n=12), primary tumours (PT; Taylor n=131 and Grasso n=49) and metastasis (Met; Taylor n=19 and Grasso n=27). C, qRT-PCR mRNA expression analysis of PGC1α target genes from C, in benign prostatic hyperplasia (BPH) and PCa specimens from Basuto University Hospital cohort (BPH n=14 patient specimens; Prostate cancer n=16 patient specimens). D, Expression of the indicated genes (from Supplementary Table 7) in different disease states (N: normal, Lapointe n=9, Taylor n=29 and Grasso n=12; PT: primary tumour, Lapointe n=13, Taylor n=131 and Grasso n=49; Met: metastasis, Lapointe n=4, Taylor n=19 and Grasso n=27) in three PCa datasets. E, Representation of “PGC1α-ERRα Q1 signature” frequency within different tumour types (N: normal; PT: primary tumour; Met: metastasis) in two datasets (Taylor: N, n=29; PT, n=131; Met, n=19; Grasso: N, n=12; PT, n=49; Met, n=27). Error bars represent s.e.m. (A, B), median with interquartile range (C) and maximum and minimum (D). Statistic tests: ANOVA (A, B, D); two tailed Student T test (A, B), one tailed Mann Whitney U test (C), Chi Square (E). Asterisks in A, B indicates statistics between normal and metastasis and hash between primary tumours and metastasis. p: p-value. *# p < 0.05, **##/## p < 0.01, ***p < 0.001.
Supplementary Figure 8 Unprocessed blots. **A**, Western blot corresponding to Figure 3a. **B**, Western blot corresponding to Figure 3b. **C**, Western blot corresponding to Supplementary Figure 3I. **D**, Western blot corresponding to Supplementary Figure 6B. **E**, Western blot corresponding to Supplementary Figure 6D. Precision Plus Protein™ Dual Color Standards (Ref #1610374) markers was used in A-D. Pink Pre-stained protein ladder, Nippon Genetics, Cat.No. MWP02, was used in E.
**Table titles and legends**

**Supplementary Table 1** Gene expression profiling in PC3 TRIPZ-HA-Pgc1α cells (Doxycycline vs. No Doxycycline, (0.5µg/ml).

**Supplementary Table 2** Untargeted LC-HRMS metabolomic profiling in PC3 TRIPZ-HA-Pgc1α cells (Doxycycline vs. No Doxycycline, (0.5µg/ml).

**Supplementary Table 3** Untargeted LC-HRMS metabolomic profiling in DU145 TRIPZ-HA-Pgc1α cells (Doxycycline vs. No Doxycycline, (0.5µg/ml).

**Supplementary Table 4** Untargeted LC-HRMS metabolomic profiling in xenograft-derived tissues (from PC3 TRIPZ-HA-Pgc1α cells) upon induction of Pgc1α expression (Doxycycline diet vs. chow).

**Supplementary Table 5** Untargeted LC-HRMS metabolomic profiling in GEMM-derived prostate tissues (Ptenpc−/−, Pgc1apc−/− vs. Ptenpc−/−, Pgc1apc+/+).

**Supplementary Table 6** Definition of ERRα signature within the PGC1α gene list. Genes included in the TGACCTY_V$ERR1_Q2 dataset or identified in the study by Stein et al (STEIN_ESRRA_Targets8) were considered as ERRα targets.

**Supplementary Table 7** List of Pgc1α-regulated genes in PC3 (Supplementary Table 1) that show significant and consistent correlation with PGC1A in human prostate cancer datasets (R>0.2; p<0.05) in at least three out five datasets.

**Supplementary Table 8** List of primers and probes (Universal Probe Library, Roche) used in qRTPCR.

**Supplementary Table 9** Statistics source data for animal experiments reported in Fig. 3k, and Fig. 6e, h. All data are organized into different sheets and named based on the corresponding figure/panel numbers.

**References:**